WO2008013838A2 - Pyridizinone derivatives - Google Patents

Pyridizinone derivatives Download PDF

Info

Publication number
WO2008013838A2
WO2008013838A2 PCT/US2007/016699 US2007016699W WO2008013838A2 WO 2008013838 A2 WO2008013838 A2 WO 2008013838A2 US 2007016699 W US2007016699 W US 2007016699W WO 2008013838 A2 WO2008013838 A2 WO 2008013838A2
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
methyl
pyridazin
propoxy
pyrrolidin
Prior art date
Application number
PCT/US2007/016699
Other languages
French (fr)
Other versions
WO2008013838A3 (en
Inventor
Robert L. Hudkins
Kurt A. Josef
Ming Tao
Nadine C. Becknell
Greg Hostetler
Lars J. S. Knutson
Allison L. Zulli
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES07810758T priority Critical patent/ES2397283T3/en
Priority to NZ574873A priority patent/NZ574873A/en
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Priority to KR1020097003799A priority patent/KR101429311B1/en
Priority to JP2009521813A priority patent/JP5335675B2/en
Priority to CN2007800345556A priority patent/CN101522638B/en
Priority to SI200731142T priority patent/SI2069312T1/en
Priority to RS20130013A priority patent/RS52626B/en
Priority to PL07810758T priority patent/PL2069312T3/en
Priority to MX2009000884A priority patent/MX2009000884A/en
Priority to EA200970156A priority patent/EA017004B1/en
Priority to EP07810758A priority patent/EP2069312B1/en
Priority to BRPI0713836-9A priority patent/BRPI0713836A2/en
Priority to DK07810758.8T priority patent/DK2069312T3/en
Priority to KR1020147004736A priority patent/KR20140037967A/en
Priority to CA2658821A priority patent/CA2658821C/en
Priority to AU2007277163A priority patent/AU2007277163B2/en
Publication of WO2008013838A2 publication Critical patent/WO2008013838A2/en
Publication of WO2008013838A3 publication Critical patent/WO2008013838A3/en
Priority to IL196543A priority patent/IL196543A/en
Priority to NO20090628A priority patent/NO20090628L/en
Priority to HK09111622.4A priority patent/HK1134284A1/en
Priority to HRP20130044TT priority patent/HRP20130044T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/36—Benzo-cinnolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention is related to pyridizinone derivatives, their use as H 3 inhibitors, processes for their preparation, and pharmaceutical compositions thereof.
  • Histamine is a well established modulator of neuronal activity. At least four subtypes of histamine receptors have been reported in the literature — Hi, H 2 , H 3 , H 4 .
  • the histamine H 3 receptors play a key role in neurotransmission in the central nervous system.
  • the H 3 receptor was discovered in 1983 originally on histamine-containing neurons where it was shown to function presynaptically, regulating the release and synthesis of the biogenic amine histamine (Arrang et al, 1983) now a well established neurotransmitter.
  • H 3 receptors are predominately expressed in the brain, localizing to the cerebral cortex, amygdala, hippocampus, striatum, thalamus and hypothalamus.
  • H 3 receptors are also localized presynaptically on histaminergic nerve terminals and act as inhibitory autoreceptors (Alguacil and Perez-Garcia, 2003; Passani et al, 2004; Leurs at al, 2005; Celanire et al, 2005; Witkin and Nelson, 2004). When these receptors are activated by histamine, histamine release is inhibited. H 3 receptors can also be found in the periphery (skin, lung, cardiovascular system, intestine, GI tract, etc).
  • H 3 receptors are also involved in presynaptic regulation of the release of acetylcholine, dopamine, GABA, glutamate and serotonin (see Repka-Ramirez, 2003; Chazot and Hann, 2001 ; Leurs et al, 1998).
  • the H 3 receptor demonstrates a high degree of constitutive or spontaneous activity (e.g., receptor is active in the absence of agonist stimulation) in vitro and in vivo, thus, ligands to the receptor can display, agonist, neutral antagonist or inverse agonist effects.
  • H 3 receptor may have utility in a number of therapeutic applications including narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders and epilepsy (Leurs et al, 2005; Witkin and Nelson, 2004, Hancock and Fox 2004; Esbenshade et al. 2006).
  • An H 3 antagonist/inverse agonist could be important for gastrointestinal disorders, respiratory disorders such as asthma, inflammation, and myocardial infarction.
  • Ohtake et al. (US 2006/0178375 Al) disclosed compounds that reportedly exhibit histamine receptor H 3 antagonist or inverse agonist activity and may be useful for the treatment or prevention of obesity, diabetes, hormonal secretion abnormality, or sleep disorders.
  • Celanire et al. (WO 2006/103057 Al and WO 2006/103045) have disclosed compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, their pharmaceutical compositions and their uses as H 3 ligands.
  • Bertrand et al. (WO 2006/117609 A2) disclosed novel histamine H 3 receptor ligands, processes for their preparation, and their therapeutic applications.
  • Schwartz et al. (WO 2006/103546 A2) disclosed certain methods of treatment for Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, and/or vascular dementia using non-imidazole alkylamine derivatives that are antagonists of the H 3 receptors of histamine.
  • Apodaca et al. (EP 1 311 482 Bl) disclosed certain non-imidazole aryloxypiperidines as H 3 receptor ligands, their synthesis, and their use for the treatment of disorders and conditions mediated by the histamine receptor.
  • Xu et al. disclosed certain 6-substituted phenyl-4,5-dihydro-3(2H)-pyridazinones, their synthesis, and rabbit platelet aggregation inhibitory activity induced by ADP in vitro.
  • the- present invention is directed, in part, to novel pyridizinone compounds which may be useful as H3 inhibitors, and thus may be useful, inter alia, in methods for treating diseases, disorders, and/or conditions that may be mediated or modulated by inhibition of H3, or otherwise associated with the H 3 receptor system, including, for example, narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders (such as asthma), inflammation, and myocardial infarction.
  • the novel compounds of the invention have the following formula I*:
  • X and X a are each independently CH or N; Y is S(O) q , O, or NR 15 ; R 1 is NR 10 R 1 ' or a 4- to 9-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R 20 groups; R 2 is
  • each R 4 is independently H, Cj-C ⁇ alkyl, or OR 21 , wherein the alkyl group is optionally substituted with 1 to 3 R 20 groups;
  • R 10 and R 11 are each independently H, d-Cgalkyl, or C 3 -C 6 cycloalkyl, wherein the alkyl or cycloalkyl group is optionally substituted with 1 to 3 R 20 groups;
  • R 13a , R 13b , R I3c 5 and R 14a are each independently H, Ci-C 6 alkyl; or R 13 and R 14 , taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or C 3 -Cgcycloalkyl ring; or R 13b and R 14 , or R 13 and I4a , or R I3b and 14a , or R 13c and R 14a , taken together with the carbon atoms through which they are connected form a fused Ca-C ⁇ cycloalkyl ring; or R 13 and R 13a , or R 14 and R 14a , taken together with the carbon atom to which they are attached form a C 3 -Cgcycloalkyl ring; provided that no more than one pair of R 13 and R 14 , R 13b and R 14 , R 13 and R I4a , R I3
  • R 25 is Ci-Cealkyl. aryl, or alkylaryl;
  • R 26 is H 5 Ci-Cealkyl, aryl, or alkylaryl
  • R ⁇ is H or CrCealkyl
  • m is 1, 2, 3, 4, or 5 when R 1 is attached via a nitrogen atom, and m is 0, 1, 2, 3, 4, or 5 when R 1 is attached via a carbon atom
  • n is 1, 2, or 3
  • q is O, 1, or 2
  • s is 1, 2, or 3
  • y is 0, 1, or 2.
  • the present invention is directed to pharmaceutical compositions which comprise a pharmaceutically acceptable carrier and a compound of the present invention, preferably in a therapeutically effective amount.
  • the present invention is directed to methods for treating a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of the present invention.
  • a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardi
  • the invention is generally directed to pyridizinone derivatives, processes for their preparation, and pharmaceuticals compositions their and methods of their pharmaceutical use.
  • the term “about” refers to a range of values from ⁇ 10% of a specified value.
  • the phrase “about 50” includes ⁇ 10% of 50, or from 45 to 55.
  • the phrase “from about 10 to 100” includes ⁇ 10% of 10 and ⁇ 10% of 100, or from 9 to 110.
  • a range of values in the form “x-y” or “x to y", or “x through y”, include integers x, y, and the integers therebetween.
  • the phrases “1-6", or “1 to 6” or “1 through 6” are intended to include the integers 1, 2, 3, 4, 5, and 6.
  • Preferred embodiments include each individual integer in the range, as well as any subcombination of integers.
  • preferred integers for "1-6" can include 1, 2, 3, 4, 5, 6, 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to3, 2 to 4, 2 to 5, 2 to 6, etc.
  • stable compound or “stable structure” refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent.
  • the present invention is directed only to stable compounds.
  • substituted refers to any one or more hydrogen atoms on the indicated atom is replaced with a selected group referred to herein as a “substituent”, provided that the substituted atom's valency is not exceeded, and that the substitution results in a stable compound.
  • a substituted group has 1 to 5, preferably 1 to 3, and more preferably 1 independently selected substituents.
  • alkyl refers to a straight-chain, or branched alkyl group having 1 to 8 carbon atoms, preferably from 1 to 6, with 1 to 3 more preferred.
  • alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, neopentyl, 1-ethylpropyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3- dimethylbutyl, hexyl, octyl, etc.
  • alkyl moiety of alkyl-containing groups such as alkoxy, alkoxycarbonyl, and alkylaminocarbonyl groups, has the same meaning as alkyl defined above.
  • alkyl groups which are preferred, are alkyl groups as defined above which contain 1 to 4 carbons.
  • a designation such as “C 1 -C 4 alkyl” refers to an alkyl radical containing from 1 to 4 carbon atoms.
  • Alkyl groups may be optionally substituted.
  • alkenyl refers to a straight chain, or branched hydrocarbon chains of 2 to 8 carbon atoms having at least one carbon-carbon double bond.
  • C 2 -C 8 alkenyl refers to an alkenyl radical containing from 2 to 8 carbon atoms. Examples of alkenyl groups include ethenyl, propenyl, isopropenyl, 2,4-pentadienyl, etc. Alkenyl groups may be optionally substituted.
  • alkynyl refers to a straight chain, or branched hydrocarbon chains of 2 to 8 carbon atoms having at least one carbon-carbon triple bond.
  • a designation "C 2 -C 8 alkynyl” refers to an alkynyl radical containing from 2 to 8 carbon atoms. Examples include ethynyl, propynyl, isopropynyl, 3,5-hexadiynyl, etc. Alkynyl groups may be optionally substituted.
  • cycloalkyl refers to a saturated or partially saturated mono- or bicyclic alkyl ring system containing 3 to 10 carbon atoms. Certain embodiments contain 3 to 6 carbon atoms, preferably 3 or 4 carbon atoms, and other embodiments contain 5 or 6 carbon atoms.
  • a designation such as “C5-C7 cycloalkyl” refers to a cycloalkyl radical containing from 5 to 7 ring carbon atoms.
  • cycloalkyl groups include such groups as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, pinenyl, pinanyl, and adamantanyl. Cycloalkyl groups may be optionally substituted.
  • aryl refers to a substituted or unsubstituted, mono- or bicyclic hydrocarbon aromatic ring system having 6 to 12 ring carbon atoms. Examples include phenyl and naphthyl. Preferred aryl groups include unsubstituted or substituted phenyl and naphthyl groups. Included within the definition of "aryl” are fused ring systems, including, for example, ring systems in which an aromatic ring is fused to a cycloalkyl ring. Examples of such fused ring systems include, for example, indane, indene, and tetrahydronaphthalene. Aryl groups may be optionally substituted.
  • heterocycle refers to a substituted or unsubstituted carbocyclic group in which one or more ring carbon atoms are replaced by at least one hetero atom such as -O-, -N-, or -S-. Certain embodiments include 4 to 9 membered rings preferably 3 to 7 membered rings, and other embodiments include 5 or 6 membered rings.
  • the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen may be optionally substituted in non-aromatic rings.
  • Heterocycles are intended to include heteroaryl and heterocycloalkyl groups. Heterocyclic groups may be optionally substituted.
  • heteroaryl refers to an aromatic group containing 5 to 10 ring carbon atoms in which one or more ring carbon atoms are replaced by at least one hetero atom such as -O-, -N-, or -S-. Certain embodiments include 5 or 6 membered rings.
  • heteroaryl groups include pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, isoxazolyl, oxazolyl, oxathiolyl, oxadiazolyl, triazolyl, oxatriazolyl, furazanyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, picolinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, isobenzofuranyl, purinyl, quinazolinyl, quinolyl, isoquinolyl, benzoimidazolyl, benzothiazolyl, benzothiophenyl, thianaphthenyl, benzoxazolyl, benzisoxazolyl,
  • heteroaryl include fused ring systems, including, for example, ring systems in which an aromatic ring is fused to a heterocycloalkyl ring.
  • fused ring systems include, for example, phthalamide, phthalic anhydride, indoline, isoindoline, tetrahydroisoquinoline, chroman, isochroman, chromene, and isochromene.
  • Heteroaryl groups may be optionally substituted.
  • heteroaryl is pyridinyl, more preferably pyridine-2-yl, or thienyl
  • heterocycloalkyl refers to a cycloalkyl group in which one or more ring carbon atoms are replaced by at least one hetero atom such as -O-, -N-, or - S-. Certain embodiments include 4 to 9 membered rings, preferably 3 to 7, more preferably 3 to 6 membered rings, and other embodiments include 5 or 6 membered rings.
  • heterocycloalkyl groups include pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pirazolidinyl, pirazolinyl, pyrazalinyl, piperidinyl, piperazinyl, hexahydropyrimidinyl, morpholinyl- thiomorpholinyl, tetrahydrofuranyl, dithiolyl, oxathiolyl, dioxazolyl, oxathiazolyl, pyranyl, oxazinyl, oxathiazinyl, and oxadiazinyl, preferably pyrrolidinyl, morpholinyl, piperidinyl, orazapanyl, more preferably pyrrolidinyl or piperidinyl. Heterocycloalkyl groups may be optionally substituted.
  • arylalkyl refers to an alkyl group that is substituted with an aryl group.
  • arylalkyl groups include, but are not limited to, benzyl, bromobenzyl, phenethyl, benzhydryl, diphenylmethyl, triphenylmethyl, diphenylethyl, naphthylmethyl, etc. preferably benzyl.
  • Arylalkyl groups may be optionally substituted.
  • amino acid refers to a group containing both an amino group and a carboxyl group. Embodiments of amino acids include ⁇ -amino, ⁇ -amino, ⁇ - amino acids.
  • the ⁇ -amino acids have a general formula HOOC-CH(side chain)-NH 2 .
  • the amino acids can be in their D, L or racemic configurations.
  • Amino acids include naturally- occurring and non-naturally occurring moieties.
  • the naturally-occurring amino acids include the standard 20 ⁇ -amino acids found in proteins, such as glycine, serine, tyrosine, proline, histidine, glutamine, etc.
  • Naturally-occurring aniino acids can also include non- ⁇ - amino acids (such as ⁇ -alanine, ⁇ -aminobutyric acid, homocysteine, etc.), rare amino acids (such as 4-hydroxyproline, 5 -hydroxy Iy sine, 3-methylhistidine, etc.) and non-protein amino acids (such as citrulline, ornithine, canavanine, etc.).
  • Non-naturally occurring amino acids are well-known in the art, and include analogs of natural amino acids. See Lehninger, A. L. Biochemistry, 2 nd ed.; Worth Publishers: New York, 1975; 71-77, the disclosure of which is incorporated herein by reference.
  • Non-naturally occurring amino acids also include ⁇ - amino acids wherein the side chains are replaced with synthetic derivatives.
  • Representative side chains of naturally occurring and non-naturally occurring ⁇ -amino acids include are shown below in Table A.
  • H 2 N-CC NH)-NH-CH 2 -CH 2 -CH 2 -
  • the term "subject” or “patient” refers to a warm blooded animal such as a mammal, preferably a human, or a human child, which is afflicted with, or has the potential to be afflicted with one or more diseases and conditions described herein.
  • a "therapeutically effective amount” refers to an amount of a compound of the present invention effective to prevent or treat the symptoms of particular disorder.
  • disorders include, but are not limited to, those pathological and neurological disorders associated with the aberrant activity of the receptors described herein, wherein the treatment or prevention comprises inhibiting, inducing, or enhancing the activity thereof by contacting the receptor with a compound of the present invention.
  • the term "pharmaceutically acceptable” refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
  • unit dose refers to a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition, as described hereinafter.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carb ' oxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic,
  • physiologically acceptable salts are prepared by methods known in the art, e.g., by dissolving the free amine bases with an excess of the acid in aqueous alcohol, or neutralizing a free carboxylic acid with an alkali metal base such as a hydroxide, or with an amine.
  • Certain acidic or basic compounds of the present invention may exist as zwitterions. All forms of the compounds, including free acid, free base and zwitterions, are contemplated to be within the scope of the present invention. It is well known in the art that compounds containing both amino and carboxy groups often exist in equilibrium with their zwitterionic forms. Thus, any of the compounds described herein throughout that contain, for example, both amino and carboxy groups, also include reference to their corresponding zwitterions.
  • prodrug refers to compounds specifically designed to maximize the amount of active species that reaches the desired site of reaction, which are of themselves typically inactive or minimally active for the activity desired, but through biotransformation are converted into biologically active metabolites.
  • prodrugs include, for example, compounds described herein in which a hydroxy, amino, or carboxy group is bonded to any group that, when the prodrug is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or carboxylic acid, respectively.
  • Examples include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups; and alkyl, cycloalkyl, aryl, and alkylaryl esters such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert- butyl, cyclopropyl, phenyl, benzyl, and phenethyl esters, and the like.
  • alkyl, cycloalkyl, aryl, and alkylaryl esters such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert- butyl, cyclopropyl, phenyl, benzyl, and phenethyl esters, and the like.
  • Compounds described herein may contain one or more asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic forms.
  • all isomeric forms of a structure including all stereogenic (such as enantiomeric, diastereomeric, and/or meso forms, whether chiral or racemic), all achiral, all geometric, and/or all conformational isomeric forms are intended, unless the specific stereochemical or other isomeric form is specifically indicated and/or achiral. It is well known in the art how to prepare and isolate such isomeric forms of a structure including those having stereogenic centers including those stereogenic forms wherein the structure is present in optically active form.
  • stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate synthesis of target chiral centers.
  • stereoisomers refers to compounds that have identical chemical constitution, but differ as regards the arrangement of the atoms or groups in space.
  • treatment and “treating” as used herein include preventative (e.g., prophylactic), curative and/or palliative treatment.
  • preventative e.g., prophylactic
  • curative e.g., palliative
  • palliative treatment e.g., palliative treatment
  • the present invention is directed, in part, to novel pyridizinone compounds which have the following formula I*:
  • X and X a are each independently CH or N; Y is S(O) q , O, or NR !5 ; R 1 is NR 10 R 1 ' or a 4- to 9-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R 20 groups; R 2 is
  • each R 4 is independently H, Cj-Cgalkyl, or OR 21 , wherein the alkyl group is optionally substituted with 1 to 3 R 20 groups;
  • R 10 and R 11 are each independently H, Ci-C ⁇ alkyl, or Ca-C ⁇ cycloalkyl, wherein the alkyl or cycloalkyl group is optionally substituted with 1 to 3 R 20 groups;
  • R 13 and R 14 are each independently H, Ci-C ⁇ alkyl, aryl, arylalkyl Ci-C 6 alkoxyl,
  • R 13a , R 13b 5 R I3c 5 and R 14a are each independently H 5 Ci-C 6 alkyl; or R 13 and R 14 , taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or C 3 -C ⁇ cycloalkyl ring; or R 13b and R 14 , or R 13 and 14a , or R 13b and 14a , or R 13c and R 14a , taken together with the carbon atoms through which they are connected form a fused Cs-C ⁇ cycloalkyl ring; or R 13 and R 13a , or R 14 and R 14a , taken together with the carbon atom to which they are attached form a C 3 -C 8 cycloalkyl ring;
  • R 25 is C,-C 6 alkyl, aryl, or alkylaryl
  • R 26 is H, d-C ⁇ alkyl, aryl, or alkylaryl
  • R 27 is H or Ci-C 6 alkyl; m is 1, 2, 3, 4, or 5 when R 1 is attached via a nitrogen atom, and m is O, 1, 2, 3, 4, or 5 when R 1 is attached via a carbon atom; n is 1, 2, or 3; q is 0, 1 , or 2; s is 1, 2, or 3; and y is 0, 1, or 2.
  • the compounds of formula I or I* are other than 6-
  • each R 4 is H, m is 2, 3, or 4, R 1 is methylamino, hydroxyethylamino, pyrolidin-1-yl, piperidin-1 -yl, morpholin-4-yl, and R 2 is para to the Y-CCHR ⁇ m -J ⁇ group, then R 2 is other than 4,5-dihydro-2H-pyridazin-3-one-6-yl.
  • the present invention provides a novel of formula I:
  • X and X a are each independently CH or N;
  • Y is selected from S(O) q , O 5 and NR 15 ;
  • R 1 is NR 10 R 1 ' or a 4 to 9 membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R 20 groups;
  • R 2 is
  • R 4 is H, Ci-Cg alkyl, or OR 21 , wherein the alk ⁇ yl group is optionally substituted with 1 to
  • R 27 wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heterocycloalkyl groups are optionally substituted with 1 to 3 R 20 groups;
  • R 13 and R 14 are independently H, Ci-C 6 alkyl, aryl, or arylalkyl or R 13 and R 14 can combine to form a fused phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl ring; wherein the phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl rings are optionally substituted with 1 to 3 R 20 groups;
  • R 15 is H 5 C 1 -C 6 alkyl, C(O)R 25 , CO 2 R 25 ;
  • R 20 at each occurrence is independently, H, F, Cl, Br 5 1, OR 21 , OR 22 , NR 23 R 24 , NHOH, NO 2 ,
  • R 21 at each occurrence is independently H 3 C 1 -C 6 alkyl, aryl, or arylalkyl; R 22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
  • R 25 is C J -C 6 alkyl, aryl, or alkylaryl;
  • R 26 is H, Ci-C 6 alkyl, aryl, or alkylaryl;
  • R 27 is H or Ci-C 6 alkyl; m is 1, 2, 3, 4, or 5 when R 1 is attached via a nitrogen atom, and m is 0, 1, 2, 3, 4, or 5 when
  • R 1 is attached via a carbon atom; n is O, 1. 2, or 3; q is 0, 1, or 2; s is 1, 2, or 3.
  • Embodiments of the present invention include those compounds of formula I having the structure I**:
  • R 1 is NR 10 R 11 or a 5 to 6 membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R 20 groups; or R 1 is NR 10 R 11 , pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R 20 groups; or R 1 is pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R 20 groups; R 4 is H or Ci-C 6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R 20 groups;
  • R 10 and R u are each, independently H or Ci-C 6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R 20 groups;
  • R 12 is H, Ci-C 6 alkyl, phenyl, or benzyl, wherein the alkyl, phenyl and benzyl groups are optionally substituted with 1 to 3 R 20 groups;
  • R 22 at each occurrence is independently the residue of an amino acid after the hydroxy! group of the carboxyl group is removed;
  • R 26 is H, C 1 -C 6 alkyl, aryl, or alkylaryl;
  • R 27 is H or Ci-C 6 alkyl; m is 3 when R 1 is attached via a nitrogen atom, and m is 0 or 1 when R 1 is attached via a carbon atom; n is 0 or 1 ; q is O, I, or 2.
  • the present invention includes compounds of formula (Ia):
  • each variable is defined in formula I.
  • Additional aspects of the present invention include compounds of formula (Ia) which incorporate the embodiments described above for compounds of formula I, as is appropriate.
  • additional embodiments include compound of formula (Ia) with the preferred moieties of groups R 1 and R 2 ; or R 1 and Y; or R 1 , R 2 and Y; etc.
  • the present invention includes compounds of formula (Ib):
  • the present invention includes compounds of formula (Ic):
  • each variable is defined in formula I.
  • Additional aspects of the present invention include compounds of formula (Ic) which incorporate the embodiments described above for compounds of formula I, as is appropriate.
  • additional embodiments include compound of formula (Ic) with the preferred moieties of groups R 1 and R 2 ; or R 1 and Y; or R 1 , R 2 and Y; etc.
  • the present invention includes compounds of formula (Id):
  • each variable is defined in formula I.
  • Additional aspects of the present invention include compounds of formula (Id) which incorporate the embodiments described above for compounds of formula I, as is appropriate.
  • additional embodiments include compound of formula (Id) with the preferred moieties of groups R ; or R and m; or R . 1 5 r R> 13 and R 14. : etc.
  • the present invention includes compounds of formula (Ie):
  • each variable is defined in formula I.
  • Additional aspects of the present invention include compounds of formula (If) which incorporate the embodiments described above for compounds of formula I, as is appropriate.
  • additional embodiments include compound of formula (If) with the preferred moieties of groups R 1 ; or R 12 ; or R 1 and R 12 .
  • the present invention includes compounds of formula (Ig):
  • each variable is defined in formula I.
  • Additional aspects of the present invention include compounds of formula (Ig) which incorporate the embodiments described above for compounds of formula I 5 as is appropriate.
  • additional embodiments include compound of formula (Ig) with the preferred moieties of groups R 1 ; or R 12 ; or R 1 and R 12 .
  • the present invention includes compounds of formula (Ih):
  • each variable is defined in formula I.
  • Additional aspects of the present invention include compounds of formula (Ih) which incorporate the embodiments described above for compounds of formula I, as is appropriate.
  • additional embodiments include compound of formula (Ih) with the preferred moieties of groups R 1 ; or R 1 and R 13 ; or R 1 , R 23 and R 24 .
  • the present invention includes compounds of formula (Ii):
  • R 1 is NR 10 R 1 ' or a 5 to 6 membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R 20 groups;
  • R 2 is
  • R 3 is: at each occurrence is independently, H, F, CI 5 Br, I, OR 21 , NR 23 R 24 , NO 2 , CN,
  • R 3 and R 14 can combine to form -CH 2 CH 2 -; or when R 3 is ortho to X a and R 2 is ortho to R 3 and meta to X a , then R 2 and R 3 combine to form:
  • R 4 is H or Ci-C 6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R 20 groups;
  • R 10 and R 11 are each, independently H or C 1 -C 6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R 20 groups;
  • R 12 is H, Ci-C 6 alkyl, phenyl, or benzyl, wherein the alkyl, phenyl and benzyl groups are optionally substituted with 1 to 3 R 20 groups;
  • R 13 and R 14 are independently H, Ci-C 6 alkyl, phenyl, or benzyl, or R 13 and R 14 can combine to form a fused phenyl, thienyl, cyclopentyl or cyclohexyl ring; wherein the phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl rings are optionally substituted with 1 to 3 R 20 groups;
  • R 26 is H 5 Ci-C 6 alkyl, aryl, or alkylaryl;
  • R 27 is H or Ci-C 6 alkyl; m is 3 when R 1 is attached via a nitrogen atom, and m is 0 or 1 when R 1 is attached via a carbon atom; n is 0 or 1; q is 0, I, or 2.
  • Embodiments of the present invention include those compounds where Y is O. In other embodiments Y is S(O) q , or Y is NR 15 .
  • Embodiments of the present invention include those compounds where R 1 is NR 10 R 11 , and those compounds where R 10 and R 11 are each, independently H or C I -C O alkyl, preferably both are Ci-Ce alkyl.
  • Embodiments of the present invention include those compounds where R 1 is a 4- to 9-membered heterocycloalkyl ring, preferably a 5- to 6-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms, more preferably 1 nitrogen atom, and optionally substituted with 1 to 3 R 20 groups.
  • R 1 is an optionally substituted 5- membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms, such as pyrrolidinyl, imidazolidinyl, or pyrazolidinyl.
  • R 1 is an optionally substituted 6- membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms, such as piperidinyl, piperazinyl, or hexahydropyrimidinyl.
  • R 1 is attached to Y through a ring nitrogen atom.
  • R 1 is attached to Y through a ring carbon atom.
  • R 1 is:
  • one or more of the carbon centers [(i.e., the subgroup "— (CHR 4 ) m -") ? said subgroup which is present in the Y-(CHR 4 ) m -R' moiety "m" times] may have the potential to be chiral in nature. That is to say, there may be 4 different groups attached to a carbon center in the subgroup. Each — (CHR 4 )- independently may be chiral and all possible stereoisomeric combinations are within the scope of the present invention.
  • m is 3, more preferably the moiety Y-(CHR 4 ) m -R I is
  • Embodiments of the present invention include those compounds where R 2 is
  • R 2 is
  • R 2 is
  • the R 2 can be a combination of R 2A through R 2E .
  • such combinations include: R 2A , R 2C , R 2D , and R 2E ; R 2A , R 2B , R 2D , and R 2E ; R 2A , R 2B , and R 2C ; R 2A , R 2D , and R 2E ; R 2A , R 2D , and R 2E ; R 2A and R 2B ; R 2B and R 2C ; R 2D and R 2E ; etc.
  • R 2 is:
  • R 3 and R 14 taken together may form -(CH 2 ) S -, -CH 2 Z- , -ZCH 2 -, -ZCH 2 CH 2 - or CH 2 CH 2 Z-; wherein Z is O, S(O) y , or NR 27 ; or when R 3 is ortho to R 2 , and R 2 is (iv), (v), or (viii), then R 3 and R 13 taken together may form -(CH 2 ) S -, -CH 2 Z- , -ZCH 2 -, -ZCH 2 CH 2 - or CH 2 CH 2 Z-; or when R 3 is ortho to R 2 , and R 2 is (viii), then R 3 and R 13b taken together may form -(CH 2 ) S -, -CH 2 Z- , -ZCH 2 -, -ZCH 2 CH 2 - or CH 2 CH 2 Z-; or when R 3 is ortho to R 2 , and R 2 is (viii), then R 3 and R 13b
  • R 2 is (i), (ii), (iv), (vi), (viii), or (ix).
  • R 2 is (iv); or it is (i); more preferably ; or it is
  • R2 is (vi), (viii), or (ix).
  • R" is:
  • R is:
  • R 2 is para to the Y-(CHR 4 )- R'group.
  • R 2 is meta to the Y- (CHR 4 )-R' group, or R 2 is para to the Y-CCHR ⁇ -R'group-
  • R 2 is meta or para to the Y-(CHR 4 )-R 2 group.
  • R 13 and R 14 are independently H, or they are each independently C 1 -C 6 alkyl, or they are each independently aryl, or they are each independently arylalkyl.
  • R 2 , R 13 and R 14 can combine to form a fused phenyl ring, or they can form a fused thienyl ring, or they can form a fused pyrrolyl ring, or they can form a fused cyclopentyl ring or they can form a fused cyclohexyl ring.
  • An example of R 13 and R 14 combining to form a fused thienyl ring has the following structure:
  • Embodiments of the present invention include those compounds where n is 0. Certain embodiments include those compounds where n is 1. Still other embodiments include those compounds where n is 2.
  • R 3 is ortho to R 2 , then R 3 and R 14 can combine to form -CH 2 CH 2 -.
  • R 3 is ortho to R 2 , then R 3 and R 14 can combine to form -(CH 2 ) S -.
  • An example includes a compound where s is 2 b which has the following structure:
  • s is 2, or s is 3.
  • R 3 and R 14 can combine to form -CH 2 Z- or CH 2 CH 2 Z-; wherein Z is O, S(O) y , NR 27 .
  • R 3 and R 14 can combine to form -CH 2 Z- or they can combine to form CH 2 CH 2 Z-.
  • Z is O and in others, Z is -S-.
  • R 3 is ortho to X a and R 2 is ortho to R 3 and meta to X a , then R 2 and R 3 combine to form:
  • An example includes a compound of the following structure:
  • Embodiments of the present invention include those compounds where R 4 is H 5 optionally substituted Ci-C 6 alkyl, or optionally substituted Ci-C 6 alkoxyl, preferably H or optionally substituted Ci-C ⁇ alkyl. In certain embodiments. R 4 is optionally substituted C 1 - C ⁇ alkyl. In embodiments where R4 is alkyl, it is preferably Ci-C 3 alkyl, more preferably, CiC ⁇ alkyl, with methyl being even more preferred.
  • Embodiments of the present invention include those compounds where m is 1, 2, 3, 4, or 5 when R 1 is attached via a nitrogen atom.
  • m is 1, or m is 2, or m is 3, or m is 4, or m is 5, or m can be any combination of the above including, 1 and 2; 1 and 3; 2 and 3; 1, 2, and 3; etc.
  • Other embodiments include those compounds where m is 0, 1, 2, 3, 4, or 5 when R 1 is attached via a carbon atom.
  • m is 0, or m is 1
  • or m is 2, or m is 3, or m is 4, or m is 5, or m can be any combination of the above including, 0 and 1; 0 and 2; 0, I 5 and 2; 1, 2, and 3; etc.
  • s is 2.
  • R 12 is H, Ci-C ⁇ alkyl, cycloalkyl, aryl, arylalkyl, or heteroaryl, more preferably H or heteroaryl, with heteroaryl being even more preferred.
  • Ci-C ⁇ alkyl, aryl, arylalkyl, or heteroaryl is preferred in some embodiments.
  • R 13 , R 14 R 13a , R 13b , R 13c , and R 14a are each independently H or Ci-C ⁇ alkyl, more preferably wherein at least one of is R 13 , R 14 R 13a , R I3b , R 13c , and R 14a is Ci-C 6 alkyl.
  • R 13a and R 13 are each independently C 1 -C 3 alkyl; or R 14a and R 14 are each independently C 1 -C 3 alkyl.
  • R 13 and R 14 taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, oxazolyl, pyridinyl, or C 3 -C 6 cycloalkyl ring; or R 13b and R 14 , or R 13 and 14a , or R I3b and l4a , or R 13c and R 14a , taken together with the carbon atoms through which they are connected form a fused C 3 -C 6 cycloalkyl ring; or R 13 and R 13a , or R 14 and R 14a , taken together with the carbon atom to which they are attached form a C 3 -Cgcycloalkyl ring; provided that no more than one pair of R 13 and R 14 , R 13b and R 14 , R 13 and R 14a , R 13b and R l4a , R I3c and R 14a , R 13 and R 13a , R 13 and R 13a
  • R 13 and R 14 , R 13b and R 14 , or R 13 and 14a , or R 13b and 14a , or R 13c and R 14a taken together with the carbon atoms through which they are connected form a fused C 3 -C 6 cycloalkyl ring; or R 13 and R l3a , or R 14 and R I4a , taken together with the carbon atom to which they are attached form a C 3 -C 8 cycloalkyl ring; then the cycloalkyl ring is a is C 3 -C4cycloalkyl ring.
  • R 14 is heteroaryl
  • R 20 is alkyl; in others it is cycloalkyl, more preferably cyclobutyl. In still others, R 20 is F, Cl, CF 3 , NR 23 R 24 , or C r C ⁇ alkyl optionally substituted with OR 26 , cycloalkylCo-C4alkyl, or heterocycloalkylCo- C4alkyl, more preferably Ci-C ⁇ alkyl optionally substituted with OR 26 .
  • R 21 is H or Ci- C ⁇ alkyl.
  • R 23 and R 24 are each independently Ci-C ⁇ alkyL
  • R 26 is H or Q-Cgalkyl.
  • At least one of X and X a is CH, more preferably X and X 3 are each CH.
  • Embodiments of the present invention include those compounds of formula I wherein: X and X a are CH;
  • Y is O
  • R 1 is NR 10 R 1 ' or a 5 to 6 membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R 20 groups; or R 1 is NR 10 R 11 , pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R 20 groups; or R 1 is pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R 20 groups;
  • R 3 at each occurrence is independently, H, F, Cl, Br, I, OR 21 , NR 23 R 24 , NO 2 , CN, CF 3 , Ci-
  • R 3 at each occurrence is independently, H; F; Cl; Br; I; OR 21 ; NR 23 R 24 ; NO 2 ; CN;
  • R 4 is H or Cj-C 6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R 20 groups;
  • R 10 and R 11 are each, independently H or C 1 -C 6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R 20 groups;
  • R 12 is H, CpC 6 alkyl, phenyl, or benzyl, wherein the alkyl, phenyl and benzyl groups are optionally substituted with 1 to 3 R 20 groups;
  • R 13 and R 14 are independently H, C 1 -C 6 alkyl, phenyl, or benzyl, or R 13 and R 14 can combine to form a fused phenyl, thienyl, cyclopentyl or cyclohexyl ring; wherein the phenyl, thienyl,
  • R 13 and R 14 are independently H, Ci-C 6 alkyl, phenyl, or benzyl; or
  • R 13 and R 14 can combine to form a fused phenyl, thienyl, cyclopentyl or cyclohexyl ring;
  • R 20 at each occurrence is independently, H, F, Cl, Br, I, OR 21 , OR 22 , NR 23 R 24 , NHOH, NO 2 ,
  • R 21 at each occurrence is independently H, Ci-C 6 alkyl, aryl, or arylalkyl;
  • R 22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
  • R 26 is H, Ci-C 6 alkyl, aryl, or alkylaryl;
  • R 27 is H or C 1 -C 6 alkyl;
  • m is 3 when R 1 is attached via a nitrogen atom, and m is 0 or 1 when R 1 is attached via a carbon atom;
  • n is 0 or 1 ;
  • q is O, 1, or 2.
  • Embodiments of the present invention include those compounds of formula I wherein: X is N and X a is N or CH; or X and X a are each N; or X is N and X a is CH; Y is O; R 1 is NR 10 R 1 ⁇ or a 5 to 6 membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R 20 groups; or R 1 is NR 10 R 11 , pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidinyl groups are optionally substituted with 1 to 3 R 20 groups; or R 1 is pyrrolidinyl or piperidinyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R 20 groups;
  • R* at each occurrence is independently, H, F, Cl, Br, I, OR 21 , NR >2 / 3 J rR>24 , NO 2 , CN, CF 3 , C r
  • R 3 at each occurrence is independently, H; F; Cl; Br; I; OR 21 ; NR 23 R 24 ; NO 2 ; CN;
  • R 4 is H or C 1 -C 6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R 20 groups;
  • R 10 and R 11 are each, independently H or Ci-C 6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R 20 groups;
  • R 12 is H, Ci-Ce alkyl, phenyl, or benzyl, wherein the alkyl, phenyl and benzyl groups are optionally substituted with 1 to 3 R 20 groups;
  • R 13 and R 14 are independently H, Ci-C 6 alkyl, phenyl, or benzyl, or R 13 and R 14 can combine to form a fused phenyl, thienyl, cyclopentyl or cyclohexyl ring; wherein the phenyl, thienyl, pyrroly
  • R 13 and R 14 are independently H, C 1 -C 6 alkyl, phenyl, or benzyl; or R 13 and R 14 can combine to form a fused phenyl, thienyl, cyclopentyl or cyclohexyl ring;
  • R 21 at each occurrence is independently H, Ci-C 6 alkyl, aryl, or arylalkyl;
  • R 22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
  • R 26 is H, Ci-C 6 alkyl, aryl, or alkylaryl;
  • R 27 is H or Ci-C 6 alkyl; m is 3 when R 1 is attached via a nitrogen atom, and m is O or 1 when R 1 is attached via a carbon atom; n is O or 1 ; q is 0, 1, or 2.
  • Embodiments of the present invention include those compounds of formula I wherein: X and X a are CH;
  • Y is O;
  • R 1 is NR 10 R 11 , pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R 20 groups;
  • R 2 is para to the Y-(CHR 4 ) m -R 1 group;
  • R 3 at each occurrence is independently, H, F, Cl, Br, I, OR 21 , NR 23 R 24 , NO 2 , CN,
  • a first embodiment includes those compounds wherein:
  • R 1 is attached by the nitrogen atom;
  • R 2 is:
  • R 13 and R 14 combine to form a fused phenyl or thienyl ring; and m is 3.
  • R 2 is:
  • R 2 is:
  • R 1 is attached by the nitrogen atom;
  • R 2 is:
  • R 13 and R 14 combine to form a fused cyclopentyl or cyclohexyl ring; and m is 3.
  • R 1 is attached by the nitrogen atom;
  • R 2 is:
  • R 13 and R 14 are independently H, Ci-C ⁇ alkyl, phenyl, or benzyl; and m is 3.
  • R 13 and R 14 are independently H, Ci-C ⁇ alkyl, phenyl, or benzyl; and m is 3.
  • R 1 is pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are attached by a ring carbon atom and each are optionally substituted with 1 to
  • R 2 is:
  • R 4 is H
  • R 13 and R 14 are independently H, C 1 -C 6 alkyl, phenyl, or benzyl; m is 0 or 1.
  • R 1 is attached by the nitrogen atom;
  • R 2 is:
  • R !3 and R 14 are independently H, C 1 -C 6 alkyl, phenyl, or benzyl; m is 3.
  • R !3 and R 14 are independently H, C 1 -C 6 alkyl, phenyl, or benzyl; m is 3.
  • R 1 is attached by the nitrogen atom;
  • R 2 is:
  • R 13 and R 14 are independently H, Ci-C 6 alkyl, phenyl, or benzyl; m is 3.
  • R 1 is attached by the nitrogen atom; R 2 is ortho to R 3 , and R 2 is: .
  • R 3 and R 14 combine to form -CH 2 CH 2 -; m is 3.
  • X and X a are CH;
  • Y is O
  • R 1 is NR 10 R 1 ', pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R groups;
  • R 2 is para to the Y-(CHR 4 ) m -R l group;
  • R 3 at each occurrence is independently, H, F, Cl, Br, I, OR 21 , NR 23 R 24 , NO 2 , CN, CF 3 , Q-
  • R 3 and R 14 can combine to form -CH 2 CH 2 -; m is 3 when R 1 is attached via a nitrogen atom, and m is 0 or 1 when R 1 is attached via a carbon atom; n is 0 or 1.
  • Additional aspects of the present invention include compounds of formula II which incorporate the embodiments described above for compounds of formula I 3 as is appropriate.
  • additional embodiments include compound of formula II with the preferred moieties of groups R 1 ; or R 1 and R 13 ; or R 1 , R 23 and R 24 , etc.
  • R 1 is NR 10 R 1 ', pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R 20 groups.
  • R 1 is NR 10 R 1 ', pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R 20 groups.
  • R 3 at each occurrence is independently, H, F, Cl, Br, I, OR 21 , NR 23 R 24 , NO 2 , CN, CF 3 , C r
  • R 3 and R 14 can combine to form -CH 2 CH 2 -.
  • I* are selected from the group consisting of:
  • the compounds of formula I are selected from the group consisting of:
  • the compounds of formula I are selected from Examples 22 to 38, 49 to 50 and 52 to 55.
  • the compounds are selected from Examples 12, and 56 to 61.
  • the compounds are selected from Examples 1 to 3, 5 to 7, 9 to 11, 13 to 15, 18, 20, 39 to 48, and 81.
  • the compounds are selected from Examples 51, and 62 to 74.
  • the compounds are selected from Examples 4, 8, 16 to 17, and 19.
  • the compounds are selected from Examples 75 to 78.
  • the compounds are Examples 79 and 80.
  • the present invention is directed to pharmaceutically acceptable salts of the compounds described above.
  • salts include salts of compounds of the present invention derived from the combination of such compounds with non-toxic acid or base addition salts.
  • Acid addition salts include inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric and phosphoric acid, as well as organic acids such as acetic, citric, propionic, tartaric, glutamic, salicylic, oxalic, methanesulfonic, para-toluenesulfonic, succinic, and benzoic acid, and related inorganic and organic acids.
  • Base addition salts include those derived from inorganic bases such as ammonium and alkali and alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, as well as salts derived from basic organic amines such as aliphatic and aromatic amines, aliphatic diamines, hydroxy alkamines, and the like.
  • bases useful in preparing the salts of this invention thus include ammonium hydroxide, potassium carbonate, sodium bicarbonate, calcium hydroxide, methylamine, diethylamine, ethylenediamine, cyclohexylamine, ethanolamine and the like.
  • salts are included in the invention. They may serve as intermediates in the purification of the compounds, in the preparation of other salts, or in the identification and characterization of the compounds or intermediates.
  • the pharmaceutically acceptable salts of compounds of the present invention can also exist as various solvates, such as with water, methanol, ethanol, dimethylformamide, ethyl acetate and the like. Mixtures of such solvates can also be prepared.
  • the source of such solvate can be from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent. Such solvates are within the scope of the present invention.
  • prodrug is intended to include any compounds which are converted by metabolic processes within the body of a subject to an active agent that has a formula within the scope of the present invention. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.) the compounds of the present invention may be delivered in prodrug form. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Prodrugs, Sloane, K. B., Ed.; Marcel Dekker: New York, 1992, incorporated by reference herein in its entirety
  • compounds of the present invention may exist in various stereoisomeric forms.
  • the compounds of the present invention include both diastereomers and enantiomers.
  • the compounds are normally prepared as racemates and can conveniently be used as such, but individual enantiomers can be isolated or synthesized by conventional techniques if so desired. Such racemates and individual enantiomers and mixtures thereof form part of the present invention.
  • Stereoisomers can be prepared by stereospecific synthesis using enantiomerically pure or enantiomerically enriched starting materials.
  • the specific stereoisomers of either starting materials or products can be resolved and recovered by techniques known in the art, such as resolution of racemic forms, normal, reverse-phase, and chiral chromatography, recrystallization, enzymatic resolution, or fractional recrystallization of addition salts formed by reagents used for that purpose.
  • functional groups present on the compounds of Formula I may contain protecting groups.
  • the amino acid side chain substituents of the compounds of Formula I can be substituted with protecting groups such as benzyloxycarbonyl or t-butoxycarbonyl groups.
  • protecting groups are known per se as chemical functional groups that can be selectively appended to and removed from functionalities, such as hydroxyl groups and carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention.
  • Preferred groups for protecting lactams include silyl groups such as t-butyldimethylsilyl ("TBDMS”), dimethoxybenzhydryl (“DMB”), acyl, benzyl (“Bn”), and methoxybenzyl groups.
  • Preferred groups for protecting hydroxy groups include TBS, acyl, benzyl, benzyloxycarbonyl (“CBZ”), t-butyloxycarbonyl (“Boc”), and methoxymethyl.
  • the compounds of the present invention can be administered by any means that results in the contact of the active agent with the agent's site of action in the body of the subject.
  • the compounds may be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in combination with other therapeutic agents, such as, for example, analgesics.
  • the compounds employed in the methods of the present invention including, for example, the compounds of Formula I, I*, I**, I(a-i), and/or II, may be administered by any means that results in the contact of the active agents with the agents' site or site(s)of action in the body of a patient.
  • the compounds of the present invention are preferably administered in therapeutically effective amounts for the treatment of the diseases and disorders described herein to a subject in need thereof.
  • a therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques.
  • the effective dose will vary depending upon a number of factors, including the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the active agent with appropriate excipients, and the route of administration.
  • the compounds are administered at lower dosage levels, with a gradual increase until the desired effect is achieved.
  • Typical dose ranges are from about 0.01 mg/kg to about 100 mg/kg of body weight per day, with a preferred dose from about 0.01 mg/kg to 10 mg/kg of body weight per day.
  • a preferred daily dose for adult humans includes about 25, 50, 100 and 200 mg, and an equivalent dose in a human child.
  • the compounds may be administered in one or more unit dose forms.
  • the unit dose ranges from about 1 to about 500 mg administered one to four times a day, preferably from about 10 mg to about 300 mg, two times a day.
  • an oral unit dose is one that is necessary to achieve a blood serum level of about 0.05 to 20 ⁇ g/ml in a subject, and preferably about 1 to 20 ⁇ g/ml.
  • the compounds of the present invention may be administered as the pure chemicals, it is preferable to present the active ingredient as a pharmaceutical composition.
  • therapeutic compounds of this invention may be administered to a patient alone or in combination with a pharmaceutically acceptable carrier.
  • the compounds of the invention for example, compounds of Formula I, I*, I**, I(a-i), and/or II, are preferably combined with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice as described, for example, in Remington 's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA, 1980), the disclosures of which are hereby incorporated herein by reference, in their entireties.
  • the carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
  • the relative proportions of active ingredient and carrier may be determined, for example, by the solubility and chemical nature of the compounds, chosen route of administration and standard pharmaceutical practice.
  • the compounds of the present invention may be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients.
  • the ' excipients are selected on the basis of the chosen route of administration and standard pharmaceutical practice, as described, for example, in Remington: The Science and Practice of Pharmacy, 20 th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000.
  • the compositions may be formulated to control and/or delay the release of the active agent(s), as in fast-dissolve, modified-release, or sustained-release formulations.
  • Such controlled-release, or extended-release compositions may utilize, for example biocompatible, biodegradable lactide polymers, lactide/glycolide copolymers, polyoxyethylene-polyoxypropylene copolymers, or other solid or semisolid polymeric matrices known in the art.
  • compositions can be prepared for administration by oral means; parenteral means, including intravenous, intramuscular, and subcutaneous routes; topical or transdermal means; transmucosal means, including rectal, vaginal, sublingual and buccal routes; ophthalmic means; or inhalation means.
  • parenteral means including intravenous, intramuscular, and subcutaneous routes
  • transmucosal means including rectal, vaginal, sublingual and buccal routes
  • ophthalmic means or inhalation means.
  • the compositions are prepared for oral administration, particularly in the form of tablets, capsules or syrups; for parenteral administration, particularly in the form of liquid solutions, suspensions or emulsions; for intranasal administration, particularly in the form of powders, nasal drops, or aerosols; or for topical administration, such as creams, ointments, solutions, suspensions aerosols, powders and the like.
  • the tablets, pills, powders, capsules, troches and the like can contain one or more of the following: diluents or fillers such as starch, or cellulose; binders such as macrocrystalline cellulose, gelatins, or polyvinylpyrrolidones; disintegrants such as starch or cellulose derivatives; lubricants such as talc or magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; or flavoring agents such as peppermint or cherry flavoring.
  • Capsules may contain any of the afore listed excipients, and may additionally contain a semi-solid or liquid carrier, such as a polyethylene glycol.
  • the solid oral dosage forms may have coatings of sugar, shellac, or enteric agents.
  • Liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups, elixirs, etc., or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as surfactants, suspending agents, emulsifying agents, diluents, sweetening and flavoring agents, dyes and preservatives.
  • compositions may also be administered parenterally.
  • the pharmaceutical forms acceptable for injectable use include, for example, sterile aqueous solutions, or suspensions.
  • Aqueous carriers include mixtures of alcohols and water, buffered media, and the like.
  • Nonaqueous solvents include alcohols and glycols, such as ethanol, and polyethylene glycols; oils, such as vegetable oils; fatty acids and fatty acid esters, and the like.
  • compositions can be added including surfactants; such as hydroxypropylcellulose; isotonic agents, such as sodium chloride; fluid and nutrient replenishers; electrolyte replenishers; agents which control the release of the active compounds, such as aluminum monostearate, and various co-polymers; antibacterial agents, such as chlorobutanol, or phenol; buffers, and the like.
  • surfactants such as hydroxypropylcellulose; isotonic agents, such as sodium chloride; fluid and nutrient replenishers; electrolyte replenishers; agents which control the release of the active compounds, such as aluminum monostearate, and various co-polymers; antibacterial agents, such as chlorobutanol, or phenol; buffers, and the like.
  • the parenteral preparations can be enclosed in ampules, disposable syringes or multiple dose vials.
  • Other potentially useful parenteral delivery systems for the active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps
  • formulations for inhalation which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.
  • Formulations for topical use are in the form of an ointment, cream, or gel. Typically these forms include a carrier, such as petrolatum, lanolin, stearyl alcohol, polyethylene glycols, or their combinations, and either an emulsifying agent, such as sodium lauryl sulfate, or a gelling agent, such as tragacanth.
  • Formulations suitable for transdermal administration can be presented as discrete patches, as in a reservoir or microreservoir system, adhesive diffusion-controlled system or a matrix dispersion-type system.
  • Formulations for buccal administration include, for example lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate.
  • Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate.
  • kits useful in, for example, the treatment of pain which comprise a therapeutically effective amount of a compound of the invention and/or other therapeutic compounds described herein, in one or more sterile containers, are also within the ambit of the present invention. Sterilization of the container may be carried out using conventional sterilization methodology well known to those skilled in the art.
  • the sterile containers of materials may comprise separate containers, or one or more multi-part containers, as exemplified by the UNIVIALTM two-part container (available from Abbott Labs, Chicago, Illinois), as desired.
  • the compound of the invention and/or other therapeutic compound as described herein may be separate, or combined into a single dosage form as described above.
  • kits may further include, if desired, one or more of various conventional pharmaceutical kit components, such as for example, one or more pharmaceutically acceptable carriers, additional vials for mixing the components, etc., as will be readily apparent to those skilled in the art.
  • kit components such as for example, one or more pharmaceutically acceptable carriers, additional vials for mixing the components, etc., as will be readily apparent to those skilled in the art.
  • Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit.
  • the compounds of the present invention may be used in methods to bind histamine receptors, more preferably histamine H 3 receptors. Such binding may be accomplished by contacting the receptor with an effective amount of a compound of Formula I, I*, I**, I(a-i), and/or II.
  • the histamine receptors may be located in the central nervous system or located peripherally to the central nervous system or in both locations.
  • the contacting step conducted in an aqueous medium, preferably at physiologically relevant ionic strength, pH, and the like.
  • the invention is directed to methods of binding histamine receptors, more preferably histamine H 3 receptors, comprising the step of administering to a patient in need thereof, an effective amount of a compound of the invention including, for example, a compound of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof.
  • the methods comprise the step of administering to said patient an therapeutically effective amount of a compound of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof.
  • the histamine receptors are H 3 histamine receptors.
  • the compound selectively binds H 3 histamine receptors relative to Hi, H 2 and/or FL» receptors.
  • the H 3 histamine receptors are located in the central nervous system.
  • the compound of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof exhibits activity toward the histamine receptors.
  • the binding agonizes the activity of the cannabinoid receptors.
  • the binding antagonizes the activity of the cannabinoid receptors, more preferably as a neutral antagonist.
  • the binding inversely agonizes the activity of the cannabinoid receptors.
  • the compounds of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof exhibit activity toward the histamine receptors in vivo.
  • the compounds of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof exhibit activity toward the histamine receptors in vitro.
  • a disease, disorder or condition that may be affected, modulated or controlled through the binding of histamine, preferably H3 histamine receptors. More preferably these diseases, disorders, and/or conditions selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction.
  • the methods herein provided comprise administering to a subject in need of such treatment a therapeutically effective amount of a compound of the invention, preferably a compound of formula:
  • the disorder is narcolepsy or sleep/wake disorders.
  • the disorder treated is attention deficit hyperactivity disorder.
  • the compounds of the present invention may be prepared in a number of methods well known to those skilled in the art, including, but not limited to those described below, or through modifications of these methods by applying standard techniques known to those skilled in the art of organic synthesis. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale.
  • NH (N2) pyridazinones were alkylated with alkyl or substituted alkyl groups using an R 12 -halide, a base, for example K2CO 3 , CS 2 CO 3 or NaH, in an inert solvent such as DMF or CH 3 CN.
  • R 13 or R 14 substituted 4,5-dihydropyridazinone formed a mixture of isomers
  • the isomers were separated by standard methods known in the art.
  • Intermediates wherein R 12 is H may be converted to analogs wherein R 12 is aryl or heteroaryl by standard palladium or copper coupling reactions using the appropriate aryl or heteroaryl halide.
  • the 4,5-dihydropyridazinone may be oxidized to an aromatic pyridazinone using MnC ⁇ , CuCl 2 , DDQ, selenium oxide, DMSO / base or sodium 3-nitrobenzenesulfonate in the presence of sodium hydroxide.
  • Scheme 1 General synthesis of N2 H and substituted examples
  • examples of compounds disclosed herein may be obtained by condensation of an intermediate keto acid for example, 4-(4-methoxyphenyl)-4-oxobutyric acid (or an ester derivative) with hydrazine or an n-substituted hydrazine derivative in a solvent such as ethanol or 2-propanol to produce a dihydropyridazinone intermediate.
  • keto-acid intermediates not commercially available are readily prepared and described using literature methods. Keto-acid intermediates with R 13 or R 14 groups in the 4 or 5-positons or fused aryl or heteroaryl groups are described (Heterocycles, 2002, 57, 39; Indian J.
  • N2 position may be substituted with alkyl or substituted alkyl groups using a base, for example K 2 CO 3 , CS 2 CO 3 or NaH in an inert solvent such as DMF or CH 3 CN.
  • a base for example K 2 CO 3 , CS 2 CO 3 or NaH in an inert solvent such as DMF or CH 3 CN.
  • R 13 or R 14 substituted dihydropyridazinone form isomers the individual isomers may be separated using conventional methods known to the art.
  • R 13 aryl or heteroaryl groups may be introduced by standard palladium or copper coupling reactions using the appropriate aryl or heteroaryl halide.
  • the 4,5 -position may be oxidized to the pyridizinone intermediate using for example MnC> 2 , CuCl 2 , DDQ or selenium oxide as the oxidizing agent.
  • the N2 nitrogen may be H, or further substituted using methods outlined previously.
  • the pyridizinone or dihydro pyridizinone methoxy intermediate is demethylated using BBr 3 in dichloromethane to produce the phenol.
  • Alkylation of the phenol with bromochloropropane or a dibromoalkane intermediate in a suitable solvent such as DMF, acetone, butanone or CH 3 CN with K 2 CO 3 produces the halogen intermediate.
  • Alkylation of the halide intermediate with an amine gives the target dihydropyridazinone examples of the invention.
  • Other suitable leaving groups may be used such as mesylates as precursors to amines.
  • Scheme 6 discloses an Aidol condensation route to examples wherein R 12 is H.
  • 4-Hydroxy-acetophenone or a derivative thereof was condensed with a keto-acid, for example glycolic acid in acetic acid, and cyclized with hydrazine to give an aromatic pyridazinone (J. Med. Chem., 1989, 32, 528).
  • Bridged examples (Scheme 1 l)were prepared using methoxy tetralones and glycolic acid in an aldol synthesis. Phenol formation and alkylations as described previously produced the N-substituted examples. Alternatively, the use of ⁇ -tetralones provided a route to pyridazinone regioisomers.
  • Scheme 12 shows bridged analogs where R 12 is H , prepared by varying the order of the reactions. Addition of Zn dust to the aldol/ring closure procedure gave a one-pot synthesis of the dihydropyridazinone. Scheme 12.
  • Method A In a IL round bottom flask, 6-(4-methoxyphenyl)-2-methyl-4,5- dihyrdo-2H-pyridazin-3-one (27 g, 124 mmol) and MnO 2 (30 g, 345 mmol) in xylene (250 mL) was stirred at vigorous reflux 14 h. The reaction was cqoled to rt and filtered through a pad of celite. The xylene was concentrated and the resulting yellow solid was triturated with ether/hexane (1:2) and collected to produce 20 g (75%, HPLC 98% purity) of product.
  • Method B A mixture of 6-(4-methoxy ⁇ heny l)-2-methy 1-4,5 -dihyrdo-2H-pyridazin- 3-one (3.27g, 15 mmol) and Cu(II)Cl 2 (3.96g, 2 eq., anhydrous, Acros) in 45ml of anhydrous acetonitrile was refiuxed for 2 hr.
  • the reaction was cooled to rt and poured into ice-water (-100 ml) and the acetonitrile removed at reduced pressure. The resulting off- white solid was filtered off, washed with water, and then crystallized from EtOH:Et 2 O to give the product (2.47 g, 76%).
  • the product was purified by ISCO chromatography (8Og silica gel column, 95:5 DCM: MeOH). The fractions were combined and concentrated to yield 850 mg (48%) of free base.
  • the HCl was prepared by adding a IN HCl-ether solution to the based in ether. The product was collected, and recrystallized from CH 3 CN-ether. mp 183-185 0 C.
  • Example 21 was recrystallized from Et 2 ⁇ -hexanes to give 210 mg of Example 21 as a white solid; Mp 106-107 0 C.
  • the HCl salt was prepared by dissolving the base in MeOH and adding IN Et 2 O-HCl: Mp 175-177 0 C (MeOH-Et 2 O); MS m/z 314 (M + H).
  • step 4 The resulting solid was collected, washed with water (3 x 15 mL), and Et 2 O (2 x 15 mL) to give the product of step 3 (868 mg, 92%): Mp 256-257 0 C; MS m/z 287 (M + H). Step 4.
  • step 3 A solution of the product of step 3 (858 mg, 3 mmol), K 2 CO 3 (1.24 g, 3.0 eq.), and 3-bromo-l-chloropropane (0.3 mL, 1.05 eq.) in acetone:DMF (25 mL:3 mL) was heated to 80 0 C overnight. The mixture was then filtered, washed with acetone, and concentrated to dryness to afford the product of step 4 (1.17 mg, 98% yield): Mp 92-4 0 C; MS m/z 363 (M + H).
  • Step 1 A solution of 2-methoxy-4-oxo-4-(4'-methoxyphenyl) butyric acid (2.22 g, 10 mmol) and hydrazine hydrate (1.5 eq., 688 ⁇ L) in 20 mL of EtOH was stirred at 80 0 C overnight. The solvent was removed and the solid was collected and washed with cold EtOH to give 6-(4-methoxy-phenyl)-4-methyl-4.5-dihydro-2H-pyridazin-3-one (2.05 g , 94%): Mp 203-6 0 C.
  • Step 2 A mixture of the product from step 1 (6-(4-methoxy-phenyl)-4-methyl-4,5- dihydro-2H-pyridazin-3-one; 1.96 g, 9 mmol) and Cu(II)Cl 2 (2.48 g, 2 eq.) in of acetonitrile (15 mL) was heated to 70 0 C for 2 h.
  • step 3 6-(4-Methoxy-p h e ny l)-2,4-d imethyl-2 H-pyridazin-3-one Step 3.
  • the product of step 2 (6-(4-methoxy-phenyl)-2,4-dimethyl-2H-pyridazin-3- one) was prepared as described for example 22 step 2 using 6-(4-methoxy-phenyl)-4- methyl-4,5-dihydro-2H-pyridazin-3-one, MeI and Cs 2 CC>3.
  • 6-(4-(3-Chloropropoxy)-phenyl)-2,4-dimethyl-2H- pyridazin-3-one was prepared from the product of step 3 and 3-bromo-l-chloropropane using the procedure described for Example 22 step 4.
  • Example 39 (2,4-dimethyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H- pyridazin-3-one) was prepared using 6-(4-(3-chloropropoxy)-phenyl)-2,4-dimethyl-2H- pyridazin-3-one and piperidine by the methods described for example 22 step 5.
  • the hydrochloride salt was prepared; Mp 222-3 0 C; MS m/z 342 (M + H).
  • 6-(4-methoxy-phenyl)-4,5-dihydro-2H-pyridazin-3-one (1.65 g, 7.5 mmol) in 15 mL OfEtOH was heated to 80 0 C as 20 mL of 4 % of KOH /EtOH solution was added dropwise. After 5 min., benzaldehyde (1.0 eq. 0.76 mL) was added and the mixture stirred at 80 0 C for 2 h.
  • Step 1 A suspension of NaH (12.8 mmol, 512 mg) in DMSO (23 mL) was added 4'-methoxy-2-phenylacetophenone (12.8 mmol, 2.89 g) in 10 ml toluene dropwise under argon. After 30 minutes of stirring, ethyl bromoacetate (1.4 mL, 1 eq.) in 10 mL of toluene was added and the mixture was stirred at rt overnight. The reaction was quenched by addition of 2N HCl (4 mL), and then 60 mL of water.
  • Step 3 A solution of 4-(4-methoxy-phenyl)-4-oxo-3-phenyl-butyric acid (1.5 g, 5.28 mmol) and hydrazine hydrate (1.5 eq., 363 ⁇ L) in 20 mL of EtOH was stirred at 80 0 C overnight. The solvent was reduced and the solid was filtered and then washed with cold EtOH to give 6-(4-methoxy-phenyl)-5-phenyl-4,5-dihydro-2H-pyridazin-3-one (1.46 g , 99%): mp 176-7 0 C; MS m/z 281 (M + H).
  • Examples 47 and 48 were prepared from 6-(4-methoxy-phenyl)-5-phenyl-4,5- dihydro-2H-pyridazin-3-one as described in Example 39.
  • HCl salts were prepared from 6-(4-hydroxy-phenyl)-2- methyl-2H-pyridazin-3-one using the procedures for examples 62-64.
  • Example 65 is the base.
  • Example 73 To a solution of example 73 (0.25 g, 0.9 mmol) and cyclobutanone in MeOH (10 mL) was added HOAc (0.5 mL) then solid sodium cyanoborohydride (560 mg, 62.8 mmol). The reaction was stirred 4 h then concentrated. Na 2 CO 3 solution was added, and extracted with EtOAc (2 x 50 mL), dried over MgSO 4 , filtered and concentrated. To the residue in CH 3 CN (3 mL) was added a IN HClZEt 2 O solution and concentrated. Example 74 was recrystallized from CH 3 CN-Et 2 O to give 180 mg of a white solid. Mp 250-252 0 C. MS m/z 340 (M + H).
  • Step 2-3 7-(3-Chloro-propoxy)-2-methyl-2H-phthalazin-l-one was prepared from 7-methyl-2-methyl-2H-phthalazin-l-one using the procedure described in Example 22 Step 3, and Step 4.
  • This compound was prepared using the same method as example 74 using example 73 and cyclopentanone in MeOH (10 mL) / HOAc (0.5 mL) followed by solid sodium cyanoborohydride. The reaction was stirred 4 h then concentrated. Na 2 COs solution was added, and extracted with EtOAc (2 x 50 mL), dried over MgSO 4 , filtered and concentrated. Example 83 was recrystallized from CH 3 CN-Et 2 O to give a white solid. Mp 129-132 0 C. MS m/z 354 (M + H).
  • step 3 A mixture of the product of step 3 (481mg, 1.65 mraol), K 2 CO 3 (3.5 eq, 795 mg), 50 mg of NaI, and R-2-methylpyrrolidine hydrochloride (2.0 eq., 773 mg) in acetonitrile (10 mL) was heated to 80 0 C for 2 days. The reaction was then filtered, washed with CH 2 Cl 2 (2 x 2OmL) and concentrated. The residue was dissolved in 30 mL OfCH 2 Cl 2 and washed with saturated NaHCO 3 , saturated NaCl solution, dried with Na 2 SO 4 and then concentrated.
  • 5-(4-Hydroxyphenyl)-2-methyl-2H-py ⁇ idazin-3-one was prepared from 5-(4- methoxy-phenyl)-2-methyl-2H-pyridazin-3-one with BBr 3 using the procedure described in Example 86 Step 2; Mp 296-8 0 C; MS m/z 203 (M + H).
  • This compound was prepared as the hydrochloride salt from 5-[4-(3-chloropropoxy)- phenyl]-2-methyl-2H-pyridazin-3-one and R-2-methylpyrrolidine using the procedure described in Example 86 Step 4; Mp 222-3 0 C; MS m/z 328 (M + H).
  • This compound was prepared as the hydrochloride salt using 5-[4-(3- chloropropoxy)-phenyl]-2-methyl-2H-pyridazin-3-one and piperidine using the procedure described in Example 91 Step 5; Mp 253-4 0 C; MS m/z 328 (M + H).
  • This compound was prepared using the procedure for example 94 to give the HCl salt; Mp 230-2 0 C; MS m/z 405 (M + H).
  • Example 98 was prepared from the product of step 3 using procedures described in
  • Example 99 was prepared as the hydrochloride salt using procedures described for Example 98; Mp 98-100 0 C; MS m/z 405 (M + H).
  • Example 100 was prepared as the hydrochloride salt using procedures described for Example 98; Mp 155-7 0 C; MS m/z 405 (M + H).
  • Example 101 was prepared as the hydrochloride salt using procedures described for Example 98; Mp 106 0 C (dec); MS m/z 419(M + H).
  • 5-(4-Methoxy-phenyl)-6-methyl-2H-py ridazin-3-one 5-(4-methoxyphenyl)-6-methyl-2H-pyridazin-3-one was prepared from l-(4- methoxy-phenyl)propan-2-one and glyoxalic acid and hydrazine hydrate using the procedure described in Example 86 Step 1; Mp 255-256 0 C; MS m/z 203 (M + H).
  • 5-(4-Methoxy-phenyl)-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one was prepared from 5-(4-methoxy-phenyl)-6-methyl-2H-pyridazin-3-one and 2-bromopyridine in the presence of copper iodide using the procedure described in Example 98 Step 2; Mp 156-7 0 C; MS m/z 294 (M + H).
  • 5-(4-Hydroxy-phenyl)-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one was prepared from 5-(4-Methoxy-phenyl)-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one and BBr 3 in CH 2 Cl 2 using the procedure described in Example 91 Step 3; Mp 252-4 0 C; MS m/z 280 (M + H).
  • This compound was prepared as the HCl salt using the procedure for example 103; Mp 296-8 0 C; MS m/z 326 (M + H).
  • This compound was prepared as the HCl salt using the procedure for example 104;
  • This compound was prepared as the HCl salt using the procedure for example 98; Mp 212-3 0 C; MS m/z 410 (M + H).
  • Example 109 was prepared using the same procedure as Example 94 except using S- 2-methylpyrrolidine HCl; Mp 218-220 0 C; MS m/z 391 (M + H).
  • Example 110 was prepared from the product of step 1 using procedures described in Example 102 and Example 103; Mp 178-9 0 C; MS m/z 342 (M + H).
  • 4-(4-Ethoxycarbonylphenoxy)piperidine-l-carboxylic acid tert-butyl ester was prepared from 4-hydroxy benzoic acid ethyl ester and 4-hydroxypiperidine-l-carboxylic acid tert-butyl ester using the procedure described in Example 103 step 1; Mp 76-78 0 C; MS m/z 350 (M + H).

Abstract

The present invention provides compounds of formula (I*): their use as H3 inhibitors, processes for their preparation, and pharmaceutical compositions thereof.

Description

PYRIDIZINONE DERIVATIVES
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Application Serial No. 60/833,164 filed July 25, 2006, the disclosure of which is incorporated herein by reference in its entirety.
FIELD OF THE INVENTION
The present invention is related to pyridizinone derivatives, their use as H3 inhibitors, processes for their preparation, and pharmaceutical compositions thereof.
BACKGROUND OF THE INVENTION
Histamine is a well established modulator of neuronal activity. At least four subtypes of histamine receptors have been reported in the literature — Hi, H2, H3, H4. The histamine H3 receptors play a key role in neurotransmission in the central nervous system. The H3 receptor was discovered in 1983 originally on histamine-containing neurons where it was shown to function presynaptically, regulating the release and synthesis of the biogenic amine histamine (Arrang et al, 1983) now a well established neurotransmitter. H3 receptors are predominately expressed in the brain, localizing to the cerebral cortex, amygdala, hippocampus, striatum, thalamus and hypothalamus. H3 receptors are also localized presynaptically on histaminergic nerve terminals and act as inhibitory autoreceptors (Alguacil and Perez-Garcia, 2003; Passani et al, 2004; Leurs at al, 2005; Celanire et al, 2005; Witkin and Nelson, 2004). When these receptors are activated by histamine, histamine release is inhibited. H3 receptors can also be found in the periphery (skin, lung, cardiovascular system, intestine, GI tract, etc). H3 receptors are also involved in presynaptic regulation of the release of acetylcholine, dopamine, GABA, glutamate and serotonin (see Repka-Ramirez, 2003; Chazot and Hann, 2001 ; Leurs et al, 1998). The H3 receptor demonstrates a high degree of constitutive or spontaneous activity (e.g., receptor is active in the absence of agonist stimulation) in vitro and in vivo, thus, ligands to the receptor can display, agonist, neutral antagonist or inverse agonist effects.
The location and function of histaminergic neurons in the CNS suggests that compounds interacting with the H3 receptor may have utility in a number of therapeutic applications including narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders and epilepsy (Leurs et al, 2005; Witkin and Nelson, 2004, Hancock and Fox 2004; Esbenshade et al. 2006). An H3 antagonist/inverse agonist could be important for gastrointestinal disorders, respiratory disorders such as asthma, inflammation, and myocardial infarction.
Ohtake et al. (US 2006/0178375 Al) disclosed compounds that reportedly exhibit histamine receptor H3 antagonist or inverse agonist activity and may be useful for the treatment or prevention of obesity, diabetes, hormonal secretion abnormality, or sleep disorders.
Celanire et al.(WO 2006/103057 Al and WO 2006/103045) have disclosed compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, their pharmaceutical compositions and their uses as H3 ligands. Bertrand et al. (WO 2006/117609 A2) disclosed novel histamine H3 receptor ligands, processes for their preparation, and their therapeutic applications.
Schwartz et al. (WO 2006/103546 A2) disclosed certain methods of treatment for Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, and/or vascular dementia using non-imidazole alkylamine derivatives that are antagonists of the H3 receptors of histamine.
Apodaca et al. (EP 1 311 482 Bl) disclosed certain non-imidazole aryloxypiperidines as H3 receptor ligands, their synthesis, and their use for the treatment of disorders and conditions mediated by the histamine receptor.
Xu et al. disclosed certain 6-substituted phenyl-4,5-dihydro-3(2H)-pyridazinones, their synthesis, and rabbit platelet aggregation inhibitory activity induced by ADP in vitro.
Thus, there is a need for novel classes of compounds that possess the beneficial properties. It has been discovered that currently disclosed class of compounds, referred to herein as substituted pyridizinone derivatives, are useful as agents for treating or preventing various diseases or disorders disclosed herein.
SUMMARY OF THE INVENTION
Accordingly, the- present invention is directed, in part, to novel pyridizinone compounds which may be useful as H3 inhibitors, and thus may be useful, inter alia, in methods for treating diseases, disorders, and/or conditions that may be mediated or modulated by inhibition of H3, or otherwise associated with the H3 receptor system, including, for example, narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders (such as asthma), inflammation, and myocardial infarction. In preferred form, the novel compounds of the invention have the following formula I*:
Figure imgf000004_0001
I* or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt forms thereof, wherein: X and Xa are each independently CH or N; Y is S(O)q, O, or NR15; R1 is NR10R1 ' or a 4- to 9-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R20 groups; R2 is
Figure imgf000004_0002
(iv) (V)
Figure imgf000005_0001
(vi) (vii)
(viii)
Figure imgf000005_0002
(ix) wherein: when X and Xa are both CH, then R2 is meta or para to the Y-(CHR4)m-R' group; and when either X or Xa are N, then R2 is para to the Y-(CHR4)m-RI group; each R is: independently H, F, Cl, Br3 1, OR21, NR23R24, NO2, CN5 CF3, Ci-C6alkyl, C(O)R21, CO2R21, or C(=O)NR23R24; or when R3 is ortho to R2, and R2 is (i), (ii), (iv), (vi), or (ix), then R3 and R14 taken together may form -(CH2)S-, -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; wherein Z is O, S(O)y, orNR27; or when R3 is ortho to R2, and R2 is (iv), (v), or (viii), then R3 and R13 taken together may form -(CH2)S-, -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; or when R3 is ortho to R2, and R2 is (viii), then R3 and R13b taken together may form -(CH2)S-, -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; or when R3 is ortho to Xa and R2 is ortho to R3 and meta to Xa, then R2 and R3 taken together may form:
Figure imgf000006_0001
each R4 is independently H, Cj-Cβalkyl, or OR21, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups;
R10 and R11 are each independently H, d-Cgalkyl, or C3-C6cycloalkyl, wherein the alkyl or cycloalkyl group is optionally substituted with 1 to 3 R20 groups;
R12 is H5 Ci-Cβalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, CC=O)R27, or CO2R27, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl group is optionally substituted with 1 to 3 R20 groups; R13 and R14 are each independently H, Ci-Cgalkyl, aryl, arylalkyl Ci-C6alkoxyl, S(=O)y-C] -Cgalkyl, cycloalkyl, heterocycloalkyl, or heteroaryl;
R13a, R13b, RI3c 5 and R14a are each independently H, Ci-C6alkyl; or R13 and R14, taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or C3-Cgcycloalkyl ring; or R13b and R14, or R13 and I4a, or RI3b and 14a, or R13c and R14a, taken together with the carbon atoms through which they are connected form a fused Ca-Cβcycloalkyl ring; or R13 and R13a, or R14 and R14a, taken together with the carbon atom to which they are attached form a C3-Cgcycloalkyl ring; provided that no more than one pair of R13 and R14, R13b and R14, R13 and RI4a, RI3b and Rl4a, R13c and R14\ R13 and RI3a, and R14 and R14a are taken together with the carbon atoms through which they are connected or to which they are attached to form a ring; and wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or cycloalkyl ring is optionally substituted with 1 to 3 R20 groups; R15 is H, Ci-C6 alkyl, C(=O)R25, CO2R25;
R20 at each occurrence is independently, H, F5 Cl, Br, I, OR21, OR22, NR23R24, NHOH5 NO2, CN5 CF3, Ci-C6 alkyl optionally substituted with OR26, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7CycloalkylCo-C4alkyl, 3- to 7-membered heterocycloalkylCo-C4alkyI, phenyl, 5- or 6-membered heteroarylC0-C4alkyl, arylalkyl, (=0), CC=O)R21, CO2R21, OC(=O)R21 5 C(=O)NR23R24, NR27C(=O)R21 5 NR27CC=O)OR2 !, OCC=O)NR23R24, NR27C(=S)R21, or SCO)qR21; each R21 is independently H5 Ci-C6alkyl, aryl, or arylalkyl; each R22 is independently the residue of an amino' acid after the hydroxyl group of the carboxyl group is removed; each R23 and R24 is independently selected from H, Ci-Cβalkyl, and aryl, or R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with =O;
R25 is Ci-Cealkyl. aryl, or alkylaryl;
R26 is H5 Ci-Cealkyl, aryl, or alkylaryl;
R^ is H or CrCealkyl; m is 1, 2, 3, 4, or 5 when R1 is attached via a nitrogen atom, and m is 0, 1, 2, 3, 4, or 5 when R1 is attached via a carbon atom; n is 1, 2, or 3; q is O, 1, or 2; s is 1, 2, or 3; and y is 0, 1, or 2. In another aspect, the present invention is directed to pharmaceutical compositions which comprise a pharmaceutically acceptable carrier and a compound of the present invention, preferably in a therapeutically effective amount.
In other aspects, the present invention is directed to methods for treating a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of the present invention.
These and other aspects of the invention will become more apparent from the following detailed description.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
The invention is generally directed to pyridizinone derivatives, processes for their preparation, and pharmaceuticals compositions their and methods of their pharmaceutical use.
As employed above and throughout the disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings. As used herein, the term "about" refers to a range of values from ± 10% of a specified value. For example, the phrase "about 50" includes ± 10% of 50, or from 45 to 55. The phrase "from about 10 to 100" includes ± 10% of 10 and ± 10% of 100, or from 9 to 110. As used herein, a range of values in the form "x-y" or "x to y", or "x through y", include integers x, y, and the integers therebetween. For example, the phrases "1-6", or "1 to 6" or "1 through 6" are intended to include the integers 1, 2, 3, 4, 5, and 6. Preferred embodiments include each individual integer in the range, as well as any subcombination of integers. For example, preferred integers for "1-6" can include 1, 2, 3, 4, 5, 6, 1 to 2, 1 to 3, 1 to 4, 1 to 5, 2 to3, 2 to 4, 2 to 5, 2 to 6, etc.
As used herein "stable compound" or "stable structure" refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent. The present invention is directed only to stable compounds. As used herein, "substituted" refers to any one or more hydrogen atoms on the indicated atom is replaced with a selected group referred to herein as a "substituent", provided that the substituted atom's valency is not exceeded, and that the substitution results in a stable compound. A substituted group has 1 to 5, preferably 1 to 3, and more preferably 1 independently selected substituents. Preferred substituents include, but are not limited to F, Cl, Br, I3 OH, OR, NH2, NHR, NR2, NHOH, NO2, CN, CF3, CF2CF3, C1-C6 alkyl, C2-C6 alkenyl, C2-Cg alkynyl, C1-CO alkoxy, C3-C7 cycloalkyl, heterocyclyl, Cβ-Cio aryl, heteroaryl, arylalkyl, =O, C(=O)R, COOH, CO2R, O-C(=O)R, C(=O)NRR', NRC(=0)R", NRCO2R', OC(=O)NRR', -NRC(=O)NRR?, -NRC(=S)NRR', and -SO2NRR1, wherein R and R' are each independently hydrogen, Ci-Cβ alkyl, or Ce-C 10 aryl. As used herein, the term "alkyl" refers to a straight-chain, or branched alkyl group having 1 to 8 carbon atoms, preferably from 1 to 6, with 1 to 3 more preferred. Exemplary alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, neopentyl, 1-ethylpropyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3- dimethylbutyl, hexyl, octyl, etc. The alkyl moiety of alkyl-containing groups, such as alkoxy, alkoxycarbonyl, and alkylaminocarbonyl groups, has the same meaning as alkyl defined above. Lower alkyl groups, which are preferred, are alkyl groups as defined above which contain 1 to 4 carbons. A designation such as "C1-C4 alkyl" refers to an alkyl radical containing from 1 to 4 carbon atoms. Alkyl groups may be optionally substituted. As used herein, the term "alkenyl" refers to a straight chain, or branched hydrocarbon chains of 2 to 8 carbon atoms having at least one carbon-carbon double bond. A designation "C2-C8 alkenyl" refers to an alkenyl radical containing from 2 to 8 carbon atoms. Examples of alkenyl groups include ethenyl, propenyl, isopropenyl, 2,4-pentadienyl, etc. Alkenyl groups may be optionally substituted.
As used herein, the term "alkynyl" refers to a straight chain, or branched hydrocarbon chains of 2 to 8 carbon atoms having at least one carbon-carbon triple bond. A designation "C2-C8 alkynyl" refers to an alkynyl radical containing from 2 to 8 carbon atoms. Examples include ethynyl, propynyl, isopropynyl, 3,5-hexadiynyl, etc. Alkynyl groups may be optionally substituted.
As used herein, the term "cycloalkyl" refers to a saturated or partially saturated mono- or bicyclic alkyl ring system containing 3 to 10 carbon atoms. Certain embodiments contain 3 to 6 carbon atoms, preferably 3 or 4 carbon atoms, and other embodiments contain 5 or 6 carbon atoms. A designation such as "C5-C7 cycloalkyl" refers to a cycloalkyl radical containing from 5 to 7 ring carbon atoms. Examples of cycloalkyl groups include such groups as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, pinenyl, pinanyl, and adamantanyl. Cycloalkyl groups may be optionally substituted.
As used herein, the term "aryl" refers to a substituted or unsubstituted, mono- or bicyclic hydrocarbon aromatic ring system having 6 to 12 ring carbon atoms. Examples include phenyl and naphthyl. Preferred aryl groups include unsubstituted or substituted phenyl and naphthyl groups. Included within the definition of "aryl" are fused ring systems, including, for example, ring systems in which an aromatic ring is fused to a cycloalkyl ring. Examples of such fused ring systems include, for example, indane, indene, and tetrahydronaphthalene. Aryl groups may be optionally substituted. As used herein, the terms "heterocycle", "heterocyclic" or "heterocyclyl" refer to a substituted or unsubstituted carbocyclic group in which one or more ring carbon atoms are replaced by at least one hetero atom such as -O-, -N-, or -S-. Certain embodiments include 4 to 9 membered rings preferably 3 to 7 membered rings, and other embodiments include 5 or 6 membered rings. The nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen may be optionally substituted in non-aromatic rings. Heterocycles are intended to include heteroaryl and heterocycloalkyl groups. Heterocyclic groups may be optionally substituted.
As used herein, the term "heteroaryl" refers to an aromatic group containing 5 to 10 ring carbon atoms in which one or more ring carbon atoms are replaced by at least one hetero atom such as -O-, -N-, or -S-. Certain embodiments include 5 or 6 membered rings. Examples of heteroaryl groups include pyrrolyl, furanyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, isothiazolyl, isoxazolyl, oxazolyl, oxathiolyl, oxadiazolyl, triazolyl, oxatriazolyl, furazanyl, tetrazolyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, picolinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, isobenzofuranyl, purinyl, quinazolinyl, quinolyl, isoquinolyl, benzoimidazolyl, benzothiazolyl, benzothiophenyl, thianaphthenyl, benzoxazolyl, benzisoxazolyl, cinnolinyl, phthalazinyl, naphthyridinyl, and quinoxalinyl. Included within the definition of "heteroaryl" are fused ring systems, including, for example, ring systems in which an aromatic ring is fused to a heterocycloalkyl ring. Examples of such fused ring systems include, for example, phthalamide, phthalic anhydride, indoline, isoindoline, tetrahydroisoquinoline, chroman, isochroman, chromene, and isochromene. Heteroaryl groups may be optionally substituted. In certain preferred embodiments, heteroaryl is pyridinyl, more preferably pyridine-2-yl, or thienyl
As used herein, the term "heterocycloalkyl" refers to a cycloalkyl group in which one or more ring carbon atoms are replaced by at least one hetero atom such as -O-, -N-, or - S-. Certain embodiments include 4 to 9 membered rings, preferably 3 to 7, more preferably 3 to 6 membered rings, and other embodiments include 5 or 6 membered rings. Examples of heterocycloalkyl groups include pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pirazolidinyl, pirazolinyl, pyrazalinyl, piperidinyl, piperazinyl, hexahydropyrimidinyl, morpholinyl- thiomorpholinyl, tetrahydrofuranyl, dithiolyl, oxathiolyl, dioxazolyl, oxathiazolyl, pyranyl, oxazinyl, oxathiazinyl, and oxadiazinyl, preferably pyrrolidinyl, morpholinyl, piperidinyl, orazapanyl, more preferably pyrrolidinyl or piperidinyl. Heterocycloalkyl groups may be optionally substituted.
As used herein, the term "arylalkyl" refers to an alkyl group that is substituted with an aryl group. Examples of arylalkyl groups include, but are not limited to, benzyl, bromobenzyl, phenethyl, benzhydryl, diphenylmethyl, triphenylmethyl, diphenylethyl, naphthylmethyl, etc. preferably benzyl. Arylalkyl groups may be optionally substituted. As used herein, the term "amino acid" refers to a group containing both an amino group and a carboxyl group. Embodiments of amino acids include α-amino, β-amino, γ- amino acids. The α-amino acids have a general formula HOOC-CH(side chain)-NH2. The amino acids can be in their D, L or racemic configurations. Amino acids include naturally- occurring and non-naturally occurring moieties. The naturally-occurring amino acids include the standard 20 α-amino acids found in proteins, such as glycine, serine, tyrosine, proline, histidine, glutamine, etc. Naturally-occurring aniino acids can also include non-α- amino acids (such as β-alanine, γ-aminobutyric acid, homocysteine, etc.), rare amino acids (such as 4-hydroxyproline, 5 -hydroxy Iy sine, 3-methylhistidine, etc.) and non-protein amino acids (such as citrulline, ornithine, canavanine, etc.). Non-naturally occurring amino acids are well-known in the art, and include analogs of natural amino acids. See Lehninger, A. L. Biochemistry, 2nd ed.; Worth Publishers: New York, 1975; 71-77, the disclosure of which is incorporated herein by reference. Non-naturally occurring amino acids also include α- amino acids wherein the side chains are replaced with synthetic derivatives. In certain embodiments, substituent groups for the compounds of the present invention include the residue of an amino acid after removal of the hydroxyl moiety of the carboxyl group thereof; i.e., groups of formula -C(=O)CH(side chain)-NH2. Representative side chains of naturally occurring and non-naturally occurring α-amino acids include are shown below in Table A.
Table.A
H HS-CH2- CH3- HO2C-CH(NH2)-CH2-S-S-CH2-
HO-CH2- CH3-CH2-
C6H5-CH2- CH3-S-CH2-CH2-
HO-C6H4-CH2- CH3-CH2-S-CH2-CH2-
HO-CH2-CH2-
Figure imgf000012_0001
CH3-CH(OH)- -CH2-
Figure imgf000012_0002
H2N-CC=NH)-NH-CH2-CH2-CH2-
H2N-CC=O)-NH-CH2-CH2-CH2-
Figure imgf000012_0003
CH3-CH2-CHCCH3)-
CH3-CH2-CH2-CH2-
H2N-CH2-CH2-CH2-CH2-
As used herein, the term "subject" or "patient" refers to a warm blooded animal such as a mammal, preferably a human, or a human child, which is afflicted with, or has the potential to be afflicted with one or more diseases and conditions described herein.
As used herein, a "therapeutically effective amount" refers to an amount of a compound of the present invention effective to prevent or treat the symptoms of particular disorder. Such disorders include, but are not limited to, those pathological and neurological disorders associated with the aberrant activity of the receptors described herein, wherein the treatment or prevention comprises inhibiting, inducing, or enhancing the activity thereof by contacting the receptor with a compound of the present invention.
As used herein, the term "pharmaceutically acceptable" refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
As used herein, the term "unit dose" refers to a single dose which is capable of being administered to a patient, and which can be readily handled and packaged, remaining as a physically and chemically stable unit dose comprising either the active compound itself, or as a pharmaceutically acceptable composition, as described hereinafter.
As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carb'oxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like. These physiologically acceptable salts are prepared by methods known in the art, e.g., by dissolving the free amine bases with an excess of the acid in aqueous alcohol, or neutralizing a free carboxylic acid with an alkali metal base such as a hydroxide, or with an amine.
Compounds described herein throughout, can be used or prepared in alternate forms. For example, many amino-containing compounds can be used or prepared as an acid addition salt. Often such salts improve isolation and handling properties of the compound. For example, depending on the reagents, reaction conditions and the like, compounds as described herein can be used or prepared, for example, as their hydrochloride or tosylate salts. Isomorphic crystalline forms, all chiral and racemic forms, N-oxide, hydrates, solvates, and acid salt hydrates, are also contemplated to be within the scope of the present invention.
Certain acidic or basic compounds of the present invention may exist as zwitterions. All forms of the compounds, including free acid, free base and zwitterions, are contemplated to be within the scope of the present invention. It is well known in the art that compounds containing both amino and carboxy groups often exist in equilibrium with their zwitterionic forms. Thus, any of the compounds described herein throughout that contain, for example, both amino and carboxy groups, also include reference to their corresponding zwitterions. As used herein, "prodrug" refers to compounds specifically designed to maximize the amount of active species that reaches the desired site of reaction, which are of themselves typically inactive or minimally active for the activity desired, but through biotransformation are converted into biologically active metabolites.
Accordingly, prodrugs include, for example, compounds described herein in which a hydroxy, amino, or carboxy group is bonded to any group that, when the prodrug is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or carboxylic acid, respectively. Examples include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups; and alkyl, cycloalkyl, aryl, and alkylaryl esters such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert- butyl, cyclopropyl, phenyl, benzyl, and phenethyl esters, and the like.
Compounds described herein may contain one or more asymmetrically substituted carbon atoms, and may be isolated in optically active or racemic forms. Thus, all isomeric forms of a structure, including all stereogenic ( such as enantiomeric, diastereomeric, and/or meso forms, whether chiral or racemic), all achiral, all geometric, and/or all conformational isomeric forms are intended, unless the specific stereochemical or other isomeric form is specifically indicated and/or achiral. It is well known in the art how to prepare and isolate such isomeric forms of a structure including those having stereogenic centers including those stereogenic forms wherein the structure is present in optically active form. For example, mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse-phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate synthesis of target chiral centers. As used herein, the term "stereoisomers" refers to compounds that have identical chemical constitution, but differ as regards the arrangement of the atoms or groups in space.
The terms "treatment" and "treating" as used herein include preventative (e.g., prophylactic), curative and/or palliative treatment. When any variable occurs more than one time in any constituent or in any formula, its definition in each occurrence is independent of its definition at every other occurrence. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
It is believed the chemical formulas and names used herein correctly and accurately reflect the underlying chemical compounds. However, the nature and value of the present invention does not depend upon the theoretical correctness of these formulae, in whole or in part. Thus it is understood that the formulas used herein, as well as the chemical names attributed to the correspondingly indicated compounds, are not intended to limit the invention in any way, including restricting it to any specific tautomeric form or to any specific optical or geometric isomer, except where such stereochemistry is clearly defined.
Accordingly, the present invention is directed, in part, to novel pyridizinone compounds which have the following formula I*:
Figure imgf000015_0001
I* or a stereoisomer^ form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt forms thereof, wherein: X and Xa are each independently CH or N; Y is S(O)q, O, or NR!5; R1 is NR10R1 ' or a 4- to 9-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R20 groups; R2 is
Figure imgf000016_0001
(iv) (V)
Figure imgf000016_0002
(ix) wherein: when X and Xa are both CH, then R2 is meta or para to the Y-CCHR^m-R/group; and when either X or Xa are N, then R2 is para to the
Figure imgf000016_0003
each R3 is: independently H5 F, Cl3 Br, I5 OR21, NR23R24, NO2, CN5 CF3, Ci-C6alkyl, C(O)R21, CO2R21, or C(=O)NR23R24; or when R3 is ortho to R2, and R2 is (i), (ii), (iv)5 (vi), or (ix), then R3 and R14 taken together may form -(CH2)S-, -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; wherein Z is O, S(O)x, or NR27; or when R3 is ortho to R2, and R2 is (iv), (v), or (viii), then R3 and R13 taken together may form -(CH2)S-, -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; or when R3 is ortho to R2, and R2 is (viii), then R3 and R13b taken together may form -(CH2)S-, -CH2Z- , -ZCH2-. -ZCH2CH2- or CH2CH2Z-; or when R3 is ortho to Xa and R2 is ortho to R3 and meta to Xa, then R2 and R3 taken together may form:
Figure imgf000017_0001
each R4 is independently H, Cj-Cgalkyl, or OR21, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups; R10 and R11 are each independently H, Ci-Cβalkyl, or Ca-Cβcycloalkyl, wherein the alkyl or cycloalkyl group is optionally substituted with 1 to 3 R20 groups;
R12 is H, Ci-Cήalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, C(=O)R27, or CO2R27, wherein the alkyl, cycloalkyl, aryl, arylalkyl. heteroaryl, or heterocycloalkyl group is optionally substituted with 1 to 3 R20 groups; R13 and R14 are each independently H, Ci-Cβalkyl, aryl, arylalkyl Ci-C6alkoxyl,
S(=0)y-Ci-C6alkyl, cycloalkyl, heterocycloalkyl, or heteroaryl; R13a, R13b 5 RI3c 5 and R14a are each independently H5 Ci-C6alkyl; or R13 and R14, taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or C3-Cδcycloalkyl ring; or R13b and R14, or R13 and 14a, or R13b and 14a, or R13c and R14a, taken together with the carbon atoms through which they are connected form a fused Cs-Cβcycloalkyl ring; or R13 and R13a, or R14 and R14a, taken together with the carbon atom to which they are attached form a C3-C8cycloalkyl ring; provided that no more than one pair of R13 and R14, R13b and R14, R13 and R14a, R13b and R14\ R13c and R14a, R13 and R13a, and R14 and R14a are taken together with the carbon atoms through which they are connected or to which they are attached to form a ring; and wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or cycloalkyl ring is optionally substituted with 1 to 3 R20 groups;
R15 is H5 C1-C6 alkyl, C(=O)R25, CO2R25; R20 at each occurrence is independently, H, F, Cl, Br, I, OR2 ' , OR22, NR23R24, NHOH, NO2, CN, CF3, C1-C6 alkyl optionally substituted with OR26, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7cycloalkylCo-C4alkyl, 3- to 7-membered heterocycloalkylCo-C4alkyl, phenyl, 5- or 6-membered heteroarylC0-C4alkyl, arylalkyl, (=O), C(=O)R21, CO2R21, OC(O)R21, C(=O)NR23R24, NR27C(=O)R21, NR27C(=O)OR21, OC(=O)NR23R24, NR27C(=S)R21, or S(O)qR21; each R21 is independently H, Ci-C6alkyl, aryl, or arylalkyl; each R is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; each R23 and R24 is independently selected from H, Ct-C6alkyl, and aryl, or R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with =0;
R25 is C,-C6alkyl, aryl, or alkylaryl;
R26 is H, d-Cβalkyl, aryl, or alkylaryl;
R27 is H or Ci-C6alkyl; m is 1, 2, 3, 4, or 5 when R1 is attached via a nitrogen atom, and m is O, 1, 2, 3, 4, or 5 when R1 is attached via a carbon atom; n is 1, 2, or 3; q is 0, 1 , or 2; s is 1, 2, or 3; and y is 0, 1, or 2.
In certain preferred embodiments, the compounds of formula I or I* are other than 6-
[4-(3-Diethylamino-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one. In other preferred embodiments of the compounds of formula I or I*; when Xa and X are each CH, Y is O, n is
O, each R4 is H, m is 2, 3, or 4, R1 is methylamino, hydroxyethylamino, pyrolidin-1-yl, piperidin-1 -yl, morpholin-4-yl, and R2 is para to the Y-CCHR^m-J^group, then R2 is other than 4,5-dihydro-2H-pyridazin-3-one-6-yl.
In some preferred embodiments, the present invention provides a novel of formula I:
Figure imgf000019_0001
and stereoisomeric forms, mixtures of stereoisomers forms or pharmaceutically acceptable salt forms thereof, wherein:
X and Xa are each independently CH or N;
Y is selected from S(O)q, O5 and NR15;
R1 is NR10R1 ' or a 4 to 9 membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R20 groups; R2 is
Figure imgf000019_0002
wherein: when X and Xa are both CH, then R2 is meta or para to the
Figure imgf000019_0003
and when either X or Xa are N, then R2 is para to the Y-CCHR^m-R1 group;
R3 is: at each occurrence is independently, H, F3 Cl, Br, I, OR21, NR23R24, NO2, CN, CF3, C1-C6 alkyl, C(=O)R21, CO2R21, or C(O)NR23R24; or when R3 is ortho to R2, then R3 and R14 can combine to form -(CH2)S-, -CH2Z- , CH2CH2Z-; wherein Z is O, S(O)y, NR27; or when R3 is ortho to Xa and R2 is ortho to R3 and meta to Xa, then R2 and R3 combine to form:
Figure imgf000020_0001
R4 is H, Ci-Cg alkyl, or OR21, wherein the alk^yl group is optionally substituted with 1 to
R20 groups; R10 and R11 are each, independently H or Ci-Cg alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups; R!2 is H, Cj-C6 alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, C(=O)R27, or
CO2R27, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heterocycloalkyl groups are optionally substituted with 1 to 3 R20 groups; R13 and R14 are independently H, Ci-C6 alkyl, aryl, or arylalkyl or R13 and R14 can combine to form a fused phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl ring; wherein the phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl rings are optionally substituted with 1 to 3 R20 groups; R15 is H5 C1-C6 alkyl, C(O)R25, CO2R25; R20 at each occurrence is independently, H, F, Cl, Br5 1, OR21, OR22, NR23R24, NHOH, NO2,
CN5 CF3, Ci-C6 alkyl optionally substituted with OR26, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered heteroaryl, arylalkyl, (=O), C(=0)R21, CO2R2', OC(=O)R21, C(=O)NR23R24,
NR27C(=O)R21, NR27C(=O)OR21, OC(=O)NR23R24, NR27C(=S)R21, or S(O)qR21; R21 at each occurrence is independently H3 C1-C6 alkyl, aryl, or arylalkyl; R22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
R23 and R24 at each occurrence are each independently selected from H, Ci-C6 alkyl, and aryl, or R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with =O; R25 is CJ-C6 alkyl, aryl, or alkylaryl; R26 is H, Ci-C6 alkyl, aryl, or alkylaryl; R27 is H or Ci-C6 alkyl; m is 1, 2, 3, 4, or 5 when R1 is attached via a nitrogen atom, and m is 0, 1, 2, 3, 4, or 5 when
R1 is attached via a carbon atom; n is O, 1. 2, or 3; q is 0, 1, or 2; s is 1, 2, or 3.
Embodiments of the present invention include those compounds of formula I having the structure I**:
Figure imgf000021_0001
I** wherein: Y is O;
R1 is NR10R11 or a 5 to 6 membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R20 groups; or R1 is NR10R11, pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R20 groups; or R1 is pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R20 groups; R4 is H or Ci-C6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups;
R10 and Ru are each, independently H or Ci-C6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups; R12 is H, Ci-C6 alkyl, phenyl, or benzyl, wherein the alkyl, phenyl and benzyl groups are optionally substituted with 1 to 3 R20 groups; R20 at each occurrence is independently, H, F, Cl, Br, I, OR21, OR22, NR23R24, NHOH, NO2, CN, CF3, Ci-C6 alkyl optionally substituted with OR26, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered heteroaryl, arylalkyl, (=O), C(=0)R21, CO2R21, OC(=O)R21, C(=O)NR23R24, NR27C(=O)R21, NR27C(=O)OR21, OC(=O)NR23R24, NR27C(=S)R21, or S(O)qR21; R21 at each occurrence is independently H, Ci-Ce alkyl, aryl, or arylalkyl;
R22 at each occurrence is independently the residue of an amino acid after the hydroxy! group of the carboxyl group is removed; R23 and R24 at each occurrence are each independently selected from H5
Figure imgf000022_0001
alkyl, and aryl, or R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with =0; R26 is H, C1-C6 alkyl, aryl, or alkylaryl; R27 is H or Ci-C6 alkyl; m is 3 when R1 is attached via a nitrogen atom, and m is 0 or 1 when R1 is attached via a carbon atom; n is 0 or 1 ; q is O, I, or 2. In another embodiment, the present invention includes compounds of formula (Ia):
Figure imgf000022_0002
(Ia)
wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ia) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Ia) with the preferred moieties of groups R1 and R2; or R1 and Y; or R1, R2 and Y; etc.
In another embodiment, the present invention includes compounds of formula (Ib):
Figure imgf000022_0003
(Ib) wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ib) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Ib) with the preferred moieties of groups R1 and R2; or R1 and Y; or R1, R2 and Y; etc.
In another embodiment, the present invention includes compounds of formula (Ic):
Figure imgf000023_0001
(Ic)
wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ic) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Ic) with the preferred moieties of groups R1 and R2; or R1 and Y; or R1, R2 and Y; etc.
In another embodiment, the present invention includes compounds of formula (Id):
Figure imgf000023_0002
(Id)
wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Id) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Id) with the preferred moieties of groups R ; or R and m; or R . 15 r R> 13 and R 14. : etc.
In another embodiment, the present invention includes compounds of formula (Ie):
Figure imgf000024_0001
(Ie) wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ie) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Ie) with the preferred moieties of groups R1; or R1, Ru and R14; etc. In another embodiment, the present invention includes compounds of formula (If):
Figure imgf000024_0002
(if)
wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (If) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (If) with the preferred moieties of groups R1; or R12; or R1 and R12. In another embodiment, the present invention includes compounds of formula (Ig):
Figure imgf000025_0001
(Ig)
wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ig) which incorporate the embodiments described above for compounds of formula I5 as is appropriate. For example, additional embodiments include compound of formula (Ig) with the preferred moieties of groups R1; or R12; or R1 and R12. In another embodiment, the present invention includes compounds of formula (Ih):
Figure imgf000025_0002
(Ih)
wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ih) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Ih) with the preferred moieties of groups R1; or R1 and R13; or R1, R23 and R24.
In another embodiment, the present invention includes compounds of formula (Ii):
Figure imgf000026_0001
wherein each variable is defined in formula I. Additional aspects of the present invention include compounds of formula (Ii) which incorporate the embodiments described above for compounds of formula I, as is appropriate. For example, additional embodiments include compound of formula (Ii) with the preferred moieties of the R1 and R12 groups.
In a further embodiment of the present invention, there are included compounds having a structure of Formula II:
Figure imgf000026_0002
(H)
and stereoisomer^ forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof, wherein:
R1 is NR10R1 ' or a 5 to 6 membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R20 groups; R2 is
Figure imgf000026_0003
R3 is: at each occurrence is independently, H, F, CI5 Br, I, OR21, NR23R24, NO2, CN,
CF3, Ci-C6 alkyl, C(=O)R2l 5 CO2R21, or C(=O)NR23R24; or when R3 is ortho to R2, then R3 and R14 can combine to form -CH2CH2-; or when R3 is ortho to Xa and R2 is ortho to R3 and meta to Xa, then R2 and R3 combine to form:
Figure imgf000027_0001
R4 is H or Ci-C6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups;
R10 and R11 are each, independently H or C1-C6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups; R12 is H, Ci-C6 alkyl, phenyl, or benzyl, wherein the alkyl, phenyl and benzyl groups are optionally substituted with 1 to 3 R20 groups; R13 and R14 are independently H, Ci-C6 alkyl, phenyl, or benzyl, or R13 and R14 can combine to form a fused phenyl, thienyl, cyclopentyl or cyclohexyl ring; wherein the phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl rings are optionally substituted with 1 to 3 R20 groups;
R20 at each occurrence is independently, H, F, Cl, Br, I, OR21, OR22, NR23R24, NHOH, NO2, CN, CF3, Ci-C6 alkyl optionally substituted with OR26, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered heteroaryl, arylalkyl, (=O), C(=O)R21, CO2R21, OC(O)R21, C(=O)NR23R24, NR27C(=O)R21, NR27C(=O)OR21, OC(=O)NR23R24, NR27C(=S)R21, or S(O)qR21; R21 at each occurrence is independently H5 Ci-C6 alkyl, aryl, or arylalkyl; R22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
R23 and R24 at each occurrence are each independently selected from H, Ci-C6 alkyl, and aryl, or R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with =0; R26 is H5 Ci-C6 alkyl, aryl, or alkylaryl; R27 is H or Ci-C6 alkyl; m is 3 when R1 is attached via a nitrogen atom, and m is 0 or 1 when R1 is attached via a carbon atom; n is 0 or 1; q is 0, I, or 2.
As used herein, "embodiments of the present invention" is intended to include the full scope of compounds of any of formulas I, I*, I**, I(a-i), and H5 or any combination or subcombination thereof, unless specifically otherwise provided.
Embodiments of the present invention include those compounds where Y is O. In other embodiments Y is S(O)q, or Y is NR15.
Embodiments of the present invention include those compounds where R1 is NR10R11, and those compounds where R10 and R11 are each, independently H or CI-CO alkyl, preferably both are Ci-Ce alkyl.
Embodiments of the present invention include those compounds where R1 is a 4- to 9-membered heterocycloalkyl ring, preferably a 5- to 6-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms, more preferably 1 nitrogen atom, and optionally substituted with 1 to 3 R20 groups. In certain embodiments R1 is an optionally substituted 5- membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms, such as pyrrolidinyl, imidazolidinyl, or pyrazolidinyl. In other embodiments, R1 is an optionally substituted 6- membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms, such as piperidinyl, piperazinyl, or hexahydropyrimidinyl. In certain preferred embodiments, R1 is attached to Y through a ring nitrogen atom. In other preferred embodiments, R1 is attached to Y through a ring carbon atom.
In other preferred embodiments, R1 is:
Figure imgf000028_0001
; more preferably:
Figure imgf000029_0001
In certain preferred embodiments of the moiety Y-(CHR4)m-R1, one or more of the carbon centers [(i.e., the subgroup "— (CHR4)m-")? said subgroup which is present in the Y-(CHR4)m-R' moiety "m" times] may have the potential to be chiral in nature. That is to say, there may be 4 different groups attached to a carbon center in the subgroup. Each — (CHR4)- independently may be chiral and all possible stereoisomeric combinations are within the scope of the present invention. In certain more preferable embodiments, m is 3, more preferably the moiety Y-(CHR4)m-RI is
Embodiments of the present invention include those compounds where R2 is
Figure imgf000029_0003
(R2A)
In certain embodiments R is
Figure imgf000029_0004
In other embodiments, R 2 i-s
Figure imgf000030_0001
(R2C)
In other embodiments, R2 is
Figure imgf000030_0002
(R2D)
In other embodiments, R2 is
Figure imgf000030_0003
(R2E)
In other embodiments; the R2 can be a combination of R2A through R2E. For example, such combinations include: R2A, R2C, R2D, and R2E; R2A, R2B, R2D, and R2E; R2A, R2B, and R2C; R2A, R2D, and R2E; R2A, R2D, and R2E; R2A and R2B; R2B and R2C; R2D and R2E; etc.
In other embodiments, R2 is:
Figure imgf000031_0001
(Iv) (V)
Figure imgf000031_0002
(Vi) (vϋ)
(viii)
Figure imgf000031_0003
Ox) wherein: when X and Xa are both CH, then R2 is meta or para to the Y-CCHR^m-R1 group; and when either X or Xa are N, then R2 is para to the Y-(CHR4)m-R1gr°uP; each R3 is: independently H, F, Cl, Br, I, OR21J NR23R24; NO2, CN3 CF3, CrCgalkyl. C(=O)R2 ', CO2R21, or C(=O)NR23R24; or when R3 is ortho to R2, and R2 is (i), (ii), (iv), (vi), or (ix), then R3 and R14 taken together may form -(CH2)S-, -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; wherein Z is O, S(O)y, or NR27; or when R3 is ortho to R2, and R2 is (iv), (v), or (viii), then R3 and R13 taken together may form -(CH2)S-, -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; or when R3 is ortho to R2, and R2 is (viii), then R3 and R13b taken together may form -(CH2)S-, -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; or when R3 is ortho to Xa and R2 is ortho to R3 and meta to Xa, then R2 and R3 taken together may form:
Figure imgf000032_0001
; preferably wherein R2 is (i), (ii), (iv), (vi), (viii), or (ix). In certain
more preferred embodiments, R2 is (iv); or it is (i); more preferably
Figure imgf000032_0002
; or it is
(iii) and one of R13 is cyclopropyl. In other alternatively preferred embodiments, R2 is (vi), (viii), or (ix).
In some preferred embodiments, R" is:
Figure imgf000032_0003
still more preferably
Figure imgf000033_0001
Alternatively preferred in some embodiments, R is:
In still other embodiments, R 2 i •s:
Figure imgf000033_0002
In further embodiments of the present invention, R2 is para to the Y-(CHR4)- R'group. In certain embodiments when X and Xa are both CH, then R2 is meta to the Y- (CHR4)-R' group, or R2 is para to the Y-CCHR^-R'group- In other embodiments when X and Xa are both CH, then R2 is meta or para to the Y-(CHR4)-R2 group. In other embodiments in combination with any of the three R2 groups, R13 and R14 are independently H, or they are each independently C1-C6 alkyl, or they are each independently aryl, or they are each independently arylalkyl. In further embodiments of R2, R13 and R14 can combine to form a fused phenyl ring, or they can form a fused thienyl ring, or they can form a fused pyrrolyl ring, or they can form a fused cyclopentyl ring or they can form a fused cyclohexyl ring. An example of R13 and R14 combining to form a fused thienyl ring has the following structure:
Figure imgf000034_0001
Embodiments of the present invention include those compounds where n is 0. Certain embodiments include those compounds where n is 1. Still other embodiments include those compounds where n is 2.
Embodiments of the present invention include those compounds where R at each occurrence is independently, H, F, Cl, Br, I, OR21, NR23R24, NO2, CN, CF3, CrC6 alkyl, C(=O)R21, CO2R21, or C(=O)NR23R24, preferably F, Cl, Br, or d-Cgalkyl, more preferably F. In other preferred embodiments when R3 is ortho to R2, then R3 and R14 can combine to form -CH2CH2-. In certain embodiments R3 at each occurrence is independently, H, F, Cl, Br, I, OR21, NR23R24, NO2, CN, CF3, Ci-C6 alkyl, C(=O)R21, CO2R21, or C(=O)NR23R24. In other embodiments, R3 is ortho to R2, then R3 and R14 can combine to form -(CH2)S-. An example includes a compound where s is 2b which has the following structure:
Figure imgf000034_0002
In certain embodiments of the present invention, s is 2, or s is 3. In other embodiments, R 3 and R14 can combine to form -CH2Z- or CH2CH2Z-; wherein Z is O, S(O)y, NR27. In particular, R3 and R14 can combine to form -CH2Z- or they can combine to form CH2CH2Z-. In particular embodiments, Z is O and in others, Z is -S-. In further embodiments of the present invention, R3 is ortho to Xa and R2 is ortho to R3 and meta to Xa, then R2 and R3 combine to form:
Figure imgf000035_0001
An example includes a compound of the following structure:
Figure imgf000035_0002
Embodiments of the present invention include those compounds where R4 is H5 optionally substituted Ci-C6alkyl, or optionally substituted Ci-C6 alkoxyl, preferably H or optionally substituted Ci-Cβalkyl. In certain embodiments. R4 is optionally substituted C1- Cβ alkyl. In embodiments where R4 is alkyl, it is preferably Ci-C3alkyl, more preferably, CiCβalkyl, with methyl being even more preferred.
Embodiments of the present invention include those compounds where m is 1, 2, 3, 4, or 5 when R1 is attached via a nitrogen atom. In particular, m is 1, or m is 2, or m is 3, or m is 4, or m is 5, or m can be any combination of the above including, 1 and 2; 1 and 3; 2 and 3; 1, 2, and 3; etc. Other embodiments include those compounds where m is 0, 1, 2, 3, 4, or 5 when R1 is attached via a carbon atom. In particular, m is 0, or m is 1 , or m is 2, or m is 3, or m is 4, or m is 5, or m can be any combination of the above including, 0 and 1; 0 and 2; 0, I5 and 2; 1, 2, and 3; etc.
In certain preferred embodiments of the present invention, s is 2. In other preferred embodiments of the present invention, R12 is H, Ci-Cβalkyl, cycloalkyl, aryl, arylalkyl, or heteroaryl, more preferably H or heteroaryl, with heteroaryl being even more preferred. Alternatively, Ci-Cδalkyl, aryl, arylalkyl, or heteroaryl is preferred in some embodiments. In certain preferred embodiments of the present invention, R13, R14 R13a, R13b, R13c, and R14a are each independently H or Ci-Cβalkyl, more preferably wherein at least one of is R13, R14 R13a, RI3b, R13c, and R14a is Ci-C6alkyl. In other alternatively preferred embodiments, R13a and R13 are each independently C1-C3 alkyl; or R14a and R14 are each independently C1-C3 alkyl.
In still other preferred embodiments of the present invention, R13 and R14, taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, oxazolyl, pyridinyl, or C3-C6cycloalkyl ring; or R13b and R14, or R13 and 14a, or RI3b and l4a, or R13c and R14a, taken together with the carbon atoms through which they are connected form a fused C3-C6cycloalkyl ring; or R13 and R13a, or R14 and R14a, taken together with the carbon atom to which they are attached form a C3-Cgcycloalkyl ring; provided that no more than one pair of R13 and R14, R13b and R14, R13 and R14a, R13b and Rl4a, RI3c and R14a, R13 and R13a, and R14 and R14a are taken together with the carbon atoms through which they are connected or to which they are attached to form a ring; and wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or cycloalkyl ring is optionally substituted with 1 to 3 R20 groups. More preferably, R13 and R14, R13b and R14, or R13 and 14a, or R13b and 14a, or R13c and R14a, taken together with the carbon atoms through which they are connected form a fused C3-C6cycloalkyl ring; or R13 and Rl3a, or R14 and RI4a, taken together with the carbon atom to which they are attached form a C3-C8cycloalkyl ring; then the cycloalkyl ring is a is C3-C4cycloalkyl ring.
In some preferred embodiments of the present invention, R14 is heteroaryl.
In some preferred embodiments of the present invention, R20 is alkyl; in others it is cycloalkyl, more preferably cyclobutyl. In still others, R20 is F, Cl, CF3, NR23R24, or Cr Cβalkyl optionally substituted with OR26, cycloalkylCo-C4alkyl, or heterocycloalkylCo- C4alkyl, more preferably Ci-Cβalkyl optionally substituted with OR26.
In certain other preferred embodiments of the present invention, R21 is H or Ci- Cβalkyl.
In some preferred embodiments of the present invention, R23 and R24 are each independently Ci-CβalkyL In yet other preferred embodiments of the present invention, R26 is H or Q-Cgalkyl.
In some preferred embodiments of the present invention, at least one of X and Xa is CH, more preferably X and X3 are each CH.
Embodiments of the present invention include those compounds of formula I wherein: X and Xa are CH;
Y is O;
R1 is NR10R1 ' or a 5 to 6 membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R20 groups; or R1 is NR10R11, pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R20 groups; or R1 is pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R20 groups;
R2 is
Figure imgf000037_0001
R2 is
Figure imgf000037_0002
R3 at each occurrence is independently, H, F, Cl, Br, I, OR21, NR23R24, NO2, CN, CF3, Ci-
C6 alkyl, C(=O)R21, CO2R21, or C(K))NR23R24; or when R3 is ortho to R2, then R3 and R14 can combine to form -CH2CH2-; or
R3 at each occurrence is independently, H; F; Cl; Br; I; OR21; NR23R24; NO2; CN;
CF3; C-C6 alkyl; C(=O)R21; CO2R21; or C(O)NR23R24; R4 is H or Cj-C6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups; R10 and R11 are each, independently H or C1-C6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups; R12 is H, CpC6 alkyl, phenyl, or benzyl, wherein the alkyl, phenyl and benzyl groups are optionally substituted with 1 to 3 R20 groups; R13 and R14 are independently H, C1-C6 alkyl, phenyl, or benzyl, or R13 and R14 can combine to form a fused phenyl, thienyl, cyclopentyl or cyclohexyl ring; wherein the phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl rings are optionally substituted with 1 to 3 R20 groups; or
R13 and R14 are independently H, Ci-C6 alkyl, phenyl, or benzyl; or
R13 and R14 can combine to form a fused phenyl, thienyl, cyclopentyl or cyclohexyl ring; R20 at each occurrence is independently, H, F, Cl, Br, I, OR21, OR22, NR23R24, NHOH, NO2,
CN, CF3, Ci-C6 alkyl optionally substituted with OR26, C2-C6 alkenyl, C2-C6 alkynyl, C3-C? cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered heteroaryl, arylalkyl, (=0), C(=0)R21, CO2R21, OC(K))R21, C(=O)NR23R24,
NR27C(=O)R21, NR27C(=O)OR21, OC(=O)NR23R24, NR27C(^S)R21, or S(O)qR21; R21 at each occurrence is independently H, Ci-C6 alkyl, aryl, or arylalkyl;
R22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; R23 and R24 at each occurrence are each independently selected from H, Cj-C6 alkyl, and aryl, or R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with =O;
R26 is H, Ci-C6 alkyl, aryl, or alkylaryl; R27 is H or C1-C6 alkyl; m is 3 when R1 is attached via a nitrogen atom, and m is 0 or 1 when R1 is attached via a carbon atom; n is 0 or 1 ; q is O, 1, or 2.
Embodiments of the present invention include those compounds of formula I wherein: X is N and Xa is N or CH; or X and Xa are each N; or X is N and Xa is CH; Y is O; R1 is NR10R1 λ or a 5 to 6 membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R20 groups; or R1 is NR10R11, pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidinyl groups are optionally substituted with 1 to 3 R20 groups; or R1 is pyrrolidinyl or piperidinyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R20 groups;
R2 is
Figure imgf000039_0001
R2 is
Figure imgf000039_0002
R* at each occurrence is independently, H, F, Cl, Br, I, OR 21 , NR >2/3JrR>24 , NO2, CN, CF3, Cr
C6 alkyl, C(=0)R21, CO2R21, or C(=O)NR23R24; or when R3 is ortho to R2, then R3 and R14 can combine to form -CH2CH2-; or
R3 at each occurrence is independently, H; F; Cl; Br; I; OR21; NR23R24; NO2; CN;
CF3; Ci-C6 alkyl; Q=O)R21; CO2R21; or C(=O)NR23R24; R4 is H or C1-C6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups; R10 and R11 are each, independently H or Ci-C6 alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups; R12 is H, Ci-Ce alkyl, phenyl, or benzyl, wherein the alkyl, phenyl and benzyl groups are optionally substituted with 1 to 3 R20 groups; R13 and R14 are independently H, Ci-C6 alkyl, phenyl, or benzyl, or R13 and R14 can combine to form a fused phenyl, thienyl, cyclopentyl or cyclohexyl ring; wherein the phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexsyl rings axe optionally substituted with 1 to 3 R20 groups; or
R13 and R14 are independently H, C1-C6 alkyl, phenyl, or benzyl; or R13 and R14 can combine to form a fused phenyl, thienyl, cyclopentyl or cyclohexyl ring;
R20 at each occurrence is independently, H, F, Cl, Br, I, OR21, OR22, NR23R24, NHOH, NO2, CN, CF3, C1-C6 alkyl optionally substituted with OR26, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered heteroaryl, arylalkyl, (=O), CC=O)R21, CO2R21, OC(=O)R21, CC=O)NR23R24, NR27C(=O)R21, NR27C(=O)OR21, OCC=O)NR23R24, NR27C(=S)R21, or SCO)qR21;
R21 at each occurrence is independently H, Ci-C6 alkyl, aryl, or arylalkyl; R22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
R23 and R24 at each occurrence are each independently selected from H, Ci-C6 alkyl, and aryl, or R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with =0; R26 is H, Ci-C6 alkyl, aryl, or alkylaryl; R27 is H or Ci-C6 alkyl; m is 3 when R1 is attached via a nitrogen atom, and m is O or 1 when R1 is attached via a carbon atom; n is O or 1 ; q is 0, 1, or 2.
Embodiments of the present invention include those compounds of formula I wherein: X and Xa are CH;
Y is O; R1 is NR10R11, pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R20 groups; R2 is para to the Y-(CHR4)m-R1 group; R3 at each occurrence is independently, H, F, Cl, Br, I, OR21 , NR23R24, NO2, CN,
CF3, C1-C6 alkyl, CC=O)R21, CO2R21, or CC=O)NR23R24; or when R3 is ortho to R2, then R3 and R14 can combine to form -CH2CH2-; m is 3 when R1 is attached via a nitrogen atom, and m is O or 1 when R1 is attached via a carbon atom; n is 0 or 1. In particular, a first embodiment includes those compounds wherein:
R1 is attached by the nitrogen atom; R2 is:
Figure imgf000041_0001
R13 and R14 combine to form a fused phenyl or thienyl ring; and m is 3. In other embodiments, R2 is:
Figure imgf000041_0002
In further embodiments, R 2 is:
Figure imgf000041_0003
In a second particular embodiment:
R1 is attached by the nitrogen atom; R2 is:
Figure imgf000042_0001
R13 and R14 combine to form a fused cyclopentyl or cyclohexyl ring; and m is 3. In a third particular embodiment:
R1 is attached by the nitrogen atom; R2 is:
Figure imgf000042_0002
R13 and R14 are independently H, Ci-Cδ alkyl, phenyl, or benzyl; and m is 3. In a fourth particular embodiment:
R1 is pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are attached by a ring carbon atom and each are optionally substituted with 1 to
3 R20 groups;
R2 is:
Figure imgf000042_0003
R4 is H;
R13 and R14 are independently H, C1-C6 alkyl, phenyl, or benzyl; m is 0 or 1. In a fifth particular embodiment:
R1 is attached by the nitrogen atom; R2 is:
Figure imgf000043_0001
R!3 and R14 are independently H, C1-C6 alkyl, phenyl, or benzyl; m is 3. In a sixth particular embodiment:
R1 is attached by the nitrogen atom; R2 is:
Figure imgf000043_0002
R13 and R14 are independently H, Ci-C6 alkyl, phenyl, or benzyl; m is 3.
In a seventh particular embodiment:
R1 is attached by the nitrogen atom; R2 is ortho to R3, and R2 is:
Figure imgf000044_0001
.
R3 and R14 combine to form -CH2CH2-; m is 3.
Embodiments of the present invention include those compounds of formula I wherein:
X and Xa are CH;
Y is O;
R1 is NR10R1 ', pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R groups; R2 is para to the Y-(CHR4)m-Rl group;
R3 at each occurrence is independently, H, F, Cl, Br, I, OR21, NR23R24, NO2, CN, CF3, Q-
C6 alkyl, C(=O)R2\ CO2R21, or C(=O)NR23R24; or when R3 is ortho to R2, then R3 and R14 can combine to form -CH2CH2-; m is 3 when R1 is attached via a nitrogen atom, and m is 0 or 1 when R1 is attached via a carbon atom; n is 0 or 1.
Additional aspects of the present invention include compounds of formula II which incorporate the embodiments described above for compounds of formula I3 as is appropriate. For example, additional embodiments include compound of formula II with the preferred moieties of groups R1; or R1 and R13; or R1, R23 and R24, etc.
For example, in certain embodiments of compounds of formula II:
R1 is NR10R1 ', pyrrolidinyl or piperidyl, wherein the pyrrolidinyl and piperidyl groups are optionally substituted with 1 to 3 R20 groups. For example, in other embodiments of compounds of formula II:
R3 at each occurrence is independently, H, F, Cl, Br, I, OR21, NR23R24, NO2, CN, CF3, Cr
C6 alkyl, C(=O)R21, CO2R21, or C(=O)NR23R24; or when R3 is ortho to R2, then R3 and R14 can combine to form -CH2CH2-.
In certain embodiments, the compounds of the formula I*:
Figure imgf000045_0001
I* are selected from the group consisting of:
2-methyl-6- {4-[(R)-2-methyl-3 -((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl } - 2H-pyridazin-3-one;
6-[4-(l-cyclopentyl-piperidin-4-yloxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-methyl- 2H-pyridazin-3-one;
6- { 3-chloro-4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-proρoxy]-phenyl} -2-methyl-2H- pyridazin-3-one;
2,6-dimethyl-5- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl} -2H- pyridazin-3-one;
2,6-dimethyl-5-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
6-methyl-5-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 5-[4-(3-azepan-l-yl-propoxy)-phenyl]-6-methyl-2H-pyridazin-3-one; 2-methyl-5- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy]-phenyl } -2H-pyridazin-3- one; 2-methyl-5-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
5-[4-(3-azepan-l-yl-propoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 5- {4-[3 -((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy]-phenyl } -2-pyridin-2-yl-2H- pyridazin-3-one;
5- [4-(3 -piperidin- 1 -yl-propoxy)-phenyl] -2-pyridin-2-yl-2H-pyridazin-3 -one; 5-[4-(3-azepan- 1 -yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one;
2-methyl-5-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 2-(6-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methyl-pyrrplidin-l-yl)-propoxy]-phenyl}- 2H- pyridazin-3-one; 2-(3-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methylpyrrolidin-l -yl)-propoxy] -phenyl } - 2H- pyridazin-3-one;
6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-pyridin-2-yl- 2H-pyridazin-3 -one;
6-methyl-2-(3-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)- propoxy]-phenyl} -2H-pyridazin-3-one;
6-methyl-5-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; hydrochloride;
5-[4-(l-cyclobutyl-piperidin-4-yIoxy)-ρhenyl]-6-methyl-2H-pyridazin-3-one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2-pyridin-2-yl-2H- pyridazin-3-one; 5 - [4-(piperidin-4-yloxy)-phenyl] -2H-pyridazin-3 -one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyI-2-thiophen-3-yl-2H- pyridazin-3-one;
6-methyI-5-{4-[3-((R)-2-methyl-pyrrolϊdin-l-yl)-propoxy]-phenyl}-2-thiophen-3-yl- 2H-pyridazin-3-one;
5-{4-[3-((S)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H- pyridazin-3-one;
5-[4-(l-cyclobυtyl-piperidin-4-yloxy)-phenyl]-6-methyl-4J5-dihydro-2H-pyridazin- 3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5-pyridin-2-yl-4.5- dihydro-2H-pyridazin-3-one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5-pyridin-2-yl-2H- pyridazin-3-one;
6-[4-(piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; 6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-4,5-dihydro-2H- pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-2H-pyridazϊn-3-One;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-4-methyl-4,5-dihydro-2H-pyridazin- 3-one; 5-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2H-pyτidazin-3-one;
2-(2-fluoro-ethyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3 -one;
6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyτidazin-3- one; 6-[3-fluoro-4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one;
4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
4-methyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 4-{4-[3-((S)-2-hydroxymethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-methyl-5,6,7,8- tetrahydro-2H-phthalazin- 1 -one;
2-methyl-4-{3-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2,5,657- tetrahydro-cyclopenta[d]pyridazin-l -one;
2-methyl-4-[3-(3-piperidin-l-yl-propoxy)-phenyl]-2,5,6,7-tetrahydro- cyclopenta[d]pyridazin-l -one;
4-{3-[3-((S)-2-hydroxymethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-methyl-2,5,6,7- tetrahydro-cyclopenta[d]pyridazin-l-one; 2-isopropyl-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyxidazin-
3-one;
2-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-5-(6-oxo-l,6-dihydro-pyridazin-3- yl)-benzonitrile;
2-[3-(piperidin-l-yl)-propoxy]-5-(6-oxo-l,6-dihydro-pyridazin-3-yl)-benzonitrile; 2-(2-hydroxyethyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
4-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2,5,6,7-tetrahydro-cyclopenta[d]pyridazin- 1-one;
6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-[3-methoxy-4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6- { 3-methoxy-4-[3 -((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl}-2H-pyridazin- 3-one; 6-[2-methyl-4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-pyrimidin-2-yl-2H- pyridazin-3-one;
6- [6-( 1 -cyclopentyl~piperidin-4-yloxy)-pyridin-3 -yl] -2H-pyridazin-3 -one;
6- [6-(l -isopropyl-piperidin-4-ylmethoxy)-ρyridin-3 -yl] -2H-pyridazin-3 -one ; 6-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one;
6-[6-( l-isopropyl-piρeridin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one;
6-[6-(l-cyclopentyl-piperidin-4-yloxy)-pyridin-3-yl]-2-methyl-2H-pyridazin-3-one;
6-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-methyl-2H-pyridazin-3-one; 6-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-isopropyl-2H-pyridazin-3- one;
6-{6-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-pyridin-3-yl}-2H-pyridazin-3-one;
6-[6-(3-piperidin-l-yl-propoxy)-pyridin-3-yl]-2H-pyridazin-3-one;
6-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-4,4-dimethyl-4,5-dihydro-2H- pyridazin-3-one;
6-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-pyridin-2-yl-2H-pyridazin-3- one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-4,5-dihydro-2H-pyridazin-3- one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H- pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyI]-4,4-dimethyl-4,5-dihydro- 2H-pyridazin-3-one; 6-[4-(l-cyclopentyl-piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one;
6-[4-(piperidin-4-yloxy)-phenyl]-2-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one; 6-[4-((R)- 1 -cyclohexyl-pyrrolidin-3-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3- one;
6-[4-((R)-l-cyclohexyI-pyrrolidin-3-yloxy)-phenyl]-2H-pyridazin-3-one;
6-[4-((R)-l-cyclobutyl-pyrrolidin-3-yloxy)-phenyl]-2H-pyridazin-3-one;
6-[4-((R)- 1 -cyclopentyl-pyrrolidin-3 -yloxy)-phenyl] -4,5 -dihydro-2H-pyridazin-3- one;
2-cyclobutyl-6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-4;>5-dihydro-2H- pyridazin-3-one;
2-cyclobutyl-6-[4-(l-cyclopentyl-piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H- pyridazin-3-one; 2-cyclobutyl-6-[4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro- 2H-pyridazin-3-one;
6-[4-(l-cyclopentyl-piperidin-4-yloxy)-phenyl]-2-(2,252-trifluoro-ethyl)-4,5- dihydro-2H-pyridazin-3-one;
6-{4-[3-((R)-2-methyl-ρyrrolidin-l-yl)-propoxy]-phenyl}-2-(252,2-trifluoro-ethyl)- 4,5-dihydro-2H-pyridazin-3-one;
6-{4-[3-piperidin-l-yl-propoxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro-2H- yridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)-
2H-pyridazin-3-one;
6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2-(2,2,2-trifluoro-ethyl)-2H-pyridazin-3- one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-334-diaza-bicyclo[4.2.0]oct-4-en-2- one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.2.0]oct-4-en-2-one;
4-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-2.4a,5,6,7,7a-hexahydro- cyclopenta[d]pyridazin- 1 -one; 4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2,4a,5:,6,7,7a-hexahydro- cyclopenta[d]pyτidazin-l-one;
4-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-2,5,6,7-tetrahydro- cyclopenta[d]pyridazin- 1 -one;
2-cyclobutyl-6-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-4,5-dihydro-2H- pyridazin-3-one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one;
4J4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydτo- 2H-pyridazin-3-one; 6- {3-fluoro-4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy]-phenyl} -455-dihydro-2H- pyridazin-3-one;
6-[3-fluoro-4-(3-piperidin-l-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one;
5 ,5-dimethy 1-6- {4- [3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl} -4,5 -dihydro-
2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-ρhenyl}-2-pyridin-2-yl-4,5- dihydro-2H-pyridazin-3-one;
6-{3,5-difluoro-4-[3-((R)-2-methyl-pyτroildin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3 -one; 6-{3,5-dibromo-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro- 2H-pyridazin-3-one;
6- [4-( 1 -cyclobutyl-piperidin-4-yloxy)-3,5 -difluoro-phenyl] -4,5 -dihydro-2H- pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-3,5-difluoro-phenyl]-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-4,5-dihydro-2H-pyridazin- 3-one;
(R)-6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-4,5-dihydro-2H- pyridazin-3-one;
(S)-6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-4,5-dihydro-2H- pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-ethyl-4,5-dihydro-2H-pyridazin-3- one; 6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-2-pyridin-2-yl-4,5-dihydro-
2H-pyridazin-3 -one;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one racemate;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydxo-2H- pyridazin-3-one diastereomer;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one diastereomer;
5-methyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one;
5-methyl-6-[4-(3-pyrrolidin-l-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 6-{(R)-2-methyl-4-[3-(2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyriazin-3-one;
2-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-6-phenyl-2H-pyridazin-3- one; 6-methyl-2-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyI}-2H-pyridazin-3- one;
2-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-phthalazin-l-one;
2- [6-( 1 -cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl] -6-phenyl-2H-pyridazin-3 -one ; 2-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-6-pyridin-3-yl-2H- pyridazin-3 -one;
4-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-6H-isoxazolo[3,4- d]pyridazin-7-one;
3-methyl-4-[4-(pipeτidin-4-yloxy)-phenyl]-6H-isoxazolo[3,4-d]pyridazin-7-one; 3-methyl-4-[4-(3-piperidin-l-yl-propoxy)-phenyl]-6H-isoxazolo[3,4-d]pyridazin-7- one;
3-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-6H- isoxazolo[3.4-d]pyridazin-7-one;
8-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-5,6-dihydro-2H-benzo[h]cinnolin-3- one;
5-methy 1-6- { 4- [3 -((R)-2 -m ethyl-pyrrolidin- 1 -y l)-propoxy] -phenyl } -2H-pyridazin-3- one;
5-ethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one; 8-[3-(2-methyl-pyrrolidin-l-yl)-propoxy]-434a,5,6-tetrahydro-2H-benzo[h]cinnolϊn-
3-one;
6-{2-methoxy-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin- 3-one;
6-{2-fluoro-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H- pyridazin-3 -one; ;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4-pyridin-2-yl-4,5- dihydro-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4-pyridin-2-yl-2H- pyridazin-3-one;
8-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-5,6-dihydro-3H-benzo[f]cinnolin-2- one; 6-[4-(l-cyclobutyl-piperidin-4-yloxy)-2-fluoro-phenyl]-4,5-dihydro-2H-pyridazin-3- one;
8-(l-cyclobutyl-piperidin-4-yloxy)-4,4a,5,6-tetrahydro-2H-benzo[h]cinnolin-3-one;
6-[4-(l-cycIobutyl-piperidin-4-yloxy)-2-fluoro-phenyl]-2H-pyridazin-3-one; 6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-2H-pyridazin-3-one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
2-methoxymethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3 -one;
5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
5 - {4- [(R)-2-methyl-3 -((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl } -2H- pyridazin-3 -one;
5-[4-((S)-2-methyl-3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
5-[4-((R)-2-methyl-3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 5-{3,5-dibromo-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3 -one;
2-methoxymethyl-5-{2-methyl-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]- phenyl}-2H-pyridazin-3-one;
5-{2-methyl-4-[3-((R)-2-methyl-pyrτolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
2-methoxymethyl-5-[2-methyl-4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin- 3-one;
5-[2-methyl-4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-2-methyl-phenyI]-2-methoxyraethyl-2H- pyridazin-3-one;
4-methoxy-2-methoxymethyl-5- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy]- phenyl} -2H-pyridazin-3-one;
5-methoxy-2-methoxymethyl-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yI)-propoxy]- phenyl } -2H-pyridazin-3-one; 5-methoxy-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-
3-one;
6-[4-(3-morpholin-4-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
6-{4-[3-((S)-2-methyl-pyrrolidin-l-yl)-ρropoxy]-phenyl}-2H-pyridazin-3
-one; 6-[4-(3-pyrrolidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
6- {4- [3 -(cyclobutyl-m ethyl -arnino)-prόpόxy] -phenyl } -2H-pyridazin-3 -one;
6-{4-[3-(cyclopentyl-methyl-amino)-propoxy]-phenyl}-2H-pyridazin-3-one;
5 - {4- [3-((R)-2-methy 1-pyrrolidin- 1 -yl)-propoxy] -phenyl } -3 ,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5- {4- [(S)-2-methyl-3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy]-phenyl} -3 ,4-diaza- bicycto[4.1.0]hept-4-en-2-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one single isomer;
5 - {4- [3 -((R)-2-methy 1-pyrrolidin- 1 -yl)-propoxy] -phenyl } -3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one single isomer;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one single isomer;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one single isomer;
5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3-ethyl-3,4-diaza-bicyclo[4.1.0]hept- 4-en-2-one; 5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-isopropyl-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-[4-(l-cycloburyl-piperidin-4-yloxy)-phenyl]-3-methyl-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-(4-fluoro-phenyl)-3,4-diaza- bicyclo [4.1.0]hept-4-en-2-one;
5-[4-(l-cyclobutyl-piperidin-4-yIoxy)-phenyl]-3-(232,2-trifluoro-ethyl)-3,4-diaza- bicyclo[4.1 ,0]hept-4-en-2-one;
6-[4-(2-hydroxy-3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
6-{4-[2-hydroxy-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin- 3-one;
6-{4- [(S)-2-hydroxy-3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl > -2H- pyridazin-3-one;
6-{4-[(R)-2-hydroxy-3-((R)-2-rnethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one; 6-[4-((R)-2-hydroxy-3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 5-[4-(l-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-3:,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-[4-(l-cyclopentyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- onejand
6-cyclopropyl-2-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one; or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof. More preferably, they are selected from the group consisting of:
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2H-pyridazin-3-one; 6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3 -one; 6-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H- pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-4,4-dimethyl-4,5-dihydro- 2H-pyridazin-3-one;
6-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-4,4-dimethyl-4,5-dihydro-2H- pyridazin-3-one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl>-2-pyridin-2-yl-2H- pyridazin-3-one;
5-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one; 6-{4-[(S)-2-Methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro- 2H-pyridazin-3 -one ;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5- {4- [(S)-2-methyl-3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl} -3, 4-diaza- bicyclo[4.1.0]hept-4-en-2-one; 5- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl} -3 ,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5 - {4- [3 -((R)-2-m ethy 1-pyrrolidin- 1 -yl)-propoxy] -phenyl } -3 ,4-diaza- bicyclo[4.1.0]hept-4-en-2-one; i5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-354-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2- one;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one one diastereomer;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one one diastereomer; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one; and
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof. Still more preferably, they are selected from the group consisting of:
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H- pyridazin-3 -one;
5-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one;
6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolϊdin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3 -one;
4,4-dimethyl-6-{4-[3-((R)-2-methyI-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro- 2H-pyridazin-3-one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3.4-diaza- bicyclo[4.1.0]hept-4-en-2-one; 5-;[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3;,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-prdpoxy3-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-354-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2- one;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one one diastereomer;
5-methyl-6- {4- [3 -((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl } -4,5 -dihydro-2H- pyridazin-3-one one diastereomer; 5-methyl-6-{4-[3-((R)-2-methyl-pyrroIidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one; and
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof. Even more preferably, they are selected from the group consisting of:
4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro- 2H-pyridazin-3-one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-{4-[(S)-2-methyl-3-((R)-2-methyI-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0] hept-4-en-2-one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-354-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one; 5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2- one; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyτidazin-3-one one diastereomer;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one one diastereomer;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4.5-dihydro-2H- pyridazin-3-one; and
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.; with the compound 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)- propoxy] -phenyl }-2H-pyridazin-3 -one, or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof being most preferred.
In certain alternatively preferred embodiments, the compounds of formula I are selected from the group consisting of:
2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
2-methyl-6- [4-(3 -piperidin- 1 -yl-propoxy)-phenyl] -2H-pyridazin-3 -one;
2-isopropyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
2-isopropyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3- one; 2-isopropyl-6- {4- [3 -((R)-2-methyl-pyrrolidin- 1 -y l)-propoxy] -phenyl } -2H-pyridazin-
3 -one;
2-ethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-methyl-2H- pyridazin-3-one;
2-(2,4-dichloro-benzyl)-6- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy]-phenyl } - 4,5-dihydro-2H-pyridazin-3-one;
2-(3,5-dichloro-phenyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-
2H-pyridazin-3-one; 6-[3-fluoro-4-(3-piperidin-l-yl-propoxy)-phenyl]-2-phenyl-2H-pyτidazin-3-one;
6-{4-[3-((K)-2-methyl-pyrrolidin-l-yl)ipϊopoxy]-phenyl}-2H-pyridazin-3-one;
4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-255,6;)7-tetrahydro- cyc lopenta[d]pyridazin- 1 -one; 2-methyl-6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyτrolidin-l-yl)-propoxy]-ρhenyl}-
2H-pyridazin-3-one;
6-{4-[3-((S)-2-hydroxymethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-methyl-2H- pyτidazin-3-one;
6-{4-[3-((R)-2-hydroxymethyl-pyrrolidiπ-l-yl)-propoxy]-phenyl}-2-methyl-2H- pyridazin-3-one;
2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidiπ-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one;
2-benzyl-6- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl} -4,5-dihydro-2H- pyridazin-3 -one; 2-benzyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-phenyl-2H-pyridazin-3- one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-phenyl-2H-pyτidazin-3- one;
2-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
5-Isopropyl-7-{4-[3-((R)-2-methyi-pyrrolidin-l-yl)-propoxy]-phenyl}-5H- thieno[2,3-d]pyridazin-4-one;
7-{4-[3-(2s5-dimethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5-isopropyl-5H- thieno[2,3-d]pyridazin-4-one;
5-isopropyl-7-[4-(3-piperidin-l-yl-propoxy)-phenyl]-5H-thieno[2,3-d]pyridazin-4- one;
7-{4-[3-(3,3-dimethyl-piperidin-l-yl)-propoxy]-phenyl}-5-isopropyl-5H-thieno[2,3- d]pyridazin-4-one; 5-isopropyl-7- {4-[3-((S)-2-methoxymethyl-pyrrolidin- 1 -yl)-propoxy] -phenyl } -5H- thieno[2,3-d]pyridazin-4-one; .
5-isopropyl-7-{4-[3-((R)-2-methoxymethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5H- thieno[2,3-d]pyridazin-4-one; 7-[4-(3-diethylamino-propoxy)-phenyl]-5-isopropyl-5H-thieno[2,3-d]pyridazin-4- one;
5-isopropyl-7-[4-(3-pyrrolidin-l-yl-propoxy)-phenyl]-5H-thieno[2,3-d]-pyridazin-4- one; 5-isopropyl-7-{4-[3-(4-pyrrolidin-l-yl-piperidin-l-yl)-propoxy]-phenyl}-5H- thieno[2,3-d]pyridazin-4-one;
7-{4-[3-((2R,5R)-2,5-dimethyl-ρyrrolidin-l-yI)-propoxy3-phenyl}-5-isopropyl-5H- thieno [2,3 -d] pyridazin-4-one;
7-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5-propyl-5H-thieno[2,3- d]pyridazin-4-one;
7-{4-[3-((2R,5R)-2,5-dimethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5-propyl-5H- thieno [2,3 -d] pyridazin-4-one;
7-{4-[3-(4-methyl-piperidin-l-yl)-propoxy]-phenyl}-5-propyl-5H-thieno[2,3- d]pyridazin-4-one; 7-{4-[3-(4-dimethylamino-piperidin-l-yl)-propoxy]-phenyl}-5-ρropyl-5H- thieno[2,3-d]pyridazin-4-one;
5-propyl-7-{4-[3-((S)-2-pyrrolidin-l-ylmethyI-pyrrolidin-l-yl)-propoxy]-phenyl}- 5H-thieno[2, 3 -d]pyridazin-4-one;
5-(4-chloro-benzyl)-7-[4-(3-piperidin-l-yl-propoxy)-phenyl]-5H-thieno[2,3- d]pyridazin-4-one;
5-(4-chloro-benzyl)-7-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5H- thieno[2,3-d]pyridazin-4-one;
2,4-dimethyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
234-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
2-isopropyl-4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
2-isopropyl-4-methyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
2-benzyl-4-methyl-6-{4-[3-((R)-2-methyl-pyrroIidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
2-benzyl-4-methyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
4-benzyl-2-methyl-6- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl } -2H- pyridazin-3-one;
4-benzyl-2-methyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 2-methyl-6-{4-[3-((R)-2-methyl-pyrrόlidiii-l-yl)-propoxy]-ρhenyl}-5-phenyl-2H- pyridazin-3-one;
2-methyl-5-phenyl-6-[4-(3-piperidin-l-yI-propoxy)-phenyl]-2H-pyridazin-3-one;
2-methyl-4-{4-[3-(CR)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-phthalazin- 1 -one;
2-methyl-4-[4-(3-piperidin- 1 -yl-propoxy)-phenyl]-2H-phthalazin- 1 -one;
2-methy 1-4- [4-(2-piperidin- 1 -yl-ethoxy)-phenyl] -2H-phthalazin- 1 -one;
2-methyl-4-[4-(3-pyrrolidin-l -yl-propoxy)-phenyl]-2H-phthalazin- 1 -one;
4-[4-(3-azepan-l-yl-propoxy)-phenyl]-2-methyl-2H-phthalazin-l-one; 2-(4-chloro-benzyl)-4-{4-[3-((R)-2-methyI-pyrroIidin-l-yl)-propoxy]-phenyl}-2H- phthalazin- 1 -one;
2-(4-chloro-benzyl)-4-[4-(3-piperidin- 1 -yl-propoxy)-phenyl]-2H-phthalazin- 1 -one;
2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2.5,6,7- tetrahydro-cyclopenta[d]pyridazin- 1 -one; 2-methyl-4-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2,5,637-tetrahydro- cyclopenta[d]pyridazin-l -one;
2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2.4a,5,6>757a- hexahydro-cyclopenta[d]pyridazin- 1 -one;
2-methyl-4-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2,4a,5,6,7,7a-hexahydro- cyclopenta[d]pyridazin- 1 -one;
2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5>6,7,8- tetrahydro-2H-phthalazin- 1 -one;
4-{4-[3-(butyl-ethyl-amino)-propoxy]-phenyl}-2-methyl-5>6,7>8-tetrahydro-2H- phthalazin-1-one; 4-[4-(3-nαethyl-4-oxo-3,4-dihydro-phthalazin-l-yl)-phenoxymethyl]-piperidine-l- carboxylic acid tert-butyl ester;
2-methyl-4-[4-(piperidin-4-ylmethoxy)-phenyl]-2H-phthalazin-l-one;
4-[4-(l-cyclobutyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-phthalazin-l-one;
4-[4-( 1 -m ethyl -6-oxo- 1 ,6-dihydro-pyridazin-3-yl)-phenoxymethyl]-piperidine- 1 - carboxylic acid tert-butyl ester;
2-methyl-6-[4-(piperidin-4-ylmethoxy)-phenyl]-2H-ρyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one;
6-[4-(l-isopropyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 6-[4-(l-cyclopropylmethyl-pϊperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin- 3 -one;
6-[4-(l-cyclopentyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one;
2-methyl-6-[4-(l-methyl-piperidin-4-ylmethoxy)-phenyl]-2H-pyridazin-3-one; 6-[4-(l-isopropyi-piperidin-4-yloxy)-phenyl]-2-methyl-2H-pyridaziπ-3-one;
2-methyl-6-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one;
2-methyl-6-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one;
2-methyl-8-[3-((R)-2-methyi-pyrrolidin-l-yl)-propoxy]-5,6-dihydro-2H- benzo[h]cinnolin-3-one; 8-[3-((R)-2-methyl-pyτrolidin-l-yl)-propoxy]-2-phenyl-5,6-dihydro-2H- benzo[h]cinnolin-3-one;
2-benzyI-8-(3-piperidin- 1 -yl-propoxy)-5,6-dihydro-2H-benzo [h] cinnolin-3-one;
2-isopropyl-8-(3-piperidin-l-yl-propoxy)-5,6-dihydro-2H-benzo[h]cinnolin-3-one;
2-methyl-7-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-2H-phthalazin-l-one; 2-methyl-7-(3-piperidin-l-yl-propoxy)-2H-phthalazin-l-one; and
6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-phenyl-2H- pyridazin-3-one; and stereoisomeric forms, mixtures of stereoisomeric forms or pharmaceutically acceptable salt forms thereof; with the compound 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]- phenyl}-2H-pyridazin-3-one, or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof being more preferred.
In a second embodiment, the compounds of formula I are selected from Examples 22 to 38, 49 to 50 and 52 to 55. In a third embodiment, the compounds are selected from Examples 12, and 56 to 61. In a fourth embodiment, the compounds are selected from Examples 1 to 3, 5 to 7, 9 to 11, 13 to 15, 18, 20, 39 to 48, and 81. In a fifth embodiment, the compounds are selected from Examples 51, and 62 to 74. In a sixth embodiment, the compounds are selected from Examples 4, 8, 16 to 17, and 19. In a seventh embodiment, the compounds are selected from Examples 75 to 78. In a eighth embodiment, the compounds are Examples 79 and 80. In another aspect, the present invention is directed to pharmaceutically acceptable salts of the compounds described above. As used herein, "pharmaceutically acceptable salts" includes salts of compounds of the present invention derived from the combination of such compounds with non-toxic acid or base addition salts. Acid addition salts include inorganic acids such as hydrochloric, hydrobromic, hydroiodic, sulfuric, nitric and phosphoric acid, as well as organic acids such as acetic, citric, propionic, tartaric, glutamic, salicylic, oxalic, methanesulfonic, para-toluenesulfonic, succinic, and benzoic acid, and related inorganic and organic acids. Base addition salts include those derived from inorganic bases such as ammonium and alkali and alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, as well as salts derived from basic organic amines such as aliphatic and aromatic amines, aliphatic diamines, hydroxy alkamines, and the like. Such bases useful in preparing the salts of this invention thus include ammonium hydroxide, potassium carbonate, sodium bicarbonate, calcium hydroxide, methylamine, diethylamine, ethylenediamine, cyclohexylamine, ethanolamine and the like.
In addition to pharmaceutically-acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of the compounds, in the preparation of other salts, or in the identification and characterization of the compounds or intermediates.
The pharmaceutically acceptable salts of compounds of the present invention can also exist as various solvates, such as with water, methanol, ethanol, dimethylformamide, ethyl acetate and the like. Mixtures of such solvates can also be prepared. The source of such solvate can be from the solvent of crystallization, inherent in the solvent of preparation or crystallization, or adventitious to such solvent. Such solvates are within the scope of the present invention.
The present invention also encompasses the pharmaceutically acceptable prodrugs of the compounds disclosed herein. As used herein, "prodrug" is intended to include any compounds which are converted by metabolic processes within the body of a subject to an active agent that has a formula within the scope of the present invention. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.) the compounds of the present invention may be delivered in prodrug form. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Prodrugs, Sloane, K. B., Ed.; Marcel Dekker: New York, 1992, incorporated by reference herein in its entirety
It is recognized that compounds of the present invention may exist in various stereoisomeric forms. As such, the compounds of the present invention include both diastereomers and enantiomers. The compounds are normally prepared as racemates and can conveniently be used as such, but individual enantiomers can be isolated or synthesized by conventional techniques if so desired. Such racemates and individual enantiomers and mixtures thereof form part of the present invention.
It is well known in the art how to prepare and isolate such optically active forms. Specific stereoisomers can be prepared by stereospecific synthesis using enantiomerically pure or enantiomerically enriched starting materials. The specific stereoisomers of either starting materials or products can be resolved and recovered by techniques known in the art, such as resolution of racemic forms, normal, reverse-phase, and chiral chromatography, recrystallization, enzymatic resolution, or fractional recrystallization of addition salts formed by reagents used for that purpose. Useful methods of resolving and recovering specific stereoisomers described in Eliel, E. L.; Wilen, S.H. Stereochemistry of Organic Compounds; Wiley: New York, 1994, and Jacques, J, et al. Enantiomers, Racemates, and Resolutions; Wiley: New York, 1981, each incorporated by reference herein in their entireties.
It is further recognized that functional groups present on the compounds of Formula I may contain protecting groups. For example, the amino acid side chain substituents of the compounds of Formula I can be substituted with protecting groups such as benzyloxycarbonyl or t-butoxycarbonyl groups. Protecting groups are known per se as chemical functional groups that can be selectively appended to and removed from functionalities, such as hydroxyl groups and carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention. Preferred groups for protecting lactams include silyl groups such as t-butyldimethylsilyl ("TBDMS"), dimethoxybenzhydryl ("DMB"), acyl, benzyl ("Bn"), and methoxybenzyl groups. Preferred groups for protecting hydroxy groups include TBS, acyl, benzyl, benzyloxycarbonyl ("CBZ"), t-butyloxycarbonyl ("Boc"), and methoxymethyl. Many other standard protecting groups employed by one skilled in the art can be found in Greene, T.W. and Wuts, P.G.M., "Protective Groups in Organic Synthesis" 2d. Ed., Wiley & Sons, 1991.
For therapeutic purposes, the compounds of the present invention can be administered by any means that results in the contact of the active agent with the agent's site of action in the body of the subject. The compounds may be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in combination with other therapeutic agents, such as, for example, analgesics. The compounds employed in the methods of the present invention including, for example, the compounds of Formula I, I*, I**, I(a-i), and/or II, may be administered by any means that results in the contact of the active agents with the agents' site or site(s)of action in the body of a patient. The compounds of the present invention are preferably administered in therapeutically effective amounts for the treatment of the diseases and disorders described herein to a subject in need thereof.
A therapeutically effective amount can be readily determined by the attending diagnostician, as one skilled in the art, by the use of conventional techniques. The effective dose will vary depending upon a number of factors, including the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, the formulation of the active agent with appropriate excipients, and the route of administration. Typically, the compounds are administered at lower dosage levels, with a gradual increase until the desired effect is achieved.
Typical dose ranges are from about 0.01 mg/kg to about 100 mg/kg of body weight per day, with a preferred dose from about 0.01 mg/kg to 10 mg/kg of body weight per day. A preferred daily dose for adult humans includes about 25, 50, 100 and 200 mg, and an equivalent dose in a human child. The compounds may be administered in one or more unit dose forms. The unit dose ranges from about 1 to about 500 mg administered one to four times a day, preferably from about 10 mg to about 300 mg, two times a day. In an alternate method of describing an effective dose, an oral unit dose is one that is necessary to achieve a blood serum level of about 0.05 to 20 μg/ml in a subject, and preferably about 1 to 20 μg/ml.
Although the compounds of the present invention may be administered as the pure chemicals, it is preferable to present the active ingredient as a pharmaceutical composition. Generally speaking, therapeutic compounds of this invention may be administered to a patient alone or in combination with a pharmaceutically acceptable carrier. Accordingly, the compounds of the invention, for example, compounds of Formula I, I*, I**, I(a-i), and/or II, are preferably combined with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice as described, for example, in Remington 's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA, 1980), the disclosures of which are hereby incorporated herein by reference, in their entireties. The carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof. The relative proportions of active ingredient and carrier may be determined, for example, by the solubility and chemical nature of the compounds, chosen route of administration and standard pharmaceutical practice.
The compounds of the present invention may be formulated into pharmaceutical compositions by admixture with one or more pharmaceutically acceptable excipients. The ' excipients are selected on the basis of the chosen route of administration and standard pharmaceutical practice, as described, for example, in Remington: The Science and Practice of Pharmacy, 20th ed.; Gennaro, A. R., Ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2000. The compositions may be formulated to control and/or delay the release of the active agent(s), as in fast-dissolve, modified-release, or sustained-release formulations. Such controlled-release, or extended-release compositions may utilize, for example biocompatible, biodegradable lactide polymers, lactide/glycolide copolymers, polyoxyethylene-polyoxypropylene copolymers, or other solid or semisolid polymeric matrices known in the art.
The compositions can be prepared for administration by oral means; parenteral means, including intravenous, intramuscular, and subcutaneous routes; topical or transdermal means; transmucosal means, including rectal, vaginal, sublingual and buccal routes; ophthalmic means; or inhalation means. Preferably the compositions are prepared for oral administration, particularly in the form of tablets, capsules or syrups; for parenteral administration, particularly in the form of liquid solutions, suspensions or emulsions; for intranasal administration, particularly in the form of powders, nasal drops, or aerosols; or for topical administration, such as creams, ointments, solutions, suspensions aerosols, powders and the like.
For oral administration, the tablets, pills, powders, capsules, troches and the like can contain one or more of the following: diluents or fillers such as starch, or cellulose; binders such as macrocrystalline cellulose, gelatins, or polyvinylpyrrolidones; disintegrants such as starch or cellulose derivatives; lubricants such as talc or magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; or flavoring agents such as peppermint or cherry flavoring. Capsules may contain any of the afore listed excipients, and may additionally contain a semi-solid or liquid carrier, such as a polyethylene glycol. The solid oral dosage forms may have coatings of sugar, shellac, or enteric agents. Liquid preparations may be in the form of aqueous or oily suspensions, solutions, emulsions, syrups, elixirs, etc., or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as surfactants, suspending agents, emulsifying agents, diluents, sweetening and flavoring agents, dyes and preservatives.
The compositions may also be administered parenterally. The pharmaceutical forms acceptable for injectable use include, for example, sterile aqueous solutions, or suspensions. Aqueous carriers include mixtures of alcohols and water, buffered media, and the like. Nonaqueous solvents include alcohols and glycols, such as ethanol, and polyethylene glycols; oils, such as vegetable oils; fatty acids and fatty acid esters, and the like. Other components can be added including surfactants; such as hydroxypropylcellulose; isotonic agents, such as sodium chloride; fluid and nutrient replenishers; electrolyte replenishers; agents which control the release of the active compounds, such as aluminum monostearate, and various co-polymers; antibacterial agents, such as chlorobutanol, or phenol; buffers, and the like. The parenteral preparations can be enclosed in ampules, disposable syringes or multiple dose vials. Other potentially useful parenteral delivery systems for the active compounds include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
Other possible modes of administration include formulations for inhalation, which include such means as dry powder, aerosol, or drops. They may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally. Formulations for topical use are in the form of an ointment, cream, or gel. Typically these forms include a carrier, such as petrolatum, lanolin, stearyl alcohol, polyethylene glycols, or their combinations, and either an emulsifying agent, such as sodium lauryl sulfate, or a gelling agent, such as tragacanth. Formulations suitable for transdermal administration can be presented as discrete patches, as in a reservoir or microreservoir system, adhesive diffusion-controlled system or a matrix dispersion-type system. Formulations for buccal administration include, for example lozenges or pastilles and may also include a flavored base, such as sucrose or acacia, and other excipients such as glycocholate. Formulations suitable for rectal administration are preferably presented as unit-dose suppositories, with a solid based carrier, such as cocoa butter, and may include a salicylate.
Pharmaceutical kits useful in, for example, the treatment of pain, which comprise a therapeutically effective amount of a compound of the invention and/or other therapeutic compounds described herein, in one or more sterile containers, are also within the ambit of the present invention. Sterilization of the container may be carried out using conventional sterilization methodology well known to those skilled in the art. The sterile containers of materials may comprise separate containers, or one or more multi-part containers, as exemplified by the UNIVIAL™ two-part container (available from Abbott Labs, Chicago, Illinois), as desired. The compound of the invention and/or other therapeutic compound as described herein may be separate, or combined into a single dosage form as described above. Such kits may further include, if desired, one or more of various conventional pharmaceutical kit components, such as for example, one or more pharmaceutically acceptable carriers, additional vials for mixing the components, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, may also be included in the kit.
The compounds of the present invention may be used in methods to bind histamine receptors, more preferably histamine H3 receptors. Such binding may be accomplished by contacting the receptor with an effective amount of a compound of Formula I, I*, I**, I(a-i), and/or II. The histamine receptors may be located in the central nervous system or located peripherally to the central nervous system or in both locations. Preferably, the contacting step conducted in an aqueous medium, preferably at physiologically relevant ionic strength, pH, and the like.
In yet another aspect, the invention is directed to methods of binding histamine receptors, more preferably histamine H3 receptors, comprising the step of administering to a patient in need thereof, an effective amount of a compound of the invention including, for example, a compound of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof.
In certain preferred aspects, the methods comprise the step of administering to said patient an therapeutically effective amount of a compound of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof.
In some preferred embodiments, the histamine receptors are H3 histamine receptors. In certain more preferred embodiments, the compound selectively binds H3 histamine receptors relative to Hi, H2 and/or FL» receptors. In certain preferred embodiments, the H3 histamine receptors are located in the central nervous system. In some other preferred embodiments, the compound of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof exhibits activity toward the histamine receptors. In certain preferred embodiments, the binding agonizes the activity of the cannabinoid receptors. In other preferred embodiments, the binding antagonizes the activity of the cannabinoid receptors, more preferably as a neutral antagonist. In still other preferred embodiments, the binding inversely agonizes the activity of the cannabinoid receptors.
In yet other preferred embodiments, the compounds of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof exhibit activity toward the histamine receptors in vivo. In alternatively preferred embodiments, the compounds of Formula I, I*, I**, I(a-i), and/or II, or any combination thereof, exhibit activity toward the histamine receptors in vitro.
In certain other preferred aspects of the invention, there are provided methods of treating a disease, disorder or condition that may be affected, modulated or controlled through the binding of histamine, preferably H3 histamine receptors. More preferably these diseases, disorders, and/or conditions selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction. The methods herein provided comprise administering to a subject in need of such treatment a therapeutically effective amount of a compound of the invention, preferably a compound of formula:
Figure imgf000068_0001
more preferably a compound of formula I, I*, I**, I(a-i), and/or II, or any combination thereof.
In certain preferred embodiments, the disorder is narcolepsy or sleep/wake disorders. Alternatively the disorder treated is attention deficit hyperactivity disorder.
As those skilled in the art will appreciate, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein, and the scope of the invention is intended to encompass all such variations.
Synthesis The compounds of the present invention may be prepared in a number of methods well known to those skilled in the art, including, but not limited to those described below, or through modifications of these methods by applying standard techniques known to those skilled in the art of organic synthesis. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale.
The general routes to prepare the examples shown herein are shown in the Schemes 1 and 2. The reagents and starting materials are commercially available, or readily synthesized by well-known techniques by one of ordinary skill in the arts. All substituents in the synthetic Schemes, unless otherwise indicated, are as previously defined.
Condensation of 4-(4-methoxyphenyl)-4-oxobutyric acid or ester, or a derivative there of, with hydrazine or an N-substituted hydrazine derivative in a solvent such as ethanol or 2-propanol provided a route to 4,5-dihydropyridazinone intermediates. Keto-acid intermediates with substitution at the 4- and 5-position (Examples with R13/13a and R14/14a) may be readily prepared (Heterocycles, 2002, 57, 39; Indian J. Chem, 1977, 16B, 631; Chem Pharm Bull, 1980, 42, 1850; J. Med. Chem. 2003, 46, 2008). Pyridazinones with R.1 and RI4/14a fused with heteroaryl or cycloalkyl were readily prepared from the corresponding anhydrides. NH (N2) pyridazinones were alkylated with alkyl or substituted alkyl groups using an R12-halide, a base, for example K2CO3, CS2CO3 or NaH, in an inert solvent such as DMF or CH3CN.
In cases where R13 or R14 substituted 4,5-dihydropyridazinone formed a mixture of isomers, the isomers were separated by standard methods known in the art. Intermediates wherein R12 is H may be converted to analogs wherein R12 is aryl or heteroaryl by standard palladium or copper coupling reactions using the appropriate aryl or heteroaryl halide. The 4,5-dihydropyridazinone may be oxidized to an aromatic pyridazinone using MnC^, CuCl2, DDQ, selenium oxide, DMSO / base or sodium 3-nitrobenzenesulfonate in the presence of sodium hydroxide. Scheme 1. General synthesis of N2 H and substituted examples
Figure imgf000070_0001
R1 1. CI' ~Br
2. amine
Figure imgf000070_0002
rVε amine
Figure imgf000070_0003
In Scheme 1 , examples of compounds disclosed herein may be obtained by condensation of an intermediate keto acid for example, 4-(4-methoxyphenyl)-4-oxobutyric acid (or an ester derivative) with hydrazine or an n-substituted hydrazine derivative in a solvent such as ethanol or 2-propanol to produce a dihydropyridazinone intermediate. The keto-acid intermediates not commercially available are readily prepared and described using literature methods. Keto-acid intermediates with R13 or R14 groups in the 4 or 5-positons or fused aryl or heteroaryl groups are described (Heterocycles, 2002, 57, 39; Indian J. Chem, 1977, 16B5 631; Chem Pharm Bull, 1980, 42, 1850; J. Med. Chem. 2003, 46, 2008). The N2 position may be substituted with alkyl or substituted alkyl groups using a base, for example K2CO3, CS2CO3 or NaH in an inert solvent such as DMF or CH3CN. In cases where R13 or R14 substituted dihydropyridazinone form isomers, the individual isomers may be separated using conventional methods known to the art. R13 aryl or heteroaryl groups may be introduced by standard palladium or copper coupling reactions using the appropriate aryl or heteroaryl halide. Alternatively, the 4,5 -position may be oxidized to the pyridizinone intermediate using for example MnC>2, CuCl2, DDQ or selenium oxide as the oxidizing agent. The N2 nitrogen may be H, or further substituted using methods outlined previously. Scheme 2. General synthesis of 4,5-dihydro examples
Figure imgf000071_0001
Figure imgf000071_0002
As outlined in Scheme 1 and 2, the pyridizinone or dihydro pyridizinone methoxy intermediate is demethylated using BBr3 in dichloromethane to produce the phenol. Alkylation of the phenol with bromochloropropane or a dibromoalkane intermediate in a suitable solvent such as DMF, acetone, butanone or CH3CN with K2CO3 produces the halogen intermediate. Alkylation of the halide intermediate with an amine gives the target dihydropyridazinone examples of the invention. Other suitable leaving groups may be used such as mesylates as precursors to amines. Mitsunobo reactions with cyclic amino-ethers such as 4-hydroxypiperidine, 3-hydroxypyrτolidine or substituted amino alcohols produce the corresponding examples. Alkyl bridged analogs or linker group with hetero atoms can readily be prepared for example from methoxy indanones, tetralones, benzocycloheptanones, dihydro-2H-benzo[b]oxepinones, dihydro-2H-benzo[b]thiepinones, chromanones, or thiochromanones.
As outlined in Schemes 3 and 4, the pyridazinone or 4,5-dihydropyridazinone was demethylated using BBr3 in dichloromethane to produce phenol intermediates III and Ilia. Alkylation of the phenol intermediates with 3-bromo-l-chloropropane or a dibromo intermediate in a suitable solvent such as DMF, acetone, butanone or CH3CN with K2CO3 produced the corresponding alkylated intermediate. Displacement of the halide with an amine gave the target dihydropyridazinone examples of general structures V and Va. Scheme 3. General synthesis of R H and substituted examples
Figure imgf000072_0001
BBr3/CH2CI2 1. Cl' "Br
2. amine
Figure imgf000072_0003
Figure imgf000072_0002
III
Figure imgf000072_0004
Scheme 4. General synthesis of 4,5-dihydro examples
Figure imgf000072_0005
As outlined in Scheme 5, the phenol intermediate was coupled under Mitsunobo conditions with hydroxypiperidines, pyrrolidines or azepines to give the piperidine or cyclic amine derivatives of general structure VI. Using reaction conditions described previously, examples of general structure VII was prepared. Scheme 5. General synthesis of 4,5-dihydro examples
Figure imgf000073_0001
VII
Scheme 6 discloses an Aidol condensation route to examples wherein R12 is H. 4-Hydroxy-acetophenone or a derivative thereof was condensed with a keto-acid, for example glycolic acid in acetic acid, and cyclized with hydrazine to give an aromatic pyridazinone (J. Med. Chem., 1989, 32, 528).
Scheme 6.
Figure imgf000073_0002
5-Aryl pyridazinone examples were synthesized as outlined in Schemes 7 and 8. Condensation of 4-methoxyphenyl acetone (R14 = Me) with glyoxylic acid (Scheme 7), followed by cyclization with hydrazine hydrate or N-substituted hydrazine derivatives afforded 5-(4-methoxy-phenyl)-6-methyl-2H-pyridazin-3-one, and N-R12 examples (Farmaco, 1996, 51, 693-688). Scheme 7.
Figure imgf000074_0001
BBr3ZCH2CI2 BrCH2CH2CH2CI
Figure imgf000074_0002
(R)-2-methyl pyrrolidine K2CO3ZNaIZCH3CN
Figure imgf000074_0003
5-Aryl examples where R14 is H were prepared as outlined in Scheme 8 starting from 4-methoxyphenylacetaldehyde using conditions shown in Scheme 7.
Scheme 8. Synthesis of 5-Aryl Example 91 to 93
Figure imgf000075_0001
CH3NHNH2 BrCH2CH2CH2CI EtOH KjCOj/acetone
Figure imgf000075_0002
Figure imgf000075_0003
Example 93 Example 92
Aza examples (X = N) where R13 and R13a are each methyl were prepared as outlined in Scheme 9 by alkylation of l-(6-chloropyridin-3-yl)ethanone with 4-hydroxy-N- Boc-piperidine and a base such as NaH, potassium tertiary butoxide, or KHMDS in DMSO, DMF or THF. A second alkylation step using potassium bis(trimethylsilyl)amide in toluene and, for example 2-bromo-2-methyl-propionic acid ethyl ester, produced the keto-ester intermediates VIII. Example 148 was produced as shown in Scheme 9 using conditions described previously.
Scheme 9. 4-boc-hydroxy-piperidine
Figure imgf000076_0001
KtOBu
Figure imgf000076_0002
Figure imgf000076_0003
Example 148
Scheme 10 shows the route to aza (X = N) examples where R12 is heteroaryl(For example, Example 149 (6-[6-(l-Cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-pyridin-2-yl- 2H-pyridazin-3-one). 6-(6-Chloropyridin-3-yl)-4,5-dihydro-2H-pyridazin-3-one intermediate IX, prepared from ethyl-4-(4-chloro-3-pyridyl)-4-oxobutyrate and hydrazine in ethanol was alkylated with 4-hydroxy-boc-piperidine and a base (KHMDS, DMSO) to intermediate X and converted to example 141 using methods described previously. Treatment of Example 141 with 2-bromopyridine in the presence of copper(I)iodide gives Example 149. Using aryl halides or heteroaryl halides gave examples where R12 is aryl or heteroaryl.
Scheme 10.
TFA, CH2CI2, quant. cyclobutanone, NaCNBH3
Figure imgf000077_0001
Figure imgf000077_0002
Example 141
Example 149
Bridged examples (Scheme 1 l)were prepared using methoxy tetralones and glycolic acid in an aldol synthesis. Phenol formation and alkylations as described previously produced the N-substituted examples. Alternatively, the use of β-tetralones provided a route to pyridazinone regioisomers.
Scheme 11.
Figure imgf000077_0003
Scheme 12 shows bridged analogs where R12 is H , prepared by varying the order of the reactions. Addition of Zn dust to the aldol/ring closure procedure gave a one-pot synthesis of the dihydropyridazinone. Scheme 12.
K2CO3
Figure imgf000078_0001
The present invention will now be illustrated by reference to the following specific, non-limiting examples. Those skilled in the art of organic synthesis may be aware of still other synthetic routes to the invention compounds. The reagents and intermediates used herein are commercially available or may be prepared according to standard literature procedures.
EXAMPLES
Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments as shown below. The compounds shown herein have activity in the targets described herein at concentrations ranging from 0.1 nM to 10 μM. These examples are given for illustration of the invention and are not intended to be limiting thereof. Example 1.
Figure imgf000078_0002
2-Methyl-6-{4-[3-((R)-2-methyl-pyrr olidin-1-yl)-propoxy]-phenyl}-2H-py ridazin-3-one Step 1.
Figure imgf000079_0001
6-(4-Methoxy-phenyl)-2-methyl-4,5-d ihydro-2H-pyridazin-3-one
In a 500 mL round bottom flask, 4-(4-methoxyphenyl)-4-oxobutyric acid (27 g, 132 mmol) and methylhydrazine (7.3 g, 8.5 mL, 159 mmol) in 2-propanol (150 mL) were stirred at reflux 12 h. The solvent was concentrated to about 50 mL, ether was added (~ 50 mL) and the product collected by filtration, washed Ix with ether and dried under house vacuum. Yield 27 g (94%, purity >95%), mp 133-135 0C. 1H NMR (CDCl3) δ 2.57 (m, 2H), 2.9 (m, 2H), 3.4 (s, 3H), 3.8 (s, 3H), 6.9 (d, 2H), 7.6 (d, 2H). MS m/z = 218 (M + H).
Step 2.
Figure imgf000079_0002
6-(4-Methoxy-phenyl)-2-methyl-2H- pyridazin-3-one
Method A: In a IL round bottom flask, 6-(4-methoxyphenyl)-2-methyl-4,5- dihyrdo-2H-pyridazin-3-one (27 g, 124 mmol) and MnO2 (30 g, 345 mmol) in xylene (250 mL) was stirred at vigorous reflux 14 h. The reaction was cqoled to rt and filtered through a pad of celite. The xylene was concentrated and the resulting yellow solid was triturated with ether/hexane (1:2) and collected to produce 20 g (75%, HPLC 98% purity) of product. The celite/MnO2 pad was washed with CHCl3 :MeOH 9:1 (2x -100 mL), filtered and concentrated. The residue was triturated with ether/hexane (1 :2) and collected to give a second crop (4 g, 15%, 96% purity) total yield 24g (90%). mp 109-1100C. 1H NMR
(DMSCW6) δ 3.75 (s, 3H), 3.85 (s, 3H), 7.0-7.05 (d, 2H, d, IH), 7.82 (d, 2H)5 8.01 (d, IH); MS m/z = 216 (M + H).
Method B: A mixture of 6-(4-methoxyρheny l)-2-methy 1-4,5 -dihyrdo-2H-pyridazin- 3-one (3.27g, 15 mmol) and Cu(II)Cl2 (3.96g, 2 eq., anhydrous, Acros) in 45ml of anhydrous acetonitrile was refiuxed for 2 hr. HPLC indicated the completion of the reaction (rt (product) = 7.66 min, rt (SM) = 7.88 min). The reaction was cooled to rt and poured into ice-water (-100 ml) and the acetonitrile removed at reduced pressure. The resulting off- white solid was filtered off, washed with water, and then crystallized from EtOH:Et2O to give the product (2.47 g, 76%).
Step 3.
Figure imgf000080_0001
6-(4-Hydroxy-phenyl)-2-methyl-2H- pyridazin-3-one
To 6-(4-methoxyphenyl)-2-methyl-2H-pyridazin-3-one (10 g, 46.3 mmol) in 15 mL DCM cooled on an ice-water bath to ~5 0C was added 93 mL OfBBr3 (IM soln in DCM) over 5 min. The ice bath was removed and the solution stirred at rt for 4 h. The reaction was cooled on an ice-bath and saturated NH4Cl solution (100 mL) added slowly. After the addition was complete, the DCM was removed under reduced pressure, excess water added and the product collected, washed Ix with MeOH (~20 mL) and dried to give 9.2 g (98%): Mp 242-245 0C. 1H NMR (DMSOd6) 5 3.8 (s, 3H), 6.85 (d, 2H), 7.0 (d, 1 H), 7.7 (d, 2H), 7.95 (d, IH), 9.8 (s, IH); MS m/z = 203 (M + H).
Step 4.
Figure imgf000080_0002
6-[4-(3-Chloro-propoxy)-phenyl]-2- methyl-2H-pyridazin-3-one
Phenol from step 3 (500 mg, 2.3 mmol), 3-bromo-l-chloropropane (720 mg, 4.6 mmol) and K2CO3 (950 mg) in CH3CN (25 mL) was stirred at reflux 20 h. The reaction was filtered and concentrated. The resulting oil was dissolved in Et2O, and washed with water, NaCl solution, dried (MgSO4) and concentrated. The product was triturated with Et2O- hexanes to yield 580 mg (91%) mp 186-187 0C. 1H NMR (DMSO-^6) δ 2.2 (t, 2H), 3.7 (s, 3H), 3.8 (t, 2H)5 4.15 (t, 2H), 7.0-7.1 (m, 3H), 7.8 (d, 2H), 8.0 (d, IH). MS m/z = 279 (M + H).
Step 5. Example 1
Figure imgf000081_0001
2-Methyl-6-{4-[3-((R)-2-methyl-pyrr olidin-1-yl)-propoxy]-phenyl}-2H- pyridazin-3-one
6-[4-(3-Chloropropoxy)phenyl]-2-methyI-2H-pyridazin-3-one (1.5 g, 5.4 mmol), K2CO3 (2.2g 16.2 mmol), NaI (805 mg, 5.4 mmol) R-methylpyrrolidine HCl (1.3 g, 10.8 mmol) in CH3CN (30 mL) was heated under N2 at 90 0C for 2 days. The reaction was filtered and concentrated. The residue was dissolved in EtOAc and washed with 2N Na2COs (Ix), NaCl solution (Ix) dried (MgSO4) and concentrated. The product was purified by ISCO chromatography (8Og silica gel column, 95:5 DCM: MeOH). The fractions were combined and concentrated to yield 850 mg (48%) of free base. The HCl was prepared by adding a IN HCl-ether solution to the based in ether. The product was collected, and recrystallized from CH3CN-ether. mp 183-185 0C. 1H NMR (DMSO-^6) δ 1.38 (d, 3H), 1.62 (m, IH)5 1.92-1.3.1 (m, 3H)3 3.4 (m, 3H)3 3.7 (m, IH)5 3.7 (s, 3H), 4.15 (m, 2H), 7.0- 7.17 (m5 3H)5 7.8 (d, 2H)3 8.0 (d3 IH), 10.1 (s,lH). MS m/z = 328 (M + H).
Example 11
Figure imgf000081_0002
6-{4-[3-((R)-2-Methyl-pyrrolidiπ-1- yl)-propoxy]-phenyl}-2H-pyridazin-3
-one
Figure imgf000081_0003
1-[4-(3-Chloro-propoxy)-phenyl]-ethanone
A mixture of l-(4-hydroxyphenyl)ethanone (20.4 g, 150 mmol), K2CO3 (62.1 g, 3.0 eq.)5 and 3-bromo-l-chloropropane (29.6 mL, 2.0 eq.) in CH3COCH3 (200 mL) was heated to 65 0C overnight. The mixture was filtered, washed with acetone, and concentrated to dryness. The crude product was dissolved in 150 mL of CH2Cl2, and washed with saturated NaHCC>3, NaCl solution and dried OVCrNa2SO4. Concentration to dryness under vaccum afforded product (31.5 g, 99 % yield): MS m/z 213 (M + H).
Figure imgf000082_0001
6-I4-(3-Chloro-propoxy)-phenyl]-2H- pyridazin-3-one
A mixture of the product from step 1 1 (4.6 g, 1.0 eq.) and glyoxalic acid monohydrate (4.6g, 1.0 eq.) was stirred in 15 mL of acetic acid at 100 0C for 2 h. The solvent was evaporated and to the residue was added 25 mL of water, and cooled to 0 0C while cone, aqueous NH4OH was added to pH 8. To this mixture, hydrazine hydrate (4.76 mL, 2 eq.) was added and heated to 100 0C for 1 h. The resulting solid was filtered, washed with water. The crude material was dissolved in CH2Cl2ZMeOH and purified by column chromatography with CH2Cl2 to 10 % MeOH in CH2Cl2; Mp 191 -3 0C; MS m/z 265 (M + H).
Figure imgf000082_0002
6-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-pheny!}-2H-pyridazin-3-one A mixture of the product from step 2 (5.5 g, 21 mmol), K2CO3 (3.5 eq, 10.1 g), 100 mg of NaI, and R-2-methylpyrrolidine hydrochloride (2 eq., 5.1 g) in 250 mL of acetonitrile was heated to 800C for 2 days. The reaction mixture was then filtered, washed with CH2Cl2 (2 x 5OmL), and concentrated. The residue was dissolved in 200 mL Of CH2Cl2, and washed with saturated NaHCO3, saturated NaCl, dried with Na2SO4 and concentrated. The residue was purified by ISCO graduate chromatography with 100% CH2Cl2 to 5%MeOH: 95% CH2Cl2:0.5 mL of 2-aminopropane and then to 10%MeOH: 90% CH2Cl2:0.5 mL of 2- aminopropane to give the product. The product was dissolved in 15 mL of MeOH and then added 30 mL of 0.5 N HC! in EtOH. Evaporation of the solvent, and crystallization from MeOH: Et2O afforded the example 11 as the HCl salt (2.65g, 41%): Mp 240-2 0C; MS m/z 314 (M + H).
The following examples were prepared as HCl salts unless noted using methods for example 1 and example 11. The 4,5-dihydro examples were prepared using the method for step 3 on the product from step 1.
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Example 21.
Figure imgf000086_0002
2-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-phenyl}-2H-pyridazin-3
-one A mixture of R-l-[3-(4-bromo-phenoxy)-propyl]-2-methyl-pyτrolidine (560 mg. 1.87 mmol), 2H-pyridazin-3-one (180 mg, 1.87 mmol), K2CO3 (775 mg, 5.61 mmol), copper powder (120 mg, 1.87 mmol) in pyridine (75 mL) was stirred at reflux under nitrogen for 18 h. The reaction was cooled to rt and concentrated at reduced pressure. The residue was dissolved onto fluorsil for elution and purification by ISCO silica gel chromatography (95:5: 1/ DCM3 MEOH, isopropyl amine). The fractions containing pure product were collected and concentrated. The solid was recrystallized from Et2θ-hexanes to give 210 mg of Example 21 as a white solid; Mp 106-107 0C. The HCl salt was prepared by dissolving the base in MeOH and adding IN Et2O-HCl: Mp 175-177 0C (MeOH-Et2O); MS m/z 314 (M + H).
Example 22
Figure imgf000088_0001
5-!sopropyl-7-{4-[3-((R)-2-methyl-p yrrolidin-1-yl)-propoxy]-phenyl}-5H
-thieno[2,3-d]pyridazin-4-one
Step 1.
Figure imgf000088_0002
7-(4-Methoxy-phenyl)-5H-thieno- [2,3-d]pyridazin-4-one
A solution of 3-thiophenecarboxylic acid (10 g, 78 mmol) in 250 mL of THF at 0 0C under N2 was added 2.0 M LDA (2.2 eq., 86 mL) dropwise. After 10 min at 0 °C,p- anisaldehyde (10.6 mL, 1.12 eq.) was added and the mixture was slowly warmed to room temperature overnight. The reaction was stirred for ~ 14 h. after which 100 mL of ice- water was added, and the solvent was evaporated. The aqueous solution was washed with EtOAc (2 x 40 mL), and then added KMnO4 (2 eq., 12.4 g) dropwise at 0 0C. The ice-bath was removed and the reaction was heated to 60 0C for 3 h. The solid was collected and washed with hot water. The aqueous layer was acidified to pH ~3, extracted with EtOAc (3 x 50 mL). The combined EtOAc was dried and evaporated. The crude solid was dissolved in 50 mL of EtOH, and NH2NH2-H2O (1.5 eq., 1.5 mL) was added dropwise. The reaction was heated to 800C for 3 h, and the resulting solid was collected and washed with EtOH to give 3.6g (36%): MS m/z 259 (M + H). Step 2.
Figure imgf000089_0001
5-lsopropyl-7-(4-methoxy-phenyl)-5H -thieno[2,3-d]pyridazin-4-one
A solution of the product from step 1 in 10 mL of DMF was added CS2CO3 (2 eq.
1.95g) and 2-iodopropane (1.2 eq., 360 uL). The reaction was heated to 80 0C for 2 h, and then filtered through celite, washed with MeOH: CH2Cl2 (95:5). The filtrate was concentrated and purified by silica gel flash chromatography (MeOH: CH2Cl2, 97:3) to ' afford 585 mg (65%) of the product: Mp 124-60C; MS m/z 301 (M + H).
Step 3.
Figure imgf000089_0002
7-(4-Hydroxy-phenyl)-5-isopropyl-5H -thieno[2,3-d]pyridazin-4-one A solution of the product from step 2 (1.0 g, 3.3 mmol) in 25 mL of CH2Cl2 was cooled to 00C and BBr3 (IM in DCM, 16.7 mL) was added dropwise. The ice-bath was removed and the reaction was stirred at rt for 1 h. The reaction mixture was then poured into 50 mL of ice cold saturated NH4Cl solution with stirring. The resulting solid was collected, washed with water (3 x 15 mL), and Et2O (2 x 15 mL) to give the product of step 3 (868 mg, 92%): Mp 256-257 0C; MS m/z 287 (M + H). Step 4.
Figure imgf000090_0001
7-[4-(3-Chloro-propoxy)-phenyl]-5- isopropyl-5H-thieno[2,3-d]pyrϊdazin-
4-one
A solution of the product of step 3 (858 mg, 3 mmol), K2CO3 (1.24 g, 3.0 eq.), and 3-bromo-l-chloropropane (0.3 mL, 1.05 eq.) in acetone:DMF (25 mL:3 mL) was heated to 80 0C overnight. The mixture was then filtered, washed with acetone, and concentrated to dryness to afford the product of step 4 (1.17 mg, 98% yield): Mp 92-40C; MS m/z 363 (M + H).
Step 5.
Figure imgf000090_0002
5-lsopropyl-7-{4-[3-((R)-2-methyl- pyrrolidin-1-yl)-propoxy]-phenyl}-5H
-thieno[2,3-d]pyridazin-4-one
A mixture of the product of step 4 (109 mg, 0.3 mmol), K2CO3 (3.5 eq, 145 mg), 50 mg of NaI, and Λ-2-methylpyrrolidine hydrochloride (1.2 eq., 44 mg) in 10 mL of acetonitrile was heated to 800C for 2 days. The reaction mixture was then filtered, washed with CH2Cl2 (2 x 2OmL) and concentrated. The residue was dissolved in 20 mL OfCH2Cl2, and washed with saturated NaHCO3 solution, saturated NaCl solution, dried with Na2SO4, and concentrated. The residue was purified by preparative TLC or ISCO graduate silica gel chromatography (MeOH: CHaCl2 :2-aminopropane; 5:95:0.5) to give the product. The product was dissolved in 5 mL of MeOH, and added 0.5 mL of IN HCl in EtOH. Evaporation of the solvent, and crystallization from MeOH: Et2O afforded the HCl salt of example 22 (5-isopropyl-7-(4-(3-((R)-2-methyl-pyrrolidin-lyl)propoxy) phenyl)-5H-thieno [2,3-d]pyridazin-4-one) (52 mg, 42%): Mp 123-4 0C; MS m/z 412 (M + H). The following examples were prepared as HGl salts using methods of example 22.
Figure imgf000091_0001
Figure imgf000092_0001
Figure imgf000093_0001
Figure imgf000094_0001
Example 39
Figure imgf000094_0002
2,4-Dimethyl-6-[4-(3-piperidin-1-yl -propoxy)-phenyl]-2H-pyridazin-3-one
Step 1. A solution of 2-methoxy-4-oxo-4-(4'-methoxyphenyl) butyric acid (2.22 g, 10 mmol) and hydrazine hydrate (1.5 eq., 688 μL) in 20 mL of EtOH was stirred at 80 0C overnight. The solvent was removed and the solid was collected and washed with cold EtOH to give 6-(4-methoxy-phenyl)-4-methyl-4.5-dihydro-2H-pyridazin-3-one (2.05 g , 94%): Mp 203-6 0C.
Step 2. A mixture of the product from step 1 (6-(4-methoxy-phenyl)-4-methyl-4,5- dihydro-2H-pyridazin-3-one; 1.96 g, 9 mmol) and Cu(II)Cl2 (2.48 g, 2 eq.) in of acetonitrile (15 mL) was heated to 70 0C for 2 h. The reaction was quenched with ice-water (—100 mL), the resulting solid was collected and crystallized from isopropanol to give 1.42 g (73%) of 6-(4-methoxy-phenyl)-4-methyl-2H-pyridazin-3-one,:-Mp 265-7 0C; MS m/z 217 (M + H).
Figure imgf000094_0003
6-(4-Methoxy-p h e ny l)-2,4-d imethyl-2 H-pyridazin-3-one Step 3. The product of step 2 (6-(4-methoxy-phenyl)-2,4-dimethyl-2H-pyridazin-3- one) was prepared as described for example 22 step 2 using 6-(4-methoxy-phenyl)-4- methyl-4,5-dihydro-2H-pyridazin-3-one, MeI and Cs2CC>3.
Example 39.
6-(4-(3-Chloropropoxy)-phenyl)-2,4-dimethyl-2H- pyridazin-3-one was prepared from the product of step 3 and 3-bromo-l-chloropropane using the procedure described for Example 22 step 4. Example 39 (2,4-dimethyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H- pyridazin-3-one) was prepared using 6-(4-(3-chloropropoxy)-phenyl)-2,4-dimethyl-2H- pyridazin-3-one and piperidine by the methods described for example 22 step 5. The hydrochloride salt was prepared; Mp 222-3 0C; MS m/z 342 (M + H).
The following examples as HCl salts were prepared using methods described for example 1 and example 22.
Figure imgf000095_0001
Figure imgf000096_0001
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0002
Figure imgf000099_0001
4-Benzyl-6-(4-methoxy-phenyl)-2H- pyridazin-3-one
6-(4-methoxy-phenyl)-4,5-dihydro-2H-pyridazin-3-one (1.65 g, 7.5 mmol) in 15 mL OfEtOH was heated to 80 0C as 20 mL of 4 % of KOH /EtOH solution was added dropwise. After 5 min., benzaldehyde (1.0 eq. 0.76 mL) was added and the mixture stirred at 80 0C for 2 h. The reaction was cooled to rt, poured into ice-H2θ (75 mL) and the resulting solid was collected and crystallized from EtOH to give 1.67 g (76 %) of intermediate 4-benzyl-6-(4- methoxy-phenyl)-2H-pyridazin-3-one: MS m/z 293 (M+H). This intermediate was used to prepare examples 45 and example 46.
Figure imgf000100_0001
6-(4-Methoxy-phenyl)-2-methyl-5- phenyl-2H-pyridazin-3-one
Step 1. A suspension of NaH (12.8 mmol, 512 mg) in DMSO (23 mL) was added 4'-methoxy-2-phenylacetophenone (12.8 mmol, 2.89 g) in 10 ml toluene dropwise under argon. After 30 minutes of stirring, ethyl bromoacetate (1.4 mL, 1 eq.) in 10 mL of toluene was added and the mixture was stirred at rt overnight. The reaction was quenched by addition of 2N HCl (4 mL), and then 60 mL of water. The mixture was extracted with CH2Cl2 (3 x 30 mL), dried over MgSO4 and concentrated under vacuum overnight to afforded 4.0 g (99%) of 4-(4-methoxy-phenyl)-4-oxo-3-phenyl-butyric acid ethyl ester. Step 2. A solution of 4-(4-methoxy-phenyl)-4-oxo-3-phenyl-butyric acid ethyl ester
(5.0 g, 16 mmol) in EtOHrH2O (60 mL 1 :1) was stirred as ION NaOH (16 mL) was added dropwise. The reaction was stirred at rt for 1 hr. The solvent was evaporated and the residue was diluted with water (50 mL) and extracted with CH2Cl2 (2 x 20 mL). The aqueous layer was then acidified with 3N HCl to pH -2-3, extracted with CH2Cl2 (3 x 30 mL). The CH2Cl2 extracts were dried over MgSO4, and the oil was crystallized from
Et2OZMeOH to give 4.5 g (99%) of 4-(4-methoxy-phenyl)-4-oxo-3-phenyl-butyric acid: mp 157-9 0C; MS m/z 283 (M - H).
Step 3. A solution of 4-(4-methoxy-phenyl)-4-oxo-3-phenyl-butyric acid (1.5 g, 5.28 mmol) and hydrazine hydrate (1.5 eq., 363 μL) in 20 mL of EtOH was stirred at 800C overnight. The solvent was reduced and the solid was filtered and then washed with cold EtOH to give 6-(4-methoxy-phenyl)-5-phenyl-4,5-dihydro-2H-pyridazin-3-one (1.46 g , 99%): mp 176-7 0C; MS m/z 281 (M + H).
Examples 47 and 48 were prepared from 6-(4-methoxy-phenyl)-5-phenyl-4,5- dihydro-2H-pyridazin-3-one as described in Example 39.
Example 62.
Figure imgf000101_0001
4-[4-(3-Methyl-4-oxo-3,4-dihydro-ph thalazin-1-yl)-phenαxymethyl]-piper idine-1-carboxylic acid tert-butyt ester
A suspension of 4-(4-hydroxy-phenyl)-2-methyl-2H-phthalazin-l-one (252 rng, 1.0 mmol) and of 4-bromomethyl) piperidine-1-carboxylic acid t-butyl ester (786 mg, 3 eq) in 1 mL of 4N NaOH and 8 mL of DMSO was stirred at rt for 24 h. The reaction was diluted with water (20 mL), extracted with EtOAc (3 x 10 mL), and the combined extracts were washed with NaHCO3 solution, NaCl solution and dried over MgSO4. The product was purified by ISCO graduate chromatography (100% CH2Cl2 to 95:5 CH2Cl2; MeOH) to afford 198 mg (50%) of 4-(4-(l(3-methyl-4-oxo-3,4-dihydro-phthalazin-l-yl)- phenoxymethyl)-piperidine-l-carboxylic acid t-butyl ester: Mp 167-9 0C; MS m/z 450 (M + H).
Example 63.
Figure imgf000101_0002
2-Methyl-4-[4-(piperidin-4-ylmethox y)-phenyl]-2H-phthalazin-1 -one
A solution of example 62 (4-(4-(l(3,-methyl-4-oxo-3,4-dihydro-phthalazin-l-yl)- phenoxymethyl)-piperidine-l-carboxylic acid tert-butyl ester) (180 mg, 0.4 mmol) and 4N HCl (2 mL) in dioxane (5 mL) and water (0.5 mL) was heated to 500C for 2 h. The solvent was evaporated, and the product was triturated with Et2O to give 117 mg (84%) of example 63 (2-methyl-4-(4-(piperidin-4-ylmethoxy)-phenyl)-2H-phthalazin-l-one) HCl: Mp 207-9 0C; MS m/z 350 (M+H).
Example 64.
Figure imgf000102_0001
4-[4-(1-Cyclobutyl-piperidin-4-ylme thoxy)-phenyl]-2-methyl-2H-phthalaz in-1-one
A solution of example 63 (2-methyl-4-(4-(piperidin-4-ylmethoxy)-phenyl)-2H- phthalazin-1-one) (90 mg, 0.23 mg) and NaCNBH3 in DMF: MeOH: AcOH (3: 6 mL: 0.25 mL) was stirred under N2 as cyclobutanone (81.7 mg, 5 eq.) was added. The reaction was stirred at 600C for 1.5 h, quenched with 3 mL of water, extracted with CH2Cl2 (3 xlO mL), washed with NaHCθ3, NaCl solution, dried and concentrated. The crude product was purified by silica gel chromatography using 5% MeOH: 95% CH2Cl2: 0.5 mL of isopropyl amine. The fractions were collected, concentrated and the product dissolved in 5 mL of MeOH, and added 0.5 mL of IN HCl in EtOH. The solvent was evaporated, and the HCl product crystallized from MeOH-Et2O to give example 64 (4-(4-(l-cyclobutyl-piperidin-4- y lmethoxy)-pheny l)-2-methyl-2H-phthalazin- 1 -one HCl) (53 mg- 57%): Mp 256-70C; MS m/z 404 (M + H).
The following examples as HCl salts were prepared from 6-(4-hydroxy-phenyl)-2- methyl-2H-pyridazin-3-one using the procedures for examples 62-64. Example 65 is the base.
Figure imgf000102_0002
Figure imgf000103_0001
Example 72.
Figure imgf000104_0001
ovridazyr3Xo"nehenyl)"2"methyl"2H" 6-[4-(1-lsopropyl-piperidin-4-yloxy pyπdazin-J-one )-phenyl]-2-methyl-2H-pyridazin-3- one
A mixture of 6-(4-hydroxy-phenyl)-2-methyl-2H-pyridazin-3-one (500 mg, 2.6 mmol), triphenylphosphine (1.35 g, 5.2 mmol), 4-hydroxy-N-/Pr-piperidine (745 mg, 10.4 mmol) in THF (50 mL) was added DEAD (1.1 g, 6.5 mmol) dropwise. The reaction was stirred at rt overnight, then concentrated. The product was purified by ISCO silica gel chromatography (95:5. DCM: MeOH). The HCl salt was prepared by addition of IM Et2O HCl to a methanol solution of the base, mp 108-110 0C. MS m/z 328 (M + H).
Example 73.
Figure imgf000104_0002
6-(4-Hydroxy-phenyl)-2-methyl-2H- 4-[4-(1-Methyl-6-oxo-1 ,6-dihydro-py pyridazin-3-oπe ridazin-3-yl)-phenoxy]-piperidine-1 -carboxylic acid tert-butyl ester
Figure imgf000104_0003
2-Methyl-6-[4-(piperidin-4-yloxy)- phenyl]-2H-pyridazin-3-one
A solution of 6-(4-hydroxy-phenyl)-2-methyl-2H-pyridazin-3-one (1.0 mg, 4.6 mmol), triphenylphosphine (1.44 g, 5.5 mmol), 4-hydroxy-N-i?0C-piperidine (1.1 mg, 5.5 mmol), in THF (40 mL) was added DEAD (0.96 g, 5.5 mmol) dropwise on an ice-batch. The batch was removed and the reaction was stirred at rt 2-days. The reaction was concentrated at reduced pressure and Et2O (40 mL) was added and stirred 2 h and the solids removed by filtration. The solution was concentrate and the product was purified by ISCO silica gel chromatography (95:5. DCM: MeOH). The resulting 4-[4-(l-methyl-6-oxo-l,6- dihydro-pyridazin-3-yl)-phenoxy]-piperidine-l -carboxylic acid t-butyl ester was dissolved in dioxane (5 mL) and 4N HCl in dioxane (4 mL) as added and stirred 2 h. The solution was concentrated and 2N Na2CCh added to pH 9. The aqueous solution was added solid sodium chloride until saturated, then extracted with EtOAc (2 x 50 mL), dried (MgSO4) and concentrated. The HCl salt was prepared by addition of IM HCl Et2O solution to a methanol solution of the base. Mp > 210 0C. MS m/z 386 (M + H).
Example 74.
Figure imgf000105_0001
2-Methyl-6-[4-(piperidin-4-y!oxy)- 2-Methyl-6-[4-(piperidin-4-yloxy)- phenyl]-2H-pyridazin-3-one phenyl]-2H-pyridazin-3-one
To a solution of example 73 (0.25 g, 0.9 mmol) and cyclobutanone in MeOH (10 mL) was added HOAc (0.5 mL) then solid sodium cyanoborohydride (560 mg, 62.8 mmol). The reaction was stirred 4 h then concentrated. Na2CO3 solution was added, and extracted with EtOAc (2 x 50 mL), dried over MgSO4, filtered and concentrated. To the residue in CH3CN (3 mL) was added a IN HClZEt2O solution and concentrated. Example 74 was recrystallized from CH3CN-Et2O to give 180 mg of a white solid. Mp 250-252 0C. MS m/z 340 (M + H).
Example 75.
Step 1.
Figure imgf000105_0002
Hydroxy^β-methoxy-i-oxo-I^.S^-te trahydro-πaphthalen^-yO-acetic acid
A mixture of 6-methoxy-l-tetralone (20 g, 114 mmol) and glyoxylic acid monohydrate (10.5g, 114 mmol) was heated at 120 0C in a melt for 5 min. After slight cooling, EtOAc (100 mL) was carefully added. The solid which precipitated was collected to afford 8.5 g (30%) of hydroxyl-(6-methoxy-l-oxo-l,2,3,4-tetrahydro-naphthalen-2-yl)- acetic acid; Mp 212-214 0C, MS m/z 251 (M + H). Step 2.
Figure imgf000106_0001
8-Hydroxy-2-methyl-5,6-dihydro-2H- benzo[h]cinnolin-3-one
A solution of the product from step 1 (700 mg, 2.8 mmol) and N-methylhydrazine (0.3 mL) in 2-propanol (10 mL) was heated to reflux 18 h. The solvent was removed under vacuum and the solid was triturated with methanol (2 mL), collected and then suspended in methylene chloride (2 mL) at 0 °C. BBr3 (10 mL of IM solution in DCM, 10 mmol) was slowly added dropwise and the ice bath removed. After 3 h at ambient temperature, saturated NH4Cl solution (10 mL) was added. The DCM was removed under vacuum and the resulting slurry was carefully neutralized with saturated NaHCO3 solution and washed with water. The solids were collected to afford 8-hydroxy-2-methyl-5,6-dihydro-2H- benzo[h]cinnolin-3-one (175 mg, 27%) as a white solid; m p >300 °C MS m/z 229 (M + H). Step 3.
Figure imgf000106_0002
2-Methyl-8-[3-((R)-2-methyl-pyrroli din-1-yl)-propoxy]-5,6-dihydro-2H-benzo[h] cinnolin-3-one . To a slurry of the product from step 2 (166 mg, 0.7 mmol) l-bromo-3-chloro- propane (126 mg, 0.9 mmol) and K2CO3 (110 mg, 0.8 mmol) in acetonitrile (5 mL) was stirred 18 h at 100 0C. The solvent was removed under vacuum and the solids were partitioned between EtOAc (10 mL) and water (10 mL). The organics were washed with EtOAc (2 x 10 mL), dried over MgSO4 and the solvent was removed under vacuum. Silica gel chromatography with EtOAc/hexanes as eluent afforded 196 mg of the intermediate 3- chloropropylether (88%) as a white solid. The chloro intermediate was slurred (196 mg, 0.6 mmol) in acetonitrile (4 mL) and added Λ-2-methyl-pyrrolidine tartrate (227 mg, 0.9 mmol), KI (20 mg, 0.1 mmol) and K2CO3 (355 mg, 2.4 mmol). The reaction was stirred 18 h at 100 0C, and the solvent was removed under vacuum. The solids were partitioned between CH2Cl2 (10 mL) and water (10 mL). The water layer was washed with CH2Cl2 (3 x 10 mL). The combined organic layers were dried over Na2SO4 and concentrated under vacuum. Silica gel chromatography using CH2Cl2ZMeOH (95:5) as eluent gave the product as an oil. The HCl salt was prepared from EtOH and IM HCl in Et2O to give 130 mg (52%) of example 75 as a white solid; Mp 192-194 0C; MS m/z 354 (M + H).
The following examples were prepared as HCl salts using the methods described for example 75.
Figure imgf000107_0001
Example 19
Figure imgf000108_0001
2-Methyl-7-[3-((R)-2-methyl-pyrroli din-1 -yl)-propoxy]-2H-phthalazin-1 - one . Step 1. A solution of 2-formyl-5-methoxy-benzoic acid (1.0 g, 6.10 mmol) and methyl hydrazine (0.481 mL, 1.5 eq.) in ethanol (15 mL) was stirred at 85 0C for 1.5 days. The solvent was removed and the solid was collected and washed with cold EtOH to give 7- methyl-2-methyl-2H-phthalazin-l-one (780 mg): MS m/z 191 (M + H).
Step 2-3. 7-(3-Chloro-propoxy)-2-methyl-2H-phthalazin-l-one was prepared from 7-methyl-2-methyl-2H-phthalazin-l-one using the procedure described in Example 22 Step 3, and Step 4.
The hydrochloride salt of example 79 (2-methyl-7-(3-(R)-2-methyl-pyrrolidin-l-yl)- propoxy)-2H-phthalazin-l-one) was prepared using the procedure as described in Example 22 Step 5: Mp 252-3 0C; MS m/z 302 (M + H).
The following examples were prepared as HCl salts using methods of example 79.
Figure imgf000108_0002
Example 83.
Figure imgf000109_0001
6-[4-(1-Cyclopeπtyl-piperidin-4-yloxy)-phenyl]- 2-methyl-2H-pyridazin-3-one
This compound was prepared using the same method as example 74 using example 73 and cyclopentanone in MeOH (10 mL) / HOAc (0.5 mL) followed by solid sodium cyanoborohydride. The reaction was stirred 4 h then concentrated. Na2COs solution was added, and extracted with EtOAc (2 x 50 mL), dried over MgSO4, filtered and concentrated. Example 83 was recrystallized from CH3CN-Et2O to give a white solid. Mp 129-132 0C. MS m/z 354 (M + H).
Example 86.
Figure imgf000109_0002
2,6-Dimethyl-5-{4-[3-((R)-2-metHyl- pyrrolidin-1-yl)-propoxy]-phenyl}-2
H-pyridazin-3-one
Step 1.
Figure imgf000109_0003
5-(4-Methoxy-phenyl)-2 , 6-di methy I-2 H-pyridazin-3-one
A mixture of l-(4-methoxyphenyl)propan-2-one (16.4 g, 100 mmol) and glyoxalic acid hydrate (9.2Og5 100 mmol) were heated to 135 0C overnight, then the water was distilled off at 120 0C for 2 h. The residue was taken up in 40 mL of ethanol with stirring as methylhydrazine (10.5 mL, 200 mmol) was added dropwise. The reaction was heated to 85 0C overnight. The solvent was evaporated and the residue was dissolved in 200 mL of methylene chloride and washed with 5% NaHCOs solution (2 x 20 mL), saturated NaCl solution, then dried over Na2SO4 and concentrated. The residue was purified by silica gel chromatography (2% MeOH in CH2Cl2) to give 5-(4-methoxyphenyl)-2,6-dimethyl-2H- pyridazin-3-one (4.2 g) MS m/z 231 (M + H). Step 2.
Figure imgf000110_0001
5-(4-Hydroxy-phenyl)-2,6-dimethyl-2 H-pyridazin-3-one A solution of the product from step 1 (3.2 g, 14 mmol) in CH2CI2 (40 mL) was cooled to 0 0C and BBr3 (6.6 mL, 5.0 eq.) was added dropwise. The ice-bath was removed and the reaction was stirred at rt for 1 h, after which the reaction mixture was poured into 50 mL of ice cold saturated NH4Cl solution with stirring. The resulting solid was filtered, and washed with water (3 x 15 mL) then Et2O (2 x 15 mL) to give the product of step 2 (0.66 g, 22%): MS m/z 217 (M + H). Step 3.
Figure imgf000110_0002
5-[4-(3-Chloro-propoxy)-phenyl]-2,6 -dimethyl-2H-pyridazin-3-one
A solution of the product from step 2 (710 mg, 3.29 mmol), K2CO3 (1.36 g, 3.0 eq.) and 3-bromo-l-chloropropane (0.39 mL, 1.2 eq.) in CH3COCH3 (30 mL) was heated to 80 0C overnight. The mixture was then filtered, washed with acetone and concentrated to dryness to afford the product of step 3 (950 mg, 98%): MS m/z 293 (M + H). Step 4.
Figure imgf000111_0001
2,6-Dimethyl-5-{4-[3-((R)-2-methyl- pyrrolidin-1-yl)-propoxy]-phenyl}-2
H-pyridazin-3-one
A mixture of the product of step 3 (481mg, 1.65 mraol), K2CO3 (3.5 eq, 795 mg), 50 mg of NaI, and R-2-methylpyrrolidine hydrochloride (2.0 eq., 773 mg) in acetonitrile (10 mL) was heated to 80 0C for 2 days. The reaction was then filtered, washed with CH2Cl2 (2 x 2OmL) and concentrated. The residue was dissolved in 30 mL OfCH2Cl2 and washed with saturated NaHCO3, saturated NaCl solution, dried with Na2SO4 and then concentrated. The residue was purified by preparative TLC (10%MeOH: 90% CH2Cl2:0.5 mL 2- aminopropane) to give the product. The product was dissolved in 10 mL of MeOH, and was added 2.5 mL of IN HCl in EtOH. The solvents were evaporated and the product crystallized from MeOH:Et2O to give example 86 as the HCl salt (231 mg, 41%): Mp 176-8 0C; MS m/z 342 (M + H).
Example 87
Figure imgf000111_0002
2,6-Dim ethyl-5-[4-(3-piperidin-1 -yl -propoxy)-p he nyl]-2 H -pyridazin-3-one
This compounds was prepared using the procedure for example 86 using the product of step 3 and piperidine to give the hydrochloride salt; Mp 210-211 0C; MS m/z 342 (M + H). Example 88
Figure imgf000112_0001
6-M ethyl-5-{4-[3-((R)-2-m ethyl-pyrr olIdln-1-yl)-propoxy]-phenyl}-2H-py ridazin-3-oπe
Step 1.
Figure imgf000112_0002
1-[4-(3-Chloro-propoxy)-phenyl]-pro pan-2-one
A solution of 4-hydroxyphenylacetone (4.5 g, 30 mmol) and potassium carbonate (4.14g, 3.0 eq.) in 50 mL of acetone was stirred under N2 as l-bromo-3-chloro-propane was added dropwise. The reaction was heated to 80 0C overnight. The mixture was then filtered through celite, washed with acetone arid concentrated to afford l-[4-(3-chloro- propoxy)phenyl]propan-2-one (6.3g, 93% yield): MS m/z 227 (M + H).
Step 2.
Figure imgf000112_0003
5-[4-(3-Chloropropoxy)pheπyl]-6- methyl-2H-pyridazin-3-one 5-[4-(3-Chloropropoxy)phenyl]-6-methyl-2H-pyridazin-3-one was prepared from the product from step 1 using the procedure described in Example 86 stepl .
Step 3.
- I ll -
Figure imgf000113_0001
6-Methyl-5-{4-[3-((R)-2-m ethyl-pyrr olidin-1-yl)-propoxy]-phenyl}-2H-py ridazin-3-one
6-Methyl-5-{4-[3-(®-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2(-l-pyridazin-3- one) hydrochloride salt was prepared from 5-[4-(3-chloropropoxy)phenyl]-6-methyl-2H- pyridazin-3-one and R-2-methylpyrrolidine hydrochloride using the procedure described in Example 86 Step 4; Mp 115 0C (dec), MS m/z 329 (M + H).
Example 89
Figure imgf000113_0002
6-Methyl-5-[4-(3-piperidin-1 -yl-pro poxy)-phenyl]-2H-pyridazin-3-one
This compound was prepared using the procedure for example 88 using the product of step 2 and piperidine to give the hydrochloride salt Mp dec 123 (dec.) 0C; MS m/z 328 (M + H). Example 90
Figure imgf000113_0003
5-[4-(3-Azepan-1-yl-propoxy)-phenyl]-6- methyl-2H-pyridaεin-3-one
This compound was prepared using the procedure for example 88 to give the hydrochloride salt Mp 204-60C; MS m/z 342 (M + H). Example 91
Figure imgf000114_0001
2-Methyl-5-{4-[3-((R)-2-methyl-pyrr olidin-1-yl)-propoxy]-phenyl}-2H- pyridazin-3-one
Figure imgf000114_0002
5-Hydroxy-4-(4-methoxy-phenyl)-5H- furan-2-one
A solution of 4-methoxyphenyl ethanol (15.0 g, 98.2 mmol) in 150 mL of methylene chloride was stirred at 0 0C while Dess-Martin periodinane (50 g, 1.2 eq.) was added in small portions. The ice-bath was removed and the reaction was stirred at rt for 1 h. The reaction mixture was then diluted with methylene chloride (100 mL), washed with 10% sodium thiosulfate, saturated NaHCθ3 solution, water, saturated NaCl solution, and dried over Na2SO4. The product was purified using silica gel chromatography (100% hexanes to 20% EtOAC / hexanes) to afford 5.3 g (34%) of 4-methoxyphenyl acetaldehyde.
A suspension of glyoxalic acid hydrate (2.45 g, 26.6 mmol) and morpholine hydrochloride (3.28 g, 26.35 mmol) in dioxane (25 mL) was stirred as water (2 mL) was added. The homogeneous solution and 4-methoxyphenyl acetaldehyde (3.8 g, 25.3 mmol) was then added and the solution was stirred at reflux for 24 h. The solvent was evaporated and a solid was formed after addition of 20 mL of water. The solid was collected and washed with water to give 5.1 g (98%) of the product: MS m/z 189 (M-17 + H). Step 2.
Figure imgf000115_0001
5-(4-Methoxy-phenyl)-2-methyl-2H- pyridazin-3-one
A suspension of 5-hydroxy-4-(4-methoxyphenyl)-5H-furan-2-one (2.06 g, 10 mmol) in 30 mL of ethanol was stirred as methylhydrazine (0.78 mL, 1.5 eq) was added dropwise. The reaction was heated to reflux at 85 0C for 2 h, then the solvent was reduced at reduced pressure to give a solid, which was collected and washed with cold EtOH to give 1.0 g (46%) of 5-(4-methoxy-phenyl)-2-methyl-2H-pyridazin-3-one: MS m/z 217 (M + H).
Figure imgf000115_0002
5-(4-Hydroxy-phenyl)-2-methyl-2H-py ridazin-3-one
5-(4-Hydroxyphenyl)-2-methyl-2H-pyτidazin-3-one was prepared from 5-(4- methoxy-phenyl)-2-methyl-2H-pyridazin-3-one with BBr3 using the procedure described in Example 86 Step 2; Mp 296-8 0C; MS m/z 203 (M + H).
Step 4.
Figure imgf000115_0003
5-[4-(3-Chloro-propoxy)-phenyl]-2-m ethyl-2H-pyridazin-3-one 5-[4-(3-Chloro-propoxy)-phenyl]-2-methyl-2H-pyridazin-3-one was prepared from
5-(4-hydroxy-phenyl)-2-methyl-2H-pyridazin-3-one with l-bromo-3-chloro-propane using the procedure described in Example 86 Step 3; Mp 90-91 0C; MS m/z 279 (M + H). Step 5.
Figure imgf000116_0001
2-Methyl-5-{4-[3-((R)-2-methyl-pyrr olidin-1-yl)-propoxy]-phenyl}-2H-py ridazin-3-one
This compound was prepared as the hydrochloride salt from 5-[4-(3-chloropropoxy)- phenyl]-2-methyl-2H-pyridazin-3-one and R-2-methylpyrrolidine using the procedure described in Example 86 Step 4; Mp 222-3 0C; MS m/z 328 (M + H).
Example 92
Figure imgf000116_0002
2-Methyl-5-[4-(3-piperidin-1-yl-pro poxy)-phenyl]-2H-pyridazin-3-one
This compound was prepared as the hydrochloride salt using 5-[4-(3- chloropropoxy)-phenyl]-2-methyl-2H-pyridazin-3-one and piperidine using the procedure described in Example 91 Step 5; Mp 253-4 0C; MS m/z 328 (M + H).
Example 93
Figure imgf000116_0003
5-[4-(3-Azepan-1-yl-propoxy)-phenyl ]-2- m ethy l-2H-pyridazin-3-one This compound was prepared as the hydrochloride salt using 5-[4-(3- chloropropoxy)-phenyl]-2-methyl-2H-pyridazin-3-one and azepine using the procedure described in Example 91 Step 5; Mp 247-8 0C; MS m/z 342 (M + H).
Example 94
Figure imgf000117_0001
5-{4-[3-((R)-2-Methyl-pyrrolidin-1-yl)- propoxy]-phenyl}-2-pyridin-2-yl-2H- pyridazin-3-one
Figure imgf000117_0002
2-[4-(3-Chloro-propoxy)-phenyl]-ethanol
A mixture of 2-(4-hydroxyphenyl)ethanol (13.82 g, 100.0 mmol) and potassium carbonate (34.0 g, 250.0 mmol) in 125.0 mL of acetone was stirred as l-bromo-3- chloropropane (24.0 g, 150.0 mmol) was added dropwise. The reaction was stirred at 600C overnight, and then filtered through celite, washed with acetone and concentrated. The residue was dissolved in EtOAc (250 mL) and washed with 2N Na2CO3, water, and saturated NaCl solution. After drying over Na2SO4 the solution was concentrated to give 21 g (98 %): Mp 49-50 0C; MS m/z 197 (M - H).
Figure imgf000117_0003
[4-(3-Chloro-propoxy)-phenyl]-aceta ldehyde
A solution of Dess-Martin periodinane (20.4 g, 48.0 mmol) in 200 mL of methylene chloride was stirred as 2-[4-(3-chloropropoxy)ethanol (8.59 g, 40.0 mmol) in 60.0 mL of methylene chloride was added dropwise via addition funnel. The reaction was stirred at rt for 1 h3 diluted with ether (400 niL) and poured into 200 mL of 1.3 M NaOH solution. The ether layer was separated and washed with 1.3 M NaOH solution (100 mL), water until pH 7, and dried over Na2SO4. The product was purified using silica gel flash chromatography with 20% Et2O in hexane to give 6.75 g (79.3%) of [4-(3-chloro- propoxy)phenyl]acetaldehyde : MS m/z 213 (M + H).
Figure imgf000118_0001
4-[4-(3-Chloro-propoxy)-phenyl]-5- hydroxy-5H-furan-2-one
A suspension of glyoxalic acid hydrate (3.04 g, 33.1 mmol) and morpholine hydrochloride (4.09 g, 33.1 mmol) in dioxane (48 mL) was stirred as 4.5 mL of water was added. To the homogeneous solution [4-(3-chIoropropoxy)phenyl]acetaldehyde (6.70 g, 31.5 mmol) was then added and the solution was stirred at reflux for 24 h. The solvent was evaporated and 50 mL of water was added. The solid was collected and washed with water to give 8.3 g (98%): MS m/z 251 (M - 17 + H).
Step 4.
Figure imgf000118_0002
5-[4-(3-Chloro-propoxy)-phenyl]-2-p yridJn-2-yl-2H-pyridazin-3-one
A solution of the product from step 3 (8.0 g, 29.8 mmol) and 2-hydrazinopyridine
(9.75 g, 3.0 mmol) in 80 mL of acetic acid was stirred at 110 0C for 24 h. The solvent was evaporated and the residue was purified with ISCO Combiflash chromatography with 2% MeOH in methylene chloride. The product was crystallized from EtOH and ether to give 5.88 g (58%) of 5-[4-(3-chloropropoxy)-phenyl)-5-hydroxy-5H-furan-2-one: Mp 219-220 0C; MS m/z 391 (M + H). Step 5.
Figure imgf000119_0001
5-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoκy]-phenyl}-2-pyridiπ-2-yl -2H-pyridazin-3-one
A mixture of the product from step 4, R-2-methyl-pyrrolidine benzenesulfonic acid salt (12.0 g, 51.0 mmol), potassium carbonate (8.2 g, 59.0 mmol) and sodium iodide (50 mg, 0.334 mmol) in 150.0 mL of acetonitrile was heated to 80 0C for 24 h. The reaction mixture was then filtered, washed with methylene chloride (2 X 20 mL) and concentrated. The residue was dissolved in 100 mL of methylene chloride and washed with saturated NaHCO3, saturated NaCl solution, dried over Na2SO4 and concentrated. The residue was purified by ISCO graduate silica gel chromatography with 10% MeOH in CH2Cl2 with 0.5% of .PrNH2 to give the product. The product was dissolved in MeOH and added 40.0 mL of IN HCl in EtOH and concentrated to dryness. Crystallization using MeOH and CH3CN afforded the HCl salt (5.45 g, 75%) Mp 219-220 0C; MS m/z 391 (M + H).
Example 95
Figure imgf000119_0002
5-[4-(3-Piperidin-1-yl-propoxy)-phe nyl]-2-pyridin-2-yl-2H-pyridazin-3- one
This compound was prepared using the procedure for example 94 to give the HCl salt; Mp 266-8 0C; MS m/z 391 (M + H). Example 96
Figure imgf000120_0001
5-[4-(3-Azepan-1-yl-propoxy)-phenyl ]-2-pyridin-2-yl-2H-pyridazin-3-one
This compound was prepared using the procedure for example 94 to give the HCl salt; Mp 230-2 0C; MS m/z 405 (M + H).
Example 97
Figure imgf000120_0002
2-Methyl-5-[4-(3-piperidin-1-yl-pro poxy)-phenyl]-2H-pyridazin-3-one
Figure imgf000120_0003
5-[4-(3-Chloro-propoxy)-phenyl]-2H~ pyridazin-3-one
A solution of the product from example 94 step 3 (2.0 g, 7.45 mmol) and hydrazine hydrate (0.59 g, 1.5 eq.) in 20 mL of EtOH was stirred at 85 0C for 2 h. The solvent was reduced and the solid was collected and washed with cold EtOH to give 1.2 g (61%) of 5- [4-(3-chloropropoxy)phenyl)-2H-pyridazin-3-one: Mp 197-9 0C; MS m/z 265 (M + H).
Step 2.
This compound was prepared from the product of step 1 (5.8 g, 17.0 mmol) and piperidine using the procedure for example 88. The hydrochloride salt of the product was prepared; Mp 249-250 0C; MS m/z 314 (M + H). Example 98
Figure imgf000121_0001
2-(6-Methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methyl
-pyrrolidin-1-yl)-propoxy]-phenyl}-2H- pyridazin-3-oπe
Step 1.
Figure imgf000121_0002
5-(4-Methoxy-phenyl)-2H-pyridazin-3 -one
A suspension of 5-hydroxy-4-(4-methoxyphenyl)-5H-furan-2-one (2.00 g, 9.7 mmol) in 15 mL of ethanol was stirred as hydrazine hydrate (0.97g, 2.0 eq) was added in dropwise. The reaction was stirred at 85 0C overnight, and then the solvent was reduced. The solid was collected and washed with cold EtOH to give 1.7 g (87%) of 5-(4-methoxy- phenyl)-2H-pyridazin-3-one: MS m/z 203 (M + H).
Step 2.
Figure imgf000121_0003
5-(4-Methoxy-phenyl)-2-(6-methyl-py ridin-2-yl)-2H-pyridazin-3-one
A mixture of the product from step 1 (1.34 g, 6.62 mmol), copper (I) iodide (0.4 g, 2.0 mmol) and potassium carbonate (1.4 g, 9.9 mmol) in DMF (15 mL) was stirred and degassed with N2 for 3 min. Then 2-bromo-6-methylpyridine was added dropwise. After stirred at 1200C overnight, the mixture was filtered through celite, washed with 50 mL of CH2Cl2, 15% OfNH4OH solution (3 x 15 mL), water, saturated NaCl solution, and dried over Na2SCH. The residue was purified by ISCO graduate chromatography (5% MeOH in CH2Cl2) to give 5-(4-methoxyphenyl)-2-(6-methylpyridin-2-yl)-2H-pyridazin-3-one (0.30 g, 15%): Mp 167-8 0C; MS m/z 294 (M + H).
Step 3.
Figure imgf000122_0001
5-(4-Hydroxy-phenyl)-2-(6-methyl-pyridin- 2-yl)-2H-py ridazi n-3-one
This compound was prepared using the procedure described for Example 91 step 3; MS m/z = 280 (M + H).
Step 4
Example 98 was prepared from the product of step 3 using procedures described in
Example 91 Step 4 and Step 5; Mp 118-120 0C; MS m/z 405 (M + H).
Example 99
Figure imgf000122_0002
2-(3-Methyl-pyridin-2-yl)-5-{4-[3-((R)-2-me thylpyrrolidin-1-yl)-propoxy]-phenyl}-2H- pyridazin-3-one
Example 99 was prepared as the hydrochloride salt using procedures described for Example 98; Mp 98-100 0C; MS m/z 405 (M + H).
Example 100
Figure imgf000123_0001
6-Methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-1-yl )-propoxy]-phenyl}-2-pyridin-2-yl-2H-pyridazi n-3-one
Example 100 was prepared as the hydrochloride salt using procedures described for Example 98; Mp 155-7 0C; MS m/z 405 (M + H).
Example 101
Figure imgf000123_0002
6-Methyl-2-(3-methyl-pyridin-2-yl)- 5-{4-[3-((R)-2-methyl-pyrrolidin-1- yl)-propoxy]-phenyl}-2H-pyridazin-3 -one
Example 101 was prepared as the hydrochloride salt using procedures described for Example 98; Mp 106 0C (dec); MS m/z 419(M + H).
Example 102
Step 1.
Figure imgf000123_0003
4-[4-(2-Oxo-propyl)-phenoxy]-piperi dine-1-carboxylic acid tert-butyl e ster
A solution of triphenylphosphine (18.5 g, 70.6 mmol) and 40% DEAD in toluene (12.3 g, 70.6 mmol) in 125.0 mL of tetrahydrofuran was cooled to 0 oC under N2 as a solution of l-(4-hydroxy-phenyl)-propan-2-one (6.54 g, 43.6 mmol) and 4-hydroxy- piperidine-1-carboxylic acid tert-butyl ester (10.7 g, 53.2 mmol) inl25.0 mL of tetrahydrofuran was added dropwise via addition funnel. After stirred at rt overnight, the solvent was evaporated. The residue was stirred in hexane/EtOAc, the solid formed was filtered. The hexane/EtOAC solution was concentrated and purified by ISCO graduate chromatography (hexane-20% EtOAc in hexane) to give 4-[4-2-oxo-propyl)-phenoxy]- piperidine-1-carboxylic acid tert-butyl ester (8.52 g, 59%).
Figure imgf000125_0001
4-[4-(3-Methy 1-6-oxo- 1,6-dihydro-py ridazin-4-yl)-phenoxy]-piperϊdine-1 -carboxylic acid tert-butyl ester
A mixture of 4- [4-(2-oxo-propyl)-phenoxy]-piperidine-l -carboxylic acid tert-butyl ester (7.01 g, 21.03 mmol) and glyoxalic acid hydrate (1.9 g, 21 mmol) was heated to 100 0C for 5 h. The resulting dark thick oil was stirred in 30 mL of EtOH as hydrazine hydrate (2.1 g, 42 mmol) was added. After stirred at 90 0C for 5 hr, the reaction was cooled to rt, and the solvent was evaporated. The crude product was purified by flash chromatography (10% MeOH in CH2Cl2), followed by trituration with ether to give 4-[4-(3-methyl-6-oxo- l,6-dihydro-pyridazin-4-yl)-phenoxy]-piperidine-l -carboxylic acid tert-butyl ester (3.25 g, 46%): Mp 184-6 0C; MS m/z 386(M+H).
Example 102
Figure imgf000125_0002
6-Methyl-5-[4-(piperidin-4-yloxy)-p henyl]-2H-pyridazin-3-one; hydrochl oride
A solution of the product from step 2 (4-[4-(3-methyl-6-oxo-l,6-dihydro-pyridazin- 4-yl)-phenoxy]-piperidine-l-carboxylic acid tert-butyl ester) (7.6 g, 20 mmol) in 30 mL of dioxane and 3.0 mL of water was cooled to 0 0C as 24 mL of 4M HCl in dioxane was added dropwise. After stirring at 50 0C for 1 h, the solvent was evaporated. The white solid was triturated with ether to give 6-methyl-5-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one HCl (6.2 g, 92%): Mp 225-7 0C; MS m/z 286 (M + H). Example 103
Figure imgf000126_0001
5-[4-( 1 -Cyclobutyl-piperidin-4-ylox y)-pheny!]-6-methyl-2H-pyridazin-3- oπe
A solution of example 102 (5.4 g, 18.9 minol), sodium cyanoborohydride (2.4 g, 38 mmol) and cyclobutanone (6.6 g, 95 mmol) in 40.0 mL of DMF5 80.0 mL of MeOH and 5.0 mL of acetic acid was stirred at 60 0C for 1 h. The reaction was cooled to rt, quenched with ice-water and the solvent evaporated. The residue was diluted with 100 mL Of CH2Cl2, washed with saturated NaHCO3 solution (3 x 30 mL), water (2 x 20 mL), NaCl solution (30 mL) and dried over Na2SO4. The crude product was purified by Combiflash chromatography (CH2Cl2 to 10% MeOH in CH2Cl2 with 0.5% of iPrNH2) to give the free base of the product. The product was then dissolved in MeOH and filtered. Then 30 mL of IN HCl was added and the solution evaporated. The hydrochloride salt was crystallized from MeOH and Et2O to give example 103 HCl (6.03 g, 90%): Mp 296-7 0C; MS m/z 340 (M + H).
Example 104
Figure imgf000126_0002
5-(4-Methoxy-phenyl)-6-methyl-2H-py ridazin-3-one 5-(4-methoxyphenyl)-6-methyl-2H-pyridazin-3-one was prepared from l-(4- methoxy-phenyl)propan-2-one and glyoxalic acid and hydrazine hydrate using the procedure described in Example 86 Step 1; Mp 255-256 0C; MS m/z 203 (M + H).
Figure imgf000127_0001
5-(4-Methoxy-phenyl)-6-methyl-2-pyr idin-2-yI-2H-pyridazin-3-one
5-(4-Methoxy-phenyl)-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one was prepared from 5-(4-methoxy-phenyl)-6-methyl-2H-pyridazin-3-one and 2-bromopyridine in the presence of copper iodide using the procedure described in Example 98 Step 2; Mp 156-7 0C; MS m/z 294 (M + H).
Figure imgf000127_0002
5-(4-Hydroxy-phenyl)-6-methyl-2-pyr idin-2-yl-2H-pyridazin-3-one
5-(4-Hydroxy-phenyl)-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one was prepared from 5-(4-Methoxy-phenyl)-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one and BBr3 in CH2Cl2 using the procedure described in Example 91 Step 3; Mp 252-4 0C; MS m/z 280 (M + H).
Figure imgf000127_0003
4-[4-(3-Methyl-6-oxo-1-pyridin-2-yl -1,6-dihydro-pyridazin-4-yl)-phenox y]-piperidine-1-carboxylic acid ter t-butyl ester
A mixture of 5-(4-hydroxyphenyl)-6-methyl-2-pyridin-2-yl-2H-pyridazin-3-one (97.7g, 28 mmol), t-butyl 4-methanesulfonyloxypiperidine-l-carboxylic acid ester (15 g, 55 mmol) and cesium carbonate (18 g, 55 mmol) in 75 mL of DMF was stirred at 100 0C overnight. The reaction mixture was cooled to rt, filtered through celite, and concentrated. The crude product was diluted with 100 mL OfCH2Cl2, washed with 2N NaCO3, water, NaCl solution, then dried over Na2SCM, and concentrated. The product was purified by flash chromatography (5% MeOH in CH2Cl2) and triturated with EtOAc and hexane to give 4-[4-(3-methyl-6-oxo-l -pyridin-2-yl-l ,6-dihydropyridazin-4-yl)-phenoxy]-piperidine-l - carboxylic acid tert-butyl ester (6.7 g, 72%): MS m/z 463 (M + H).
Example 104
Figure imgf000128_0001
5-[4-(1-Cyclobutyl-piperidin-4-ylox y)-phenyl]-6-methyl-2-pyridin-2-yl- 2H-pyridazin-3-one This compound was prepared using the product from step 4 and the procedures described in Example 103 Step 3 and Step 4; HCL salt mp 285-6 0C; MZ m/z 417 (M + H).
Example 105
Step l.
Figure imgf000128_0002
4-I4-(2-Hydroxy-ethyl)-phenoxy]- piperidine-1 -carboxylic acid tert-butyl ester
A mixture of 2-(4-hydroxyphenyl)ethanol (4.15 g, 30 mmol), 4- methanesulfonyloxy-piperidine-1 -carboxylic acid t-butyl ester (10.51 g, 37.6 mmol) and cesium carbonate (19.6 g, 60 mmol) in 100 mL of DMF was stirred at 100 0C overnight. The reaction mixture was cooled to rt, filtered through celite and concentrated. The crude product was diluted with 100 mL Of CH2Cl2, washed with 2N Na2CO3, water, NaCl solution, dried over Na2SO4, and concentrated. The product was purified by flash chromatography (60% EtOAc in hexanes) to give 4-[4-(2-hydroxy-ethyl)-phenoxy]- piperidine-1 -carboxylic ester (8.2 g, 59%): MS m/z 222 (M-Boc+H).
Step 2.
Figure imgf000129_0001
4-[4-(2-Oxo-ethyl)-phenoxy]-piperid ine-1-carboxylic acid tert-butyl ester
A solution of 4-[4-(2-hydroxyethyl)-phenoxy]piρeridine-l-carboxylic acid tert-butyl ester (8.10 g, 25.2 mmol) in 90 mL Of CH2Cl2 was cooled to 0 0C as Dess-Martin periodinane (11.2 g, 26.5 mmol) was added in portions. After stirred at rt overnight, the reaction was diluted with 100 mL OfCH2Cl2, and washed with saturated NaHCO3 (5 x 100 mL), water, and dried over Na2SO4. Flash chromatography with 60% Et2O in hexane gave 2.83 g (35%) of 4-[4-(2-oxo-ethyl)-phenoxy]-piperidine-l-carboxylic acid tert-butyl ester: MS m/z 220 (M-Boc+H).
Figure imgf000129_0002
4-[4-(2-Hydroxy-5-oxo-2,5-dihydro-furan-3 -yl)-phenoxy]-piperidine-1 -carboxylic acid j Λ tert-butyl ester
4-[4-(2-hydro-5-oxo-255-dihydro-furan-3-yl)-phenoxy]-piperidine-l -carboxylic acid tert-butyl ester was prepared from 4-[4-(2-oxo-ethyl)-phenoxy]-piperidine-l -carboxylic acid tert-butyl ester and glyoxalic acid hydrate using procedure described in Example 94 Step 3; 15 MS m/z 275 (M-Boc+H).
Figure imgf000129_0003
4-[4-(6-Oxc-1 ,6-dihydrc~pyridazin-4 -yl)-phenoxy]-piperidine-1-carboxyl ic acid tert-butyl ester 0 A solution of the product from step 3 (1.0 g, 2.7 mmol) and hydrazine hydrate
(0.27g, 5.3 mmol) in 12 mL of MeOH was stirred at 80 0C overnight. After being cooled to rt, the solvent was reduced and the solid was filtered and washed with cold EtOH to give 0.63 g (57%) of 4-[4-(6-oxo-l,6-dihydro-pyridazin-4-yl)-phenoxy]piperidine-l-carboxylic acid tert-butyl ester: Mp 222-3 0C; MS m/z 372 (M + H).
Example 105
Figure imgf000130_0001
5-[4-(Piperidin-4-yloxy)-phenyQ-2H -pyridaziπ-3-one
This compound was prepared using the procedure for example 102; Mp 0C; MS m/z 272 (M + H). Example 106
Figure imgf000130_0002
5-[4-( 1 -Cyclobutyl-piperidin-A-y lox y)-phenyl)-2H-pyridazin-3-one
This compound was prepared as the HCl salt using the procedure for example 103; Mp 296-8 0C; MS m/z 326 (M + H).
Example 107
Figure imgf000130_0003
5-[4-(1-Cyclobutyl-piperidin-4-ylox y)-ph e ny l]-6-methy !-2-th iophen-3-y I -2H-pyridazin-3-one
This compound was prepared as the HCl salt using the procedure for example 104;
Mp 277-90C; MS m/z 422 (M + H). Example 108
Figure imgf000131_0001
6-Methy!-5-{4-[3-((R)-2-methy)-pyrr olidin-1-yI)~propoxy]-phenyl}-2-thi ophen-3-yl-2H-pyridazin-3-one
This compound was prepared as the HCl salt using the procedure for example 98; Mp 212-3 0C; MS m/z 410 (M + H).
Example 109
Figure imgf000131_0002
5-{4-[3-((S)-2-Methyl-pyrrolidin-1- yl)-proρoxy]-phenyl}-2-pyridin-2-yl -2H-pyridazin-3-one
Example 109 was prepared using the same procedure as Example 94 except using S- 2-methylpyrrolidine HCl; Mp 218-2200C; MS m/z 391 (M + H).
Example 110.
Figure imgf000131_0003
4-[4-(3-Methyl-6-oxo-1,4,5,6-tetrah ydro-pyridazin-4-yl)-phenoxy]-piper idine-1-carboxylic acid tert-butyl ester
A solution of the intermediate from Example 102 step 1 (1.0 g, 3.0 mmol) in THF (10 mL) at -78 0C under N2 was added KHMDS (0.5 M in toluene, 9.0 mL) dropwise. After 30 min at -78 0C, ethyl bromoacetate (0.75 g, 4.5 mmol) was added drop wise. After 1 hr at -78 0C, the reaction was quenched with 1 N HCI (4.0 mL), diluted with 20 mL of EtOAc and the layers separated. The EtOAc layer was washed with 5% NaHCO3, NaCi solution, then dried over Na2SO4 and concentrated. To the crude solid in 10 mL of EtOH was added hydrazine hydrate (0.22 g, 0.45 mmol) and the reaction then stirred at 85 0C for 2 h. The mixture was cooled to rt, the solvent was reduced and the solid was filtered and washed with cold EtOH to give 0.65 g (56%) of 4-[4-(3-methyl-6-oxo-l,4,5,6-tetrahydro-pyridazin- 4-yl)-phenoxyl]-piperidine-l-carboxylic acid tert-butyl ester: Mp 165-7 0C; MS m/z 288 (M-Boc + H).
Figure imgf000132_0001
5-[4-(1-Cyclobutyl-piperidin-4-ylox y)-phenyl]-6-methyl-4,5-dihydro-2H- pyridazin-3-one
Example 110 was prepared from the product of step 1 using procedures described in Example 102 and Example 103; Mp 178-9 0C; MS m/z 342 (M + H).
Example 111
Figure imgf000132_0002
4-(3-Chloro-propoxy)-benzoic acid e thyl ester
A suspension of 4-hydroxybenzoic acid ethyl ester (5.0 g, 30 mmol), l-bromo-3- chloropropane (7.1 g, 45 mmol) and potassium carbonate (14 g, 100 mmol) in 50 mL of acetone using the procedure described in Example 88 Step 1 gave the product as a clear oil.
Figure imgf000132_0003
4-[3-((R)-2-Methyl-pyrrolidin-1-yl) -propoxy]-benzoic acid ethyl ester A mixture of the product from step 1 (6.5 g, 27 mrnol), R-2-methyIpyrroIidine benzene sulfonic acid (16 g, 67 mmol)., potassium carbonate (11 g, 80 mmol) and sodium iodide (50mg, 0.3 mmol) in 100 mL of acetonitrile was stirred at 80 0C overnight. The reaction mixture was filtered through celite, washed with CH2Cl2, combined and concentrated. The residue was dissolved in CH2Cl2, washed with saturated NaHCO3, water, saturated NaCl, then dried over Na2SO4 to give 7.5 g (96%) of 4-[3-R-2-methylpyrrolidin- 1-yl-propoxy] benzoic acid ethyl ester; MS m/z 292 (M + H).
Step 3.
Figure imgf000133_0001
1 -{4-[3-((R)-2-Methyl-pyrrolidin-1 - yl)-propoxy]-phenyl}-2-pyridin-2-yl -ethanone
A solution of the product from step 2 (4.0 g, 14 mmol) and 2-methylpyrϊdine (2.6 g, 27 mmol) in 60 mL of THF was cooled to 0 0C, then LiHMDS (1.0 M, 27 mmol) was added dropwise. After addition, the reaction was stirred at 45 0C overnight. The reaction was quenched with ice-water, extracted with CH2Cl2 (3 x 50 mL), combined, washed with saturated NaHCO3, water, then dried over Na2SO.*. Flash chromatography using 10% MeOH in CH2Cl2 gave the product (3.7 g, 78%); Mp 40-42 0C; MS m/z 339 (M + H).
Step 4.
Figure imgf000133_0002
4-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-pheπyl}-4-oxo-3-pyridi n-2-yl-butyric acid ethyl ester
A mixture of sodium hydride (0.092 g, 3.8 mmoL) in 10 mL of DMSO was stirred under N2 as the product from step 3 (l.Og, 3.8 mmol) in 5.0 mL of DMSO was added dropwise. After the reaction was stirred for 30 min, a solution of ethyl bromoacetate (0.64 g, 8.83 mmol) in 6.0 mL of toluene was added dropwise, and the reaction was stirred at rt for 1 h. The reaction was then quenched with NH4Cl solution and the solvent was evaporated. The residue was extracted with CH2CI2 (3 x 20 mL), combined, washed with saturated NaHCCb, saturated NaCl then dried over Na2SO4. The crude product was purified by flash chromatography using 10% MeOH in CH2Cl2 to give the product (0.65 g, 52%).
Figure imgf000134_0001
6-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-phenyl}-5-pyridin-2-yl -4,5-dihydro-2H-pyridazin-3-one
A solution of the ester intermediate (4-{4-[3-R-2-methyl-pyrrolidin-l-yl)-phenyl}-4- oxo-3-pyridin-2-yl-butyric acid ethyl ester) (9.2 g, 22 mmol) and hydrazine hydrate (2.2 g, 43 mmol) in 150 mL of EtOH was stirred at reflux overnight. Flash chromatography using 15% MeOH in CH2Cl2 with 0.5% of JPrNH2 followed by treatment of the product with IN HCl in EtOH gave hydrochloride of 6-{4-[3-R-2-methyl-pyrroIidin-l-yl)-propoxy]-phenyl}- 5-pyridin-2-yl-4,5dihydro-2H-pyridazin-3-one (6.1 g, 71%); Mp 133 0C (dec); MS m/z 393 (M + H).
Example 112.
Figure imgf000134_0002
6-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-phenyl}-5-pyridin-2-yl -2H-pyridazin-3-one
A mixture of example 111 (0.39 g, 1.0 mmol) in 4.0 mL of water was added sodium 3-nitrobenzenesulfonate (0.18 g, 0.78 mmol) and NaOH (0.12 g, 3.0 mmol). The reaction was heated to 100 0C as 2.5 mL of EtOH was added to make the reaction homogeneous. After 2 h at 100 0C, the reaction was cooled to rt. 2N HCl was added to adjust pH to ~6, then the reaction was extracted with CH2CI2 (3 x 20 mL), which was washed with saturated
NaHCOj, saturated NaCl, and then dried over Na2SO4. The product was purified by preparative TLC using 10% MeOH in CH2Cl2 and 0.5% of iPrNH2 to give the product. The hydrochloride salt was prepaed by treating the free base with IN HCl in EtOH (0.14 g, 35%); Mp 234 0C (dec); MS m/z 391 (M + H).
Example 113
Figure imgf000136_0001
4-(4-Ethoxycarbonyl-phenoxy)-piperi dine-1-carboxylic acid tert-butyl e ster
4-(4-Ethoxycarbonylphenoxy)piperidine-l-carboxylic acid tert-butyl ester was prepared from 4-hydroxy benzoic acid ethyl ester and 4-hydroxypiperidine-l-carboxylic acid tert-butyl ester using the procedure described in Example 103 step 1; Mp 76-78 0C; MS m/z 350 (M + H).
Step 2.
Figure imgf000136_0002
4-[4-(2-Pyridin-2-yl-acetyl)-phenox y]-piperidine-1-carboxylic acid ter t-butyl ester
A solution of 4-(4-ethoxycarbonylphenoxy)piperidine-l-carboxylic acid tert-butyl ester (3.5 g, 10 mmol) and 2-methyIpyridine (1.9g, 2.0 mmol) in 50 mL of THF was stirred at 0 0C as LiHMDS (LOM, 22 mL) was added dropwise. The reaction was stirred at 45 0C overnight, then quenched with ice-water and the solvent evaporated. The residue was extracted with CH2CI2 (3 x 30 mL), and the combined CH2Cb layers were washed with saturated NaHCC»3, saturated NaCl solution, dried OVCrNa2SO4, and concentrated to give the product; Mp 138-140 0C; MS m/z 397 (M + H).
Step 3.
Figure imgf000136_0003
4-[4-(3-Ethoxycarbonyl-2-pyridin-2- yl-propionyl)-phenoxy]-piperidine-1 -carboxylic acid tert-butyl ester A mixture of sodium hydride (0.21 g, 8.8 mmoL) in 10 mL of DMSO was stirred under N2 as 4-[4-(2-pyridine-2-yl-acetyl)-phenoxy]-piperidine-l-carboxylic acid tert-butyl ester (3.50 g, 8.83 mmol) in 15 mL of DMSO was added dropwise. After 30 min, a solution of ethyl bromoacetate (I AIg, 8.83 mmol) in 8.0 mL of toluene was added dropwise. The reaction was stirred at it for 2 h and then quenched with saturated NH4Cl solution, and the solvent was evaporated. The residue was extracted with CH2Cl2 (3 x 20 mL), combined, washed with saturated NaHCO3, saturated NaCl solution and dried over Na2SO4. The crude product was purified by Combiflash chromatography (CH2Cl2 to 1% MeOH in CH2Cl2) to give the product (4.0 g, 94%): Mp 118-120 0C; MS m/z 483 (M + H).
Figure imgf000137_0001
4-[4-(6-Oxo-4-pyridin-2-yl-1,4,5,6- tetranydro-pyridazin-3-yl)-phenoxy] -piperidine-1-carboxylic acid tert- butyl ester
A solution of the product from step 3 (4.Og, 8.3 mmol) and hydrazine hydrate (0.83 g, 16 mmol) in 30 mL of EtOH was stirred at 90 0C overnight. The yellow suspension was reduced to ~15 mL of EtOH. The solid was collected and washed with cold EtOH to give the product (2.05 g, 55%): Mp 213-214 °C; MS m/z 395 (M-tBu + H).
Example 113
Figure imgf000137_0002
6-[4-(Piperidin-4-yloxy)-phenyl]-5- pyridin-2-yl-4,5-dihydro-2H-pyridazin-3- one
This compound was prepared from the product of step 4 using procedures described in Example 102 Step 3 MS m/z 351 (M + H). Example 114
Figure imgf000138_0001
6-[4-(1-Cyclobutyl-piperϊdin-4-ylox y)-phenyl]-5-pyridin-2-yl-4,5-dihyd ro-2H-pyridazin-3-one
This compound was prepared using the procedure for Example 103; Mp 1990C (dec); MS m/z 405 (M + H).
Example 115
Figure imgf000138_0002
6-[4-(1-Cyclobutyl-piperidin-4-y!ox y)-phenyl]-5-pyridin-2-yl-2H-pyrida zin-3-one
Figure imgf000138_0003
4-[4-(6-Oxo-4-pyridin-2-yl-1,6-dihy dro-pyridazin-3-yl)-pheπoxy]-piperi dine-1-carboxylic acid tert-butyl e ster
A mixture of the product from Example 113 step 4 (0.3 g, 0.67 mmol) and cesium carbonate (0.65 g, 2 mmol) in 4.0 mL of DMSO was heated under air at 1500C for 0.5 h. The reaction was cooled to it, filtered, washed with CH2CI2 (3 x 15mL) and combined. The CH2CI2 solution was washed with saturated NaHCO35 water and dried over Na2SO4. The crude product was crystallized from MeOH and ether to give the Boc product; Mp 210-20C; MS m/z 449 (M + H). 6-[4-(l-Cyclobutyl-piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-2H-pyridazin-3-one was prepared from the product in step 1 using procedures described in Example 102 Step 3 and Example 103; Mp 203 0C (dec); MS m/z 403(M + H).
Example 116
Figure imgf000139_0001
6-[4-( 1 -Cyclobutyl-pipetϊdin-4-ylox y)-phenyl]-4-methyl-4,5-dihydro-2H- pyridazin-3-one Step 1.
Figure imgf000139_0002
4-(4-H yd roxy-ph eπy l)-2-methyl-4-oxo -butyric acid ethyl ester
A solution of 4-(4-methoxyphenyl)-2-methyl-4-oxobutyric acid (10 g, 45 mmol) and
150 mL of 48% HBr in 20 mL of AcOH was heated to 100 0C for 48 h. The solvent was evaporated and EtOH (3 x 30 mL) was added and evaporated to give 4-(4-methoxy- phenyl)-2-methyl-4-oxobutyric acid ethyl ester (9.96 g, 93%); MS m/z 259 (M + 23).
Step 2.
Figure imgf000139_0003
4-[4-(3-Ethoxycarbonyl-butyryl)-phe noxy]-piperidine-1-carboxylic acid tert-butyl ester
4-[4-(3-Ethoxycarbonyl-butyryl)-phenoxy]piperidine-l-carboxylic acid tert-butyl ester was prepared using procedure described in Example 102 step 1 ; MS m/z 442 (M + 23).
The final product 6-[4-(l-cyclobutylpiperidin-4-yloxy)phenyl]-4-methyl-4,5- dihydro-2H-pyridazin-3-one HCl was prepared from 4-[4-(3-ethoxycarbonyl- butyryl)phenoxy]-piperidine-l-carboxylic acid tert-butyl ester using procedures described in Example 102 Step 3 and Example 103; Mp 257-9 0C; MS m/z 342 (M + H). Example 117
Figure imgf000140_0001
5-[6-(1-Cyclobutyl-piperidin-4-yloxy)- pyridin-3-y!]-2H-pyridazin-3-one
Figure imgf000140_0002
5-(6-Chloro-pyridin-3-y!)-2H- pyridazin-3-one
4,5-Dichloropyridazin-6-one (10 g, 60.6 mmol) and 57 wt.% hydroiodic acid in water (80 mL, 1.0 mmol) was heated to 150 0C for 24 h. The reaction was cooled to rt, the solid was washed with sodium thiosulfate. The crude product was triturated with CH2Cl2: MeOH (1 : 1) and filtered to give 5-iodo-2H-pyridazin-3-one (4.64g, 35%).
A mixture of 5-iodo-2H-pyridazin-3-one (4.64g, 21 mmol) and 30% formaldehyde in water was heated to reflux for overnight. The reaction was cooled to rt, and the resulting solid was filtered to give 2-hydromethyl-5-iodo-2H-pyridazin-3-one (5.2 g, 99%).
A mixture of 2-hydromethyl-5-iodo-2H-pyridazin-3-one (1.15 g, 4.56 mmol) and 2- chloro-5-pyridineboronic acid (0.72 g, 4.57 mmol), tetrakis(triphenylphosphine)- palladium(O) (0.53 g, 0.46 mmol) and potassium carbonate (1.89 g, 13.7 mmol) in 30 mL of 1,2-dimethoxyethane and 10 mL of water was degassed for 3 min, then heated to 85 0C overnight. The reaction was cooled to rt, filtered and washed with ethyl acetate. The organic layer was separated, concentrated, and triturated with ether to give 5-(6-chloro- pyridin-3-yl)-2H-pyridazin-3-one (0.4 g, 36%); MS m/z 208 (M + H).
Figure imgf000141_0001
4-[5-(6-Oxo-1 ,6-dihydro-pyridazin-4 -yl)-pyridin-2-yloxy]-pipeιϊdine-1- carboxylic acid tert-butyl ester
A solution of 5-(6-chloropyridin-3-yl)-2H-pyridazin-3-one (73 mg5 0.35 mmol) and 4-hydroxypiperidine-l-carboxylic acid tert-butyl ester (140 rag, 0.70 mmol) in 2.7 mL of DMSO was stirred as KOtBu in 2-methyl-2-propanol (1.0 M3 14.4 mL) was added dropwise. After stirring at 110 0C overnight, the reaction was cooled to it, and 2 mL of water was added. The mixture was extracted with CH2Cl2 (3 x 10 mL), the extracts combined and dried OVCrNa2SO4. The crude product was purified by prep. TLC with 10% MeOH in CH2CI2 to give 71 mg (54%) of 4-[5-(6-oxo- 1 ,6-dihydropyridazin-4-yl)-pyridin- 2-yloxy]piperidine-l-carboxylic acid tert-butyl ester; MS m/z 273 (M-Boc-H).
Example 117 hydrochloride was prepared from the product in step 2 using procedures described in Example 102 Step 3 and Example 103; Mp 232-4 0C; MS m/z 327 (M + H).
Example 118
Figure imgf000141_0002
2-(2-Fluoro-ethyl)-6-{4-[3-((R)-2-m ethyl-pyrrolidin-1-yl)-propoxy]-phenyl}-2H- pyridazin-3-one
Step 1.
Figure imgf000142_0001
2-(2-Fluoro-ethyl)-6-(4-methoxy-phe nyl)-2H-pyridazin-3-one
A mixture of 6-(4-methoxyphenyl)-2H-pyridazin-3-one (170 mg, 0.83 mmol), 1- bromo-2-fluoroethane (122.5 mg, 1.5 eq.), NaI (20 mg) and cesium carbonate (553 mg, 2.0 eq.) in 5 mL OfCH3CN was heated to 70 0C overnight. The reaction mixture was filtered and concentrated. The product was purified by ISCO combifiash with 50% hexane and EtOAc to give 2-(2-fluoroethyl)-6-(4-methoxyphenyl)-2H-pyridazin-3-one (200 mg, 97%); MS m/z 349 (M + H).
Example 118 hydrochloride was prepared from the product in step 1 using procedures described in Example 1 and example 86; mp 135-6 0C; MS m/z 360 (M + H).
The following compounds were prepared as HCl salts unless noted using methods for example 1, example 11 or example 91.
Figure imgf000142_0002
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000146_0003
Example 139
Figure imgf000146_0001
6-[6-(1-Cyclopentyl-piperidin-4-ylo xy)-pyridin-3-yl]-2H-pyridazin-3-one
Step 1
Figure imgf000146_0002
6-(6-Chloro-pyridin-3-yl)-4,5-dihydro- 2H-pyridazin-3-one
To ethyl-4-(4-chloro-3-pyridyl)-4-oxobutyrate (5 g, 20.7 mtnol) in ethanol (30 mL) was added hydrazine monohydrate (964 μM, 31 mmol). After overnight stirring at 80 0C, the reaction was concentrated to half of the volume and the resulting yellow solid was filtered off and dried to give 3.4 g of product (77%); MS m/z 210 (M + H). Step 2
Figure imgf000147_0001
4-[5-(6-Oxo-1,6-dihydro-pyridazin-3 -yl)-pyridin-2-yloxy]-piperidiπe-1- carboxylic acid tert-butyl ester
To 6-(6-chloro-pyridin-3-yl)-4,5-dihydro-2H-pyridazin-3-one (3 g, 14.4 mmol) in
DMSO (40 mL) was added 4-hydroxy-boc-piperidine (2.9 g, 14.4 mmol), followed by IM KtOBu (19 mL). After overnight stirring at 100 0C open to air, the reaction was cooled, diluted with dichloromethane and washed several times with water/brine, dried over sodium sulfate, and concentrated under vacuum to obtain 4.9 g crude product (92%); MS m/z 373 (M H- H).
Step 3
Figure imgf000147_0002
6-[6-(Piperidin-4-yloxy)-pyridin-3- yl]-2H-pyridazin-3-one
To 4-[5-(6-oxo-l,6-dihydro-pyridazin-3-yl)-pyridin-2-yloxy]-piperidine-l- carboxylic acid tert-butyl ester (4.9 g, 13.2 mmol) in dioxane (30 mL) was added 4N HCl/dioxane (6.6 mL, 3 mmol). After overnight stirring at 60 0C, the reaction was concentrated under vacuum to obtain 4 g of product as the HCl salt (quantitative); MS m/z 327 (M + H).
Step 4 Example 139
Figure imgf000147_0003
6-[6-(piperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one hydrochloride (407 mg, 1.18 mmol) in a mixture of DMF (5 mL), methanol (15 mL), and acetic acid (250 μL) was added cyclopentanone (314 μL, 3.54 mmol), followed by sodium cyanoborohydride (371 mg, 5.9 mmol). After stirring at 60 0C for 2 h, the reaction was concentrated, partitioned between dichloromethane/lN sodium carbonate, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using prep TLC plates (9:1 dichloromethane:methanol) (25%); Mp 233-237 0C; MS m/z 341 (M + H).
Example 140
Figure imgf000148_0001
6-[6-(1-lsopropyl-piperidin-4-ylmethoxy)- py ridin-3-y l]-2 H -py ridazi n-3-one
To the product from step 1 Example 139 (115 mg, 0.55 mmol) in DMSO (5 mL) was added (l-isopropanol-piperidin-4-yl)methanol (130 mg, 0.83 mmol) and IM KtOBu (1.1 mL, 1.1 mmol). After overnight stirring at 1000C, the reaction was diluted with dichloromethane, washed with water/brine several times, dried over sodium sulfate, and concentrated. The product was purified by prep TLC plates to obtain 64 mg (35%); Mp 188-191 0C; MS m/z 329 (M + H).
The following examples were prepared using methods for example 139
Figure imgf000149_0003
Example 143
Figure imgf000149_0001
6-[6-(1-Cyclopentyl-piperidin-4-ylo xy)-pyridin-3-yl]-2-methyl-2H-pyrid azin-3-one
Step 1
Figure imgf000149_0002
6-(6-Chloro-pyridin-3-yl)-2-methyl- 2H-pyridazin-3-one
To 6-(6-chloropyridin-3-yl)-4,5-dihydro-2H-pyridazin-3-one (1.03 g, 4.93 mmol) in DMSO (40 mL) was added iodomethane (460 μL, 7.4 mmol) and cesium carbonate (3.2 g, 9.86 mmol). After overnight stirring at 100 0C open to air, the reaction was cooled, diluted with dichloromethane, washed several times with water/brine, dried over sodium sulfate, and concentrated under vacuum to obtain 835 mg product (79%); MS m/z 222 (M + H). Step 2
Figure imgf000150_0001
4-[5-(1-Methyl-6-oxo-1,6-dihydro-pyridazin-3- yl)-pyridin-2-yloxy]-piperidine-1-carboxylic acid tert-butylester
To 6-(6-chloro-pyridin-3-yl)-2-methyl-2H-pyridazin-3-one (3 g, 13.6 mmol) in toluene (50 mL) was added 4-hydroxy-boc-piperidine (2.7 g, 13.6 mmol) and IM KtOBu (16.3 mL, 16.3 mmol). After overnight stirring at 80 0C, the reaction was concentrated, partitioned between dichloromethane/lN sodium carbonate, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified by column chromatography (99:1 dichloromethane:methanol) to obtain 2.7 g (51%); MS m/z 387 (M + H).
Example 143-145 were synthesized using Example 139 step 3 and step 4 (deprotection and reductive amination) and Example 143 Step 1 alkylation.
Figure imgf000150_0002
Figure imgf000151_0004
Example 146
Figure imgf000151_0001
6-{6-[3-((R)-2-Methyl-pyrrolιdin-1- yl)-propoxy]-pyridin-3-yl}-2H-pyrid azin-3-one
Step 1
Figure imgf000151_0002
3-((R)-2-Methyl-pyrrolidin-1-yl)-pr opan-1-ol
To 3-chloro-l-propanol (1.00 g, 10.6 mmol) in 2-butanone (10.00 mL) was added R-
2-methyl-pyrrolidine hydrochloride (1.93 g, 15.9 mmol), potassium carbonate (3.65 g, 26.44 mmol), and potassium iodide (1.76 g, 10.6 mmol). After overnight stirring at 1,00 0C, the reaction was filtered, partitioned between dichloromethane/water, washed with brine, dried over sodium sulfate, and concentrated under vacuum to obtain 495 mg product (33%); MS m/z 144 (M + H).
Chiral
Figure imgf000151_0003
6-{6-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-pyridin-3-yl}-2H-pyrid azin-3-one Step 2
To 6-(6-chloro-pyridin-3-yl)-4,5-dihydro-2H-pyridazin-3-one (599 mg, 2.86 mmol) (step 1 example 139) in DMSO (15 mL) was added 3-(R)-2-methylpyrrolidin-l-yl)-propan- l-ol (495 mg, 3.46 mmol) and IM KOtBu (5.72 mL). After overnight stirring at 110 0C open to air, the reaction mixture was cooled and poured into water, extracted with dichloromethane, washed with brine, dried over sodium sulfate, and concentrated. The product was purified using prep TLC plates (9:1 dichloromethane:methanol) to obtain 68 mg; Mp 178-181 0C; MS m/z 315 (M + H).
Example 147
Figure imgf000152_0001
6-[6-(3-Piperidin-1 -yl-propoxy)-pyr idin-3-yl]-2H-pyridazin-3-one
This compound was prepared using the intermediate from step 1 example 139 and 3- piperidin-1 -yl-propanol using methods described for example 146; Mp 155-158 0C MS m/z 315 (M + H).
Example 148
Figure imgf000152_0002
Step 1
Figure imgf000152_0003
4-(5-Acetyl-pyιϊdin-2-yloxy)-piperi dine-1-carboxylic acid tert-butyl e ster To 4-hydroxy-boc-piperidine (1.55 g, 7.71 mmol) in DMSO (12 mL) was added IM KtOBu (8.36 mL), followed by l-(6-chloropyridin-3-y])ethanone (1.00 g, 6.43 mmol). After overnight stirring at 100 0C, the reaction was poured into water, extracted with dichloromethane, washed with brine, dried over sodium sulfate, and concentrated. The product was purified using a Single Step column (7:3 hexanesrethyl acetate) to obtain 0.5 g (25%); MS m/z 321 (M + H).
Step 2
Figure imgf000153_0001
4-[5-(3-Ethoxycarbonyl-3-methyl-but yryl)-pyridin-2-yloxy]-piperidine-1 -carboxylic acid tert-butyl ester
To 4-(5-acetyl-pyridin-2-yloxy)-piperidine-l-carboxylic acid tert-butyl ester (1.36 g, 4.24 mmol) in THF (15 mL) at -78 0C was added 0.5M potassium bis(trimethylsilyl)amide in toluene (17 mL) and stirred for 30 min before adding 2-bromo-2-methyl-propionic acid ethyl ester (1.25 mL, 8.49 mmol) at -78 0C. After overnight stirring at r.t., the reaction was quenched with IN HCl, extracted with dichloromethane, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using a Single Step column (7:3 hexanesrethyl acetate) to obtain 0.458 g (25%); MS m/z 435 (M + H).
Step 3
Figure imgf000153_0002
4-[5-(5,5-Dimethyl-6-oxo-1 l4,5,6-te trahydro-pyridazin-3-yl)-pyridin-2- yloxy]-piperidine-1-carboxylic acid tert-butyl ester
To 4-[5-(3-ethoxycarbonyl-3-methyl-butyryl-pyridin-2-yloxy]piperidine-l- carboxylic acid tert-butyl ester (0.318 g, 0.732 mmol) in 2-propanol (8 mL) was added hydrazine monohydrate (2 mL). After overnight stirring at 1200C, the reaction was partitioned between dichloromethane/water, washed with brine, dried over sodium sulfate, and concentrated under vacuum to obtain 0.235 mg product (80%); MS m/z 403 (M + H).
Step 4
Figure imgf000154_0001
4,4-Dimethy!-6-[6-(piperidin-4-ylox y)-pyridin-3-yl]-4,5-dihydro-2H-pyr idazin-3-one
To 4-[5-(5,5-dimethyl-6-oxo-l,4,5,6-tetrahydro-pyridazin-3-yl)-pyridin-2~yloxy]- piperidine-1-carboxylic acid tert-butyl ester (0.340 g, 0.845 mmol) in dichloromethane (5 mL) was added TFA (0.700 mL). After stirring at r.t. for ~3 h, the reaction was concentrated under vacuum to obtain product as the TFA salt (quantitative); MS m/z 303 (M + H).
Example 148 was prepared using the product from step 4 and cyclobutanone using the procedure for example 139 step 4 ; m 240-245; MS m/z 357 (M + H).
Example 149
Figure imgf000154_0002
6-[6-( 1 -Cyclobutyl-piperidin-4-ylox y)-pyridin-3-yl]-2-pyιϊdin-2-yl-2H- pyridazin-3-one
Step 1
To example 141 (0.509 g, 1.56 mmol) in DMF (8 mL) was added potassium carbonate (0.431 g, 3.12 mmol), 2-bromopyridine (0.223 mL, 2.34 mmol), and copper(I) iodide (0.0297 g, 0.156 mmol). After stirring at 150 0C for 4 h, the reaction was cooled, diluted with dichloromethane, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using Prep. TLC plates (9:1 dϊchloromethane:methanol), dissolved in methanol with IN HCl/ether (~2 mL) added, concentrated, and recrystallized from methanol/ether as the HCl salt to give 0.223 mg (33%); Mp 261-262 ° C; MS m/z 404 (M + H).
Example 150
Step 1
Figure imgf000155_0001
4-(4-Hydroxy-phenyl)-4-oxo-butyric acid ethyl ester To 4-(4-methoxy-phenyl)-4-oxo-butyric acid ethyl ester (4.5 g, 19.0 mmol) was added 48% HBr (50 mL). After overnight stirring at 120 0C, the reaction was concentrated and ethanol was added several times and concentrated to obtain 4.18 g product (94%); MS m/z 223 (M + H).
Figure imgf000155_0002
To triphenylphosphine (2.48 g, 9.48 mmol) in THF (25 mL) was added 40% w/w DEAD in toluene (4.00 mL, 8.95 mmol) and the reaction was cooled at 0 0C before adding a mixture of 4-hydroxy-boc-piperidine (1.44, 7.14 mmol) and 4-(4-hydroxyphenyl)-oxo- butyric acid ethyl ester (1.3 g, 5.8 mmol) in THF (25 mL). After overnight stirring at r.t., the reaction was concentrated and the product was purified using a Single Step column (7:3 hexanes:ethyl acetate) to obtain 2.17 g (91%); MS m/z 406 (M + H). Step 3
Figure imgf000156_0001
4-[4-(6-Oxo-1,4,5,6-tetrahydro-pyridazin- 3-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester
To 4-[4-(3-ethoxycarbonyl-propionyl)-phenoxy]-piperidine-l-carboxylic acid tert- butyl ester (2.68 g, 6.61 mraol) in 2-propanol (25 mL) was added hydrazine monohydrate (0.662 g, 13.2 mmol). After overnight stirring at 120 0C, the reaction was concentrated down, partitioned between dichloromethane/water, washed with brine, dried over sodium sulfate, and concentrated under vacuum to obtain 2.18 g product (88%); MS m/z 374 (M + H).
Example 150
Figure imgf000156_0002
6-[4-(1-Cyclobutyl-piperidin-4-ylox y)-phenyl]-4,5-dihydro-2H-pyridazin-3-one
6-[4-(piperidin-4-yloxy)-phenyl] -4,5-dihydro-2H-pyridazin-3-one trifluoroacetate was prepared using conditions for Example 148 step 4.
To 6-[4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one trifluoroacetate (6.50 g, 23.8 mmol) in DMF (10 mL), methanol (50 mL), and acetic acid (2 mL) was added cyclobutanone (5.33 mL, 71.3 mmol) and sodium cyanoborohydride (7.47 g, 119 mmol) in portions. After stirring at 60 0C for 4 h, the reaction was concentrated, diluted with dichloromethane, washed with water/brine, dried over sodium' sulfate, and concentrated. The product was purified using a Single Step column (9:1 dichloromethane:methanol) and recrystallized from chloroform/ether to obtain 2.2 g (40%); Mp = 196-198 0C; MS m/z 328 (M+H).
Examples 151-153 were synthesized using procedures for Example 150.
Figure imgf000157_0002
Example 154
Figure imgf000157_0001
6-[4-( 1 -Cyclopenty l-pi peridin-4-ylo xy)-phenyl]-2H-pyridazin-3-one
To example 150 (130 mg, 3.81 mmol) in DMSO (3 mL) was added cesium carbonate (248 mg, 7.61 mmol). After stirring at 130 0C for 2 h open to air, the reaction was filtered, diluted with dichloromethane, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using Prep. TLC plates (9:1 dichloromethane: methanol) to obtain 48 mg (37 %); Mp 211-213 0C; MS m/z 340 (M + H). Examples 155-156 were synthesized using methods for example 154.
Figure imgf000158_0002
Example 157
Figure imgf000158_0001
To example 150 (1.50 g, 4.58 mmol) in DMSO (20 mL) was added potassium carbonate (1.90 g, 13.7 mmol), 2-bromopyridine (0.872 mL, 9.16 mmol), and copper(I) iodide (0.0872 g, 0.458 mmol). After overnight stirring at 150 0C open to air, the reaction was filtered, diluted with dichloromethane. washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using a single step column (9:1 dichloromethane:methanol), dissolved in methanol and IN HCl/ether (~2 mL) was added, concentrated, and the product was recrystallized from methanol/ether as the HCl salt to obtain 53 mg; Mp >2400C (dec); MS m/z 403 (M + H).
Example 158
Step 1
Figure imgf000159_0001
6-[4-(Piperidin-4-yloxy)-phenyl]-2- pyridin-2-yl-4,5-dihydro-2H-pyridaz in-3-one
To 4-[4-(3-carboxy-propionyl)-phenoxy]-piperidine-l-carboxylic acid tert-butyl ester (1.34 g, 3.55 mmol) in acetic acid (20 mL) was added 2-hydrazinopyridine (1.94 g,
17.8 mmol). After overnight stirring at 120 0C, the reaction was concentrated under vacuum and the product was purified using a Single Step column (9:1 dichloromethanermethanol) to obtain 295 mg; MS m/z 351 (M + H).
Figure imgf000159_0002
6-[4-(1-Cyclobutyl-piperidin-4-ylox y)-phenylj-2-pyridin-2-yl-4,5-dihyd ro-2H-pyridazin-3-one
Example 158 was synthesized from the product in step 1 by reductive amination described for example 150 and forming the HCl salt; Mp 263-265 MS m/z 405 (M + H).
Examples 159-167 were prepared using methods described for examples 150-157.
Figure imgf000160_0001
Figure imgf000161_0002
Example 172
Figure imgf000161_0001
5-[4-( 1 -Cyclobutyl-piperidin-4-ylox y)-phenyl]-3,4-diaza-bicyclo[4.2.0] oct-4-en-2-one Step 1
Figure imgf000162_0001
2-(4-Methoxy-benzoyl)-cyclobutaneca rboxylic acid
To 3-oxabicyclo[3.2.0]heptane-2,4-dione (8.00 g, 63.4 mmol) in THF (90.00 mL) at
-78 0C was added 0.500 M of p-anisyl magnesium bromide (133 mL, 66.6 mmol) in THF (90 mL) dropwise. After stirring at -78 0C for 2 h, the reaction was quenched with ice cold water and concentrated. The aqueous layer was acidified and the white solid was filtered off and dried to obtain 9.72 g product (65%); MS m/z 233 (M - H).
Step 2
Figure imgf000162_0002
2-(4-Hydroxy-benzoyl)-cyclobutaneca rboxylic acid ethyl ester
To 2-(4-methoxy-benzoyl)-cyclobutanecarboxylic acid (10.28 g, 43.88 mmol) was added 48% hydrogen bromide in water (50 mL) and acetic acid (50 mL). After overnight stirring at 120 0C, the reaction was concentrated, stirred with ethanol a few times, and the product was purified using a Single Step column (7:3 hexanes:ethyl acetate) to obtain 7.70 g (71 %); MS m/z 247 (M - H)
Example 172 HCl was synthesized from the product in step 2 using procedures desribed for example 150; Mp 285-288 0C; MS m/z 354 (M + H)
Example 173
Figure imgf000162_0003
5-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-phenyl}-3,4-diaza-bicy clo[4.2.0]oct-4-en-2-αne
Figure imgf000163_0001
2-[4-(3-Chloro-propoxy)-benzoyl]-cy clobutanecarboxylic acid ethyl este r To 2-(4-hydroxy-benzoyl)-cyclobutanecarboxylic acid ethyl ester (0.55 g, 2.20 mmol) in acetone (10 mL) was added potassium carbonate (0.91 g, 6.58 mmol) and 1- bromo-chloropropane (0.26 mL, 2.63 mmol). After overnight stirring at 70 0C, the reaction was filtered, partitioned between dichloromethane/water, washed with brine, dried over sodium sulfate, and concentrated. The product was purified using a Single Step column (9:1 hexanesrethyl acetate) to obtain 0.30 g (42%); MS m/z 325 (M + H).
Step 2
Figure imgf000163_0002
rboxylic acid ethyl ester
To 2-[4-(3-chloro-propoxy)-benzoyl]-cyclobutanecarboxylic acid ethyl ester (0.300 g, 0.924 mmol) in acetonitrile (15 mL) was added (R)-2-methyl-pyrrolidine, benzenesulfonic acid salt (0.337 g, 1.38 mmol), potassium carbonate (0.383 g, 2.77 mmol), and potassium iodide (0.153 g, 0.924 mmol). After overnight stirring at 80 0C, the reaction was filtered, diluted with dichloromethane, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using a Single Step column (5%methanol/dichloromethane) to obtain 0.213 g (62%); MS m/z 374 (M+H).
Example 173 was synthesized using methods described for example 1 and example 11. Example 176
Figure imgf000164_0001
penta[d]pyridazin-1-one
To example 174 (0.500 g, 1.36 mmol) in DMSO (5 mL) was added cesium carbonate (0.887 g, 2.72 mmol). After overnight stirring at 140 oC open to air, the reaction was poured into water, extracted with dichloromethane, washed with water/brine, dried over sodium sulfate, and concentrated. The product was purified using Prep. TLC plates (9: 1 dichloromethane:methanol); Mp = 210-213 0C; MS m/z 366 (M + H).
Figure imgf000164_0002
Figure imgf000165_0003
Example 177
Figure imgf000165_0001
2-Cyc!obutyl-6-[6-(1-cyclobutyl-piperidin-4- yloxy)-pyridin-3-yl]-4,5-dihydro-2H-pyridazi n-3-one
This compound was prepared using ethyl-4-(4-chloro-3-pyridyl)-4-oxobutyrate and cyclobutyl hydrazine using methods described for examples 139 and 143; Mp 146-49 MS m/z 384 (M + H).
Example 178 Method A
Figure imgf000165_0002
6-{4-[3-((R)-2-Methyl-pyrrolidin-1- ylJ-propoxyl-phenyl^.δ-dihydro^H
-pyridazin-3-one
Step 1 4-(4-Hydroxy-phenyl)-4-oxo-butyric acid ethyl ester (3.0 g, 13.5 mmol), 1- bromo-3-chloropropane (4.2 g, 27 mmol) and K2CO3 (5.6 g, 41 mmol) in acetonitrile (50 mL) was stirred at reflux for 12 h. The reaction was filtered, concentrated and purified by silica gel chromatography to give 3.2 g (80%).
Figure imgf000166_0001
4-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-phenyl}-4-oxo-butyric acid ethyl ester
The product from step 1 (3.1 g, 10.4 mmol), R-2-methylpyrrolidine HCl (2.5g, 21 mmol), KI (0.9 g) and K2CO3 (4.1 g, 2.9 mmol) in acetonitrile (75 mL) was stirred at 90 0C for 2 days. The reaction was cooled, filtered and concentrated. The residue was dissolved in Et20 (75 mL) and washed with water and NaCL solution, dried (MgSO4) and concentrated to an oil; MS m/e 348 (M + H).
Figure imgf000166_0002
6-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-phenyl}-4,5-dihydro-2H
-pyridazin-3-one
The product from step 2 (3.0 g, 8.6 mmol) and hydrazine hydrate (0.33 g, 10 mmol) in isopropanol (50 mL) was stirred at 95 0C for 24 h. The reaction was cooled to rt, concentrated and the product recrystallized from EtOAc - hexane; Mp 142-45 ; MS m/z 316 (M + H).
The examples in the following table were synthesized using conditions for example 178 starting with 4-(4-hydroxy-phenyl)-2,2-dimethyl-4-oxo-butyric acid ethyl ester or 4-(3- fluoro-4-hydroxy-phenyl)-4-oxo-butyric acid ethyl ester.
Figure imgf000167_0002
Example 182
Figure imgf000167_0001
5,5-Dimethyl-6-{4-[3-((R)-2-methyl- pyrrolidin-1-yl)-propoxy]-phenyl}-4 , 5-d ihydro-2H-pyridazin-3-o ne Step 1.
Figure imgf000168_0001
4-(4- Benzyloxy-phenyl)-3, 3-d im ethyl -4-oxo-butyric acid ethyl ester
(4-Benzyloxy-phenyl)-trimethylsilanyloxy-acetonitrile (3.0 g, 9.63 mmol) in THF (100 mL) under a nitrogen atmosphere was added LDA (7.2 mL of 2 M in THF) at -72 0C. After 0.5 h, methyl 3-methylbut-2-enoate (1.23 mL, 10.1 mmol) in 1 THF (15 mL) was added dropwise. The reaction was stirred at 0 0C for 4 h, and then saturated NH4C1 was added. The THF was removed at reduced pressure; Et2O was added (50 mL) and washed with saturated NH4C1, water, dried (Na2SO4). and concentrated to give an oil. The oil was dissolved in THF (50 mL) and TBAF (10.1 mL of 1 M THF solution) was added at 0O C dropwise. After stirring 12 h at rt the reaction was concentrated, dissolved in Et2O and washed with water, NaCl solution and dried (MgSO4). The product was purified by silica gel chromatography (10-20% EtOAc/hexanes) to give 1.5 g; Mp 72-73. Step 2.
Figure imgf000168_0002
4-(4-Hydroxy-phenyl)-3,3-dimethyl-4 -oxo-butyric acid ethyl ester
The product from step 1 (1.25 g, 3.83 mmol) and 10% Pd/C (0.3 g) in MeOH (50 mL) was hydrogenated on a Parr apparatus until TLC indicated completion of the reaction. The mixture was filtered, concentrated to an oil and used directly in the next step; MS m/z 204 (M - OMe).
Figure imgf000168_0003
4-[4-(3-Chloro-propoxy)-phenyl]-3,3 -dimethyl-4-oxo-butyric acid ethyl ester The product from step 2 (1.0 g, 4.2 mmol), l-bromo-3-chloropropane (1.0 g, 8 mmol) and K2CO3 in acetonitrile (20 mL) was heated to reflux for 24 h. The reaction was cooled, filtered, concentrated to an oil and purified by ISCO siliga gel chromatography (10% EtOAc/hexanes) to give 0.7 g.
Step 4.
Figure imgf000169_0001
3,3-Dimethyl-4-{4-[3-((R)-2-methyl- pyrrolidin-1-yl)-propoxy]-phenyl}-4 -oxo-butyric acid ethyl ester
The product from step 3 (0.75 g, 2.4 mmol), R-2-methylpyrroIidine benzene sulfonic acid salt (1.0 g, 5 mmol), K2CO3 (1 g, 7 mmol) and KI (0.1 g) in acetonitrile (25 mL) were heated at 900C for 2 days. The reaction was filtered, concentrated, dissolved in Et2O and washed with water, NaCl solution and dried (MgSO4) to give 0.7 g as an oil; MS m/z 376 (M + H).
Example 182. Step 5.
Figure imgf000169_0002
5,5-Dimethyl-6-{4-[3-((R)-2-methyl- pyrrolidin-1-yl)-propoxy]-phenyl}-4
,5-dihydro-2H-pyridazin-3-one The product from step 4 (0.75 g, 2.1 mmol) and hydrazine hydrate (2.0 mL) in acetonitrile (25 mL) were heated to reflux for 24 h. The reaction was cooled, concentrated and the product recrystallized using Et2O-hexanes to give 600 mg (71%); Mp 118-121; MS m/z 344 (M + H). Example 183
Figure imgf000170_0001
6-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-phenyl}-2-pyridin-2-yl -4,5-dihydro-2H-pyridazin-3-one
Step 1.
Figure imgf000170_0002
6-(4-Methoxy-phenyl)-2-pyridin-2-yl -4, 5-dihydro-2H-pyridazin-3-one
In a 1 neck round bottom flask equipped with a Dean- Stark trap and condenser, 4-(4- methoxyphenyl)-4-oxo-butyric acid (5.0 g, 20 mmol), 2-hydrazinopyridine (3.9 g, 36 mmol) and p-toluene sulfonic acid(0.3 g) in 100 mL benzene were heated to reflux for 2 h while water was removed. The reaction was cooled to rt, an equal volume OfEt2O was added and the product collected; Mp > 300 0C. This solid was dissolved in HOAc (50 mL) and heated at 100 0C for 6 h. The reaction was concentrated, dissolved in EtOAc and washed with saturated NaHCO3 solution, water, NaCl solution and dried (MgSO4). The solvent was concentrated to a thick oil; MS m/z 282 (M + H).
Step 2.
Figure imgf000170_0003
6-(4-Hydroxy-phenyl)-2-pyridin-2-yl -4,5-dihydro-2H-pyridazin-3-one The product from step 1 (1.25 g, 4.4 mmol) in DCM (30 mL) was added BBr3 (30 mL, 1 M in DCM) dropwise at 0 0C. After stirring 4 h at rt, the mixture was cooled to 0-5 0C on an ice-bath while saturated NH4Cl solution (30 mL) was added dropwise. Additional water was added and the DCM was removed at reduced pressure. The solid was collected and dried to give 1.1 g (93%) of a tan solid; Mp > 2200C; MS m/z 268 (M + H).
Step 3.
Figure imgf000171_0001
6-[4-(3-Chloro-propoxy)-phenyl]-2- pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one The product from step 3 (5.0 g, 20 mmol), l-bromo-3-chloropropane (5.9 g, 37.4 mmol) and K2CO3 (7.8 g, 56 mmol) in acetonitrile (50 mL) was heated to reflux for 24 h. The reaction was cooled to rt, filtered and concentrated to a thick oil. The product was dissolved in EtOAc and washed with water, NaCl solution and dried (MgSO4). The product was purified by ISCO silica gel chromatography (95/5/1 DCM/MeOH/i-propylamine) to give 3.7 g of a dark oil; MS m/z 344 (M + H).
Example 183, step 4.
Figure imgf000171_0002
6-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-phenyl}-2-pyridin-2-yl -4,5-dihydro-2H-pyridazin-3-one
The product from step 3 (3.7 g, 10.8 mmol), R-2-methylpyrrolidine benzene sulfonic acid salt (5.24 g, 21.5 mmol), K2CO3 (4.46 g, 32.3 mmol) and KI (0.9 g) in acetonitrile (50 mL) were heated to reflux for 2 days. The reaction was cooled, filtered and concentrated. The residue was purified by ISCO silica gel chromatography (95/5/1 DCM/MeOH/i- propylamine). The fractions were concentrated and the HCl salt was prepared using 2M HCl / ether and recrystallized from CH3CN/ether; Mp 203-205 0C; MS m/z 393 (M + H).
Example 184
Figure imgf000172_0001
6-{3,5-pifluoro-4-[3-((R)-2-methyI- pyrrolidin-1-yl)-propoxy]-phenyl}-2 H-pyridazin-3-one
Step 1
Figure imgf000172_0002
1-(3,5-Difluoro-4-hydroxy-phenyl)-e thanone
A mixture of l-(3,5-difluoro-4-methoxyphenyl)ethanone (12 g, 64.5 mmol) and 48% aqueous HBr (32 mL) was stirred at reflux for 30 h. The reaction was cooled to rt and diluted with water and the aqueous layer was extracted twice with methylene chloride. The combined organics were dried (Na2SO4), filtered, and concentrated to give l-(3,5-difluoro- 4-hydroxyphenyl)ethanone (10 g, 91%), mp 141-143 0C; MS m/z 171 (M - H).
Step 2
Figure imgf000172_0003
1-[4-(3-Chloro-propoxy)-3,5-difluoro-phenyl]-ethanone
A mixture of l-(3,5-difluoro-4-hydroxyphenyl)ethanone (8.1 g, 47 mmol), 3-bromo- l-chloropropane (14.7 g, 93 mmol) and K2CO3 (21.3 g, 154 mmol) in acetone (120 mL) was stirred at reflux for 20 h. The reaction was cooled to rt and concentrated at reduced pressure, then partitioned between water and methylene chloride. The aqueous layer was extracted twice with methylene chloride to obtain l-[4-(3-chloropropoxy)-3,5~difluoro- phenyl]ethanone (12.9 g, quantitative yield); MS m/z 249 (M + H).
Step 3
Figure imgf000173_0001
6-[4-(3-ChIOrO-PrOpOXy)-S1S-CUfIuOr o-phenyl]-2 H-pyridazin-3-one
A mixture of l-(4-(3-chIoropropoxy)-3,5-difluoro-phenyl]ethanone (11 g, 44.7 mmol) and glyoxalic acid monohydrate (4.2 g, 46.5 mmol) in acetic acid (16 mL) was stirred at 100 0C for 4 h. The acetic acid was evaporated at reduced pressure and diluted with water then cooled to 00C and neutralized with ammonium hydroxide to pH 8. To this mixture, hydrazine monohydrate (4.3 mL, 86 mmol) was added and heated at 100 0C for 1 h. The reaction was cooled to rt and the solid was filtered, then dried to give a crude product. The crude product was triturated sequentially with 5% aqueous sodium bicarbonate solution and with a mixture of methylene chloride, methanol, ether and hexane to provide relatively pure product. The product was purified by ISCO (120 g silica gel column) chromatography using 2 to 8% methanol in methylene chloride to furnish 6-[4-(3- chloroproρoxy)-3,5-difluorophenyl]-2H-pyridazin-3-one (7.9 g, 59%), MS m/z 301 (M + H).
Step 4
Figure imgf000173_0002
6-{3,5-Difluoro-4-[3-((R)-2-methyl- pyrrolidin-1-yl)-propoxy]-phenyl}-2 H-pyridazi n-3-one A mixture of 6-[4-(3-chloropropoxy)-3,5-difluorophenyl]-2H-pyridazin-3-one (7.9 g, 26.3 mmol), K2CO3 (12.7 g 91.9 mmol), NaI (144 mg, 0.96 mmol) and i?-methyl- pyrrolidinium benzenesulfonate (13.4 g, 55.3 ramol) in CH3CN (200 mL) was heated under argon at 800C for 35 h. The mixture was filtered over celite and concentrated at reduced pressure and partitioned between saturated aqueous sodium bicarbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics were washed with brine, dried (Na2SO4). and concentrated. The crude product was purified by ISCO (120 g silica gel column) chromatography using 2 to 5% methanol in methylene chloride to 10% methanol containing 0.25% ammonium hydroxide in methylene chloride to obtain 6-{3,5-difluoro-4-[3-(i?)-2-methylpyrrolidin-l-yl)- propoxy]-phenyl}-2H-pyridazin-3-one (4.3 g). The product was precipitated using a mixture of ethanol and acetonitrile to provide a pure product (0.5 g). Mp 169-171 0C; MS m/z 350 (M + H).
Example 185
Figure imgf000174_0001
e^S.δ-Dibromo-A-ta-CCR^-rnethyl-pyrrolidin-i- yl)-propoxy]-pheπyl}-2H-pyridazin-3-one
Example 185 was synthesized using the procedure for example 184; Mp 165-167 0C; MS m/z 472 (M + H).
Example 186
Figure imgf000174_0002
6-{3,5-Difluoro-4-[3-((R)-2-methyl- pyrrolidin-1-yl)-propoxy]-pheπyl}-4 ,5-dihydro-2H-pyridazin-3-one
Step l
Figure imgf000175_0001
4-(3,5-Difluoro-4-methoxy-phenyl)-4 -oxo-butyric acid ethyl ester
A mixture of 1 ,3-difluoro-2-methoxybenzene (2.5 g, 17.3 mmol) and ethyl succinyl chloride (4.29 g, 26 mmol) in 1, 2-dichloroethane (25 mL) was cooled to 0 0C. Aluminum chloride (8 g, 60.1 mmol) was added slowly at 0 0C then stirred at rt for 2 h and quenched with ice and aqueous 2N HCl at 0 0C. The aqueous layer was extracted twice with methylene chloride and the combined organics were washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (80 g silica gel column) chromatography using 8.5% EtOAc in hexane to furnish 4- (3,5-difluoro-4-methoxyphenyl)-4-oxo-butyric acid ethyl ester (2.9 g, 61%),
Step 2
Figure imgf000175_0002
4-(3,5-Dif(uoro-4-hydroxy-phenyl)-4 -oxo-butyric acid ethyl ester
A mixture of 4-(3,5-difluoro-4-methoxy-phenyl)-4-oxo-butyric acid ethyl ester (2.9 g, 10.6 mmol) and 48% aqueous HBr (15 mL) in acetic acid (30 mL) was stirred at reflux for 8 h. The reaction was cooled to rt and treated three times with ethanol and then concentrated at reduced pressure to provide a crude material. The crude material was dissolved in methylene chloride and washed with water, brine, dried Q^SO4)- filtered, and concentrated to afford 4-(3,5-difluoro-4-hydroxyphenyl-4oxo-butyric acid ethyl ester (2.5 g, 92%), MS m/z 257 (M + H).
Figure imgf000176_0001
4-[4-(3-Ch!oro-propoxy)-3,5-difluor o-phenyl]-4-oxo-butyric acid ethyl ester
A mixture of 4-[4-(3-chloropropoxy))-4-oxo-butyric acid ethyl ester (2.5 g, 9.6 mmol), 3-bromo-l-chloropropane (1.9 mL, 18.5 mmol) and K2CO3 (4 g, 28.9 mmol) in acetone (25 mL) was stirred at reflux for 15 h. The reaction was cooled to rt and concentrated at reduced pressure, then partitioned between water and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics were washed with brine, dried (Na2SO4), filtered, and concentrated to obtain a crude product. The crude product was purified by ISCO (80 g silica gel column) chromatography using 10 to 12.5% EtOAc in hexane to provide 4-[4-(3-chloro-propoxy)-3,5-difluoro- phenyl]-4-oxo-butyric acid ethyl ester (3.1 g, 96%).
Step 4
Figure imgf000176_0002
4-{3,5-Difluoro-4-[3-((R)-2-methyl- pyrrolfdin-1-yl)-propoxy]-phenyl}-4 -oxo-butyric acid ethyl ester
A mixture of 4-[4-(3-chloropropoxy)-3,5-difluorophenyl]-4-oxo-butyric acid ethyl ester (5 g, 14.9 mmol), K2CO3 (7.2 g, 52.1mmol), NaI (220 mg, 1.4 mmol), and Benzenesulfonate; (J?)-methylpyrrolidinium (8 g, 33 mmol) in CH3CN (110 mL) was heated under argon at 80 0C for 36 h. The reaction was concentrated and partitioned between saturated aqueous sodium bicarbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude material (96% purity). The crude material was purified by ISCO (80 g silica gel column) chromatography using 2% to 9% methanol in methylene chloride to 10% methanol containing 0.1% ammonium hydroxide in methylene chloride. The isolated material was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated. The isolated material was crystallized with a mixture of methylene chloride, ether and hexane to obtain 4-{3,5-difluoro-4[3-(Λ)-2-methyl-pyrroiidin- l-yl)-propoxy] -phenyl }-4-oxo-butyric acid ethyl ester (3.97 g, 70%, 99% purity), MS m/z = 384 (M + H).
Step 5
Figure imgf000177_0001
6-{3,5-pifluoro-4-[3-((R)-2-methyl- pyrrolidin-1-yl)-propoxy]-phenyl}-4 ,5-dihydro-2H-pyridazin-3-one
A mixture of 4-{3, 5-difluoro-4[3-(R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}- 4-oxo-butyric acid ethyl ester (3.97 g, 10.4 mmol) and hydrazine monohydrate (1 mL, 20.7 mmol) in isopropanol (25 mL) was heated at 110 0C for 17 h. Isopropanol was evaporated at reduced pressure and partitioned between saturated aqueous sodium bicarbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude material. The crude material was purified by ISCO (80 g) chromatography using 2 to 8% methanol in methylene chloride to 10%methanol containing 0.2% ammonium hydroxide in methylene chloride. The isolated material was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated. The pure material was crystallized using a mixture of methylene chloride, ether and hexane to obtain 6-{3,5-difluoro-4-[3-(/,)-2- methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H-pyridazin-3-one (2 g, 55%, 98% purity), mp 102-1040C, MS m/z 352 (M + H). Example 187
Figure imgf000178_0001
6-[4-(1-Cyclobutyl-pipeιϊdin-4-ylox y)-3,5-difluoro-phenyl]-4,5-dihydro -2H-pyridazin-3-one
Step l
Figure imgf000178_0002
To a solution of triphenylphosphine (5.79 g, 22.1 mmol) in THF (35 nαL) was added 40% w/w DEAD in toluene (10 mL, 15 mmol). The mixture was cooled to 0 0C and a mixture of 4-(3.5-difluoro-4-hydroxy-phenyl)-4-oxo-butyric acid ethyl ester (example 186 step 2) (3.8 g, 14.7 mmol) and 4-hydroxy-piρeridirie-l-carboxylic acid tert-butyl ester (3.6 g, 18 mmol) in THF (35 mL) was added dropwise under argon. After the addition, the cooling bath was removed and stirred at rt overnight. The reaction mixture was concentrated at reduced pressure and purified by ISCO (120 g) chromatography using 15 to 30% EtOAc in hexane to provide 4-[4-(3-ethoxycarbonyl-propionyl)-2,6-difluoro- phenoxy]-piperidine-l-carboxylic acid tert-butyl ester (3.21 g, 49% yield).
Step 2
Figure imgf000178_0003
4-[2,6-Difluoro-4-(6-oxo-1,4,5,6-te trahydro-pyridazin-3-yl)-phenoxy]-p iperidine-1-carboxylic acid tert-bu tyl ester A mixture of 4-[4-(3-ethoxycarbόnyl-propionyl)-2,6-difluόro-phenoxy]-piperidine- 1-carboxylic acid tert-butyl ester (3.21 g, 7.27 mmol) and hydrazine monohydrate (0.7 mL, 14.1 mmol) in isopropanol (20 mL) was stirred at reflux overnight. Isopropanol was concentrated at reduced pressure and partitioned between saturated aqueous sodium bicarbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude material. The crude material was purified by ISCO (80 g silica gel column) chromatography using 15 to 60% EtOAc in hexane to obtain 4-[2,6-difluoro-4-(6-oxo- 1 ,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]-piperidine-l - carboxylic acid tert-butyl ester (0.42 g, 14%).
Figure imgf000179_0001
6-[3,5-Difluoro-4-(piperidin-4-ylox y)-phenyl]-4,5-dihydro-2H-pyridazin
-3-one
A solution of 4-[2,6-difluoro-4-(6-oxo- 1 ,4,5,6-tetrahydro-pyridazin-3-yl)-phenoxy]- piperidine-1 -carboxylic acid tert-butyl ester (0.42 g, 1 mmol) in methylene chloride (5 mL) was treated with trifluoro acetic acid (10 mL). The mixture was stirred at RT for 3 h and TFA was concentrated at reduced pressure to give 6-[3,5-difluoro-4-(piperidin-4-yloxy)- phenyl]-4,5-dihydro-2H-pyridazin-3-one (0.35 g, quantitative yield), MS m/z 310 (M + H).
Step 4
Figure imgf000179_0002
6-[4-(1-Cyclobutyl-piperidin-4-ylox y)-3,5-difluoro-phenyl]-4,5-dihydro -2H-pyridazin-3-one A solution of 6-[3,5-difluoro-4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H- pyridazin-3-one (350 mg, 1.1 mmol) in a mixture of DMF (2 mL) and MeOH (9 mL) was stirred under argon. Cyclobutanone (0.38 mL, 5 mmol), sodium cyanoborohydride (0.53 g, 8.45 mmol) and acetic acid (0.4 mL, 7 mmol) were added sequentially and stirred at 60 0C for 3 h. The reaction mixture was concentrated at reduced pressure and partitioned between aqueous IM sodium carbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered and concentrated to provide a crude product. The crude product was purified by ISCO (40 g) chromatography using 2 to 5% methanol in methylene chloride to 10% methanol containing 0.2% ammonium hydroxide in methylene chloride. The recovered product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated to furnish a pure product. The pure product was crystallized with a mixture of methylene chloride, ethanol, ether and hexane to obtain 6-[4-(l-cyclobutyl-piperidin-4-yloxy)-3,5-difluoro- phenyl]-4,5-dihydro-2H-pyridazin-3-one (110 mg, yield), mp 162-164 0C; MS m/z 364 (M + H)
Example 188
Figure imgf000180_0001
6-[4-(1-Cyclobutyl-piperidin-4-yloxy)-3,5-di fluoro-phenyl]-2H-pyridazin-3-one
A mixture of 6-[4-(l-cyclobutyl-piperidin-4-yloxy)-3,5-difluoro-phenyl]-4,5- dihydro-2H-pyridazih-3-one (137 mg, 0.37 mmol) and cesium carbonate (232 mg, 0.71 mmol) in dimethyl sulfoxide (5 mL) was heated at 130 0C 45 min. The mixture was cooled to rt and partitioned between water and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (40 g silica gel column) chromatography using 2% to 8% methanol in methylene chloride to 10% methanol containing 0.2% ammonium hydroxide in methylene chloride. The recovered product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated. The product was crystallized using a mixture of ethanol, ethyl acetate, ether and hexane to give 6-[4-(l-cyclobutyl-piperidin-4yloxy)-3.5-difluoro-phenyl]-2H- pyridazin-3-one (40 mg, 29%); Mp 195-197 0C; MS m/z 362 (M + H).
Example 189
Figure imgf000182_0001
6-[4-(1-Cyclobutyl-piperidin-4-yloxy)-phenyl] -5-methy!-4,5-dihydro-2H-pyridazin-3-one
Step l
Figure imgf000182_0002
4-(4-Propionyl-phenoxy)-piperidine- 1-carboxylic acid tert-butyl ester
A solution of triphenylphosphine (22.4 g, 85.2 mmol) and 40% w/w DEAD in toluene (12.6 mL, 79.9 mmol) in tetrahydrofiiran (100 mL) was cooled to 0 0C- A mixture ofp- propiophenol (8 g, 53.3 mmol) and 4-hydroxypiperidine- 1-carboxylic acid tert-butyl ester (12.9 g, 63.9 mmol) in THF (75 mL) was added dropwise at 0 0C. After the addition, the cooling bath was removed and stirred at it overnight. The reaction mixture was concentrated at reduced pressure and purified by ISCO (12O g silica gel column) chromatography using 5 to 30% EtOAc in hexane to provide an impure product (12 g). The product was again treated with triphenylphosphine and 40% w/w DEAD in toluene, after the completion, the reaction was concentrated at reduced pressure. The crude residue was triturated with a mixture of methylene chloride and hexane and filtered and the filtrate was concentrated at reduced pressure and purified by ISCO (12O g silica gel column) chromatography using 5 to 30% EtOAc in hexane to provide 4-(4-propionylphenoxy)- piperidine- 1-carboxylic acid tert-butyl ester (10 g, 56%).
Step 2
Figure imgf000182_0003
4-[4-(3-Ethoxycarbonyl-2-methyl-pro pionyl)-phenoxy]-piperidine-1-carbo xylic acid tert-butyl ester A solution of 4-(4-propionyl-phenoxy)-piperidine-l-carboxylic acid ethyl ester (5 g, 15 mmol) in tetrahydrofuran (40 mL) was cooled to 0 0C Lithium diisopropylamide, (2M solution in THF) (8 mL, 16.4 mmol) was added dropwise and warmed to rt for 30 min. The reaction was cooled again to 0 0C and ethyl bromoacetate (1.8 mL, 16 mmol) was added dropwise and warmed to rt for 30 min and then quenched with aqueous IM HCl acid at 0 0C. The aqueous layer was extracted twice with methylene chloride and the combined organics were washed with brine, dried (Na2SO4), filtered, and concentrated to give 4-[4-(3- ethoxycarbonyl-2-memyl-propionyl)-phenoxy] -piperidine-1 -carboxylic acid tert-butyl ester (5.8 g, 92%), MS m/z 364 (M - 55).
Step 3
Figure imgf000183_0001
4-[4-(4-Methyl-6-oxo-1 ,4, 5,6-tetrah ydro-pyridazin-3-yl)-phenoxy]-piperidine-1- carboxylic acid tert-butyl ester
A mixture of crude 4-[4-(3-ethoxycarbonyl-2-methyl-propionyl)~phenoxy]- piperidine-1 -carboxylic acid tert-butyl ester (9 g, 21.4 mmol) and hydrazine monohydrate (3.58 ml, 71.6 mmol) in isopropanol (70 mL) was heated at 90 °C for 2 days and concentrated at reduced pressure to give a crude residue. The crude reside was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated to give a crude product. The crude product was purified by ISCO (120 g silica gel column) chromatography using 2 to 5% methanol in methylene chloride to obtain 4-[4-(4-methyl-6-oxo-l54,5,6-tetrahydro-pyridazin-3-yl)- phenoxy] -piperidine-1 -carboxylic acid tert-butyl ester (4.4 g, 53%), MS m/z 388 (M + H) Step 4
Figure imgf000184_0001
5-Methyl-6-[4-(piperidin-4-yloxy)-p henyl]-4,5-dihydro-2H-pyridazin-3-σne
A solution of 4-[4-(4-methyl-6-oxo- 1 ,4,5 ,6-tetrahydro-pyridazin-3-yl)-phenoxy]- piperidine-1-carboxylic acid tert-butyl ester (1 g, 2.5 mmol) in methylene chloride at RT was treated with trifluoroacetic acid (3 mL, 38.9 mmol) and stirred at RT for 3 h. TFA was evaporated at reduced pressure to obtain 5-methyl-6-[4-(ρiperidin-4-yloxy)-phenyl]-4,5- dihydro-2H-pyridazin-3-one (0.35 g, 47%), MS m/z 288 (M + H).
Step 5
Figure imgf000184_0002
6-[4-(1-Cyc!obutyl-piperidin-4-ylox y)-phenyl]-5-methyl-4,5-dihydro-2H- pyridazin-3-oπe
A solution of 5-methyl-6-[4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin- 3-one (3.2 mg, 11 mmol) in a mixture of DMF (4 mL) and MeOH (20 mL) was stirred under argon. Cyclobutanone (4.2 mL, 56 mmol), sodium cyanoborohydride (7 g, 111 mmol) and acetic acid (1.5 mL, 26 mmol) were added sequentially and stirred at 60 0C for 20 h. The reaction mixture was concentrated at reduced pressure then quenched with IM sodium carbonate solution at 0 0C and extracted twice with methylene chloride to provide a crude product. The crude product was purified by ISCO (40 g silica gel column) chromatography using 2 to 5% methanol in methylene chloride to 10% methanol containing 0.2% ammonium hydroxide in methylene chloride. The recovered product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated to furnish a pure product. The pure product was crystallized using from a mixture of EtOAc, ethanol, ether and hexane to obtain 6-[4-(l- cyclobutyl-piperidin-4-yloxy)-3,5-difluoro-phenyl]-4,5-dihydro-2H-pyridazin-3-one (640 mg, 17%), mp 163-165 0C; MS m/z 342 (M + H).
Example 190
Figure imgf000185_0001
(R)-6-[4-(1-Cyclobutyl-piperidin-4- yloxy)-phenyl]-5-methyl-4,5-dihydro
-2H-pyridazin-3-one
Example 191
Figure imgf000186_0001
(S)-6-[4-(1-Cyclobutyl-piperidin-4- yloxy)-phenyl]-5-methyl-4,5-dihydro
-2H-pyridazin-3-one
Racemic Example 189 (660 mg) was separated into two enantiomers by chiral chromatography using chiralPak and 0.1% diethylamine in methanol.
Example 190: Λ(-)-6-[4-(cyclobutyl-piperidin-4-yloxy)-phenyl-5-methyl-4,5- dihydro-2H-pyradazin-3-one mp 188-190 0C, MS m/z 342 (M + H), Hg 365 = -29.2, Cone. -0.1 g/mL
• Example 191 : S'(+)-6-[4-(cyclobutyl-piperidin-4-yloxy)-phenyl-5-methyl-4,5- dihydro-2H-pyradazin-3-one one mp 188-190 0C, MS m/z 342 (M + H), Hg 365 = +30.5, Cone. -0.1 g/mL ).
Example 192
Figure imgf000186_0002
Example 192 was synthesized from l-(4-methoxyphenyl)butan-l-one using procedures for example 189; Mp 152-1540C; MS m/z 356 (M + H).
Example 193
Figure imgf000186_0003
6-[4-(1-Cyclobutyl-piperidin-4-yloxy)-phen yl]-5-methyl-2-pyridin-2-yl-4,5-dihydro-2H- pyridazin-3-one
Step 1
Figure imgf000187_0001
4-[4-{3-Carboxy-2-methyl-propionyl) -phenoxy]-piperidine-1 -carboxylic a cid tert-butyl ester
A mixture of 4-[4-(3-ethoxycarbonyl-2-methyl-propionyl)-phenoxy] -piperidine- 1 - carboxylic acid tert-butyl ester (Example 189 step 2) (5.7 g, 14 mmol) and IN NaOH (18 mL) in methanol was heated at 65 0C for 1 h. Methanol was evaporated at reduced pressure and diluted with water then cooled to 0 0C. The aqueous layer was neutralized carefully with citric acid and extracted twice with methylene chloride to obtain a crude 4-[4-(3- carboxy-2-methyl-propionyl)phenoxy] -piperidine- 1 -carboxylic acid tert-butyl ester (4.3 g, 81%), MS m/z 390 (M - I)
Step 2
Figure imgf000187_0002
4-[4-(4-Methyl-6-oxo-1-pyridin-2-yl -1 ,4,5,6-tetrahydro-pyridazin-3-yl) -phenoxy]-piperidine-1 -carboxylic a cid tert-butyl ester
A mixture of 4-[4-(3-carboxy-2-methyl-propionyl)-phenoxy] -piperidine- 1 - carboxylic acid tert-butyl ester (4.3 g, 11 mmol) and 2-hydrazinopyridine (1.5 g, 14 mmol) in isopropanol (45 mL) was heated in a microwave reactor (300 Watts) at 160 0C for 150 min. Isopropanol was evaporated at reduced pressure and triturated with ether (150 mL) to obtain an orange solid (3 g). The filtrate was concentrated and purified by ISCO (80 g silica gel column) chromatography using 1.5 to 3.5% methanol in methylene chloride to obtain 4- [4-(4-methyl-6-oxo-l -pyridin-2-yl-l ,435,6-tetrahydropyridazin-3-yl)phenoxy]-piperidine-l- carboxylic acid tert-butyl ester (0.3 g), mp 164-166 0C, MS m/z 465 (M + H).
Example 193 was synthesized using the product from step 2 and methods described for example 189 step 4 and step 5.
Figure imgf000188_0001
Example 194
Figure imgf000188_0002
5-Methyl-6-{4-[3-((R)-2-methyl-pyrτ olidin-1-yl)-propoxy]-phenyl}-4,5-d ihydro-2H-pyridazin-3-one
Step 1
Figure imgf000188_0003
4-(4-Methoxy-phenyl)-3-methyl-4-oxo -butyric acid ethyl ester
A solution of 4-methoxypropiophenone (24 g, 140 mmol) in tetrahydrofuran (220 mL) was cooled to 0 0C. Lithium diisopropylamide, (2M solution in THF) (126 mL, 248 mmol) was added drop wise and wanned to rt for 30 min. The reaction was cooled again to 0 0C and ethyl bromoacetate (18 mL, 161 mmol) was added dropwise and warmed to rt for 30 min and then quenched with aqueouslM HCl acid at 0 0C. The aqueous layer was extracted twice with methylene chloride and the combined organics were washed with brine, dried (Na2SO4), filtered, and concentrated to give 4-(4-methoxyphenyl)-3-methyl-4- oxobutyric acid ethyl ester (44 g), MS m/z 205 (M - 45)
Step 2
Figure imgf000189_0001
4-(4-Hydroxy-phenyl)-3-methyl-4-oxo -butyric acid ethyl ester
A mixture of crude 4-(4-methoxy-phenyl)-3-methyl-4-oxo-butyric acid ethyl ester (44 g, 175.8 mmol), acetic acid (300 mL) and 48% aqueous HBr (150 mL) was stirred at reflux for 1O h. The reaction was cooled to it, concentrated at reduced pressure then partitioned between methylene chloride and water amd the aqueous layer was extracted three times with methylene chloride and concentrated to provide a crude material. The crude material was dissolved in ethanol (125 mL) and added amberlyst then heated at 85 °C for 15 h. The reaction mixture was filtered over celite at rt and the filtrate was concentrated at reduced pressure and then partitioned between water and methylene chloride. The aqueous layer was extracted twice with methylene chloride to furnish a crude product and the crude product was purified by ISCO (330 g silica gel column) chromatography using 20 to 30% EtOAc in hexane to obtain a mixture (19 g) of 4-(4-hydroxyphenyl)-3-methyl-4- oxo-butyric acid ethyl ester (MS m/z 235 (M - H) and p-hydroxypropiophenone. The mixture was used for the next reaction without further purification.
Step 3
Figure imgf000189_0002
4-[4-(3-Chloro-propoxy)-phenyl]-3-m ethyl-4-oxo-butyric acid ethyl ester
A mixture of 4-(4-hydroxyphenyl)-3-methyl-4-oxo-butyric acid ethyl ester (12.5 g, 52.9 mmol), l-bromo-3-chloropropane (11.3 mL, 114.6 mmol) and K2CO3 (21.9 g, 159 mmol) in acetone (200 mL) was stirred at 60 0C for 15 h: The reaction was cooled to RT and filtered over celite and the filtrate was evaporated at reduced pressure to give a crude residue. The crude residue was partitioned between methylene chloride and saturated aqueous sodium bicarbonate solution and the aqueous layer was extracted twice with methylene chloride. The combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude product. The crude product was purified by ISCO (330 g) chromatography using 15% EtOAc in hexane to produce 4-[4-(3-chloro- propoxy)-phenyl]-3-methyl-4-oxo-butyric acid ethyl ester (9.7 g, 56%), MS m/z 267 (M - 45)
Step 4
Figure imgf000190_0001
3-Methyl-4-{4-[3-((R)-2-methyl-pyrr olidin-1-yl)-propoxy]-phenyl}-4-oxo -butyric acid ethyl ester
A mixture of 4-[4-(3-chloro-propoxy)-phenyl]-3-methyl-4-oxo-butyric acid ethyl ester (7 g, 22 mmol), K2CO3 (9.3 g, 67 mmol), NaI (330 mg, 2.2 mmol), and (Λ)-methyl- pyrrolidinium benzenesulfonate (11 g, 47 mmol) in CH3CN (160 mL) was heated under argon at 80 0C for 36 h. The reaction mixture was concentrated at reduced pressure and partitioned between saturated aqueous sodium bicarbonate solution and methylene chloride. The aqueous layer was extracted twice with methylene chloride and the combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to provide a crude material. The crude material was purified by ISCO (80 g siliga gel column) chromatography using 2% to 9% methanol in methylene chloride to 10% methanol containing 2.5 mL ammonium hydroxide in methylene chloride to afford a pure product. The pure product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated to give 3- methyl-4-{4-J?-2methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4-oxo-butyric acid ethyl ester (8.39 g, quantitative yield), MS m/z 362 (M + H). Step 5
Figure imgf000191_0001
5-Methyl-6-{4-[3-((R)-2-methyl-pyrr olidin-1-yl)-propoxy]-phenyl}-4,5-d ihydro-2H-pyridazin-3-one
A mixture of 3-methyl-4-{4-/--2methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4-oxo- butyric acid ethyl ester (8.39 g, 23.2 mmol) and hydrazine monohydrate (5 mL, 100 mmol) in isopropanol was heated at 100 0C for 36 h. Isopropanol was evaporated at reduced pressure and quenched with saturated aqueous sodium bicarbonate solution and extracted twice with methylene chloride. The combined organics was washed with brine, dried (Na2SO4), filtered, and concentrated to afford a crude product. The crude product was purified by ISCO (80 g) chromatography using 2 to 10% methanol in methylene chloride to 10% methanol containing 4 mL ammonium hydroxide in methylene chloride to afford a pure product. The pure product was dissolved in methylene chloride and washed with saturated aqueous sodium bicarbonate solution, brine, dried (Na2SO4), filtered, and concentrated to give 5-methyl-6-{4-[3-i?-2-methyl-pyrrolidin-l-yl)propoxy3-phenyl}-4,5- dihydro-2H-pyridazin-3-one (6.1 g, 80%, > 95% purity). The product was dissolved in a mixture of ethanol and ethyl acetate and IM HCl (18 mL) in ether was added and the mixture was concentrated at reduced pressure. Fresh ethanol and ethyl acetate were added and concentrated under vacuum and again dissolved in ethanol and slowly added ethyl acetate, ether and hexane. After stirring for 15 min at RT solid separated, and the solid was filtered, washed with ether and dried at 85 °C in a ChemDry for 15 h to provide example 194 HCl as an off-white solid (5.8 g), mp 169-171 0C, MS m/z 330 (M + H).
Example 195
Figure imgf000191_0002
5-Methyl-6-{4-[3-((R)-2-methyl-pyrr olidin-1-yl)-propoxy]-phenyl}-4,5-d ihydro-2H-pyridazin-3-one Example 196
Figure imgf000192_0001
5-Methyl-6-{4-[3-(( R)-2-methyl-pyrr olidin-1-yl)-propoxy]-phenyl}-4,5-d ihy dro-2H-py rid azin-3-on e
Racemic example 194 (5.8 g) of was separated into two diastereomers using chiralCel and 0.1% diethylamine in methanol.
Example 195: 5-methyl-6-[4-[3-(Λ)-2-methyl-pyπOlidin-l-yl)-propoxy]-phenyl}- 4,5-dihydro-2H-pyridazin-3-one HCl (2.4 g), mp 149-151 0C, MS m/z 367 (M + H).
Example 196: 5-methyl-6-[4-[3-(S)-2-methyl-pyrrolidin-l -yl)-propoxy] -phenyl }- 4,5-dihydro-2H-pyridazin-3-one HCl (2.6 g), mp 189-191 0C, MS m/z 367 (M + H)
Example 197 (racemic) and example 198 (racemic) were synthesized as HCl salts using methods described for example 194.
Figure imgf000192_0002
Example 199
Figure imgf000193_0001
6-{(R)-2-Methyl-4-[3-(2-methyl-pyrrolidin-1-yl)-propox y]-phenyl}-4,5-dihydro-2H-pyriazin-3-one
Step 1
Figure imgf000193_0002
4-(4-Hydroxy-2-methyl-phenyl)-4-oxo -butyric acid ethyl ester
A mixture of 4-(4-methoxy-2-methyl-phenyl)-4-oxo-butyric acid (2 g, 9 mmol), acetic acid (30 mL) and 48% aqueous HBr (10 mL) was heated at 130 0C for 5.5 h. The reaction was cooled to rt and concentrated at reduced pressure and azeotrope twice with benzene to give a crude residue. The crude residue was dissolved in ethanol (25 mL) and added amberlyst then heated at 90 0C for 18 h. The reaction was filtered over celite and evaporated ethanol at reduced pressure then quenched with water and extracted twice with methylene chloride to obtain 4-(4-hydroxy-2-methyl-phenyl)-4-oxo-butyric acid ethyl ester (1.6 g, 75%). The crude material was used for the next reaction without purification.
Step 2
Figure imgf000193_0003
4-[4-(3-Chloro-propoxy)-2-methyl-ph enyl]-4-oxo-butyric acid ethyl ester 4-[4-(3-chloro-propoxy)-2-methyl-phenyl]-4-oxd-butyric acid ethyl ester was prepared from 4-(4-hydroxy-2-methyl-phenyl)-4-oxo-butyric acid ethyl ester according to the procedure in step 3 example 184 MS m/z 267 (M - 45).
Step 3
Figure imgf000194_0001
4-{2-Methyl-4-[3-((R)-2-methyl-pyrr olidin-1-yl)-propoxy]-phenyl}-4-oxo -butyric acid ethyl ester
4-{2-methyl-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4-oxo-butyric acid ethyl ester (0.28 g, 67%) was prepared from 4-[4-(3-chloro-propoxy)-2-methyl- phenyl]-4-oxo-butyric acid ethyl ester (0.36 g, 1.15 mmol) according to the procedure in step 4 of example 184; MS m/z 362 (M + H).
Step 4
Figure imgf000194_0002
6-{(R)-2-Methyl-4-[3-(2-nrcethyl-pyrr olidin-1-yl)-propoxy]-phenyl}-4,5-d ihydro-2H-pyridazin-3-one
6-{(Λ)-2-methyl-4-[3-(2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4!>5-dihydro-2H- pyridazin-3-one was prepared from 4-[4-(3-chloro-propoxy)-2-methyl-phenyl]-4-oxo- butyric acid ethyl ester (0.28 g, 0.77 mmol) according to the procedure in step 5 of example 184 HCl; Mp 121-123 0C; MS m/z = 330 (M + H).
Examples 200-204 were synthesized using Cu(O) coupling, methods according to Example 21 or CuI / dioxane / 1 ,2-diaminocyclohexane / CS2CO3 and starting with R-I -[3- (4-bromo-phenoxy)propyl]-2-methyl-pyτrolidine or 4-(5-bromopyridin-2-yloxy)-piperidine-
1-carboxylic acid tert-butyl ester.
Figure imgf000195_0001
Figure imgf000196_0001
Example 205
Figure imgf000196_0002
4-[4-( 1 -Cyclobuty!-piperidin-4-yloxy)-phenyl]- 3-methyl-6H-isoxa2olo[3,4-d]pyridazin-7-one
Stepl
Figure imgf000196_0003
1 -(4-Methoxy-phenyl)-butane-1 ,3-dione
To 9.80 mL of ethyl acetate (100 mmol) in 40 mL dry THF at room temperature was added 2.0 g of 60% sodium hydride (49.9 mmol), 7.50 g of 4'-methoxyacetophenone (49.9 mmol), 100.0 mg of 18-crown-6 (0.40 mmol), and 2 drops of ethanol. After 30 minutes, the reaction was refiuxed for 1 h, and then 100 mL of dry THF was added. After an additional 1 h, 30 mL THF was added. After 1 h the reaction was cooled to 00C and 25 mL of 10% aqueous sulfuric acid was added. The product was extracted with diethyl ether. The ether extracts were dried with Na2SO4, filtered, and concentrated in vacuo. The crude material was purified via silica gel chromatography eluting with 4:1 hexanerethyl acetate to give 5.8 g of l-(4-methoxyphenyl)butane-l,3-dione containing 30% starting material (via 1H NMR 42% yield).
Figure imgf000197_0001
4-(4-Methoxy-benzoyl)-5-methyl-isoxazole-3- carboxylic acid ethyl ester
To 7.04 mL of 21% sodium ethoxide in ethanol (18.8 mmol) in 60 mL ethanol at 0 0C was added 4.70 g of l-(4-methoxyphenyl)butane-l,3-dione (17.1 mmol) in 60 mL ethanol dropwise over 24 minutes. After 30 min a solution of 2.59 g of ethyl chloro- (hydroximino)acetate (17.1 mmol) in 30 mL ethanol was added dropwise over 6 minutes. The reaction was warmed to room temperature slowly. When TLC indicated the reaction was complete, the reaction was concentrated in vacuo. Water and saturaated NaHCO3 was added and the product extracted with ethyl acetate. The ethyl acetate extracts were dried with Na2SO4, filtered, and concentrated in vacuo. The crude material was purified via silica gel chromatography eluting with 8:1 hexane:ethyl acetate to give 4-(4-methoxybenzoyl)-5- methylisoxazole-3-carboxylic acid ethyl ester which was dried overnight under high vacuum to give 3.74 g (71.8%).
Step 3.
Figure imgf000197_0002
4-(4-Methoxyphenyl)-3-methyl-6H- isoxazolo[3,4-d]pyridazin-7-one
A solution of 2.47 g of 4-(4-methoxybenzoyl)-5-methylisoxazole-3-carboxylic acid ethyl ester (8.54 mmol) and 0.598 mL of hydrazine monohydrate (12.0 mmol) in 18.4 mL ethanol was stirred at room temperature for 19 hours. The heterogeneous reaction was cooled in an ice bath then filtered off the white solid, washing with cold ethanol then diethyl ether. Dried on under high vacuum to give 2.06 g (92%) of 4-(4-methoxyphenyl)-3-methyl- 6 h-isoxazolo[3,4-d]pyridazin-7-one. Step 4
Figure imgf000198_0001
4-(4-Hydroxy-phenyl)-3-methyl-6H- isoxazolo[3,4-d]pyridazin-7-one
To 1.05 g of 4-(4-methoxyphenyl)-3-methyl-6 h-isoxazolo[3,4-d]pyridazin-7-one (4.08 mmol) in 15 mL dry DMF was added 1.03 g of sodium ethanethiolate in 15 mL dry DMF at room temperature. The reaction was then heated at 100 0C for 2.5 h. Added water andlM HCl until acidic. Extracted the product with diethyl ether and dried the extracts with Na2SO4, filtered, and concentrated in vacuo. The product was purified via silica gel chromatography eluting with 95:5 dichloromethane:methanol to give 533 mg of 4-(4- hydroxyphenyl)-3-methyl-6 h-isoxazoIo[3,4-d]pyridazin-7-one; Mp 268-276 0C; MS m/z 216 (M-N2 + H).
Figure imgf000198_0002
4-[4-(3-Methyl-7-oxo-6,7-dihydro-isoxazolo[3,4-d] pyridaziπ-4-yl)-phenoxy]-piperidine-1-carboxylic acid tert-butyl ester
To a solution of 805 mg of triphenylphosphine (3.07 mmol) in 10 mL dry THF at 0 0C was added 1.30 mL 40% w/w diethylazodicarboxylate in toluene (8.26 mmol). After 15 min, a solution of 524 mg of 4-(4-hydroxyphenyl)-3-methyl-6 h-isoxazolo[3,4-djpyridazin- 7-one (2.05 mmol) and 494 mg of 4-hydroxypiperidine-l-carboxylic acid tert-butyl ester (2.46 mmol) in 18 mL dry THF were added dropwise. The reaction was slowly warmed to room temperature. After 14 h water was added and the product was extracted with ethyl acetate. The extracts were dried with Na2SOzJ, filtered, and concentrated in vacuo. The product was purified via silica gel chromatography eluting with 1:1 hexane:ethyl acetate to give 985 mg of 4-[4-(3-methyl-7-oxo-6,7-dihydroisoxazole[3,4-d]pyridazin-4- yl)phenoxy]piperidine-l-carboxylic acid tert-butyl ester 65.4%. Step 6 Example 206
Figure imgf000199_0001
3-Methyl-4-[4-(piperidin-4-yloxy)-phenyl]-6H- isoxazolo[3,4-d]pyridazin-7-one To 980 mg of 4-[4-(3-methyl-7-oxo-6,7-dihydroisoxazole[3,4-d]pyridazin-4- yl)phenoxy]-piperidine-l-carboxylic acid tert-butyl ester (1.3 mmol) in 20 mL of dichloromethane was added 1.0 mL of trifluoroacetic acid (13 mmol). After stirring at room temperature for 3 hours, an additional 0.5 mL of trifluoroacetic acid was added. The reaction was concentrated in vacuo as monitored by TLC and concentrated and triturated with diethyl ether to give 375 mg (98% pure) (63% yield) of example 206 as an off-white solid 3-methyl-4-[4-(piperidin-4-yloxy)phenyl]-6 h-isoxazolo-[3,4-d]pyridazin-7-one TFA salt. Mp 283-2390C; MS m/z 299 (M-N2 + H).
Step 7 Example 205
Figure imgf000199_0002
4-[4-(1-Cyclobutyl-ρiperidin-4-yloxy)-phenyl]-3 -methyl-6H-isoxazolo[3,4-d]pyridazin-7-one
To 369 mg of example 206 (3-methyl-4-[4-(piperidin-4-yloxy)phenyl]-6 h- isoxazolo-[3,4-d]pyridazin-7-one trifluoroacetic acid salt) (0.838 mmol) and 84 μL acetic acid (1.5 mmol) in 6 mL dry methanol and 2 mL dry DMF at 00C was added 260 mg of sodium cyanoborohydride (4.2 mmol) and then 190 μL of cyclobutanone (2.5 mmol). The reaction was heated at 60 0C. After 1 h, the reaction was complete as determined by LC/MS and was concentrated in vacuo. Water and 2M Na2CO3 was added and the product was extracted with dichloromethane. The extracts were dried with Na2SO4, filtered, and concentrated in vacuo. The crude product was purified via silica gel chromatography eluting with 500:15:10 dichloromethane :methanol:7N ammonia in methanol to give a colorless oil which was re-concentrated in vacuo with diethyl ether. Added diethyl ether and upon standing, a white solid formed which was triturated with ether to yield 56 mg (17%) of example 205 Mp 182.5-184.00C; MS m/z 353 (M-N2 + H).
Example 207
Figure imgf000200_0001
3-Methyl-4-[4-(3-piperidin-1~yl-propoxy)- phenyl]-6H-isoxazolo[3,4-d]pyridazin-7-one
Step 1
Figure imgf000200_0002
A mixture of 5.97 g of 4'-hydroxyacetophenone (43.8 mmol), 13.0 g of l-(3- chloropropyl)-piperidine hydrochloride (65.8 mmol), 12.70 g of potassium carbonate (91.89 mmol), and 3.28 g of sodium iodide (21.9 mmol) in 100 mL dry acetone was stirred at reflux. After 1.5 h, the reaction was cooled to room temperature, filtered and concentrated. Ethyl acetate was added and the white solid that remained was filtered off. The filtrate was concentrated in vacuo and the crude residue was purified via silica gel chromatography using a gradient of ethyl acetate then 400:20: 10 ethyl acetate: 7N ammonia in methanol :methanol to yield 583 mg of l-[4-(3-piperidin-l-ylpropoxy)phenyl]ethanone as an oil. MS m/z 265 (M + H).
Step 2
Figure imgf000200_0003
1-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-butane -1,3-dione To 430 μL of ethyl acetate (4.4 mmol) in 10 mL dry THF at room temperature was added 180 mg of 60% sodium hydride (4.4 mmol), 15.0 mg of 18-crown-6 (0.0568 mmol), 2 drops of ethanol, and then 578 mg (2.212 mmol) of i-[4-(3-piperidin-l- ylpropoxy)phenyl]ethanone in 10 mL dry THF. After 30 min, the reaction was refluxed. An additional 18 mL of dry THF was added after 1.5 hours to reduce the viscosity of the reaction. After an additional 2 hours, 0.50 mL of 12.1 M aq. HCl was added to the reaction and the reaction was concentrated in vacuo. Water and saturated NaHCO3 was added and the product extracted with ethyl acetate. The ethyl acetate extracts were dried with Na2SO4, filtered, and concentrated in vacuo. The crude material was purified via silica gel chromatography eluting with 500:20:12 dichloromethane: methanol: 7N ammonia in methanol to give a yellow oil which solidified to give 450mg (66%) of l-[4-(3-piperidin-l- ylpropoxy)-phenyl]butane-l,3-dione as a yellow solid; Mp 43.0-45.50C; MS m/z 304 (M + H).
Step 3
Figure imgf000201_0001
5-Methyl-4-[4-(3-piperidin-1-yl-propoxy)-benzo yl]-isoxazole-3-carboxylic acid ethyl ester
To 597 μL of 21% sodium ethoxide in ethanol (1.595 mmol) in 4 mL ethanol at 0 0C was added 440 mg of l-[4-(3-piperidin-l-ylpropoxy)phenyl]butane-l,3-dione (1.45 mmol) in 5.5 mL ethanol dropwise. After 30 min, a solution of 220 mg of ethyl chloro(hydroximino)acetate (1.45 mmol) in 3 mL ethanol was added dropwise. The reaction was warmed to room temperature slowly. After 19.5 h the reaction was concentrated in vacuo. Water and saturated NaHCO3 was added and the product extracted with ethyl acetate. The ethyl acetate extracts were dried with Na2SO4, filtered, and concentrated in vacuo. The crude material was purified via silica gel chromatography eluting with 500: 15:10 dichloromethane: methanol: 7N ammonia in methanol to give 300 mg (50%) of a gold oil determined to be 5-methyl-4-[4-(3-piperidin-l-ylpropoxy)benzoyl]- isoxazole-3-carboxylic acid ethyl ester; MS m/z 401 (M + H).
Step 4 Example 207
Figure imgf000202_0001
3-Methyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-6H-isox azolo[3,4-d]pyridazin-7-onβ
To 291.3 mg of 5-methyl-4-[4-(3-piperidin-l-ylpropoxy)benzoyl]isoxazole-3- carboxylic acid ethyl ester (0.7057 mmol) in 1.54 mL of ethanol at room temperature was added 49.4 μL of hydrazine monohydrate (0.988 mmol). After 21 h, the heterogeneous reaction was cooled to 0 0C and filtered. The white solid was washed with cold ethanol then diethyl ether and dried at 650C under high vacuum. Yield 120 mg (46%) of a white solid Mp 178-9; MS m/z 369 (M + H).
Example 208
Figure imgf000202_0002
3-Methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-1-yl)-prop oxy]-phenyl}-6H-isoxazolo[3,4-cl]pyridaziπ-7-oπe
Example 208 was prepared using methods described for example 207; Mp 169-70
O ',C; MS m/z 369 (M + H).
Example 178 Method B
Figure imgf000202_0003
4-(4-Hydroxy-phenyl)-4-oxo-butyric acid ethyl ester In a 1 L round bottom flask, 4-(4-methoxyphenyl)-4-oxo-butyric acid (25 g, 106 mmol) in 48% HBr (125 mL) and acetic acid (250 mL) was heated to reflux 18 h. The reaction was cooled slightly and ethanaol (250 mL) was added. The solvent was concentrated under vacuum. Additional ethanol (100 mL) was added and solvent concentrated under vacuum again. The resulting oil was crystallized from ethyl acetate/ hexanes to produce 8.65 g (37%). MS m/z = 223 (M + H).
Step 2
Figure imgf000203_0001
4-[4-(3-Chloro-propoxy)-phenyl]-4-o xo-butyric acid ethyl ester
In a 1 L round bottom flask, 4-(4-hydroxyphenyl)-4-oxo-butyric acid ethyl ester (8.65 g, 39.0 mmol), l-bromo-3-chloro-propane (6.1 g, 61.0 mmol), and potassium carbonate (9.3 g, 67.1 mmol) in acetonitrile (300 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, separated and dried over MgSO4. Purification with silica gel chromatography eluting with hexanes/ethyl acetate (3:1) produced 7.9 g (68%). MS m/z 299 (M + H).
Figure imgf000203_0002
6-[4-(3-Chloro-propoxy)-phenyl]-4,5 -dihydro-2H-pyridazin-3-one
In a 500 mL round bottom flask, 4-[4-(3-chloro-propoxy)-phenyl]-4-oxo-butyric acid ethyl ester (7.85 g, 26.3 mmol), and hydrazine monohydrate (2.55 mL, 52.7 mmol), in isopropanol (20OmL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 5.2 g (74%). MS m/z 267 (M + H).
Example 178 Step 4
Figure imgf000203_0003
6-{4-[3-((R)-2-Methyl-pyrrolidin-1-yl)- propoxy]-phenyl}-4,5-dihydro-2H-pyr idazin-3-one In a 500 mL round bottom flask, 6-[4-(3-hloro-propoxy)-phenyl]-4,5-dihydro:2H- pyridazin-3-one (5.2 g, 19.5 mmol), benzenesulfonate (R)-2-methyl-pyrτolidinium (9.5 g, 39.0 mmol), potassium carbonate (10.8g, 78.0 mmol), and potassium iodide (200 mg, 1.2 mmol) in acetonitrile (300 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, then washed with water three times. The organics were extracted three times with 3% citric acid solution. The combined aqueous layers were basified with sat. N.1HCO3 sol. and extracted with methylene chloride, then dried over MgSO4. Ethereal HCl was added and the solvents reduced under vacuum. Crystallization from MeOH/Et2θ produced 3.17 g (46%). Mp 221-223 0C. MS m/z 316 (M + H).
Example 209
Figure imgf000204_0001
6-(3-Chloro-propoxy)-3,4-dihydro-2H -naphthalen-1 -one
In a 500 mL round bottom flask, 6-hydroxy-3,4-dihydro-2H-naphthalen-l-one (10 g,
61.0 mmol), l-bromo-3-chloro-propane (9.6 g, 61.0 mmol), and potassium carbonate (9.3 g,
67.1 mmol) in acetonitrile (300 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, separated, dried over MgSO4. Purification with silica gel chromatography eluting with hexanes/ethyl acetate (3:1) produced 10.6 g (73%). Mp 85-87 0C. MS m/z 239 (M + H).
Step 2
Figure imgf000204_0002
8-(3-Chloro-propoxy)-5,6-dihydro-2H -benzo[h]cinnolin-3-one
In a 100 mL round bottom flask, 6-(3-chloro-propoxy)-3,4-dihydro-2H-naphthalen- 1-one (1 g, 4.2 mmol), and glyoxylic acid monohydrate (387 mg, 4.2 mmol), in acetic acid (10 mL) was heated to reflux 6 h. The reaction was cooled and hydrazine monohydrate (0.41 mL, 8.4 mmol) was added and the reaction was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, separated, dried over MgSO4. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 620 mg (51%). MS m/z 291 (M + H).
Example 209 Step 3
Figure imgf000206_0001
8-[3-((R)-2-Methyt-pyrrolidin-1-yl)-pro poxy]-5,6-dihydro-2H-benzo[h]cinnol in-3-one
In a 100 mL round bottom flask, 8-(3-chloro-propoxy)-5,6-dihydro-2H- benzo[h]cinnol in-3-one (600 mg, 2.1 mmol), benzenesulfonate (R)-2-methyl-pyrrolidinium (1.02 g, 4.2 mmol), potassium carbonate (1.14 g, 8.3 mmol), and potassium iodide (10 mg, 0.06 mmol) in acetonitrile (60 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, and then washed with water three times. The organics were extracted three times with 3% citric acid solution. The combined aqueous layers were basified with sat. NaHCO3 sol. and extracted with methylene chloride, then dried over MgSO4. Ethereal HCl was added and the solvents reduced under vacuum. Crystallization from MeOHZEt2O produced 85 mg (11%). Mp 289-292 0C. MS m/z 340 (M + H).
Example 210
Figure imgf000206_0002
5-Methyl-6-{4-[3-((R)-2-methyl-pyrrolid in-1-yl)-propoxy]-phenyl}-2H-pyιϊda zin-3-one
Following the procedure of Example 209: Mp 253-255 0C. MS m/z = 328 (M + H).
Example 211
Figure imgf000206_0003
5-Ethyl-6-{4-[3-((R)-2-methyl-pyrrolidi n-1-yl)-propoxy]-phenyl}-2H-pyridaz in-3-one Following the procedure of Example 209: Mp 272-275 0C. MS m/z = 342 (M + H).
Example 212
Figure imgf000207_0001
6-[3-((R)-2-Methyl-pyrrolidin-1-yl)-pro poxy]-3,4-dihydro-2H-naphthalen-1-o ne
In a 1 L round bottom flask, 6-(3-chloro-propoxy)-3,4-dihydro-2H-naphthalen-l-one (10.0 g, 41.9 mmol), benzenesulfonate (R)-2-methyl-pyrrolidinium (13.15 g, 84.0 mmol), potassium carbonate (23.15 g, 168 mmol), and potassium iodide (100 mg, 0.6 mmol) in acetonitrile (600 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, then washed with water three times. The organics were extracted three times with 3% citric acid solution. The combined aqueous layers were basified with sat. NaHCO3 sol. and extracted with methylene chloride, then dried over MgSO4. Ethereal HCl was added and the solvents reduced under vacuum. Crystallization from MeOHZEt2O produced 8.75 g (65%). Mp 183-185 0C. MS m/z = 288 (M + H).
Example 212 step 2
Figure imgf000207_0002
8-[3-(2-Methyl-pyrrolidin-1-yl)-pro poxy]-4,4a,5,6-tetrahydro-2H-benzo[ h]cinnolin-3-one
In a 250 mL round bottom flask, 6-[3-((R)-2-Methyl-pyrrolidin-l-yl)-propoxy]-3,4- dihydro-2H-naphthalen-l-one (3.0 g, 9.3 mmol), and glyoxylic acid monohydrate (1.28 g, 13.9 mmol), in acetic acid (60 mL) was heated to reflux 3h. The reaction was cooled and zinc dust (1.21 g, 18.5 mmol) was added and the reaction was heated to reflux 14 h. The reaction was cooled and diluted with water (12OmL). The mixture was basified to pH 8 with NH4OH and then hydrazine monohydrate (0.93 mL, 18.5 mmol) was added. The reaction was heated to reflux 2h. The reaction was cooled and re-basified with NaHCO3, then extracted with methylene chloride three times. The organics were dried over MgSO4, then ethereal HCL was added. The solvents were removed under vacuum and the product was crystallized with MeOH/ether to produce 1.16 g (33%). Mp 193-195 0C. MS m/z 342 (M + H).
Example 213 Step 1
Figure imgf000208_0001
1-[4-(3-Chloropropoxy)-2-methoxy-p henyl]-ethaπoπe
In a 250 mL round bottom flask, l-(4-hydroxy-2-methσxy-phenyl)ethanone (5.0 g, 30.0 mmol), l-bromo-3-chloro-propane (3.27 mL, 33.1 mmol), and potassium carbonate (4.75 g, 33.1 mmol) in acetonitrile (100 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, separated, dried over MgSO4. Purification with silica gel chromatography eluting with hexanes/ethyl acetate (3:1) produced 6.18 g (85%). Mp 51-53 0C. MS m/z 243 (M + H). Step 2
Figure imgf000208_0002
1-{2-Methoxy-4-[3-((R)-2-methyl-pyrroli din-1-yl)-propoxy]-phenyl}-ethanone
In a 250 mL round bottom flask, l-[4-(3-chloro-propoxy)-2-methoxy-phenyl]- ethanone (6.18 g, 25.5 mmol), benzenesulfonate (R)-2-methyl-pyrrolidinium (12.4 g, 50.9 mmol), potassium carbonate (14.1 g, 102 mmol), and potassium iodide (20 mg, 0.12 mmol) in acetonitrile (100 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, then washed with water three times. The organics were extracted three times with 3% citric acid solution. The combined aqueous layers were basified with sat. NaHCO3 sol. and extracted with methylene chloride, then dried over MgSO4. The solvents were removed under vacuum to produce 4.25 g (57%) of oil. MS m/z 292 (M + H).
Example 213 Step 3
Figure imgf000210_0001
6-{2-iyiethoxy-4-[3-((R)-2-methyl-pyr rolidin-1-yl)-propoxy]-phenyl}-2H-py ridazin-3-one
In a 100 mL round bottom flask, l-{2-methoxy-4-[3-((R)-2-methyl-pyrrolidin-l-yl)- propoxy] -phenyl} -ethanone (4.24 g, 14.5 mmol). and glyoxylic acid monohydrate (2.01 g, 21.8 mmol), in acetic acid (20 mL) was heated to reflux 3h. The reaction was cooled and diluted with water (4OmL). The mixture was basified to pH 8 with NH4OH and then hydrazine monohydrate (1.4ImL, 29.1 mmol) was added. The reaction was heated to reflux 2h. The reaction was cooled and re-basified with NaHCO3, then extracted with methylene chloride three times. The organics were dried over MgSO4, then ethereal HCL was added. The solvents were removed under vacuum and the product was crystallized with MeOH/ether to produce 500 mg (9%). Mp 182-186 0C- MS m/z 344 (M + H).
Example 214
Figure imgf000210_0002
6-{2-Fluoro-4-[3-((R)-2-methyl-pyrro!id in-1-yl)-propoxy]-phenyl}-2H-pyrida zin-3-one
Following the procedure of Example 213: Mp 220-222 0C. MS m/z 332 (M + H).
Example 215
Figure imgf000210_0003
6-{4-[3-((R)-2-Methyl-pyrrolidin-1-yl)- propoxy]-phenyl}-2-pyridiπ-2-yl-2H- pyridazin-3-one
In a 50 mL round bottom flask, 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]- phenyl }-2H-pyridazin-3-one (250 mg, 0.71 mmol), 2-bromopyridine (105 μL, 1.07 mmol), copper(I)iodide (13.6 mg, 0.07 mmol), and potassium carbonate (296 mg, 2.14 mmol) in dimethylformamide (10 mL) was heated to reflux 14 h. The reaction was cooled and water (20 mL) was added. The sticky solids were filtered off and then partitioned between methylene chloride and water, separated, and dried over MgSO4. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 10 mg (2.4%) oil. MS m/z 391 (M + H).
Example 216
Figure imgf000211_0001
4-[4-(3-Chloro-propoxy)-phenyl]-4-o xo-2-pyridin-2-yl-butyric acid ethy I ester
In a 500 mL round bottom flask ethyl 2-pyridylacetate (2.0 g, 12.1 mmol), and 60% sodium hydride (508 mg, 12.7 mmol) in dimethylformamide (50 mL) was stirred 1 h. 2- Bromo-l-[4-(3-chloro-propoxy)-phenyl]-ethanone (3.53 g, 12.1 mmol) was then added in dimethylformamide (50 mL) via dropping funnel. The reaction was stirred 14 h. Water
(30OmL) was added and the organics were extracted three times with ethyl acetate, and then dried over MgSO4. Purification with silica gel chromatography eluting with hexanes/ethyl acetate (3:1) produced 2.8 g (62%). MS m/z 376 (M + H).
Figure imgf000211_0002
4-{4-[3-((R)-2-Methyl-pyrrolidin-1-yl)- propoxy]-phenyl}-4-oxo-2-pyridin-2- yl-butyric acid ethyl ester
In a 100 mL round bottom flask, 4-[4-(3-chloro-propoxy)-phenyl]-4-oxo-2-pyridϊn- 2-yl-butyric acid ethyl ester (2.77 g, 7.4 mmol), benzenesulfonate (R)-2-methyl- pyrrolidinium (3.59 g, 14.7 mmol), potassium carbonate (4.07 g, 29.5 mmol), and potassium iodide (100 mg, 0.6 mmol) in acetonitrile (100 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, and then washed with water 3 times. The organics were chromatographed through silica gel with methylene chloride/methanol (95:5) eluent. Ethereal HCl was added to make the bis HCl salt and produce 960 mg (28%) of an amorphous solid. MS m/z 425 (M + H).
Example 216 Step 3
Figure imgf000212_0001
6-{4-[3-((R)-2-Methyl-pyrrolidin-1-yI)- propoxy]-phenyl}-4-pyridin-2-yl-4,5
-dihydro-2H-pyridazin-3-one
In a 50 mL round bottom flask, 4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]~ phenyl }-4-oxo-2-pyridin-2-yl-butyric acid ethyl ester (950 mg, 1.84mmol), and hydrazine monohydrate (204 μL, 4.2 mmol), in acetic acid (20 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and NaHCO3 sol., extracted three times, and then dried over MgSO4. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 250 mg (33%). Ethereal HCl was added to a methanol solution to produce crystals. Mp 231-233 0C. MS m/z 393 (M + H).
Example 217
Figure imgf000212_0002
6-{4-[3-((R)-2-Methyl-pyrrolidin-1-yl)- propoxy]-phenyl}-4-pyridin-2-yl-2H- pyridazin-3-one
In a 10 mL round bottom flask, 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]- phenyl}-4-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one (120 mg, 0.31mmol), and cesium carbonate (197 mg, 0.62 mmol), in dimethylsulfoxide (3 mL) was heated to 135 0C 3 h. The reaction was cooled and the slurry was partitioned between methylene chloride and water extracted three times, and then dried over MgSO4. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5), followed by HCl salt formation produced 120 mg (33%). Mp 157-161 0C. MS m/z 391 (M + H). Example 218
Step 1
Figure imgf000213_0001
8-Methoxy-5,6-dihydro-3H-benzo[f]ci nnolin-2-one
In a 50 mL round bottom flask, 6-methoxy-3,4-dihydro-lH-naphthalen-2-one (1.0 g, 5.68 mrnol), and glyoxylic acid monohydrate (523 mg, 5.68 mmol), in acetic acid (10 mL) was heated to reflux 3h. The reaction was cooled and diluted with water (2OmL). The mixture was basified to pH 8 with NH4OH and then hydrazine monohydrate (0.55 mL, 11.4 mmol) was added. The reaction was heated to reflux 2h. The reaction was cooled and re- basified with NaHCO3, then extracted with methylene chloride three times. The organics were dried over MgSO4, and the solvents were removed under vacuum to produce 1.1 g (85%). mp dec. 270 0C. MS m/z = 229 (M + H). Step 2
Figure imgf000213_0002
8-Hydroxy-5,6-dihydro-3H-benzo[f]ci nnolin-2-one
In a 100 mL round bottom flask, 8-methoxy-5,6-dihydro-3H-benzo[f]cinnolin-2-one (1.05 g, 4.61 mmol) in methylene chloride (3 mL) was cooled to 0 0C. Boron tribromide (23 ml of a IM sol. in methylene chloride) was added and the reaction warmed to ambient temperature for 4h. Re-cooled to 0 0C and sat. NH4C1 sol. (23 mL) was added. The solvents were removed under vacuum and water was added. Solids were filtered off and washed with cold methanol to produce 587 mg (59%). Mp > 300 0C. MS m/z 215 (M + H).
Figure imgf000214_0001
8-(3-Chloro-propoxy)-5,6-dihydro-3H -benzo[f]cinnolin-2-one
In a 50 mL round bottom flask, 8-hydroxy-5,6-dihydro-3H-benzo[f]cinnolin-2-one (575 mg, 2.69 mmol), l-bromo-3-chloro-propane (0.27 mL, 2.69 mmol), and potassium carbonate (371 mg, 2.69 mmol) in acetonitrile (20 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, separated, dried over MgSO4. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 106 mg (14%) as an amorphous solid. MS m/z 291 (M + H).
Example 218, Step 4
Figure imgf000214_0002
8-[3-((R)-2-Methyl-pyrrolidin-1-yl)-pro poxy]-5,6-dihydro-3H-benzo[f]cinnol in-2-one
In a 25 mL round bottom flask, 8-(3-chloro-propoxy)-5,6-dihydro-3H- benzo[f|cinnolin-2-one (100 mg, 0.34 mmol), benzenesulfonate (R)-2-methyl-pyrrolidinium (168 mg, 0.68 mmol), potassium carbonate (190 mg, 1.36 mmol), and potassium iodide (1 mg, 0.006 mmol) in acetonitrile (10 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. The slurry was partitioned between methylene chloride and water, and then washed with water 3 times. The organics were chromatographed through silica gel with methylene chloride/methanol (95:5) eluent to produce 10 mg (9%). Mp 225 0C (dec). MS m/z 340 (M + H). Example 219
Step 1
Figure imgf000215_0001
4-(4-Acetyl-3-fluoro-phenoxy)-piper idine-1-carboxylic acid tert-butyl ester
In a 500. mL round bottom flask, diethyl azodicarboxylate (16.9 g, 97.3 mmol) and triphenylphosphine (25.5 g, 97.3 mmol) in tetrahydrofuran (200 mL) were cooled to 0 0C. l-(2-Fluoro-4-hydroxy-phenyl)-ethanone (10.0 g, 64.9 mmol) and 4-hydroxy-piperidine-l- carboxylic acid tert-butyl ester (15.67 g, 77.9 mmol) in tetrahydrofuran (100 mL) were added. The reaction was warmed to ambient temperature 14 h. The solvents were concentrated under vacuum and methylene chloride (100 mL) and hexanes (50OmL) were added. The solids were filtered off. The mother liquor was concentrated under vacuum and chromatographed through silica gel with hexanes/ethyl acetate (7:3) as eluent to produce 17.5 g (80%). Mp 72-73 0C. Step 2
Figure imgf000215_0002
-[4-(3-Ethoxycarbonyl-propionyl)-3 -fluoro-phenoxy]-piperidine-1-carbo xylic acid tert-buty! ester
In a 250 mL round bottom flask, 4-(4-acetyl-3-fluoro-phenoxy)-piperidine-l- carboxylic acid tert-butyl ester (4.0 g, 12 mmol) in tetrahydrofuran (00 mL) were cooled to - 78 0C. Lithium diisopropylamide (1.4 g, 13 mmol) was added and stirred 30 min. then warmed to 0 0C. Re-cooled to -78 0C and ethyl bromoacetate (1.4 mL, 13 mmol) in tetrahydrofuran (25 mL) was added. The reaction warmed to ambient temperature over 14 h. The reaction was quenched with NH4Cl sol. and the solvents were concentrated under vacuum. The reaction was chromatographed through silica gel with hexanes/ethyl acetate (7:3) as eluent to produce 4.10 g (82%) of oil.
Figure imgf000216_0001
4-[3-Fluoro-4-(6-oxo-1 ,4,5,6-tetrah ydro-pyιϊdazin-3-yl)-phenoxy]-piper idine-1-carboxylic acid tert-butyl ester
In a 250 mL round bottom flask, 4-[4-(3-ethoxycarbonyl-propionyl)-3-fluoro- phenoxy]-piperidine-l-carboxylic acid tert-butyl ester (4.1 g, 9.68 mmol), and hydrazine monohydrate (0.97 mL, 19.4 mmol), in isopropanol (100 mL) was heated to reflux 14 h. The reaction was cooled and the solvent concentrated under vacuum. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 945 mg (25%). Mp 146-148 0C. MS m/z 392 (M + H).
Step 4
Figure imgf000216_0002
6-[2-Fluoro-4-(pipeιϊdin-4-yloxy)-p henyl]-4,5-dihydro-2H-pyridazin-3-o ne In a 10 mL round bottom flask, 4-[3-fluoro-4-(6-oxo-l ,4,5,6-tetrahydro-pyridazin-3- yl)-phenoxy]-piperidine-l-carboxylic acid tert-butyl ester (410 mg, 1.0 mmol) in trifluoroacetic acid (3 mL) was stirred 2h. The solvent concentrated under vacuum to produce 420 mg (100%) of the salt as an oil. MS m/z = 292 (M + H).
Example 219, Step 5
Figure imgf000216_0003
6-[4-(1-Cyclobutyl-piperidin-4-ylox y)-2-fluoro-phenyl]-4,5-dihydro-2H- pyridazin-3-one
In a 25 mL round bottom flask, 6-[2-fluoro-4-(piperidin-4-yloxy)-phenyl]-4,5- dihydro-2H-pyridazin-3-one trifluoroacetic acid salt (420 mg, 1.0 mmol) was dissolved in methanol (10 mL), N,N-dimethylformamide (4 mL). and acetic acid (0.4 mL).
Cyclobutanone (0.23 mL, 3.0 mmol), and then sodium cyanoborohydride (0.32 g, 5.0 mmol) were added. The reaction was heated to 60 0C for 2 h. The reaction was cooled and diluted with methylene chloride and NaHCO3 sol. to pH 9. The organics were extracted three times and the solvent concentrated under vacuum. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) followed by salt formation with ethereal HCl produced 210 mg (54%). Mp >300 0C. MS m/z 346 (M + H).
Example 220
Figure imgf000217_0001
8-( 1 -Cyclobutyl-piperid ιn-4-yloxy)-
4,4a,5,6-tetrahydro-2H-benzo[h]cinn olin-3-one
Following the procedure of Example 219: Mρ >300 °C. MS m/z = 354 (M + H).
Example 221
Figure imgf000217_0002
4-[3-Fluoro-4-(6-oxo-1,6-dihydro-py ridazin-3-yl)-phenoxy]-piperidine-1 -carboxylic acid tert-butyl ester
In a 10 mL round bottom flask, 4-[3-fluoro-4-(6-oxo-l,4,5,6-tetrahydro-pyridazin-3- yl)-phenoxy]-piperidine-l-carboxylic acid tert-butyl ester (525 mg, 1.34 mmol), and cesium carbonate (874 mg, 2.68 mmol), in dimethylsulfoxide (5 mL) was heated to 135 0C 3h. The reaction was cooled and the slurry was partitioned between methylene chloride and water extracted three times, and then dried over MgSO4. Purification with silica gel chromatography eluting with methylene chloride/methanol (95:5) produced 500 mg (93%). Mp 117-119 0C. MS m/z 390 (M + H). Example 221 step 2
Figure imgf000218_0001
-[4-<i-Cyclobutyl-piperidin-4-ylox y)-2-fluoro-phenyl]-2H-pyridazJn-3- one
Following the final two steps of Example 219: Mp >300 0C. MS m/z 344 (M + H).
Example 222
Figure imgf000218_0002
6-[4-(1-Cyclobutyl-pϊperidin-4-ylox y)-phenyl]-5-methyl-2H-pyridazin-3- one Following the procedure of Example 221 : Mp >300 °C. MS m/z 340 (M + H).
Example 223
Figure imgf000218_0003
5-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-phenyl}-2H-pyridazin-3
-one
Step l.
To a round-bottom flask was added 4-(4,4,5,5-tetramethyl-[l,3s2]dioxaborolan-2- yl)-phenol (11.0 g, 50 mmol), l-bromo-3-chloropropane (9.88 mL, 100 mmol). potassium carbonate (20.7 g, 150 mmol), and acetonitrile (100 mL). The reaction mixture was heated to reflux for 24 h. The reaction was cooled to room temperature and was filtered. The filtrate was concentrated to give crude 2-[4-(3-chloro-propoxy)-phenyl]-4,4,5,5-tetramethyl- [l,3,2]dioxaborolane. This material was used for next step without purification.
Step 2. To a round-bottom flask was added crude 2-[4-(3-chloro-propoxy)-phenyl]-4,4,5,5- tetramethyl-[l,3,2]dioxaborolane, (R)-2-methyl-pyrrolidine, benzenesulfonic acid salt (24.3 g, 100 mmol), sodium iodide (7.49 g, 50 mmol), potassium carbonate (20.7 g, 150 mmol) and acetonitrile (100 mL). The reaction was heated to reflux for 2.5 days and was cooled to room temperature. The reaction was diluted with methylene chloride (100 mL) and was filtered. The filtrate was concentrated. Purification by column chromatography (5% MeOH in CH2Cl2) to give 11.3 g (65%, 2 steps) of (R)-2-methyl-l-{3-[4-(4.4.5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenoxy]-propyl}-pyrrolidine.
Step 3.
To a round-bottom flask was added 2-hydroxymethyl-5-iodo-2H-pyridazin-3-one
(2.28 g, 9.05 mmol), (R)-2-methyl-l-{3-[4-(4,435,5-tetramethyl-[lJ3,2]dioxaborolan-2-yl)- phenoxy] -propyl} -pyrrolidine (3.28 g, 9.50 mmol), tetrakis(triphenylphosphine)palladium(0) (2.1 g, 1.8 mmol), potassium carbonate (6.25 g, 45.2 mmol), 1 ,2-dϊmethoxyethane (80 mL), and water (40 mL). The reaction mixture was flushed with nitrogen for 30 min and was heated to reflux for 48 h. After cooled to room temperature, the reaction was filtered. The organic layer was separated and concentrated.
Purification by column chromatography (CH2Cl2:MeOH:iPrNH = 9:1 :0.1) to give 3.31 g
(63.5%) of example 223 (5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one).
The following examples were prepared using the procedure for example 223.
Figure imgf000219_0001
Figure imgf000220_0001
Figure imgf000221_0001
Example 235
Figure imgf000221_0002
4-Methoxy-2-methoxymethyl-5-{4-[3-(
(R)-2-methyl-pyrrolidin-1-yl)-propo xy]-phenyl}-2H-pyridazin-3-one Step 1.
To a stirred solution of 4,5-dichloropyridazin-6-one (5.00 g, 30.3 mmol) and.7V.N- diisopropylethylamine (7.92 mL, 45.5 mmol) in methylenechloride (50 mL) was added slowly, bromomethyl methyl ether (4.79 mL, 60.6 mmol) at room temperature (water-bath). The reaction was stirred for 22 h and was then concentrated. Purification by column chromatography (1% MeOH in CH2Cl2) gave 4.74 g (74.8%) of 4,5-dichloro-2- methoxymethyl-2H-pyridazin-3-one.
Step 2. To a stirred solution of 455-dichloro-2-methoxymethyl-2H-pyridazin-3one (1.00 g,
4.78 mmol) in 1,4-dioxane (25 mL) at room temperature was added sodium methoxide (271 mg, 5.02 mmol). After 19 h, the reaction was added additional 271 mg of sodium methoxide and was continued to stir for 6 h. The reaction was filtered and the filtrate was concentrated to give 915 mg (93% crude) 5-chloro-4-methoxy-2-methoxymethyl-2H- pyridazin-3-one.
Step 3.
To a round-bottom flask was added 5-chloro-4-methoxy-2-methoxymethyl-2H- pyridazin-3-one (902 mg, 4.41 mmol), (R)-2-methyl-l-{3-[4-(4,4,5,5-tetramethyl- [1 ,3,2]dioxaborolan-2-yl)-phenoxy]-propyl}-pyrrolidine (1.67 g, 4.85 mmol), tetrakis(triphenylphosphine)palladium(0) (510 mg, 0.44 mmol), potassium carbonate (2.34 g, 22.0 mmol), 1,2-dimethoxyethane (15 mL) and water (15 mL). The reaction mixture was flushed with nitrogen for 30 min and was then heated to reflux for 21 h. After cooled to room temperature, the reaction was extracted with CHaCl2 (100 mL, 50 mL). The combined organic layers were washed with water (50 mL), brine, dried (Na2SO4), and concentrated. Purification by column chromatography (5% MeOH in CH2Cl2) to give 744 mg (43.6%) of example 235 (4-methoxy-2-methoxymethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)- propoxy]-phenyl}-2H-pyridazin-3-one) as an oil. MS m/z 388 (M + H).
Example 236
Figure imgf000223_0001
5-Methoxy-2-methoxymethyl-4-{4-[3-(
(R)-2-methyl-pyrrolidin-1-yl)-propo xy]-phenyl}-2H-pyridazin-3-one
Step 1.
To a stirred solution of 435-dichloro-2-methoxymethyl-2H-pyridazm-3one (500 mg, 2.39 mmol) in methanol (.12 mL) at room temperature was added sodium methoxide (258 mg, 4.78 mmol). After stirred for 2 h, the reaction was concentrated. To this residue was added water (20 mL), then extracted with CH2Cl2 (2 x 50 mL). The combined organic layer was dried (Na2SO4) and concentrated to give 480 mg (98%) 4-chloro-5-methoxy-2- methoxymethyl-2H-pyridazin-3-one.
Step 2.
To a round-bottom flask was added 4-chloro-5-methoxy-2-methoxymethyl-2H- pyridazin-3-one (480 mg, 2.34 mmol), (R)-2-methyl-l-{3-[4-(4,4,5,5-tetramethyl- [l,3,2]dioxaborolan-2-yl)-phenoxy] -propyl} -pyrrolidine (890 mg, 2.60 mmol), tetrakis(triphenylphosphine)palladium(0) (270 mg, 0.23 mmol), potassium carbonate (1.24 g, 11.7 mmol), 1,2-dimethoxyethane (15 mL), and water (15 mL). The reaction mixture was flushed with nitrogen for 20 min and was then heated to reflux for 24 h. After cooled to room temperature, the reaction was extracted with CH2Cl2 (2 x 50 mL). The combined organic layers was washed brine, dried (Na2SO4), and concentrated. Purification by column chromatography (8% MeOH in CH2Cl2) to give 250 mg (26%) example 236 (5-methoxy-2- methoxymethyl-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one). Mp 44-45 0C. MS m/z 388 (M + H). Example 237
Figure imgf000224_0001
5-Methoxy-4-{4-I3-((R)-2-methyl-pyr rolidin-1-yl)-propoxy]-phenyl}-2H-p yridazin-3-one To a round-bottom flask was added example 231 (5-Methoxy-2-methoxymethyl-4-
{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3-one) (1.07 g, 2.76 mmol), methanol (10 mL), and concentrated HCl solution (10 mL). The reaction was heated to reflux for 3 days. After cooled to room temperature, the reaction was neutralized with IO N NaOH then 5% NaOH solution to pH 7. The reaction was concentrated and the residue was washed with CH2Cl2 (100 mL). The CH2Cl2 layer was concentrated.
Purification by column chromatography (15% MeOH in CH2Cl2) to give 350 mg (37%) of 5-methoxy-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3-one. The product was converted to its hydrochloride salt. Mp 135-140. MS m/z 344 (M + H).
Example 238
Figure imgf000224_0002
6-[4-(3-Morpholin-4-yl-propoxy)- phenyl]-2H-pyridazin-3-one
Step 1. To a round-bottom flask was added l-[4-(3-chloro-propoxy)-phenyl]-ethanone (10.0 g, 47.0 mmol), morpholine (6.15 mL, 70.5 mmol), sodium iodide (7.05 g, 47.0 mmol), potassium carbonate (19.5 g, 141 mmol), and acetonitrile (100 mL). The reaction mixture was heated to reflux for 23 h. The reaction was cooled to room temperature and was diluted with methylene chloride (100 mL). The reaction was filtered and the filtrate was concentrated. Purification by column chromatography (2% MeOH in CH2Cl2) to give 10.5 g (85%) of 6-[4-(3-morpholin-4-yl-propoxy)-phenyI]-2H-pyridazin-3-one.
Step 2.
To a round-bottom flask was added 6-[4-(3-morpholin-4-yl-propoxy)-phenyl]-2H- pyridazin-3-one (5.00 g, 19.0 mmol), oxo-acetic acid, hydrate (3.51 g, 38.1 mmol), and acetic acid (15 mL). The reaction was heated to 111 0C for 2.5 h. After cooled to 0 0C, the reaction was added water (25 mL) and NH4OH solution until pH~6. To this solution was added hydrazine hydrate (2.76 mL, 57.0 mmol) and was heated to reflux for 20 h (during which additional 3 eq of hydrazine hydrate was added). The reaction was cooled to room temperature and concentrated. Purification by column chromatography (20% MeOH in CH2Cl2) gave 2.53 g (42%) of example 238 6-[4-(3-morpholin-4-yl-propoxy)-phenyl]-2H- pyridazin-3-one.
The following examples were prepared.
Figure imgf000225_0001
Figure imgf000226_0002
Example 243
Figure imgf000226_0001
5-{4-[3-((R)-2-Methyl-pyrrolidin-1- yl)-propoxy]-phenyl}-3,4-diaza-bicy clo[4.1.0]hept-4-en-2-one
Step 1.
To a round-bottom flask was added phenol (5.0 g, 53.1 mmol), l-bromo-3- chloropropane (5.52 mL, 55.8 mmol), potassium carbonate (22.0 g, 159 mmol), and acetonitrile (100 mL). The reaction mixture was heated to reflux for 15 h. To this reaction was then added (R)-2-methyl-pyrrolidine hydrochloride (12.9 g, 106 mmol) and sodium iodide (7.96 g, 53.1 mmol) at room temperature. The reaction was continued to reflux for 24 h. After cooled to room temperature, the reaction was filtered through a pad of Celite eluted with CH2CI2 (100 mL). The filtrate was concentrated. Purification by column chromatography (5% MeOH in CH2Cl2) to give 9.02 g (77%) of (R)-2-methyl- 1 -(3- phenoxy-propy l)-pyrrolidine .
Step 2.
To a stirred solution of (R)-2-methyl-l-(3-phenoxy-propyl)-pyrrolidine (1.10 g, 5.02 mmol) and 3-oxa-bicyclo[3.1 -0]hexane-2,4-dione (562 mg, 5.02 mmol) in 1,2- dichloroethane (25 mL) at 0 °C was added aluminum trichloride (2.01 g, 15.0 mmol) in small portions. The reaction was heated at 80 0C for 18 h. After cooled to room temperature, the reaction was added crushed ice followed by concentrated HCl solution to break down the complex. The water layer was separated from the organic layer. To this water solution was added hydrazine hydrate (1 mL, 20.6 rnmol) and was heated to reflux for 4 h. The reaction was cooled to room temperature and concentrated. Purification by column chromatography (10% MeOH in CH2Cl2) gave 1.38 g (76%) of example 243 (5-{4- [3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one).
The following examples were synthesized. The racemic isomers of example 243 were separated into two enantiomers example 246 and example 247 and example 244 were separated into two enantiomers example 248 and example 249 by chiral chromatography using chiralPak and 0.1% diethylamine in methanol.
Figure imgf000227_0001
Figure imgf000228_0001
Examples 250-254 were prepared as HCl salts following the method of example 243 and example 244.
Figure imgf000228_0002
Figure imgf000229_0001
Example 255
Figure imgf000230_0001
6-[4-(2-Hydroxy-3-piperidin-1-yl-pr opoxy)-phenyl]-2H-pyridazin-3-one
Stepl
4-(4A5,5-Tetramethyl.-l;>3:,2-dioxaborolan-2-yl)phenol (1.00 g, 4.50mmol) and anhydrous potassium carbonate (2.20 g, 15.90 mmol) were taken up in racemic epibromohydrin (45 mL).
Reaction mixtire was refluxed for 12 h. Potassium carbonate was filtered off and epibromohydrin was evaporated under vacuum. Purification of the product using ISCO silica gel .chromatography (hexanes/ethyl acetate 9:1) gave a white solid 1.25 g.
Step2
The product from step 1 (0.50 g, 1.80 mmol) and piperidine (0.23 g, 2.70 mmol) were dissolved in EtOH and refluxed for 5 h. The solvent was evaporated and the product was purified by ISCO silica gel chromatography eluting with EtOAc/MeOH 9:1 to give product as a white solid 0.49 g (75%).
Step 3 THF anhydrous 15 mL was added to Pd(OAc)2 (O.Oδg,, 0.35 mmol) and triphenylphosphine (0.38 g, 1.40 mmol) under N2- The reaction was stirred for 5 min and 3,6-dichloropyridazine (1.00 g, 6.70 mmol) was added and reaction mixture was stirred for another 5 min. The product from step 2 (l-piperidin-l-yl-3-[4-(4,4,5,5-tetramethyl-[l,3,2]- dioxaborolan-2-yl)phenoxy]-propan-2-ol) (0.49 g, 1.35 mmol) in 9 mL of anhydrous THF and 5 mL of EtOH was added dropwise, followed by 15 mL of saturated NaHCO3.
The reaction mixture was heated at 82 0C overnight. The solvent was removed and the residue was taken up in methylene chloride and washed with H2O and saturated NaCl, dried over Na2Sθ4 and was evaporated. The product was purified by ISCO silica gel chromatography eluting with EtOAc/MeOH 9:1 to obtain 0.22 g (46%). Step 4 The product from step 3 (0.18 g, 0.50 mmol) in 7 mL of glacial acetic acid and NaOAc (0.02 g, 0.25 mmol) was heated to 115° C for 2 h. The solvent was coevaporated with toluene and the residue was taken up in MeOH and catalytic amount OfK2CO3 was added. After 1 h at reflux, the solvent was evaporated and the product was purified by ISCO silica gel chromatography eluting with EtOAc/MeOH 9:1 to give a white solid 0.09 g (82%); Mp 185 0C; MS m/z 330 (M + H).
Example 256
Figure imgf000232_0001
6-{4-[2-Hydroxy-3-((R)-2-methyl-pyr rolidin-1-yl)-propoxy]-phenyl}-2H-pyridaz iπ-3-one
Example 256 was synthesized using the method for example 255 to give a white solid 0.07 g (54%); Mp 153 0C; MS m/z 330 (M + H).
Example 257
Figure imgf000232_0002
6-{4-[(S)-2-Hydroxy-3-((R)-2-methyl
-pyrrolidin-1-yl)-propoxy]-phenyl}-
2H-pyridazin-3-one
Example 257 was synthesized using the method for example 256 except using (S)- (+)-epichlorohydrin to give example 257 as a white solid 0.16 g (46%); Mp 156 0C; MS m/z 330 (M + H).
Example 258
Figure imgf000232_0003
6-{4-[(R)-2-Hydroxy-3-((R)-2-methyl
-pyrrolidiπ-1-yl)-propoxy]-phenyl}-
2H-pyridazin-3-one
Example 258 was synthesized using the method for example 256 except using (R)-(- )-epichlorohydrin to give example 258 as a white solid 0.16 g, (44%); Mp 1470C; MS m/z 330 (M + H). Example 259
Figure imgf000233_0001
6-[4-((R)-2-Hydroxy-3-pipeιϊdin-1-yl-prop oxy)-phenyl]-2H-pyridazin-3-one
Example 259 was synthesized using the method for example 255 using (R)-(-)- epichlorohydriri to give example 259 as a white solid 0.14 g, (48%); Mp 1670C; MS m/z 330 (M + H). Utility The compounds of the present invention are useful, inter alia, as therapeutic agents. Particularly, the compounds are useful for interacting with the H3 receptor. In one embodiment, the present invention provides a method for treating or preventing diseases and disorders, such as those disclosed herein, which comprises administering to a subject in need of such treatment or prevention a therapeutically effective amount of a compound of the present invention. In an additional embodiment, the present invention provides a method for inhibiting
H3 activity comprising providing a compound of the present invention in an amount sufficient to result in effective inhibition. Particularly, the compounds of the present invention can be administered to treat such diseases and disorders such as narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders (such as asthma), inflammation, and myocardial infarction. In certain embodiments, the compounds can be administered to treat narcolepsy or sleep/wake disorders, obesity, cognition, attention deficit hyperactivity disorder (ADHD), and dementia. In other embodiments, the compounds can be administered to treat narcolepsy or sleep/wake disorders, or they can used to treat obesity, or they can used to treat cognition, or they can used to treat attention deficit hyperactivity disorder (ADHD), or they can used to treat dementia. The inhibition of enzymatic activity by the compounds of the present invention can be determined using, for example, the following assays as set forth below. They are not intended, nor are they to be construed, as limiting the scope of the disclosure. Rat H3 Assays: Cell line development and membrane preparation. The rat H3 receptor cDNA was
PCR amplified from reverse-transcribed RNA pooled from rat thalamus, hypothalamus, striatum and prefrontal cortex with a sequence corresponding to bp #338-1672 of Genbank file #NM_053506, encoding the entire 445-amino-acid rat histamine H3 receptor. This was engineered into the pIRES-neo3 mammalian expression vector, which was stably transfected into the CHO-A3 cell line (Euroscreen, Belgium), followed by clonal selection by limiting dilution. Cells were harvested and cell pellets were frozen (-80° C). Cell pellets were resuspended in 5 mM Tris-HCl, pH 7.5 with 5 nM EDTA and a cocktail of protease inhibitors (Complete Protease Inhibitior Tablets, Roche Diagnostics). Cells were disrupted using a polytron cell homogenizer and the suspension was centrifuged at 1000 x g for 10 minutes at 4°C. The pellet was discarded and the supernatant centrifuged at 40,000 x g for 30 min at 4°C. This membrane pellet was washed in membrane buffer containing 50 mM Tris-HCl, pH 7.5 with 0.6 mM EDTA, 5 mM MgCl2 and protease inhibitors, recentrifuged as above and the final pellet resuspended in membrane buffer plus 250 mM sucrose and frozen at -8O0C.
Radioligand Binding. Membranes were resuspended in 50 mM Tris HCl (pH 7.4), 5 mM MgCl2, 0.1% BSA. The membrane suspensions (10 μg protein per well) were incubated in a 96 well microtiter plate with [3H]-N-alpha-methylhistamine (approximately 1 nM final concentration), test compounds at various concentrations ( 0.01 nM - 30 uM) and scintillation proximity beads (Perkin Elmer, FlashBIueGPCR Scintillating Beads) in a final volume of 80 μl for 4 hours at room temperature, protected from light. Non-specific binding was determined in the presence of 10 μM clobenpropit. Radioligand bound to receptor, and therefore in proximity to the scintillation beads, was measured using a MicroBeta scintillation counter.
GTPvS Bindine. Membranes were resuspended in 20 mM HEPES pH 7.4 containing: 1 mM EDTA, 0.17 mg/ml dithiothreitol, 100 mM NaCl, 30 μg/ml saponin and 5 mM MgCl2. For measurement of inverse agonist activity, increasing concentrations of test compounds were incubated in a 96 well microtiter plate with 10 μg/well membrane protein, 5 μM GDP, scintillation proximity beads (Perkin Elmer, FlashBlύeGPCR Scintillating Beads) and [35S]-GTPyS (0.1 nM final concentration). Following incubation for 45 minutes in the dark at room temperature, the microtiter plate was centrifuged at 1000 x g for 5 minutes and radioactivity bound to the membranes was counted using a MicroBeta scintillation counter. Non-specific binding was measured in the presence of 10 μM GTP. A decrease in bound [35S]-GTPyS is indicative OfH3 receptor inverse agonist activity in this assay. Antagonist activity of test compounds was determined in a similar experiment under the following conditions. Membranes were resuspended in 20 mM HEPES pH 7.4 containing: 1 mM EDTA, 0.17 mg/ml dithiothreitol, 200 mM NaCl, 30 μg/ml saponin and 20 mM MgCb. The membranes were incubated at 10 μg/well membrane protein in a microtiter plate with increasing concentrations of test compounds, 20 μM GDP, scintillation proximity beads and [35S]-GTPyS (0.1 nM final concentration) plus 30 nM R-alpha- methylhistamine. The microtiter plates were incubated and processed as described above. A decrease in R-alpha-methylhistamine stimulated [35S]-GTPyS binding is indicative of H3 receptor antagonist activity in this assay. Human H3 Assays:
Methods: CHO cells stably expressing the human H3 receptor (GenBank : NM_007232) were harvested and cell pellets were frozen (-80° C). Cell pellets were resuspended in 5 mM Tris-HCl, pH 7.5 with 5 nM EDTA and a cocktail of protease inhibitors (Complete Protease Inhibitior Tablets, Roche Diagnostics). Cells were disrupted using a polytron cell homogenizer and the suspension was centrifuged at 1000 x g for 10 minutes at 4°C. The pellet was discarded and the supernatant centrifuged at 40,000 x g for 30 min at 4°C. This membrane pellet was washed in membrane buffer containing 50 mM Tris-HCl, pH 7.5 with 0.6 mM EDTA3 5 mM MgCl2 and protease inhibitors, recentrifuged as above and the final pellet resuspended in membrane buffer plus 250 mM sucrose and frozen at -8O0C.
Radioligand Binding. Membranes were resuspended in 50 mM Tris HCl (pH 7.4), 5 mM MgCl2, 0.1% BSA. The membrane suspensions (10 μg protein per well) were incubated in a 96 well microtiter plate with [3H]-N-alpha-methylhistamine (approximately 1 nM final concentration), test compounds at various concentrations ( 0.01 nM — 30 μM) and scintillation proximity beads (Perkin Elmer, FlashBlueGPCR Scintillating Beads) in a final volume of 80 μl for 4 hours at room temperature, protected from light. Non-specific binding was determined in the presence of 10 μM clobenpropit Radioligand bound to receptor, and therefore in proximity to the scintillation beads, was measured using a MicroBeta scintillation counter.
GTPyS Binding. Membranes were resuspended in 20 mM HEPES pH 7.4 containing: 1 mM EDTA3 0.17 mg/ml dithiothreitol, 100 mM NaCl5 30 μg/ml saponin and 5 mM MgCl2. For measurement of inverse agonist activity, increasing concentrations of test compounds were incubated in a 96 well microtiter plate with 10 μg/well membrane protein, 5 μM GDP, scintillation proximity beads (Perkin Elmer, FIashBlueGPCR Scintillating Beads) and [35S]-GTPyS (0.1 nM final concentration). Following incubation for 45 minutes in the dark at room temperature, the microtiter plate was centrifuged at 1000 x g for 5 minutes and radioactivity bound to the membranes was counted using a MicroBeta scintillation counter. Non-specific binding was measured in the presence of 10 μM GTP. A decrease in bound [35S]-GTPyS is indicative OfH3 receptor inverse agonist activity in this assay. Antagonist activity of test compounds was determined in a similar experiment under the following conditions. Membranes were resuspended in 20 mM HEPES pH 7.4 containing: 1 mM EDTA, 0.17 mg/ml dithiothreitol, 200 mM NaCl, 30 μg/ml saponin and 20 mM MgCh- The membranes were incubated at 10 μg/well membrane protein in a microtiter plate with increasing concentrations of test compounds, 20 μM GDP, scintillation proximity beads and [35S]-GTPyS (0.1 nM final concentration) plus 30 nM R-alpha- methylhistamine. The microtiter plates were incubated and processed as described above. A decrease in R-alpha-methylhistamine stimulated [35S]-GTPyS binding is indicative of H3 receptor antagonist activity in this assay.
Other assays that may be used in connection with the present invention are set forth below. Examples of the present invention can be tested in the following in vivo models: Evaluation of Wake Promoting Activity in Rats
The methodology utilized for evaluating wake promoting activity of test compounds is based on that described by Edgar and Seidel, Journal of Pharmacology and Experimental Therapeutics, 283:757-769, 1997, and incorporated herein in its entirety by reference. Compounds of the invention either have demonstrated or are expected to demonstrate utility for wake promoting activity.
Dipsogenia Mode]: Inhibition of histamine agonist-induced water drinking in the rat. Histamine, and the H3-selective agonist (Λ)-α-methylhistamine (RAMH) induce water drinking behavior in the rat when administered either peripherally or centrally (Kraly, F.S., June, K.R. 1982 Physiol. Behav. 28: 841.; Leibowitz, SJF: 1973 Brain Res. 63:440; Ligneau X., Lin, J-S., Vanni-Mercier G., Jouvet M., Muir J.L., Ganellin C.R., Staxk H., EIz S., Schunack W., Schwartz, J-C. 1998 JPharmcol. Exp. Ther. 287:658-66.; Clapham, J. and Kilpatrick GJ. 1993 Eur. J. Pharmacol 232:99.-103) an effect which is blocked by H3 receptor antagonists thioperamide and ciproxifan. Compounds of the invention either have demonstrated or are expected to block RAMH induce water drinking behavior.
Novel object discrimination: Novel object discrimination (NOD; also referred to as novel object recognition) is an assay for short-term visual recognition memory that was first described by Ennaceur and Delacour (Ennaceur, A. and Delacour, J. (1988) Behav Brain Res 31: 47 '-59).
Social recognition: Social recognition (SR) is an assay for short-term social (olfactory) memory that was first described by Thor and Holloway (1982). Thor, D. and Hollo way, W. (1982) J Comp Physiolog Psychcol 96: 1000-1006.
Table A lists the Human and H3 binding data for Examples 1-78 and 81 of the present invention. TABLE A H3 Pyridazinone Binding data
Figure imgf000237_0001
Figure imgf000238_0001
Figure imgf000239_0001
Binding constants (K;) for Examples 1 to 78 and 81 in the Human H3 and Rat H3 methods described herein are expressed by letter descriptor to indicate the following ranges: A is 0.1-100 nM; B is 101-500 nM; C is 501-1000 nM; and D is >1000nM.
Table B lists the Human and Rat H3 binding data for Examples 82-262 of the present invention. The Example numbers in the Table correspond to the Actual Example numbers in the Examples Section. TABLE B H3 Pyridazinone Binding data
Example
81 82 83 84 85 86 87 88
Figure imgf000239_0002
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
Figure imgf000240_0001
111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132
Figure imgf000241_0001
133 134 135 136 137 138 139 140 141 142 143 143 144 145 146 147 148 149 150 151 152 153
Figure imgf000242_0001
154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175
Figure imgf000243_0001
176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197
Figure imgf000244_0001
198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219
Figure imgf000245_0001
220
221
222
223
224
225
226
227
228-
229
230
231
232
233
234
235
236
237
238
239
240
241
Figure imgf000246_0001
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
Figure imgf000247_0001
Binding constants (K;) for Examples 1 to 78 and 81 in the Human H3 and Rat H3 methods described herein are expressed by letter descriptor to indicate the following ranges: A is 0.1-100 nM; B is 101-500 nM; C is 501-1000 nM; and D is MOOOnM.
Compounds of the invention either have demonstrated or are expected to demonstrate inhibition OfH3 and thereby for utility for treatment of the indications described herein.
Publications cited throughout this disclosure are incorporated in their entirety herein by reference. References
Alguacil L. F.; Perez-Garcia C. Histamine H3 Receptor: A potential drug target for the treatment of central nervous systems disorders. Current Drug Targets-CNS & Neurological Disorders 2003, 2, 303-131.
Arrang, J. M.; Garbarg, M.; Schwartz, J. C, Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983, 302,
(5911), 832-7.
Celanire, S.; Wijtmans, M.; Talaga, P.; Leurs, R.; de Esch, I. J., Keynote review: histamine H3 receptor antagonists reach out for the clinic. Drug Discov Today 2005, 10, (23-24), 1613-27. Chazot P. L.;, Harm V. H3 histamine receptor isoforms: New therapeutic targets in the CNS? Current Opinions in Investigational Drugs 2001, 2, 1428-1431. Chen Z. Effect of histamine H3-receptor antagonist clobenprobit on spatial memory of radial maze performance in rats. Acta Pharmacol Sin 2000, 21, 905-910. Esbenshade, T. A.; ox, G. B.; Cowart, M. D. Histamine H3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders. Molecular interventions 2006, 6, 77-88.
Fox G. B.; Pan J. B.; Esbenshade T. A.; Bennani Y. L.; Black L. A.,- Faghih R.; Hancock A. A.; Decker M. W. Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition response in the spontaneously hypertensive rat pup. Behav. Brain Res. 2002, 131, 151-161.
Fox G. B.; Pan J. B.; Radek R. J.; Lewis A. M.; Bitner R. S.; Esbenshade T. A.;
Faghih R.; Bennani Y. L.; Williams W.; Yao B. B. Decker M. W.; Hancock A.
A. Two novel and selective nonimidazole H3 receptor Antagonists A-304121 and
A-317920: II. In vivo behavioral and neurophysiological characterization. J. Pharmacol. Exper. Ther. 2003, 505, 897-908. Hancock, A. A.; Esbenshade, T. A.; Krueger, K. M.; Yao, B. B., Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. Life Sci 2003, 73, (24), 3043-72.
Hancock, A. A.; Fox, G. B. Persepectives on cognitive domains, H3 receptor ligands and neurological disease. Expert Opin. Investig. Drugs, 2004, 13, 1237-1248.
Komater V. A.; Browman K. E.; Curzon P.; Hancock A. A., Decker M. W.; Fox B. H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology 2003, J 67, 363-372. Leurs R.; Blandina P.; Tedford C; Timmerman H. Therapeutic potential of histamine H3 receptor agonists and antagonists. Trends in Pharmacology 1998, 19, 177-
183.
Leurs, R.; Bakker, R. A.; Timmerman, H.; de Esch, I. J., The histamine H3 receptor: from gene cloning to H3 receptor drugs. Nat Rev Drug Discov 2005, 4, (2), 107- 20. Lin, J. S.; Sakai, K.; Vanni-Mercier, G.; Arrang, J. M.; Garbarg, M.; Schwartz, J. C; Jouvet, M., Involvement of histaminergic neurons in arousal mechanisms demonstrated with H3-receptor ligands in the cat. Brain Res 1990, 523, (2), 325- 30.
Lloyd G.K.; Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther. 2000, 292, 461 -467.
Monti, J. M.; Jantos, H.; Ponzoni, A.; Monti, D., Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats. Neuropsychopharmacology 1996, 15, 31-5.
Orsetti M.; Ferretti C; Gamalero S. R.; Ghi P. Histamine H3-receptor blockade in the rat nucleus basalis magnocellularis improves place recognition memory.
Psychopharmacology 2002, 159, 133-137.
Parmentier R.; Ohtsu H.; Djebbara-Hannas.Z.; Valatx J-L.; Watanabe T.; Lin J-S. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J. Neurosci. 2002, 22, 7695-7711.
Passani, M. B.; Lin, J. S.; Hancock, A.; Crochet, S.; Blandina, P., The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci 2004, 25, 618-25. Repka-Ramirez M. S. New concepts of histamine receptors and actions. Current
Allergy and Asthma Reports 2003. 3, 227-231. Ritz A.; Curley J.; Robertson J.; Raber J. Anxiety and cognition in histamine H3 receptor -/- mice. Eur JNeurosci 2004, 19, 1992-1996. Rouleau, A.; Heron, A.; Cochois, V.; Pillot, C; Schwartz, J. C; Arrang, J. M.,
Cloning and expression of the mouse histamine H3 receptor: evidence for multiple isoforms. JNeurochem 2004, 90, 1331-8. Vanni-Merci G.; Gigout S.; Debilly G.; Lin J. S. Waking selective neurons in the posterior hypothalamus and their reponse to histamine H3-receptor iigands: an electrophysiological study in freely moving cats. Behav Brain Res 2003; 144,
227-241. Witkin, J. M.; Nelson, D. L., Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. Pharmacol Ther 2004, 103, 1-20. Yao, B. B.; Sharrna, R.; Cassar, S.; Esbenshade, T. A.; Hancock, A. A., Cloning and pharmacological characterization of the monkey histamine H3 receptor. Eur J Pharmacol 2003, 482, (1-3), 49-60.

Claims

What is Claimed:
1. A compound according to formula I* :
Figure imgf000251_0001
or a stereoisomeric form, mixture of stereoisomer^ forms, or a pharmaceutically acceptable salt thereof; wherein:
X and Xa are each independently CH or N; Y is S(O)q, O, orNR15; R1 is NR10R1 ' or a 4- to 9-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R20 groups; R2 is
Figure imgf000251_0002
(IV) (V)
Figure imgf000252_0001
(Vi) (Vii)
(viii)
Figure imgf000252_0002
(ix) wherein: when X and Xa are both CH, then R2 is meta or para to the Y-CCHR^m-R1 group; and when either X or Xa are N, then R2 is para to the Y-CCHR'V-R1 group; each R3 is: independently H, F, Cl, Br, I3 OR21, NR23R24, NO2, CN, CF3, Q-Qjalkyl, C(=O)R21, CO2R21, or C(=O)NR23R24; or when R3 is ortho to R2, and R2 is (i), (ii), (iv), (vi), or (ix), then R3 and R14 taken together may form -(CH2V, -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; wherein Z is O3 S(O)y, or NR27; or when R3 is ortho to R2, and R2 is (iv), (v), or (viii), then R3 and R13 taken together may form -(CH2)S-, -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; or when R3 is ortho" to R2, and R2 is (viii), then R3 and RI3b taken together may form -(CH2)S-, -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; or when R3 is ortho to Xa and R2 is ortho to R3 and meta to Xa, then R2 and R3 taken together may form:
Figure imgf000253_0001
each R4 is independently H, Cι-C6alkyl, or OR21, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups;
R10 and R11 are each independently H5 Ci-C6alkyl, or C3-C6cycloalkyl, wherein the alkyl or cycloalkyl group is optionally substituted with 1 to 3 R20 groups;
R12 is H3 C°-C6alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, C(=O)R27, or CO2R27, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl group is optionally substituted with 1 to 3 R20 groups; R13 and R14 are each independently H5 Cι-C6alkyl, aryl, arylalkyl Ci-C6alkoxyl, S(=O)y-C 1 -C6alkyl5 cycloalkyl, heterocycloalkyl, or heteroaryl;
R13a, R13b, RI3c, and R14a are each independently H, Ci-C6alkyl; or R13 and R14, taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or C3-C6cycloalkyl ring; or RI3b and R14, or R13 and 14a, or R13b and I4a, or R13c and R14a, taken together with the carbon atoms through which they are connected form a fused C3-C6cycloalkyl ring; or R13 and R13a, or R14 and R14a, taken together with the carbon atom to which they are attached form a C3-Cgcycloalkyl ring; provided that no more than one pair of R13 and R14, RI3b and R14, R13 and R14a, R13b and Rl4a, R13c and R14\ R13 and RI3a, and R14 and Rl4a are taken together with the carbon atoms through which they are connected or to which they are attached to form a ring; and wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or cycloalkyl ring is optionally substituted with 1 to 3 R20 groups; R15 is H, Ci-C6 alkyl, C(=O)R25, CO2R25;
R20 at each occurrence is independently, H, F, Cl, Br, I, OR21, OR22, NR23R24, NHOH, NO2, CN, CF3, Ci-C6 alkyl optionally substituted with OR26, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7cycloalkylCo-C4alkyl, 3- to 7-membered heterocycloalkylC0-C4alkyl5 phenyl, 5- or 6-membered heteroarylC0-C4alkyl, arylalkyl, (=0), C(=0)R21, CO2R21, OC(=O)R21, C(=O)NR23R24, NR27C(=O)R21, NR27C(=O)OR21 5 OC(=O)NR23R24, NR27C(=S)R21, or S(O)qR21; each R21 is independently H, Ci-C6alkyl, aryl, or arylalkyl; each R22 is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; each R23 and R24 is independently selected from H, Ci-C6alkyl, and aryl, or R23 and R24, together with the nitrogen atom to which they are attached, form a.3 to 7 membered heterocyclic ring optionally substituted with =0;
R25 is Ci-Qalkyl, aryl, or alkylaryl;
R26 is H, CrCealkyl, aryl, or alkylaryl;
R27 is H or C,-C6alkyl; m is 1, 2, 3, 4, or 5 when R1 is attached via a nitrogen atom, and m is 0, 1, 2, 3, 4, or 5 when R1 is attached via a carbon atom; n is 1, 2, or 3; q is O, 1, or 2; s is 1, 2, or 3; and y is O, 1, or 2; provided that:
(1) the compound is other than 6-[4-(3-Diethylamino-propoxy)-phenyl]-4,5- dihydro-2H-pyridazin-3-one; and
(2) when Xa and X are each CH, Y is O, n is 0, each R4 is H, m is 2, 3, or 4, R1 is methylamino, hydroxyethylamino, pyrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, and R2 is para to the Y-(CHR4VR1 group, then R2 is other than 4,5-dihydro-2H-pyridazin-3-one-6-yl.
1. A compound according to claim 1, wherein at least one of X and X3 is CH.
3. A compound according to claim 1 , wherein X and Xa are each CH.
4. A compound according to claim 2, wherein Y is O.
5. A compound according to claim 1, wherein R1 is a 4- to 9-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms.
6. A compound according to claim 5, wherein R1 is a 4- to 9-membered heterocycloalkyl ring containing 1 nitrogen atom.
7. A compound according to claim 6, wherein R1 is a piperidine or pyrrolidine ring, . optionally substituted.
8. A compound according to claim 7, wherein the piperidine or pyrrolidine ring is attached to Y through a ring nitrogen atom.
9. A compound according to claim 8, wherein the piperidine or pyrrolidine ring is substituted with one or two alkyl groups.
10. A compound according to claim 7, wherein the piperidine ring is attached to Y through a ring carbon atom.
11. A compound according to claim 10, wherein the piperidine ring is N-substituted with cycloalkyl.
12. A compound according to claim 11, wherein the piperidine ring is N-substituted with cyclobutyl.
13. A compound according to claim 1, wherein R2 is para to the Y-(CHR4)m-R1group.
14. A compound according to claim 13, wherein R2 is (i), (ii), (iv), (vi), (viii), or (ix).
15. A compound according to claim 13, wherein R13 and R14, taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, oxazolyl, pyridinyl, or C3-C6cycloalkyl ring; or R13b and R14, or R13 and 14a, or R13b and 14a, or RI3c and Rl4a, taken together with the carbon atoms through which they are connected form a fused C3-C6cycloalkyl ring; or R13 and R13a, or R14 and R14a, taken together with the carbon atom to which they are attached form a C3-Cscycloalkyl ring; provided that no more than one pair of R13 and R14, R13b and R14. R13 and R14a, R13b and RHa, R13c and R14a, R13 and Rl3a, and R14 and Rl4a are taken together with the carbon atoms through which they are connected or to which they are attached to form a ring; and wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or cycloalkyl ring is optionally substituted with 1 to 3 R20 groups.
16. A compound according to claim 14, wherein when R2 is (vi), (viii), or (ix), and when R13 and R14, R13b and R14, or R13 and 14a, or Rijb and 14a, or R13c and R14a, taken together with the carbon atoms through which they are connected form a fused Cs-Cβcycloalkyl ring; or R13 and R13a, or R14 and R14a, taken together with the carbon atom to which they are attached form a C3-Cgcycloalkyl ring; then the cycloalkyl ring is a is C3-C4cycloalkyl ring.
17. A compound according to claim 1, wherein R12 is H, CrCβalkyl, cycloalkyl. aryl, arylalkyl, or heteroaryl.
18. A compound according to claim 17, wherein R12 is H or heteroaryl.
19. A compound according to claim 18, wherein when R12 is heteroaryl, said heteroaryl is pyridinyl or thienyl.
20. A compound according to claim 14, wherein R2 is (iv).
21. A compound according to claim 20, wherein R2 is (iv), R12 is H or heteroaryl, and R13 and R14 are each H or alkyl.
22. A compound according to claim 21 , wherein R2 is (iv), R12 is heteroaryl, and R13 and R14 are each H or alkyl.
23. A compound according to claim 1 , wherein R2 is:
Figure imgf000256_0001
24. A compound according to claim 4, wherein R13, R14 R13a, Rl3b, R13c, and R14a are each independently H or Ci-Cβalkyl.
25. A compound according to claim 24, wherein at least one of R13. R14 R13a, R13b, R13c, and Rl4a is Ci-C6alkyl. . .
26. A compound according to claim 1, wherein R14 is heteroaryl.
27. A compound according to claim 4, wherein at least one R3 is F5 Cl, Br, or Ci- Cealkyl.
28. A compound according to claim 1, wherein R4 is H, alkyl or alkoxyl.
29. A compound according to claim 28, wherein R4 is H or alkyl.
30. A compound according to claim 1, wherein R4 is H or Q alkyl.
31. A compound according to claim 1, wherein m is 0 or 1 when R1 is attached to Y through a ring carbon atom.
32. A compound according to claim 31 , wherein m is 0.
33. A compound according to claim 10, wherein m is 0 or 1 when R1 is attached to Y through a ring carbon atom.
34. A compound according to claim 1, wherein m is 3 when R1 is attached to Y through a ring nitrogen atom.
35. A compound according to claim 9, wherein m is 3 when R1 is attached to Y through a ring nitrogen atom.
36. A compound according to claim 1, wherein s is 2.
37. A compound according to claim 1, wherein n is 0 or 1.
38. A compound according to claim 9, wherein R1 is:
Figure imgf000257_0001
39. A compound according to claim 38, wherein R is:
Figure imgf000258_0001
40. A compound according to claim 38, wherein R20 is F, Cl, CF3, NR23R24, or G1- Cβalkyl optionally substituted with OR26, cycloalkylCo^alkyl, or heterocycloalkylCo-
C4alkyl.
41. A compound according to claim 40, wherein R20 is Q-Cealkyl optionally substituted with OR26.
42. A compound according to claim 1, wherein R23 and R24 are each independently Cp C6alkyl.
43. A compound according to claim 1, wherein Y-(CHR4)m-R! is:
Figure imgf000258_0002
44. A compound according to claim 4, wherein R2 is (iii) and one of R13 cyclopropyl.
45. A compound according to claim 1, wherein when R4 is OR21, R21 is H or Ci-Cgalkyl.
46. A compound according to claim 14, wherein R2 is:
Figure imgf000259_0001
47. A compound according to claim 16, wherein R2 is:
Figure imgf000259_0002
48. A compound according to claim 47, wherein R2 is:
Figure imgf000259_0003
49. A compound according to claim 14, wherein R2 is:
τ> 13
Figure imgf000260_0001
and R . 13a a_n_dj R are each independently C1-C3 alkyl.
50. A compound according to claim 20, wherein R2 is:
Figure imgf000260_0002
and R12 is Cj-Ce alkyl, aryl, arylalkyl, or heteroaryl.
51. A compound according to claim 50, wherein R12 is thienyl or pyridinyl.
52. A compound according to claim 51, wherein R12 is pyridin-2-yl.
53. A compound according to claim 1, selected from the group consisting of:
2-methyl-6-{4-[(R)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}- 2H-pyridazin-3-one;
6-[4-(l-cyclopentyl-piperidin-4-yloxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-methyl-
2H-pyridazin-3-one;
6-{3-chloro-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-methyl-2H- pyridazin-3-one;
2,6-dimethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
2,6-dimethyl-5-[4-(3-piρeridin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
6-methyl-5-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 5-[4-(3-azepan-l-yl-propoxy)-phenyl]-6-methyl-2H-pyridazin-3-one; 2-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
2-methyl-5-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
5-[4-(3-azepan-I-yl-propoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H- pyridazin-3-one;
5 - [4-(3-piperidin- 1 -y 1-pr opoxy)-pheny 1] -2-pyridin-2-yl-2H-pyridazin-3 -one ;
5-[4-(3-azepan-l-yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one;
2-methyl-5-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 2-(6-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-
2H- pyridazin-3-one;
2-(3-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methylpyrτolidin-l-yl)-propoxy]-phenyl}- 2H- pyridazin-3-one;
6-m ethyl-5- {4- [3-((R)-2-methy 1-pyrrolidin- 1 -y l)-propoxy] -phenyl } -2-pyridin-2-yl- 2H-pyridazin-3-one;
6-methyl-2-(3-methyl-pyridin-2-yl)-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)- propoxy]-phenyl}-2H-pyridazin-3-one; 6-methyl-5-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one; hydrochloride;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2H-pyridazin-3-one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2-pyridin-2-yl-2H- pyridazin-3 -one;
5-[4-(piperidin-4-yloxy)-phenyl]-2H-pyτidazin-3-one; 5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2-thiophen-3-yl-2H- pyridazin-3-one;
6-methyl-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-ρhenyl}-2-thiophen-3-yl- 2H-pyridazin-3-one; 5-{4-[3-((S)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl>-2-pyridin-2-yl-2H- pyr idazin-3 -one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-4,5-dihydro-2H-pyridazin- 3-one; 6- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl } -5 -pyridin-2-yl-4,5- dihy dro-2H-pyridazin-3 -one ;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5-pyridin-2-yl-2H- pyridazin-3-one; 6-[4-(piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-4,5-dihydro-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-pyridin-2-yl-4,5-dihydro-2H- pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-pyτidin-2-yl-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-4-methyl-4,5-dihydro-2H-pyridazin- 3-one;
5-[6-(l-cyclobutyl-pϊperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one;
2-(2-fluoro-ethyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one; β-fS-fluoro^-JS-C^^-methyl-pyrrolidin-l-y^-propoxyJ-phenylJ^H-pyridazin-S- one;
6-[3-fluoro-4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one;
4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
4-methyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
4-{4-[3-((S)-2-hydroxymethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-methyl-5,6,7,8- tetrahydro-2H-phthalazin-l -one;
2-methyl-4-{3-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2,5,6,7- tetrahydro-cyclopenta[d]pyridazin-l-one;
2-methyl-4-[3-(3-piperidin-l-yl-propoxy)-phenyl]-2,5,6,7-tetrahydro- cyclopenta[d]pyridazin- 1 -one;
4-{3-[3-((S)-2-hydroxymethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-methyl-2,5,6,7- tetrahydro-cyclopentafdjpyridazin- 1 -one; 2-isopropyl-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-
3 -one;
2-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-5-(6-oxo-l,6-dϊhydro-pyridazin-3- yl)-benzonitrile;
2-[3-(piperidin-l-yl)-propoxy]-5-(6-oxo-l,6-dihydro-pyridazin-3-yl)-benzonitrile; 2-(2-hydroxyethyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-ρropoxy]-phenyl}-2H- pyridazin-3-one; 4-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2,5,6,7-tetrahydro-cyclopenta[d]ρyridazin-
1-one;
6- [4-(3 -piperidin- 1 -yl-propoxy)-phenyl] -2H-pyridazin-3 -one;
6-[3-methoxy-4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
6-{3-methoxy-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin- 3-one;
6- [2-methyl-4-(3 -piperidin- 1 -yl-propoxy)-pheny 1] -2H-pyridazin-3 -one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-pyrimidin-2-yl-2H- pyridazin-3-one;
6- [6-( 1 -cyclopenty l-piperidin-4-y loxy)-pyridin-3 -y 1] -2H-pyridazin-3 -one; 6-[6-(l -isopropyl-piperidin-4-ylmethoxy)-pyridin-3-yl]-2H-pyridazin-3-one;
6- [6-( 1 -cyclobutyl-piperidin-4-y loxy)-pyridin-3 -yl] -2H-pyridazin-3 -one;
6-[6-(l-isopropyl-piperidin-4-yloxy)-pyridin-3-yl]-2H-pyridazin-3-one;
6-[6-(l-cyclopentyl-piperidin-4-yloxy)-pyridin-3-yl]-2-methyl-2H-pyridazin-3-one;
6-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-methyl-2H-pyridazin-3-one; 6-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-isopropyl-2H-pyridazin-3- one;
6-{6-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-pyridin-3-yl}-2H-pyridazin-3-one;
6-[6-(3-piperidin-l-yl-propoxy)-pyridin-3-yl]-2H-pyridazin-3-one;
6-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-4,4-dimethyl-4,5-dihydro-2H- pyridazin-3-one;
6-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-2-pyτidin-2-yl-2H-pyridazin-3- one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-4,5-dihydro-2H-pyridazin-3- one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,4-dimethyl-4,5-dihydro-2H- pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-4,4-dimethyl-4,5-dihydro-
2H-pyridazin-3-one; 6-[4-(l-cyclopentyl-piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-2H-pyrϊdazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one; 6-[4-(piperidin-4-yloxy)-phenyl]-2-pyridin-2-yl-455-dihydro-2H-pyridazin-3-one;
6-[4-((R)-l-cyclohexyl-pyτrolidin-3-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3- one;
6-[4-((R)-l-cyclohexyl-pyrrolidin-3-yloxy)-phenyl]-2H-pyridazin-3-one;
6-[4-((R)-I -cyclobutyl-pyrrolidin-3-yloxy)-phenyl]-2H-pyridazin-3-one; 6-[4-((R)- 1 -cyclopentyl-pyrrolidin-3-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3- one;
2-cyclobutyl-6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H- pyridazin-3-one;
2-cyclobutyl-6-[4-(l-cyclopentyl-piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H- pyridazin-3-one;
2-cyclobutyl-6-[4-(piperidin-4-yloxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro- 2H-pyridazin-3-one;
6-[4-(l-cyclopentyl-piperidin-4-yloxy)-phenylJ-2-(2,2,2-trifluoro-ethyl)-455- dihydro-2H-pyridazin-3-one;
6-{4-[3-((R)-2-methyl-ρyrrolidin-l-yl)-propόxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)- 4,5-dihydro-2H-pyridazin-3-one;
6-{4-[3-piperidin-l-yl-propoxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)-4,5-dihydro-2H- yridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-(2,2,2-trifluoro-ethyl)-
2H-pyridazin-3-one;
6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2-(2,2,2-trifluoro-ethyl)-2H-pyridazin-3- one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2- one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.2.0]oct-4-en-2-one;
4-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-2,4a.536,7,7a-hexahydro- cyclopenta[d]pyridazin- 1 -one; 4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-254a,5,657,7a-hexahydro- cyclopenta[d]pyridazin- 1 -one;
4-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-2,556,7-tetrahydro- cyclopenta[d]pyridazin- 1 -one; 2-cyclobutyl-6-[6-( 1 -cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-4,5-dihydro-2H- pyridazin-3-one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one;
4,4-dimethy 1-6- {4- [3 -((R)-2-methy 1-pyrrolidin- 1 -y l)-propoxy] -phenyl } -4,5 -dihydro- 2H-pyridazin-3 -one ;
6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one;
6-[3-fluoro-4-(3-piperidin-l-yl-propoxy)-phenylJ-4,5-dihydro-2H-pyridazin-3-one;
5,5-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro- 2H-pyridazin-3-one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-pyridin-2-yl-455- dihydro-2H-pyridazin-3-one;
6-{3,5-difluoro-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one; 6-{3,5-dibromo-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
6-{3,5-difluoro-4-[3-((R)-2-niethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro- 2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-3,5-difluoro-phenyl]-4,5-dihydro-2H- pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-3,5-difluoro-phenyl]-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-4,5-dihydro-2H-pyridazin- 3-one;
(R)-6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-4,5-dihydro-2H- pyridazin-3-one;
(S)-6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-4,5-dihydro-2H- pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-ethyl-4,5-dihydro-2H-pyridazin-3- one; 6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-2-pyridin-2-yl-4,5-dihydro- 2H-pyridazin-3-one;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one racemate; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one diastereomer;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one diastereomer;
5-methyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3-one; 5-methyl-6-[4-(3-pyrrolidin-l-yl-propoxy)-phenyl]-4:,5-dihydro-2H-pyridazin-3-one;
6-{(R)-2-methyl-4-[3-(2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyriazin-3-one;
2-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-6-phenyl-2H-pyridazin-3- one; 6-methyl-2-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
2-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-phthalazin-l-one;
2-[6-(l-cyclobutyl-piperidin-4-yloxy)-pyridin-3-yl]-6-phenyl-2H-pyridazin-3-one;
2- {4-[3-((R)-2-methyl -pyrrolidin- 1 -yl)-propoxy] -phenyl } -6-pyridin-3-yl-2H- pyridazin-3-one;
4-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-6H-isoxazolo[3,4- d]pyridaztn-7-one;
3-methyl-4-[4-(piperidin-4-yloxy)-phenyl]-6H-isoxazolo[3,4-d]pyridazin-7-one;
3-methyl-4-[4,-(3-piperidin-l-yl-propoxy)-phenyl]-6H-isoxazolo[3,4-d]pyridazin-7- one;
3-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-6H- isoxazolo[3,4-d]pyridazin-7-one;
8-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-5,6-dihydro-2H-benzo[h]cinnolin-3- one; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidm-l-yl)-propoxy]-phenyl>-2H-pyridazin-3- one;
5-ethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one; 8-[3-(2-methyl-pyrrolidin-l-yl)-propoxy]-4,4a3536-tetrahydro-2H-benzo[h]cinnolin- 3-one;
6-{2-methoxy-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-ρropoxy]-phenyl}-2H-pyτidazin- 3-one; 6-{2-fluoro-4-[3-((R)-2-methyl-pyiτolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H- pyridazin-3-one;;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4-pyridin-2-yl-4,5- dihydro-2H-pyridazin-3-one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4-pyridin-2-yl-2H- pyridazin-3-one;
8-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-5,6-dihydro-3H-benzo[f]cinnolin-2- one; 6-[4-(l -cyclobutyl-piperidin-4-yloxy)-2-fluoro-phenyl]-4,5-dihydro-2H-pyridazin-3- one;
8-(l-cyclobutyl-piperidin-4-yloxy)-4,4a,,556-tetrahydro-2H-benzo[h]cinnolin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-2-fluoro-phenyl]-2H-pyridazin-3-one;
6-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-5-methyl-2H-pyridazin-3-one; 5- {4-[3-((R)-2-methyl-pyrrolidin-l -yl)-propoxy] -phenyl} -2H-pyridazin-3-one;
2-methoxymethyl-5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one; 5-{4-[(R)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
5-[4-((S)-2-methyl-3-piperidin-l-yl-propoxy)-phenyl]-2H-pyτidazin-3-one;
5-[4-((R)-2-methyl-3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
5-{3,5-dibromo-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
2-methoxymethyl-5-{2-methyl-4-[3-((R)-2-methyl-pyπOlidin-l-yl)-propoxy]- phenyl } -2H-pyridazin-3-one;
5-{2-methyl-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl>-2H-pyridazin-3- one; 2-methoxymethyl-5-[2-methyl-4-(3-piperidiπ-l-yl-propoxy)-phenyl]-2H-pyridazin- 3 -one;
5-[2-methyl-4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-2-methyl-phenyl]-2-methoxymethyl-2H- pyridazin-3-one;
4-methoxy-2-methoxymethyl-5- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy]- phenyl}-2H-pyridazin-3-one;
5 -methoxy-2-methoxymethyl -4- {4- [3 -((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] - phenyl }-2H-pyridazin-3-one; 5-methoxy-4- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl) -2H-pyridazin-
3-one;
6-[4-(3-morpholin-4-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
6-{4-[3-((S)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3
-one; 6-[4-(3-pyrrolidin-l -yl-propoxy)-ρhenyl]-2H-pyridazin-3-one;
6-{4-[3-(cyclobutyl-m.ethyl-amino)-propoxy]-phenyl}-2H-pyridazin-3-one;
6-{4-[3-(cyclopentyl-methyl-amino)-propoxy]-phenyl}-2H-pyridazin-3-one;
5- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy]-ρhenyl) -3 ,4-diaza- bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en~2-one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one single isomer;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one single isomer;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one single isomer; 5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept~4-en-2- one single isomer;
5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3-ethyl-3,4-diaza-bicyclo[4.1.0]heρt- 4-en-2-one; 5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-isopropyl-3!(4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-methyl-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one; 5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-(4-fluoro-phenyl)-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3-(2,252-trifluoro-ethyl)-3i(4-diaza- bicyclo [4.1.0]hept-4-en-2-one;
6-[4-(2-hydroxy-3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-{4-[2-hydroxy-3-((R)-2-methyl-pyrτolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-
3-one;
6-{4-[(S)-2-hydroxy-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
6-{4-[(R)-2-hydroxy-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy3-phenyl}-2H- pyridazin-3-one;
6-[4-((R)-2-hydroxy-3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
5-[4-(l-cyclopentyl-piperidin-4-yloxy)-phenyl]-3-methyl-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-[4-(l-cyclopentyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;|and
6-cyclopropyl-2-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one; or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.
54. A compound according to claim 53, wherein the compound is selected from the group consisting of:
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2H-pyridazin-3-one; 6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-435-dihydro-2H- pyridazin-3-one;
6-[4-( 1 -cyclobutyl-piperidin-4-yloxy)-phenyl] -4,4-dimethyl-4,5-dihydro-2H- pyridazin-3-one; 6_[4-(l-cyclobutyl-piperidin-4-yloxy)-3-fluoro-phenyl]-4,4-dimethyl-4,5-dihydro- 2H-py ridazi n-3 -one;
6-[6-(l-cyclobutyl-piρeridin-4-yloxy)-pyridin-3-yl]-4,4-dimethyl-4,5-dihydro-2H- pyridazin-3-one; 5-{4-[3-((R)-2-methyl-pyrrolidϊn-l-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H- pyridazin-3-one;
5-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2-pyridin-2-yl-2H-pyridazin-3-one;
6-{4-[(S)-2-Methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one; 4,4-dimethyl-6- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy]-phenyl}-4,5-dihydro-
2H-pyridazin-3-one;
5- { 4- [3 -((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl } -3 ,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5- { 4- [3 -((R)-2-methyl-pyτrolidin- 1 -yl)-propoxy] -phenyl } -3 ,4-diaza- bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept>4-en-2- one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyI]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2- one;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one one diastereomer; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one one diastereomer;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one; and
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.
55. A compound according to claim 54, wherein the compound is selected from, the group consisting of: 5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-pyridin-2-yl-2H- pyridazin-3-one;
5-[4-(3-piperidin-l-yl-propoxy)-phenylJ-2-pyridin-2-yl-2H-pyridazin-3-one; 6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-ρropoxy]-ρhenyl}-2H- pyridazin-3-one; 4,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-
2H-pyridazin-3-one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-;[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one; 5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2- one;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one one diastereomer; 5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one one diastereomer;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one; and 6- {4- [3 -((R)-2-methy 1-pyrrolidin- 1 -yl)-propoxy] -phenyl } -2H-pyridazin-3-one ; or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.
56. A compound according to claim 55, wherein the compound is selected from the group consisting of:
454-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro- 2H-pyridazin-3-one;
5 - {4- [3-((R)-2-methy 1-pyrrolidin- 1 -yl)-propoxy] -phenyl } -3 ,4-diaza- bicyclo[4.1.0]hept-4-en~2-one; 5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-354-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-{4-[3-((R)-2-methyl-pyπ:olidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-3,4-diaza- bicyclo[4.1.0]hept-4-en-2-one;
5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one; 5-[4-(l -cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.1.0]hept-4-en-2- one;
5-[4-(l-cyclobutyl-piperidin-4-yloxy)-phenyl]-3,4-diaza-bicyclo[4.2.0]oct-4-en-2- one;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one one diastereomer;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one one diastereomer;
5-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-455-dihydro-2H- pyridazin-3-one; and 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3-one; or a stereoisomeric form, mixture of stereoisomeric forms ; or a pharmaceutically acceptable salt thereof.
57. A compound according to claim 55, wherein the compound is 6-{4-[3-((R)-2- methyl-pyrroIidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3-one, or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof.
58. A pharmaceutical composition comprising a compound of Claim 1 or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.
59. A method for treating a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound according to formula I*:
Figure imgf000273_0001
I* or a stereoisomeric form, mixture of stereoisomeric forms, or a pharmaceutically acceptable salt thereof. wherein:
X and Xa are each independently CH or N;
Y is S(O)q, O, or NR15;
R1 is NR10R1 ' or a 4- to 9-membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R20 groups; R2 is
Figure imgf000274_0001
(iv) (V)
Figure imgf000274_0002
(Vi) (vii) (viii)
Figure imgf000274_0003
(ix) wherein: when X and Xa are both CH, then R is meta or para to the
Figure imgf000274_0004
and when either X or Xa are N, then R is para to the Y-(CHR 4 )xm-R D I g. roup; each R3 is: independently H5 F, Cl, Br, I5 OR21, NR23R24, NO2, CN5 CF3, CrC6alkyl5 C(=O)R2\ CO2R21, or C(=O)NR23R24; or when R3 is ortho to R2, and R2 is (i), (U)5 (iv), (vi), or (ix), then R3 and R14 taken together may form -(CH2)s-5 -CH2Z- 5 -ZCH2-, -ZCH2CH2- or CH2CH2Z-; wherein Z is O5 S(O)y5 or NR27; or when R3 is ortho to R2, and R2 is (iv), (v), or (viii), then R3 and R13 taken together may form -(CH2)s-5 -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; or when R3 is ortho to R2, and R2 is (viii), then R3 and R13b taken together may form -(CH2)S-, -CH2Z- , -ZCH2-, -ZCH2CH2- or CH2CH2Z-; or when R3 is ortho to Xa and R2 is ortho to R3 and meta to Xa, then R2 and R3 taken together may form:
Figure imgf000275_0001
each R4 is independently H, Ci-C6alkyl, or OR21, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups; R10 and R11 are each independently H5 Ci-Cβalkyl, or C3-Cβcycloalkyl, wherein the alkyl or cycloalkyl group is optionally substituted with 1 to 3 R20 groups;
R12 is H, Ci-Cβalkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, C(=O)R27, or CO2R , wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl group is optionally substituted with 1 to 3 R20 groups; R13 and R14 are each independently H, Ci-C6alkyl, aryl, arylalkyl d-Cδalkoxyl,
S(=O)y-Ci-C6alkyl, cycloalkyl, heterocycloalkyl, or heteroaryl; R138, R13b, Rl3c, and Rl4a are each independently H, Cι-C6alkyl; or R13 and R14, taken together with the carbon atoms through which they are connected form a fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or C3-C6cycloalkyl ring; or R13b and R14, or R13 and 14a, or Rl3b and l4a, or R13° and RI4a, taken together with the carbon atoms through which they are connected form a fused C3-C6cycloalkyl ring; or R13 and Rl3a, or R14 and R14a, taken together with the carbon atom to which they are attached form a C3-Cscycloalkyl ring; provided that no more than one pair of R13 and R14, R13b and R14, R13 and R14a 5 R13b and R14a, R13c and R14a, R13 and R13a, and R14 and RJ4a are taken together with the carbon atoms through which they are connected or to which they are attached to form a ring; and wherein the fused phenyl, thienyl, pyrrolyl, oxazolyl, pyridinyl, or cycloalkyl ring is optionally substituted with 1 to 3 R20 groups;
R15 is H5 C1-C6 alkyl, C(O)R25, CO2R25; R20 at each occurrence is independently, H, F, Cl, Br, I, OR21, OR22, NR23R24, NHOH5 NO2, CN, CF3, Ci-C6 alkyl optionally substituted with OR26, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7cycloalkylCo-C4alkyl, 3- to 7-membered heterocycloalkylCo-C4alkyl5 phenyl, 5- or 6-membered heteroarylC0-C4alkyl, arylalkyl, (=0), C(O)R21, CO2R21, 0C(=0)R21, C(O)NR23R24, NR27C(=O)R21, NR27C(O)OR21, OC(=O)NR23R24, NR27C(=S)R21, or S(O)qR21 ; each R21 is independently H, Ci-Cδalkyl, aryl, or arylalkyl; each R22 is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed; each R23 and R24 is independently selected from H, Ci-Cδalkyl, and aryl, or R23 and R24. together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with O;
R25 is Ci-Cealkyl, aryl, or alkylaryl;
R26 is H, C|-C6alkyl, aryl, or alkylaryl;
R27 is H or C,-C6alkyl; m is 1, 2, 3, 4, or 5 when R1 is attached via a nitrogen atom, and m is O5 1, 2, 3, 4, or 5 when R1 is attached via a carbon atom; n is 1, 2, or 3; q is O, I, or 2; s is 1, 2, or 3; and y is 0, 1, or 2.
60. The method of claim 59 wherein the disorder is narcolepsy or sleep/wake disorders.
61. The method of claim 59 wherein the disorder is attention deficit hyperactivity disorder.
62. A compound according to claim 1 having the structure:
Figure imgf000277_0001
and stereoisomeric forms, mixtures of stereoisomer^ forms or pharmaceutically acceptable salt forms thereof, wherein:
X and Xa are each independently CH or N; Y is selected from S(O)q, O, and NR15; R1 is NR10R11 or a 4 to 9 membered heterocycloalkyl ring containing 1 or 2 nitrogen atoms and optionally substituted with 1 to 3 R20 groups; R2 is
Figure imgf000277_0002
wherein: when X and Xa are both CH, then R2 is meta or para to the Y-(CHR4)m-R1group; and when either X or Xa are N, then R2 is para to the Y-CCHR^m-R1 group;
R3 is: at each occurrence is independently, H, F, Cl. Br, I, OR21, NR23R24, NO2, CN, CF3, C1-C6 alkyl, C(=O)R21, CO2R21, or C(=O)NR23R24; or when R3 is ortho to R2, then R3 and R14 can combine to form -(CH2)S-, -CH2Z- , CH2CH2Z-; wherein Z is O, S(O)y, NR27; or when R3 is ortho to Xa and R2 is ortho to R3 and meta to Xa, then R2 and R3 combine to form:
Figure imgf000278_0001
R4 is H, Ci-C6 alkyl, or OR2 , wherein the alkyl group is optionally substituted with 1 to 3
R20 groups; R10 and R11 are each, independently H or Ci-Cg alkyl, wherein the alkyl group is optionally substituted with 1 to 3 R20 groups; R12 is H, Ci-C6 alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, CC=O)R27, or CO2R27, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heterocycloalkyl groups are optionally substituted with 1 to 3 R20 groups; R13 and R14 are independently H, CI-CQ alkyl, aryl, or arylalkyl or R13 and R14 can combine to form a fused phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl ring; wherein the phenyl, thienyl, pyrrolyl, cyclopentyl or cyclohexyl rings are optionally substituted with 1 to 3 R20 groups; R15 is H, Ci-C6 alkyl, C(=O)R25, CO2R25; R20 at each occurrence is independently, H, F, Cl, Br, I, OR21, OR22, NR23R24, NHOH, NO2,
CN, CF3, Cj-C6 alkyl optionally substituted with OR26, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, 3-7 membered heterocycloalkyl, phenyl, 5 or 6 membered heteroaryl, arylalkyl, C=O), C(=O)R21, CO2R21, OC(=O)R21, CC=O)NR23R24, NR27C(=O)R21, NR27C(=O)OR21, OCC=O)NR23R24, NR27CC=S)R21, or SCO)qR21; R21 at each occurrence is independently H, Ci-C6 alkyl, aryl, or arylalkyl; R22 at each occurrence is independently the residue of an amino acid after the hydroxyl group of the carboxyl group is removed;
R23 and R24 at each occurrence are each independently selected from H, Ci-C6 alkyl, and aryl, or R23 and R24, together with the nitrogen atom to which they are attached, form a 3 to 7 membered heterocyclic ring optionally substituted with =O; R2S is Ci-C6 alkyl, aryl, or alkylaryl; R26 is H, CrC6 alkyl, aryl, or alkylaryl; R27 is H or Ci-C6 alkyl; m is 1, 2, 3, 4, or 5 when R1 is attached via a nitrogen atom, and rh is 0, 1, 2, 3, 4, or 5 when
R1 is attached via a carbon atom; n is O, 1 , 2, or 3; q is O, I5 or 2; s is 1, 2, or 3.
63. The compound of claim 62 wherein the compounds are selected from:
2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one; 2-methyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
2-isopropyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
2-isopropyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-4,5-dihydro-2H-pyridazin-3- one;
2-isopropyl-6- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl} -2H-pyridazin- 3 -one;
2-ethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
6-{3-fiuoro-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-nαethyl-2H- pyridazin-3-one; 2-(2,4-dichloro-benzyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-
4,5-dihydro-2H-pyridazin-3-one;
2-(3,5-dichloro-phenyl)-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}- 2H-pyridazin-3 -one;
6-[3-fluoro-4-(3-piperidin-l-yl-propoxy)-phenyl]-2-phenyl-2H-pyridazin-3-one; 6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3-one;
4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2,5,637-tetrahydro- cyclopenta[d]pyridazin- 1 -one;
2-methyl-6-{4-[(S)-2-methyl-3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}- 2H-pyridazin-3-one; 6-{4-[3-((S)-2-hydroxymethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-methyl-2H- pyridazin-3-one;
6- {4-[3-((R)-2-hydroxymethyl-pyrrolidin- 1 -yl)-propoxy] -phenyl } -2-methyl-2H- pyridazin-3-one; 2-methyl-6- {4-[3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy]-phenyl } -455-dihydro-2H- pyridazin-3-one;
2-benzyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-4,5-dihydro-2H- pyridazin-3-one; 2-benzyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-pyridazin-3- one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-phenyl-2H-pyridazin-3- one;
6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-phenyl-2H-pyridazin-3- one;
2-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H-ρyridazin-3-one;
5-Isopropyl-7-{4-[3-((R)-2-methyl-pyiτolidin-l-yl)-propoxy]-phenyl}-5H- thieno [2,3-d]pyridazin-4-one;
7-{4-[3-(2,5-dimethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5-isopropyl-5H- thieno[2,3-d]pyridazin-4-one;
5-isopropyl-7-[4-(3-piperidin-l-yl-propoxy)-phenyl]-5H-thieno[2,3-d]pyridazin-4- one;
7-{4-[3-(3,3-diniethyl-piperidin-l-yl)-propoxy]-phenyl}-5-isopropyl-5H-thieno[2,3- d]pyridazin-4-one; 5-isopropyl-7-{4-[3-((S)-2-n-ethoxymethyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5H- thieno[2,3-d]pyridazin-4-one;
5-isopropyl-7-{4-[3-((R)-2-methoxymethyl-pyrrolidin-l-yl)-ρropoxy]-phenyl}-5H- thieno [2,3-d]pyridazin-4-one;
7-[4-(3-diethylamino-propoxy)-phenyl]-5-isopropyl-5H-thieno[2,3-d]pyridazin-4- one;
5-isopropyl-7-[4-(3-pyrrolidin-l-yl-propoxy)-phenyl]-5H-thieno[253-d]-pyridazin-4- one;
5-isopropyl-7-{4-[3-(4-pyrrolidin-l-yl-piperidin-l-yl)-propoxy]-phenyl}-5H- thieno [2,3-d]pyridazin-4-one; 7-{4-[3-((2R,5R)-2,5-dimethyl-pyrrolidin-l-yl)-proρoxy]-phenyl}-5-isopropyl-5H- thieno[2,3-d]pyridazin-4-one;
7-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5-propyl-5H-thieno[2:,3- d]pyridazin-4-one ; 7- {4-[3 -((2R,5R)-2,5-dimethyl-pyrrolidin~ 1 -yl)-propoxy]-phenyl } -5-propyl-5H- thieno[2,3-d]pyridazin-4-one;
7- {4-[3 -(4-methyl-piperidin- 1 -yl)-propoxy] -phenyl } -5-propyl-5H-thieno[2,3- d]pyridazin-4-one; 7-{4-[3-(4-dimethylamino-piperidin-l-yl)-propoxy]-phenyl}-5-propyl-5H- thieno[2,3-d]pyridazin-4-one;
5-propyl-7-{4-[3-((S)-2-pyrrolidin-l-ylmethyl-pyrrolidin-l-yl)-propoxy]-phenyl}- 5H-thieno[2,3-d]pyridazin-4-one;
5-(4-chloro-benzyl)-7-[4-(3-piperidin-l-yl-propoxy)-phenyl]-5H-thieno[2,3- d]pyτidazin-4-one;
5-(4-chloro-benzyl)-7-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5H- thieno[2,3-d]pyridazin-4-one;
2,4-dimethyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
2,4-dimethyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
2-isopropyl-4-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
2-isopropyl-4-methyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazϊn-3-one;
2-benzyl-4-methyl-6- {4- [3-((R)-2-methyl-pyrrolidin- 1 -yl)-propoxy] -phenyl }-2H- pyridazin-3-one;
2-benzyl-4-methyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
4-benzyl-2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- pyridazin-3-one;
4-benzyl-2-methyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one; 2-methyl-6-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5-phenyl-2H- pyridazin-3-one;
2-methyl-5-phenyl-6-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-pyridazin-3-one;
2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-ρhenyl}-2H-phthalazin- 1-one; 2-methyl-4-[4-(3-piperidin- l-yl-propoxy)-phenyl]-2H-phthalazin-l -one;
2-methyl-4-[4-(2-piperidin-l-yl-ethoxy)-phenyl]-2H-phthalazin-l-one;
2-methyl-4-[4-(3-pyrrolidin-l-yl-propoxy)-phenyl]-2H-phthalazin-l-one;
4-[4-(3-azepan- 1 -yl-propoxy)-phenyl]-2-methyl-2H-phthalazin- 1 -one; 2-(4-chloro-benzyl)-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2H- phthalazin- 1 -one;
2-(4-chloro-benzyl)-4-[4-(3-piperidin-l-yl-propoxy)-phenyl]-2H-phthalazin-l-one;
2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2,5,6,7- tetrahydro-cyclopenta[d]pyridazin-l-one;
2-methyl-4-[4-(3-piperidin-l-yl-propoxy)-phenyl]-255,6,7-tetrahydro- cyclopenta[d]pyridazin-l -one;
2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2,4a5536,7,7a- hexahydro-cyclopenta[d]pyridazin- 1 -one ; 2-methyl-4-[4-(3-piperidin- 1 -yl-propoxy)-phenyl]-2,4a,556,757a-hexahydro- cyclopenta[d]pyridazin-l -one;
2-methyl-4-{4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-5,6,7,8- tetrahydro-2H-phthalazin- 1 -one;
4-{4-[3-(butyl-ethyl-amino)-propoxy]-phenyl}-2-methyl-5,6;>7,8-tetrahydro-2H- phthalazin-1-one;
4-[4-(3-methyl-4-oxo-3,4-dihydro-phthalazin-l-yl)-phenoxymethyl]-piperidine-l- carboxylic acid tert-butyl ester;
2-methyl-4-[4-(piperidin-4-ylmethoxy)-phenyl]-2H-phthalazin-l-one;
4-[4-(l-cyclobutyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-phthalazin-l-one; 4-[4-(l-methyl-6-oxo-l,6-dihydro-pyridazin-3-yl)-ρhenoxymethyl]-piperidine-l- carboxylxc acid tert-butyl ester;
2-methy 1-6- [4-(piperidin-4-ylmethoxy)-phenyl] -2H-pyridazin-3 -one ;
6-[4-(l-cyclobutyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one;
6-[4-(l-isopropyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 6-[4-(l-cyclopropylmethyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-
3-one;
6-[4-(l-cyclopentyl-piperidin-4-ylmethoxy)-phenyl]-2-methyl-2H-pyridazin-3-one;
2-methyl-6-[4-(l-methyl-piperidin-4-ylmethoxy)-ρhenyl]-2H-pyridazin-3-one;
6-[4-(l-isopropyl-piperidin-4-yloxy)-phenyl]-2-methyl-2H-pyridazin-3-one; 2-methyl-6-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one;
2-methyl-6-[4-(piperidin-4-yloxy)-phenyl]-2H-pyridazin-3-one;
2-methyl-8-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-5,6-dihydro-2H- benzo[h]cinnolin-3-one; 8-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-2-phenyl-5,6-dihydro-2H- benzo[h]cinnolin-3-one;
2-benzyl-8-(3-piperidin-l-yl-propoxy)-5.6-dihydro-2H-benzo[h]cinnolin-3-one;
2-isopropyl-8-(3-piperidin-l-yl-propoxy)-5,6-dihydro-2H-berizo[h]cinnolin-3-one; 2-methyl-7-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-2H-phthalazin-l-one;
2-methyl-7-(3-piperidin-l -yl-propoxy)-2H-phthalazin-l-one; and
6-{3-fluoro-4-[3-((R)-2-methyl-pyrrolidin-l-yl)-propoxy]-phenyl}-2-phenyl-2H- pyridazin-3-one; and stereoisomeric forms, mixtures of stereoisomer^ forms or pharmaceutically acceptable salt forms thereof.
64. A pharmaceutical composition comprising a compound of Claim 62 and one or more pharmaceutically acceptable excipients.
65. A method for treating a disorder selected from the group consisting of narcolepsy or sleep/wake disorders, feeding behavior, eating disorders, obesity, cognition, arousal, memory, mood disorders, mood attention alteration, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease/dementia, schizophrenia, pain, stress, migraine, motion sickness, depression, psychiatric disorders, epilepsy, gastrointestinal disorders, respiratory disorders, inflammation, and myocardial infarction, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of claim 62.
66. The method of claim 65 wherein the disorder is narcolepsy or sleep/wake disorders.
67. The method of claim 65 wherein the disorder is attention deficit hyperactivity disorder.
PCT/US2007/016699 2006-07-25 2007-07-25 Pyridizinone derivatives WO2008013838A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
AU2007277163A AU2007277163B2 (en) 2006-07-25 2007-07-25 Pyridizinone derivatives
EA200970156A EA017004B1 (en) 2006-07-25 2007-07-25 Pyridizinone derivatives
KR1020097003799A KR101429311B1 (en) 2006-07-25 2007-07-25 Pyridazinone derivatives
JP2009521813A JP5335675B2 (en) 2006-07-25 2007-07-25 Pyrididinone derivatives
CN2007800345556A CN101522638B (en) 2006-07-25 2007-07-25 Pyridizinone derivatives
SI200731142T SI2069312T1 (en) 2006-07-25 2007-07-25 Pyridizinone derivatives
RS20130013A RS52626B (en) 2006-07-25 2007-07-25 Pyridizinone derivatives
PL07810758T PL2069312T3 (en) 2006-07-25 2007-07-25 Pyridizinone derivatives
BRPI0713836-9A BRPI0713836A2 (en) 2006-07-25 2007-07-25 compound, pharmaceutical composition and method for treating the disorder
ES07810758T ES2397283T3 (en) 2006-07-25 2007-07-25 Pyridizinone derivatives
EP07810758A EP2069312B1 (en) 2006-07-25 2007-07-25 Pyridizinone derivatives
MX2009000884A MX2009000884A (en) 2006-07-25 2007-07-25 Pyridizinone derivatives.
DK07810758.8T DK2069312T3 (en) 2006-07-25 2007-07-25 pyridazinone
KR1020147004736A KR20140037967A (en) 2006-07-25 2007-07-25 Pyridazinone derivatives
CA2658821A CA2658821C (en) 2006-07-25 2007-07-25 Pyridizinone derivatives and uses thereof to treat diseases, disorders and/or conditions that may be mediated or modulated by inhibition of h3 receptors
NZ574873A NZ574873A (en) 2006-07-25 2007-07-25 Pyridazinone derivatives as h3 inhibitors
IL196543A IL196543A (en) 2006-07-25 2009-01-15 Pyridazinone derivatives and pharmaceutical compositions comprising them for use in the treatment of disorders
NO20090628A NO20090628L (en) 2006-07-25 2009-02-10 Pyridizinone derivatives
HK09111622.4A HK1134284A1 (en) 2006-07-25 2009-12-10 Pyridizinone derivatives pyridizinone
HRP20130044TT HRP20130044T1 (en) 2006-07-25 2013-01-18 Pyridizinone derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83316406P 2006-07-25 2006-07-25
US60/833,164 2006-07-25

Publications (2)

Publication Number Publication Date
WO2008013838A2 true WO2008013838A2 (en) 2008-01-31
WO2008013838A3 WO2008013838A3 (en) 2008-07-31

Family

ID=38857882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016699 WO2008013838A2 (en) 2006-07-25 2007-07-25 Pyridizinone derivatives

Country Status (25)

Country Link
US (5) US8247414B2 (en)
EP (3) EP2492263A1 (en)
JP (1) JP5335675B2 (en)
KR (2) KR20140037967A (en)
CN (1) CN101522638B (en)
AU (1) AU2007277163B2 (en)
BR (1) BRPI0713836A2 (en)
CA (2) CA2858816A1 (en)
DK (1) DK2069312T3 (en)
EA (1) EA017004B1 (en)
ES (1) ES2397283T3 (en)
HK (1) HK1134284A1 (en)
HR (1) HRP20130044T1 (en)
IL (1) IL196543A (en)
MX (1) MX2009000884A (en)
MY (1) MY148634A (en)
NO (1) NO20090628L (en)
NZ (1) NZ574873A (en)
PL (1) PL2069312T3 (en)
PT (1) PT2069312E (en)
RS (1) RS52626B (en)
SI (1) SI2069312T1 (en)
UA (1) UA95644C2 (en)
WO (1) WO2008013838A2 (en)
ZA (1) ZA200901336B (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009097306A1 (en) * 2008-01-30 2009-08-06 Cephalon, Inc. Substituted pyridazine derivatives which have histamine h3 antagonist activity
CN101679237A (en) * 2007-05-03 2010-03-24 赛福伦公司 The method of preparation (R)-2-crassitude and (S)-2-crassitude and tartrate thereof
US20100179149A1 (en) * 2007-06-01 2010-07-15 MERCK Patent Gesellschaft mit beschränkter Haftung Aryl ether pyridazinone derivatives
US20120238551A1 (en) * 2009-07-02 2012-09-20 Cephalon France Substituted Phenoxypropylcycloamine Derivatives as Histamine-3 (H3) Receptor Ligands
KR101303283B1 (en) * 2011-03-28 2013-09-04 한국화학연구원 Pyridazinone derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
USRE44613E1 (en) 2007-01-12 2013-11-26 Glaxosmithkline Llc N-substituted glycine derivatives: hydroxylase inhibitors
WO2013188381A1 (en) * 2012-06-12 2013-12-19 Abbvie Inc. Pyridinone and pyridazinone derivatives
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
WO2017170759A1 (en) 2016-03-30 2017-10-05 石原産業株式会社 Pyridazinone-type compound or salt thereof, and herbicide comprising same
US9902696B2 (en) 2015-06-18 2018-02-27 Cephalon, Inc. 1,4-substituted piperidine derivatives
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
WO2020157199A1 (en) 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Annulated dihydropyridazinone compounds as anti-cancer compounds
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
US10919875B2 (en) 2015-06-18 2021-02-16 89Bio Ltd Substituted 4-benzyl and 4-benzoyl piperidine derivatives
WO2021105659A1 (en) * 2019-11-25 2021-06-03 Uea Enterprises Limited Method for digesting nucleic acid in a sample
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor
US11566020B1 (en) 2018-04-30 2023-01-31 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibitors
US11603523B2 (en) 2019-01-18 2023-03-14 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
US11691969B2 (en) 2019-10-30 2023-07-04 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibtors

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5241062A (en) * 1993-01-19 1993-08-31 Sun Company, Inc. (R&M) Synthetic route to meso-tetra hydrocarbyl or substituted hydrocarbyl porphyrins and derivatives
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
AU2007260836B2 (en) * 2006-06-23 2012-11-15 Abbvie Bahamas Ltd. Cyclopropyl amine derivatives as histamin H3 receptor modulators
MX2009000884A (en) 2006-07-25 2009-06-05 Cephalon Inc Pyridizinone derivatives.
US8283351B2 (en) * 2007-04-02 2012-10-09 Institute For Oneworld Health Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof
US20090221648A1 (en) * 2007-12-21 2009-09-03 Abbott Laboratories Compositions for treatment of cognitive disorders
US8383657B2 (en) * 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
EP2328586A2 (en) * 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
GB0817207D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2012032532A1 (en) * 2010-09-07 2012-03-15 Symed Labs Limited "processes for the preparation of 4'-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3'-methoxyacetophenone and intermediates thereof"
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
EP2970145B1 (en) * 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
JP6417401B2 (en) 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー ACC inhibitors and uses thereof
EA030942B1 (en) 2013-05-10 2018-10-31 Джилид Аполло, Ллс Acc inhibitors and uses thereof
JP6417402B2 (en) * 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー ACC inhibitors and uses thereof
BR112015028214A2 (en) 2013-05-10 2017-07-25 Nimbus Apollo Inc acc inhibitors and uses thereof
CN103772352B (en) * 2014-01-16 2017-01-18 四川百利药业有限责任公司 Pyridazinone derivatives and preparation method and application thereof
PL3442972T3 (en) 2016-04-15 2020-07-27 Abbvie Inc. Bromodomain inhibitors
US10995084B2 (en) 2016-07-22 2021-05-04 Kissei Pharmaceutical Co., Ltd. Pyrrolidine derivative
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
CN109111400B (en) * 2017-06-23 2020-10-16 杭州百诚医药科技股份有限公司 Preparation and application of phenylquinolinone and flavonoid derivatives
CA3075727A1 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
CN108264488A (en) * 2018-01-26 2018-07-10 天津瑞岭化工有限公司 A kind of preparation method for replacing phthalazone class compound
JP2021512103A (en) 2018-01-31 2021-05-13 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Antibody drug conjugate (ADCS) containing a NAPPT inhibitor
KR20210069652A (en) 2018-09-18 2021-06-11 골드핀치 바이오 인코포레이티드 Pyridazinone and methods of use thereof
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
CN114560814B (en) * 2022-03-02 2023-10-20 天津理工大学 Synthesis method of substituted 2, 3-naphthyridine ketone compound

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011321A (en) 1973-12-19 1977-03-08 Smith Kline & French Laboratories Limited Pharmaceutical compositions and methods of inhibiting β-adrenergic receptors
GB1488330A (en) 1973-12-19 1977-10-12 Smith Kline French Lab Dihydropyridazinones
US4111936A (en) 1974-06-18 1978-09-05 Smith Kline & French Laboratories Limited Pyridazinethiones
IE42214B1 (en) 1974-06-18 1980-07-02 Smith Kline French Lab Hydrazinopyredazines
US4111935A (en) 1975-01-02 1978-09-05 Smith Kline & French Laboratories Limited 3-chloro-6-phenylpyridazine compounds
US4082843A (en) 1975-11-26 1978-04-04 Smith Kline & French Laboratories Limited 3-(3-(3-Substituted amino-2-hydroxypropoxy)phenyl)-6-hydrazino pyridazines and their use as vasodilators and β-adrenergic blocking agents
BE836633A (en) 1975-12-15 1976-06-15 PHENYLHYDRAZINOPYRIDAZINES
GB1548601A (en) 1976-03-29 1979-07-18 Smith Kline French Lab Pyridazines
JPS5746966A (en) 1980-09-03 1982-03-17 Mitsui Toatsu Chem Inc Pyridazinone derivative and its production
EP0051217A1 (en) 1980-10-31 1982-05-12 Usv Pharmaceutical Corporation Oxidation process
US4331600A (en) 1980-10-31 1982-05-25 Usv Pharmaceutical Corporation Intermediates for the synthesis of phthalimidines
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4404203A (en) 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
HU190412B (en) 1981-09-17 1986-09-29 Warner-Lambert Co,Us Process for producing substituted 4,5-dihiydro-6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones and 6-bracket-substituted-bracket closed-phenyl-3-bracket-2h-bracket closed-pyridazinones
US4353905A (en) 1981-09-17 1982-10-12 Warner-Lambert Company Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones
JPS58113180A (en) 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc Pyridazinone derivative
US4734415A (en) 1982-08-13 1988-03-29 Warner-Lambert Company Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones
US4666902A (en) 1983-06-20 1987-05-19 Cassella Aktiengesellschaft Tetrahydropyridazinone derivatives, processes for their preparation and their use
GB8323553D0 (en) 1983-09-02 1983-10-05 Smith Kline French Lab Pharmaceutical compositions
JPS6087283A (en) * 1983-10-19 1985-05-16 Mitsubishi Chem Ind Ltd Pyridazinone derivative and its salt
US4816454A (en) 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
EP0194548A3 (en) 1985-03-12 1988-08-17 Dr. Karl Thomae GmbH Sulfonylaminoethyl compounds, medicines containing these compounds and process for their preparation
AU5428686A (en) 1985-03-12 1986-09-18 Smith Kline & French Laboratories Limited Imidazolinone and thiazolinone derivatives
GB8506319D0 (en) 1985-03-12 1985-04-11 Smith Kline French Lab Chemical compounds
GB8528633D0 (en) 1985-11-21 1985-12-24 Beecham Group Plc Compounds
JPH0629254B2 (en) 1986-09-08 1994-04-20 帝国臓器製薬株式会社 Pyridazinone derivative
JPS63145272A (en) 1986-12-09 1988-06-17 Morishita Seiyaku Kk 4,5-dihydro-6-(4-substituted phenyl)-3(2h)-pyridazinone derivative
JPS63154673A (en) 1986-12-17 1988-06-27 Mitsubishi Kasei Corp Pyridazinone derivative or salts thereof
US4819929A (en) 1987-02-24 1989-04-11 Stobb, Inc. Apparatus and method for feeding sheets to a sheet gatherer
DE3706427A1 (en) 1987-02-27 1988-09-08 Boehringer Mannheim Gmbh NEW SUBSTITUTED 3H-INDOLES, INTERMEDIATE PRODUCTS, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS
JPS63215672A (en) 1987-03-04 1988-09-08 Mitsubishi Kasei Corp Pyridazinone derivative or salts thereof
DE3728491A1 (en) * 1987-08-26 1989-03-09 Heumann Pharma Gmbh & Co DIHYDROPYRIDAZINONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3804490A1 (en) 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co SUBSTITUTED 6-PHENYLDIHYDRO-3 (2H) -PYRIDAZINONE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3814057A1 (en) 1988-04-26 1989-11-09 Heumann Pharma Gmbh & Co 6-OXO-PYRIDAZINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3826855A1 (en) 1988-08-06 1990-02-15 Cassella Ag 4,5-DIHYDRO-3 (2H) -PYRIDAZINONE, PROCESS FOR THEIR PREPARATION AND THEIR USE
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
DE3934436A1 (en) 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-HYDROXY-N-PROPYLAMINES, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
US5204463A (en) 1989-08-10 1993-04-20 Glaxo Inc. Substituted methoxyphenyl-4,5 dihydro-3(2H)-pridazinones having cardiotonic and beta blocking activities
EP0412814A3 (en) * 1989-08-10 1991-07-24 Glaxo Inc. Pyridazinones having cardiotonic and beta blocking activity
US5053338A (en) 1989-09-01 1991-10-01 Glaxo Inc. Kinetic resolution of pyridazinones using lipase
WO2008137087A1 (en) 2007-05-03 2008-11-13 Cephalon, Inc. Processes for preparing (r)-2-methylpyrrolidine and (s)-2-methylpyrrolidine and tartrate salts thereof
US5531496A (en) * 1994-07-28 1996-07-02 Saturn Corporation Automotive glass enclosure retaining fixture
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co Pyridazinone derivatives and processes for their preparation
JP3060454B2 (en) 1996-12-26 2000-07-10 田辺製薬株式会社 Pharmaceutical composition
AU1760399A (en) 1997-12-15 1999-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh New phthalazinones
US6255303B1 (en) 1998-03-14 2001-07-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone PDE III/IV inhibitors
AU6005999A (en) 1998-10-09 2000-05-01 Nihon Nohyaku Co., Ltd. Pyridazinone derivatives
AU3076700A (en) 1999-01-26 2000-08-18 Ono Pharmaceutical Co. Ltd. 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
DE19918294A1 (en) 1999-04-22 2000-10-26 Bayer Ag New 3-aryloxy-1,1-dioxo-1,4,2-dithiaza-heterocyclic compounds, used as pesticides, e.g. fungicides, bactericides, insecticides, acaricides or nematocides, for protection of plants or materials
DE10010425A1 (en) 2000-03-03 2001-09-06 Bayer Ag Medicaments for treating anemia, containing new or known 6-(4-(acylamino)-phenyl)-5-methyl-dihydropyridazinones having erythropoietin sensitizing and erythropoiesis stimulating activity
FI20000577A0 (en) 2000-03-13 2000-03-13 Orion Yhtymae Oy Pyridatsinyylifenyylihydratsoneja
GB0008264D0 (en) * 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
AU8112101A (en) 2000-08-08 2002-02-18 Ortho Mcneil Pharm Inc Non-imidazole aryloxypiperidines
BR0114836A (en) 2000-10-20 2003-07-01 Pfizer Prod Inc Beta-3 adrenergic receptor agonists and their applications
JP2005520791A (en) 2001-11-08 2005-07-14 イーラン ファーマスーティカルズ、インコーポレイテッド N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
US20040067955A1 (en) 2002-09-06 2004-04-08 Fujisawa Pharmaceutical Co. Ltd. Pyridazinone compound and pharmaceutical use thereof
GB0308333D0 (en) 2003-04-10 2003-05-14 Glaxo Group Ltd Novel compounds
JP4735261B2 (en) 2003-06-27 2011-07-27 Ｍｓｄ株式会社 Heteroaryloxy nitrogen-containing saturated heterocyclic derivatives
DE102004010194A1 (en) 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-one derivatives, their preparation and use in medicaments
DE102004010207A1 (en) * 2004-03-02 2005-09-15 Aventis Pharma S.A. New 4-benzimidazolyl-3(2H)-pyridazinone derivatives are kinase inhibitors, especially useful for treatment of cancer
WO2006060127A2 (en) 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
JP2008521805A (en) 2004-11-30 2008-06-26 アーテシアン セラピューティクス， インコーポレイテッド Cardiotonic compounds having inhibitory activity against β-adrenergic receptors and phosphodiesterases
AU2006228690A1 (en) 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
WO2006124874A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
DE102005057924A1 (en) 2005-12-05 2007-06-06 Merck Patent Gmbh pyridazinone derivatives
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
MX2009000884A (en) 2006-07-25 2009-06-05 Cephalon Inc Pyridizinone derivatives.
DE102006037478A1 (en) 2006-08-10 2008-02-14 Merck Patent Gmbh 2- (Heterocyclylbenzyl) -pyridazinone derivatives
JP2010013354A (en) 2006-09-07 2010-01-21 Kyorin Pharmaceut Co Ltd 2-alkyl-6-(pyrazolopyridin-4-yl)pyridazinone derivative and its addition salt, and pde inhibitor using them as active ingredient
US20080262226A1 (en) 2006-11-07 2008-10-23 Artesian Therapeutics, Inc. Methods of making compounds having a beta-adrenergic inhibitor and a linker and methods of making compounds having a beta-adrenergic inhibitor, a linker and a phosphodiesterase inhibitor
BRPI0718874A2 (en) 2006-12-22 2015-06-23 Novartis Ag Organic compounds
JP2008222580A (en) 2007-03-09 2008-09-25 Kyorin Pharmaceut Co Ltd 2-substituted-5-(pyrazolopyridin-4-yl)pyrazolone derivative and phosphodiesterase inhibitor comprising the same as active ingredient
JP2008222648A (en) 2007-03-14 2008-09-25 Kyorin Pharmaceut Co Ltd 2-substituted-5-(pyrazolopyridin-3-yl)pyrazolone derivative, addition salt thereof and pde inhibitor comprising the same as active ingredient
JP2008239558A (en) 2007-03-28 2008-10-09 Kyorin Pharmaceut Co Ltd 2-substituted-6-(pyrazolopyridin-3-yl)pyridazinone derivative, adduct salt of the same and pde inhibitor by using them as active ingredient
US7867980B2 (en) 2007-05-31 2011-01-11 Meiji Seika Kaisha, Ltd. Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient
DE102007025717A1 (en) 2007-06-01 2008-12-11 Merck Patent Gmbh Aryl ether pyridazinone derivatives
US20100130738A1 (en) 2007-06-19 2010-05-27 Yasushi Kohno Pyrazolone derivative and pde inhibitor containing the same as active ingredient
US20100160335A1 (en) 2007-06-19 2010-06-24 Kyorin Pharmaceutical Co., Ltd. Pyridazinone derivative and pde inhibitor containing the same as active ingredient
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
CN101842359A (en) * 2007-10-31 2010-09-22 日产化学工业株式会社 Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester Method for altering the lifespan of eukaryotic organisms
WO2009082698A1 (en) 2007-12-21 2009-07-02 Abbott Laboratories Compositions for treatment of cognitive disorders
CA2712897A1 (en) 2008-01-30 2009-08-06 Pharmacopeia, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
MX2010008382A (en) 2008-01-30 2010-11-25 Cephalon Inc Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands.
MX2010008384A (en) 2008-01-30 2010-11-30 Cephalon Inc Substituted pyridazine derivatives which have histamine h3 antagonist activity.
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
EP2396408B1 (en) * 2009-02-12 2017-09-20 CuRNA, Inc. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHEM PHARM BULL, vol. 42, 1980, pages 1850
FARMACO, vol. 51, 1996, pages 693 - 688
HETEROCYCLES, vol. 57, 2002, pages 39
INDIAN J. CHEM, vol. 16B, 1977, pages 631
J. MED CHEM., vol. 32, 1989, pages 528
J. MED. CHEM., vol. 46, 2003, pages 2008

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44613E1 (en) 2007-01-12 2013-11-26 Glaxosmithkline Llc N-substituted glycine derivatives: hydroxylase inhibitors
CN101679237A (en) * 2007-05-03 2010-03-24 赛福伦公司 The method of preparation (R)-2-crassitude and (S)-2-crassitude and tartrate thereof
US8445489B2 (en) * 2007-06-01 2013-05-21 Merck Patent Gmbh Aryl ether pyridazinone derivatives
US20100179149A1 (en) * 2007-06-01 2010-07-15 MERCK Patent Gesellschaft mit beschränkter Haftung Aryl ether pyridazinone derivatives
EP2752406A1 (en) * 2008-01-30 2014-07-09 Cephalon, Inc. Substituted pyridazine derivatives which have histamine H3 antagonist activity
US8912183B2 (en) 2008-01-30 2014-12-16 Cephalon, Inc. Substituted pyridazine derivatives
WO2009097306A1 (en) * 2008-01-30 2009-08-06 Cephalon, Inc. Substituted pyridazine derivatives which have histamine h3 antagonist activity
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US20120238551A1 (en) * 2009-07-02 2012-09-20 Cephalon France Substituted Phenoxypropylcycloamine Derivatives as Histamine-3 (H3) Receptor Ligands
US8648067B2 (en) * 2009-07-02 2014-02-11 Cephalon, Inc. Substituted phenoxypropylcycloamine derivatives as histamine-3 (H3) receptor ligands
KR101303283B1 (en) * 2011-03-28 2013-09-04 한국화학연구원 Pyridazinone derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
WO2013188381A1 (en) * 2012-06-12 2013-12-19 Abbvie Inc. Pyridinone and pyridazinone derivatives
US9561231B2 (en) 2012-06-12 2017-02-07 Abbvie Inc. Pyridinone and pyridazinone derivatives
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones
US9902696B2 (en) 2015-06-18 2018-02-27 Cephalon, Inc. 1,4-substituted piperidine derivatives
US11878966B2 (en) 2015-06-18 2024-01-23 89Bio Ltd Substituted 4-benzyl and 4-benzoyl piperidine derivates
US11702388B2 (en) 2015-06-18 2023-07-18 89Bio Ltd 1,4-substituted piperidine derivatives
US10221135B2 (en) 2015-06-18 2019-03-05 89Bio Ltd 1,4-substituted piperidine derivatives
US10919875B2 (en) 2015-06-18 2021-02-16 89Bio Ltd Substituted 4-benzyl and 4-benzoyl piperidine derivatives
US10851057B2 (en) 2015-06-18 2020-12-01 89Bio Ltd 1,4-substituted piperidine derivatives
US10870638B2 (en) 2016-03-30 2020-12-22 Ishihara Sangyo Kaisha, Ltd. Pyridazinone compound or its salt, and herbicide containing it
KR20180129786A (en) 2016-03-30 2018-12-05 이시하라 산교 가부시끼가이샤 Pyridazinone compounds or salts thereof, and herbicides containing them
WO2017170759A1 (en) 2016-03-30 2017-10-05 石原産業株式会社 Pyridazinone-type compound or salt thereof, and herbicide comprising same
US11566020B1 (en) 2018-04-30 2023-01-31 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibitors
US11603523B2 (en) 2019-01-18 2023-03-14 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
WO2020157199A1 (en) 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Annulated dihydropyridazinone compounds as anti-cancer compounds
WO2020223229A1 (en) * 2019-04-29 2020-11-05 Ribon Therapeutics, Inc. Solid forms of a parp7 inhibitor
US11691969B2 (en) 2019-10-30 2023-07-04 Ribon Therapeutics, Inc. Pyridazinones as PARP7 inhibtors
WO2021105659A1 (en) * 2019-11-25 2021-06-03 Uea Enterprises Limited Method for digesting nucleic acid in a sample
US11946037B2 (en) 2019-11-25 2024-04-02 Uea Enterprises Limited Method for digesting nucleic acid in a sample
WO2022113008A1 (en) 2020-11-27 2022-06-02 Richter Gedeon Nyrt. Histamine h3 receptor antagonists/inverse agonists for the treatment of autism spectrum disorder
WO2022156708A1 (en) * 2021-01-20 2022-07-28 Jacobio Pharmaceuticals Co., Ltd. Parp7 enzyme inhibitor

Also Published As

Publication number Publication date
MY148634A (en) 2013-05-15
CN101522638B (en) 2012-02-01
AU2007277163A1 (en) 2008-01-31
US8673916B2 (en) 2014-03-18
EP2502918B1 (en) 2015-03-25
IL196543A (en) 2013-09-30
EA200970156A1 (en) 2009-08-28
PL2069312T3 (en) 2013-03-29
US20110288075A1 (en) 2011-11-24
HK1134284A1 (en) 2010-04-23
DK2069312T3 (en) 2013-02-04
EP2492263A1 (en) 2012-08-29
PT2069312E (en) 2013-01-24
SI2069312T1 (en) 2013-03-29
US20080027041A1 (en) 2008-01-31
JP5335675B2 (en) 2013-11-06
ES2397283T3 (en) 2013-03-06
US8207168B2 (en) 2012-06-26
KR20140037967A (en) 2014-03-27
KR20090031951A (en) 2009-03-30
US20100280007A1 (en) 2010-11-04
NZ574873A (en) 2012-03-30
CA2858816A1 (en) 2008-01-31
JP2009544709A (en) 2009-12-17
HRP20130044T1 (en) 2013-02-28
CA2658821C (en) 2014-10-21
UA95644C2 (en) 2011-08-25
KR101429311B1 (en) 2014-08-12
ZA200901336B (en) 2010-06-30
BRPI0713836A2 (en) 2013-05-28
US20140142088A1 (en) 2014-05-22
CN101522638A (en) 2009-09-02
NO20090628L (en) 2009-04-21
RS52626B (en) 2013-06-28
US20100273779A1 (en) 2010-10-28
WO2008013838A3 (en) 2008-07-31
US8247414B2 (en) 2012-08-21
EA017004B1 (en) 2012-09-28
EP2069312B1 (en) 2012-11-07
EP2502918A1 (en) 2012-09-26
CA2658821A1 (en) 2008-01-31
EP2069312A2 (en) 2009-06-17
MX2009000884A (en) 2009-06-05
US8586588B2 (en) 2013-11-19
IL196543A0 (en) 2009-11-18
AU2007277163B2 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
EP2502918B1 (en) Pyridazinone Derivatives
WO2009142732A2 (en) Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
EP2257553B1 (en) Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
US8076331B2 (en) Substituted pyridazine derivatives
Bacon et al. Methods of treating disorders mediated by histamine H 3 receptors using pyridazinone derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780034555.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07810758

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009010100

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 2658821

Country of ref document: CA

Ref document number: 12009500189

Country of ref document: PH

Ref document number: MX/A/2009/000884

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009521813

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007277163

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 574873

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 696/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020097003799

Country of ref document: KR

Ref document number: 200970156

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: a200901612

Country of ref document: UA

Ref document number: 2007810758

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007277163

Country of ref document: AU

Date of ref document: 20070725

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P-2013/0013

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0713836

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090126

WWE Wipo information: entry into national phase

Ref document number: 1020147004736

Country of ref document: KR